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Routinely-collected data offer great potential for epidemiological research and could be 
used to make randomised controlled trials (RCTs) more efficient. The use of routine 
data for research has been limited by concerns surrounding data quality, particularly data 
completeness. To fully exploit these information-rich data sources it is necessary to 
identify approaches capable of overcoming high proportions of missing data. 
Using a 2008 extract of the Scottish Care Information – Diabetes Collaboration (SCI-
DC) database, a population-based register of people with a diagnosis of diabetes in 
Scotland, I compared the findings of several methods for handling missing data in a 
retrospective cohort study investigating the association between body mass index (BMI) 
and all-cause mortality in patients with type 2 diabetes. 
Methods: 
Discussions with clinicians and logistic regression analyses were used to determine the 
likely mechanisms of missingness and the relative appropriateness of a selection of 
missing data methods, such as multiple imputation. Sequentially more complicated 
imputation approaches were used to handle missing data. Cox proportional hazard 
model coefficients for the association between BMI and all-cause mortality were 
compared for each missing data method. Age-standardised mortality rates by categories 
of BMI at around the time of diagnosis were also presented.  
Results: 
There were 66,472 patients diagnosed with type 2 DM between 2004 and 2008. Of these 
patients, 21% of patients did not have a recording of BMI at time of diagnosis. 
Amongst patients with complete BMI data, there were 5,491 deaths during 296,584 
person years of follow-up. Amongst patients with incomplete data, there were 2,090 
deaths during 79,067 person-years of follow-up. Analyses indicated that the primary 
mechanism of missingness was missing at random, conditional on patient year of 
diagnosis and vital status. In particular, patients with missing data had considerably 
worse survival than patients without missing data. Regardless of the method for 
handling the missing data, a U-shaped relationship between BMI and mortality was 




cause mortality was weaker using multiple imputation approaches with estimates 
moving towards the null. Closest observation imputation had the smallest effect on 
estimates compared to complete case analysis.  
Risk of mortality was consistently highest in the less than 25kg/m² BMI group. For 
example, estimates obtained using multiple imputation using chained equations 
indicated that patients with a BMI below 25kg/m² had a 38% higher risk of mortality 
than patients in the 25 to less than 30kg/m² BMI category.  
Conclusions: 
Alternative methods to complete case analysis can be computationally intensive with 
many important practical considerations. However, it remains valuable to explore the 
robustness of estimates to departures from the assumptions made by complete case 
analysis. The use of these methods can preserve the sample size and therefore may be 
useful in developing risk prediction scores.  
Mortality was lowest amongst overweight or obese patients relative to normal weight. 
Further work is required to identify optimal approaches to weight management amongst 
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 MISSING DATA IN ROUTINE DATA SOURCES 1.1
 ROUTINELY COLLECTED DATA FOR CLINICAL TRIALS 1.1.1
Routinely collected healthcare records are important, information-rich data sources that 
offer great potential for epidemiological research. These data sources are stored 
electronically in general practices and hospitals. Recent developments have also allowed 
the linkage of these datasets to other healthcare-related records, including death 
registrations and disease registries, therefore enabling the long-term, unobtrusive follow-
up of large numbers of patients at a comparatively low cost. 
These data sources not only offer huge promise in terms of observational research, 
including descriptive analyses and development of risk prediction scores, but may also 
be useful in enhancing and supplementing randomised controlled trials (RCTs). RCTs 
are widely accepted as the best way to reliably assess treatment effects. However, they 
are expensive, time-consuming and are often criticised for their lack of external validity 
and are often limited by ethical considerations (Lewsey et al., 2000; Rothwell, 2005). By 
utilising routinely assembled health records, it may be possible to improve the quality, 
efficiency and cost-effectiveness of RCTs in a number of ways. Firstly, routinely 
collected data may be used to reduce sampling bias (Staa et al., 2012). As a consequence 
of strict eligibility criteria, trials are regularly conducted on unrepresentative samples and 
are therefore unable to address questions related to the interventions efficacy in 
standard clinical care. Routinely collected data may improve recruitment processes by 
identifying and enrolling large numbers of patients quickly, rather than depending on 
patients attending a specific clinic. This process may be especially useful in trials 
conducted in patients with rare conditions. In addition, patients who were not enrolled 
could then easily be compared to enrolled patients to assess their representativeness 
(Lewsey et al., 2000). 
Secondly, routine data may enhance the feasibility of studies by providing improved 
estimates of treatment effects, thus leading to the production of more reliable and 




Finally, the use of linked electronic health records could allow for the long-term follow-
up of patients enrolled in RCTs trials, whilst allowing for the assessment of patient 
outcomes in routine clinical care, thus reducing the need for manual data collection. 
Future RCTs would be made considerably cheaper and less burdensome for both the 
patient and the clinician. Indeed, there have already been several examples of linked 
healthcare registers being successfully used as tools for long-term follow-up of patients 
and measuring patient outcomes or adverse events (Ford et al., 2007; Hemminki et al., 
2008; Dugas et al., 2010) 
 MISSING DATA IN ROUTINELY COLLECTED DATA 1.1.2
Despite the huge potential for routinely assembled data both for observational studies 
and to enhance the performance of RCTs, the practice of making use of this data has 
been limited by two major concerns. Firstly, concerns surrounding ethics approval have 
proven to be significant barriers to the use of routinely collected data for clinical trials. 
Secondly, data quality issues, such as missing data have also proven to be considerable 
challenges in the utility of these data sources. It is this feature which provides the 
motivation for this thesis.  
Though unobserved data are a well-recognised problem throughout medical research, 
missing data are a particularly substantial problem in studies which use data from clinical 
databases (Horton & Kleinman, 2007; Marston et al., 2010). This susceptibility to 
missing data arises from the fact that data collection and recording is typically clinically 
driven rather than for specific research purposes. The availability of health indicators at 
specific time-points in clinical databases is therefore largely dependent on their 
relevance to the clinical care of the patient. Motivations for recording data are likely to 
vary over time and procedures are likely to differ across large areas. Accordingly, 
available data are likely to be less reliable than when data are recorded specifically for 
the purpose of research, are likely to be available only intermittently and there are likely 
to be substantial differences between patients with and without missing data (Marston et 
al., 2010). The introduction of the Quality and Outcomes Framework (QOF) in 2004 
may have improved this situation. This programme is a National Health Service (NHS) 
care delivery plan which offers financial incentives to general practices (GPs) to improve 





Since its introduction the extent of missing data in key healthcare indicators within one 
year of registration with GP has gradually improved in primary care databases 
(Szatkowski et al., 2011; Bhaskaran et al., 2013; Marston et al., 2014). Despite these 
improvements, missing data in key health indicators are an inevitable problem. To fully 
exploit the usefulness of electronic health records, methods need to be sought which are 
capable of overcoming the problems associated with unobserved data.  
 DATA ANALYSIS WITH MISSING DATA 1.1.3
Where missing data are not appropriately accounted for, the validity of a study’s 
findings are likely to be compromised. In general, missing data can undermine the 
validity of study conclusions by reducing sample sizes and introducing bias (Rubin, 
1987). The default method for conducting research with incomplete data is to restrict 
analyses to participants with complete data, known as complete case analysis (CCA) 
(Graham, 2009). Consequently, along with decreasing study sample size, this method for 
data analysis will reduce study efficiency through the discarding of information. This 
problem is most pronounced in multivariate analyses and ultimately leads to reductions 
in statistical power for hypothesis tests.  
By excluding patients with unobserved data, CCA can also introduce bias as a result of 
the presence of systematic differences between patients with observed and unobserved 
data. This in turn leads to the production of invalid parameter estimates and therefore 
incorrect inferences (Little & Rubin, 1987). 
The extent of these problems and the respective appropriateness of any missing data 
method are dependent on the plausibility of the assumptions each technique makes, the 
proportion of unobserved data, the pattern of missing data and the research question 
(Carpenter & Kenward, 2007). 
 MECHANISMS OF MISSING DATA 1.1.4
Many researchers mistakenly believe that the proportion of missing data is the most 
important criterion on which to base the decision on the most appropriate method for 




the suitability of a missing data approach is the mechanism by which missing data came 
about, known as the mechanism of missingness.  
This is a fundamental concept in missing data methodology and describes the 
relationship between observed variables and the probability of incomplete data. It is 
formally defined as the probability that a set of values are missing given the values taken 
by the observed and missing observations (Little & Rubin, 1987). Mathematically this is:  
Pr (R | yobs, ymis) 
Whereby y represents the data that was intended to be collected. Yobs is observed and 
Ymis is missing. R denotes a missing value indicator which equals 1 if Y is observed and 
0 if Y is missing.  
In 1976, Rubin and colleagues developed a classification system to broadly define the 
three mechanisms by which missing data may occur. Within Rubin’s classification 
system there are three categories; Missing Completely at Random (MCAR), Missing at 
Random (MAR) and Missing Not at Random (MNAR) (Little & Rubin, 1987).   
1.1.4.1 MCAR 
Data are defined as MCAR when the probability of an observation being missing does 
not depend on observed or unobserved measurements (Donders et al., 2006). 
Mathematically this can be described as: 
Pr(r | yobs ymis) = Pr(r) 
Put more simply, the likelihood of a single observation being missing is influenced by 
chance alone. For example, some patients may have a missing blood cholesterol value as 
a consequence of the laboratory technician dropping test tubes containing blood 
samples. This is an example of data that are MCAR since this event could have 
happened to any patient’s blood cholesterol measurement, regardless of the patients 
observed or unobserved data. When using CCA, this mechanism is likely to introduce 
the lowest level of bias since no systematic differences between patients with and 
without observed data should exist. Nonetheless, the results are less precise than if the 





This is perhaps the strictest mechanism of missingness assumption as missingness 
cannot be related to any variables under study. Consequently, in practice this 
assumption is likely to be violated (Baraldi & Enders, 2010).  One situation in which this 
assumption may be satisfied is when data are missing by design (Allison, 2000). For 
example, researchers may not measure a biomarker for a random 25% of patients due to 
the costs associated with measurement. Data that are not recorded are MCAR.   
From the observed data it is not possible to show that data are MCAR; it is only 
possible to rule this assumption out. While no differences between patients with and 
without complete data is consistent with MCAR data, it is not possible to verify that 
differences do not exist by some unmeasured characteristic. However, systematic 
differences between patients with and without complete data indicate a clear violation of 
the MCAR assumption (Little & Rubin, 1987). 
1.1.4.2 MAR  
Data can be described as MAR when given the observed data, the missingness 
mechanism does not depend on the values of the unobserved data (Little & Rubin, 
1987).  
Pr (r |yo, ym) = Pr(r|yo)   
The cause of the missing data is therefore unrelated to the missing values but may be 
related to the observed values of other variables. For instance, differences may be 
observed in the proportion of missing blood pressure values across age groups since 
younger patients are less likely to have blood pressure values recorded. Many modern 
statistical methods such as multiple imputation and maximum likelihood approaches 
make the assumption that data are MAR. These methods work by conditioning analyses 
on the observed data so that missingness becomes completely random. Accordingly, the 
MCAR assumption is a special case of MAR data. These mechanisms are also termed 
ignorable missingness.  
If the missing data model does not control for the causes of missingness then 
missingness will become the third mechanism of missingness: MNAR (Graham, 2009). 
Continuing with the above example where missingness in systolic blood pressure was 




becoming MNAR. It is possible to make the MAR assumption more plausible by 
collecting more potential explanatory variables for the missingness. By doing so, 
researchers increase the likelihood of identifying variables which predict missingness in 
incomplete variables. However, the inclusion of more variables ultimately increases the 
likelihood of missing data and therefore a strong theoretical rationale is required to 
justify this approach (Enders, 2010). 
1.1.4.3 MNAR  
Data are MNAR when even after accounting for all the available observed information, 
the reason for observations being missing remains unexplained. Missingness may 
therefore be related to some unmeasured data, such as those of the missing values 
themselves or of some unmeasured characteristic. 
Pr (r |yo, ym)= Pr(r|ym) 
As an example of the former, study participants who have been attempting to lose 
weight but have failed to do so may be more likely to miss appointments or not disclose 
their weight. Subsequently, these patients may have more missing values (Gadbury et al., 
2003). This form of missing data is most common in clinical trials where patients drop 
out due to poor health. Alternatively, patients may have missing data on activity levels 
since their GP may not routinely record this information. If data are not available on 
which GP the patient attended then this data are MNAR. This form of missingness may 
be termed non-ignorable since the missing data mechanism must be modelled to obtain 
valid parameter estimates (Bennett, 2001).  
Dealing with MNAR data is difficult and the options to do so are limited. Since most 
mainstream approaches such as CCA are not appropriate where data are MNAR, some 
methodologists have attempted to develop methods specific to this assumption. These 
methods include selection models and pattern mixture models (Abraham & Russell, 
2004). However, these techniques are difficult to implement and tend to make dubious 
and untestable assumptions (Baraldi & Enders, 2010). As an alternative, some 
researchers have recommended addressing MNAR data by using sensitivity analyses to 
explore the robustness of parameter estimates to departures from the MAR or MCAR 





In reality, it is likely that all three mechanisms are at work within any given dataset and 
their presence is dependent on the analysis being carried out and which variables are 
included. As previously discussed, it is only possible to disprove the presence of MCAR 
data. Information from people involved in data collection is likely to provide the 
greatest insight into data collection processes and the probable mechanism of 
missingness, a process which may not be possible when routine data are used.   
 PATTERNS OF MISSING DATA 1.1.5
The pattern of missingness is an important assumption made by a number of missing 
data methods. It refers to the configuration of observed and missing values in the 
dataset. More simply, the missing data pattern describes the location of the missing 
values but does not attempt to explain the processes leading to the missingness (Enders, 
2010). Identification of the pattern of missingness and more specifically, the clarity of 
the pattern enables researchers to determine how systematic the process of missing data 
production is. Some missing data strategies are more effective with specific missing data 
configurations.  
There are several different patterns of missingness including general, univariate, 
monotone and unit nonresponse (Figure 1.1) (McKnight et al., 2007). The most 
common missing data pattern is the general pattern, also known as arbitrary or non-
monotone missingness. This configuration exhibits no clear pattern of unobserved data 
and missing data appear to be dispersed randomly across the dataset (Figure 1.1, D). In 
longitudinal data, this may mean patients have missing data for some but not all 
occasions. Nonetheless, this apparent randomness does not necessarily mean that no 
relationship between missing values and some other variable exists. The univariate 
configuration occurs when missing values are restricted to a single variable (Figure 1.1, 
A). The monotone data pattern is typical of longitudinal studies and occurs when 
patients drop out of the study. This pattern of missingness is present when the data can 
be organised in a way so that each successive variable has fewer observed values (Figure 
1.1, C) (Rubin, 2009). Finally, the unit non-response patterns occur when information 
for every participant is available for certain variables, but for other variables 





Figure 1.1: Four common patterns of missing data. ( From Enders, 2010)  
 
Though determining the missing data configuration is a useful data exploration exercise, 
its importance is lessening due to the development of flexible missing data methods 
capable of handling all missing data patterns (Enders, 2010).  
 PROPORTION OF MISSING DATA 1.1.6
The effectiveness of any given missing data method is dependent on the proportion of 
unobserved data within the dataset. Previous simulations have generally shown that 
most techniques tend to perform worse with increasing incompleteness (Janssen et al., 
2010; Langkamp et al., 2010). However, there is not currently an established cut-off 
point for the extent of missing data that is tolerable, though Schafer (1999) stated that 
5% missingness was likely to have a negligible impact on parameter estimates, regardless 
of the approach used.   
The impact the proportion of missing data can exert on estimates will depend critically 
on the underlying missing data mechanism. For example, the error introduced into 
estimates has been shown to be considerably worse when data are MNAR, even when 
the proportion of missing data is small. The bias introduced will also depend on the 





context of the study. For instance, if missing data occur predominantly in patients who 
have experienced a rare event, the impact on analyses may be more striking.  
 METHODS FOR HANDLING MISSING DATA 1.1.7
To overcome the problems associated with missing data a wide variety of methods are 
commonly employed, some with more attractive features than others. An appropriate 
statistical analysis with missing data should aim to achieve two important objectives 
(Graham, 2009). Firstly the missing data technique should be capable of producing 
unbiased parameter estimates which closely reflect the true population value. These 
estimates should remain consistent if the analysis were repeated. Secondly, the technique 
should produce valid standard errors and confidence intervals to allow for the 
assessment of the uncertainty of the estimate given the presence of missing data.  
Unfortunately, the most frequently applied techniques make strong assumptions 
regarding the mechanism of missingness and are likely to introduce significant bias into 
the study whilst understating the variability of the data (Sterne et al., 2009). Included 
amongst these popular techniques are a range of simple approaches such as CCA and 
single imputation where missing values are replaced with values obtained from the 
observed data, such as the sample mean. Despite some widely reported flaws, the use of 
these techniques remains widespread, a possible reflection of their ease of use and 
accessibility in popular statistical software (Klebanoff & Cole, 2008).  
More recently, there has been the evolution of more advanced techniques such as 
maximum likelihood methods and multiple imputation, both of which are capable of 
producing unbiased estimates under weaker assumptions. Though these approaches 
have been available for over 30 years, the use of these techniques is only now becoming 
more widespread, a movement which may be attributed to a number of software 
developments.  
A more thorough description of these methods is provided in the literature review 




 DATA SOURCE – SCOTTISH CARE INFORMATION – DIABETES 1.2
COLLABORATION (SCI-DC) 
The data for this project comes from the existing SCI-DC register, a population based 
register of people with a diagnosis of diabetes mellitus (DM) in Scotland. This register 
was established in 2000 when the Scottish Diabetes Framework recognised the need for 
an effective information technology system to facilitate the delivery of well-managed, 
integrated DM care. To achieve this, SCI-DC was formed with the aim of developing a 
Scottish diabetes register which collated information for almost all patients with 
diagnosed DM in Scotland. SCI-DC subsequently expanded existing data systems in the 
Tayside and Lanarkshire health board areas (HBAs) to the remaining 12 HBAs and 
now, 14 years later, the DM register achieves coverage of over 99.5% of patients with a 
diagnosis of DM in Scotland. This translated to approximately 230,000 still-living 
patients and a further 50,000 deceased patients in the extracted database in 2008. The 
register assembles data on numerous demographic and clinical characteristics from a 
wide range of primary and secondary care sources. In recent times, register data have 
also been linked to several other healthcare records such as mortality data, prescription 
data and renal and cancer registrations.   
With such a wealth of information,  the SCI-DC register represent a hugely valuable 
resource that can be utilised to improve service and resource planning as well as offering 
great potential for epidemiological research. Unfortunately, the registers utility for 
epidemiological research is often compromised by non-trivial proportions of incomplete 
and poor quality data. Accordingly, if research is to exploit this large information-rich 
register, approaches need to be developed to draw reliable conclusions from the data 
despite the presence of missing data.  
 DIABETES (DM) 1.3
 INTRODUCTION TO DM 1.3.1
DM represents a profound public health concern across Scotland. According to the 





end of 2013, representing a crude prevalence of 5.1%, up from 4.9% in the previous 
year (Scottish Diabetes Survey Monitoring Group, 2013). This increasing prevalence of 
DM may reflect the ageing demography of Scotland, improved survival times, the 
obesity epidemic and a lowered average age of onset of type 2 DM (Scottish 
Intercollegiate Guidelines Network, 2010). Consequently, the challenge of maintaining 
and improving the standard of DM care in a country where DM prevalence is increasing 
represents a substantial problem to healthcare providers. 
DM is a chronic metabolic disease characterised by an inherited or acquired deficiency 
in insulin production, or by the insensitivity of cells to any insulin produced. Insulin is 
an essential hormone responsible for triggering the absorption of glucose into cells and 
therefore regulating blood glucose levels. In patients with type 1 DM, insulin cannot be 
produced by the pancreas and therefore the process of glucose absorption is restricted 
(Diabetes UK Scotland, 2010). In patients with type 2 DM, either the pancreas produces 
only a limited amount of insulin or the body develops a resistance to the action of 
insulin. In the event of resistance, the body is said to be insulin insensitive, a phrase 
which describes the body’s inability to respond appropriately to the presence of insulin 
(Stevens, 2009). As a consequence, DM is typically characterised by high blood sugar 
levels (hyperglycaemia).  
DM and its associated hyperglycaemia is a source of considerable excess morbidity and 
premature mortality in Scotland. Indeed, the Scottish Diabetes Research Network 
(2010) found that between 2001 and 2007, mortality was between 10 and 25 per cent 
higher in patients with DM than those without. The majority of these deaths can be 
accounted for by significant macro- and micro- vascular problems caused by 
hyperglycaemia. One study estimates that macro-vascular deaths such as cardiovascular 
disease (CVD) and stroke are responsible for 70% of all deaths in patients with DM 
(Fisher, 2006). Patients with DM are also susceptible to numerous micro-vascular 
complications such as retinopathy, nephropathy and neuropathy.  
To overcome this problem, patients are advised to attempt to manage their blood 
glucose levels through exercise and diet. Where this is not possible, patients are 
prescribed anti-hyperglycaemic agents such as insulin, metformin, sulfonylureas or 




approximately 10% of all NHS expenditure and therefore contributes a significant 
burden to healthcare providers (Diabetes UK Scotland, 2010).  
 DM AND BMI 1.3.2
Excess adiposity is rapidly becoming a major global public health problem with the 
prevalence of obesity and overweight reaching epidemic proportions. In Scotland alone 
it is estimated that 68.5% of men and 61.8% of women are overweight or obese 
(defined as 25 to <30kg/m² and ≥30kg/m² respectively, according to the World Health 
Organisation’s international classification system), at an annual cost to the NHS of £171 
million (Scottish Intercollegiate Guidelines Network, 2010).   
Based on cross-sectional data, it has been widely recognised that raised patient BMI is a 
significant proven risk factor for many adverse health outcomes, regardless of DM 
status (Scottish Intercollegiate Guidelines Network, 2010). In patients without a DM 
diagnosis, raised BMI has been associated with an increased risk of CVD, liver disease, 
osteoarthritis, depression and numerous cancers. Importantly, the risk of developing 
type 2 DM has also been widely demonstrated to increase with increasing BMI (Chan et 
al., 1994) (Vazquez et al., 2007). For this reason, the majority of patients with type 2 
DM are overweight or obese.   
BMI is therefore an important covariate in many analyses involving patients with DM. 
Unfortunately in the SCI-DC  register, completeness levels are low (See chapter 4) and it 
was deemed beneficial to identify methods for handling unobserved BMI data. 
Furthermore, current studies investigating the association between BMI and adverse 
health outcomes fail to adequately assess the impact of missing data on the study’s 
respective findings.  
 STUDY AIMS & IMPLICATIONS 1.4
This project was multi-disciplinary in nature, occupying overlapping aspects of 
epidemiology and statistics. Its primary focus was methodological and it attempted to 
document approaches and challenges to handling unobserved data in a routine data 





remained accessible to epidemiologists who may typically be deterred from using more 
appropriate but complicated methods for handling incomplete data. The criteria upon 
which methods for handling incomplete data were chosen was largely based on their 
accessibility in general purpose statistical software such as STATA, SAS or R. Flexible 
missing data suites have been developed in each of these software packages (Horton & 
Kleinman, 2007). Despite further suites being available in alternative software 
programmes including WinBUGS and MLWIN, data analyses were restricted to the most 
commonly used packages as it was deemed unlikely that the majority of epidemiologists 
would choose to use alternative software for missing data handling purposes. It aims to 
provide practical guidance and describe issues encountered when these methods are 
applied in routine data sources. This work will also help to assess the feasibility of using 
routinely-collected databases for research using observational and interventional study 
designs.  
The project’s secondary focus was epidemiological and endeavoured to ascertain the 
association between BMI at diagnosis with type 2 DM and all-cause mortality in the 
presence of missing data. Cox proportional hazards models were applied to explore this 
relationship.   
In addition, this thesis aimed to explore missing data problems specific to the SCI-DC 
register. Missingness in this database was examined and reported, highlighting variables 
where improvements in data completeness should be sought.  
 OBJECTIVES  1.4.1
To achieve the study aims the following objectives were formulated:  
1. To conduct a thorough literature review to summarise the current available 
methods for handling incomplete data in a wide range of scenarios. A 
description of each methods strengths and weaknesses are provided. 
2. To summarise the current literature on the relationship between BMI and all-
cause mortality in patients with DM. Current analysis strategies to investigate 
this relationship are documented and important potential confounders and 




3. To document the extent of the missing data problem in the SCI-DC register. 
Proportions of missing data relative to date of diagnosis are observed, with a 
particular focus on missingness in the BMI at diagnosis variable 
4. To identify the plausibility of the separate mechanisms of missingness by 
conducting informal interviews with clinicians and data managers.  
5. To use the data to explore the plausibility of the separate mechanisms of 
missingness by examining differences between patients with and without 
complete data, conducting logistic regression analyses to identify important 
predictors of missingness in BMI at diagnosis variable. Conducting survival 
analyses to determine if missingness in BMI at diagnosis was associated with the 
outcome.  
6. To identify important predictors of BMI at diagnosis variable which may be 
included in imputation models to improve predictions of missing values 
7. To use information from points 4,5 and 6 to choose appropriate methods for 
handling missing data and apply these methods to an analysis of the association 
between BMI and all-cause mortality in the presence of univariate missingness. 
Estimates of this relationship obtained from each missing data method are 
compared.  
8. To identify patterns of BMI recording and ascertain the plausibility of using 
longitudinal BMI measurements to improve imputations. Imputation methods 
using longitudinal data are applied to an analysis between BMI and all-cause 
mortality.  
9. To explore the relationship between BMI and all-cause mortality when missing 
data occur in multiple variables. Different methods capable of handling non-
monotone missing data are applied.  
 THESIS OUTLINE  1.5
Chapter 2 presents a literature review of methods for handling missing data and details 





Chapter 3 presents a literature review of the association between BMI and all-cause 
mortality in both the general population and in patients with type 2 DM.  
Chapter 4 provides a thorough description of the routine datasets that were used 
throughout this thesis and outlines the thorough data cleaning process that was 
undertaken. 
Chapter 5 explores the extent of the unobserved data in this dataset and attempts to 
determine the plausibility of the missing data mechanisms for the incomplete BMI 
variable. To achieve this, findings from informal discussions with a number of clinicians 
are described and data exploration exercises are presented. More specifically, differences 
between patients with and without observed data were compared and logistic regression 
analyses were conducted to ascertain predictors of missing variables.  
The relative complexity of the settings to which the missing data methods were applied 
became progressively more complicated. Chapter 6 applies several missing data methods 
to an analysis of the association between BMI and all-cause mortality. These approaches 
were applied in the context of univariate missingness in the BMI at diagnosis variable 
and did not make use of any longitudinal BMI data.  
Chapter 7 builds on the work of Chapter 6 but attempts to improve imputation 
approaches by incorporating longitudinal patient data to improve the predictive power 
of imputation models. 
Chapter 8 examines the more realistic setting whereby missing data are present in 
multiple variables. Here, results from three separate multiple imputation models are 
compared.  
In Chapter 9 the thesis is concluded and an overview of the study’s main findings is 
presented along with the important strengths and limitations of the work and finally, 
























 INTRODUCTION  2.1
 REVIEW AIMS 2.1.1
In an effort to understand current approaches to handling missing data, a literature 
review was undertaken. This review aimed to provide an insight into important 
considerations when devising strategies for handling missing data along with outlining 
current available methods. For each method identified, a description of the methods 
respective strengths and limitations was reported, as well as the circumstances in which 
using this technique could result in invalid results. This review is divided into three main 
sections: simple missing data methods, methods for MAR data and methods for MNAR 
data.  
 SEARCH STRATEGY 2.1.2
Conducting a thorough literature review for missing data was a complex process. A 
search on keywords describing methods for missing data would find many thousands of 
papers, as it would find clinical papers that merely use the methods to analyse their data 
– indeed most comprehensive searches would find any paper that mentioned missing 
data. To overcome this, missing data methodological review articles were sought using 
Medline, EMBASE and the Web of Knowledge in 2011. Reference lists from reviews and 
articles citing the reviews were examined to identify further relevant articles. Method-
specific searches for missing data approaches were conducted using the above electronic 
databases. This literature review was updated in 2014. The methods found as a result of 
this search are summarised in the following narrative review.   
 SIMPLE MISSING DATA METHODS 2.2
 DELETION APPROACHES 2.2.1
Deletion techniques involve removing participants without complete data from analyses. 
These popular approaches are capable of producing valid estimates when data are 
MCAR (Horton & Kleinman, 2007). Under this condition, the set of subjects with no 




the removal of participants without complete data should produce a representative sub-
sample which can be analysed in the usual way.  
List-wise deletion or complete case analysis (CCA) is the most popular missing data 
method and involves the exclusion of cases with missing information for any studied 
variable from all analyses. This method is quick and simple to implement and is 
regularly used when the amount of missing data is small. Under this circumstance, the 
presence of missing data is unlikely to have a large impact on the overall conclusions. 
For these reasons researchers typically overlook labour intensive methods and opt for 
CCA, the default setting in most mainstream statistical packages. 
There are scenarios whereby CCA may produce unbiased estimates when data are not 
MCAR. For example, CCA is robust to violations of MCAR providing missingness on 
predictors is not dependent on the outcome (Allison, 2000).  This point is widely 
overlooked in missing data reviews, despite it having important implications (Steyerberg 
& van Veen, 2007).  
Unfortunately, there are also a number of scenarios whereby CCA analysis will produce 
biased parameter estimates when data are not MCAR (Baraldi & Enders, 2010). 
Commonly, the MCAR assumption does not hold and the resulting sub-samples are no 
longer representative of the target population. Subsequent analyses produce estimates 
which do not reflect the true population values (He, 2010). This problem has been 
confirmed in numerous simulation studies (Wood et al., 2005; van der Heijden et al., 
2006; Janssen et al., 2010). In some instances, CCA performed the worst for most 
population parameter estimates compared to other methods when data were not 
MCAR. However, the studies also demonstrated that where data were not MCAR and 
the proportion of missing data was minimal, any bias introduced was negligible. In one 
simulation study, Janssen et al., (2010) used CCA to overcome MAR missingness in D–
dimer values, a predictor of the presence of deep venous thrombosis. Here, CCA only 
caused bias when the proportion of missing values was 60% or more.  
A further drawback of CCA is the potential for significant sample size reductions and 
resultant losses in study power. This is especially likely in multivariate analyses where 
missing data in individual variables can combine to produce high rates of case-wise 





this method act to discard valuable information, it also increases the risk of type II 
errors.  
In the context of clinical trials this method creates additional problems by violating the 
intention-to-treat principle. This principle asserts that all participants in trials should be 
analysed in the groups to which they were allocated. Therefore, according to this 
principle, patients lost to follow-up cannot be excluded despite having unobserved 
outcomes (Molenberghs et al., 2004).  
CCA may also exert a large influence in studies involving rare outcomes, such as 
childhood cancer (Schafer & Graham, 2002; Abraham & Russell, 2004). In this example, 
CCA could conceivably discard a large proportion of patients with the rare condition.  
A related method for handling missing data is pairwise deletion or available case 
analysis. This technique involves the use of all available data on an analysis-by-analysis 
basis resulting in different sample sizes for each individual analysis (Baraldi & Enders, 
2010). This makes it difficult to compare related models to each other as analyses are 
based upon different populations. Though this approach may be considered more 
efficient than CCA through the reduction of sample size losses, many of the limitations 
of CCA persist in pairwise deletion. Most important of which is the technique’s 
tendency to produce biased parameter estimates when data are not MCAR.  
Furthermore, with this technique analyses are undertaken on different but over-lapping 
samples of the dataset resulting in analyses being undertaken on significantly different 
sub-samples of the dataset. This feature can negatively affect the generalisability of any 
inferences made from the data (Enders, 2010). 
 SINGLE IMPUTATION APPROACHES 2.2.2
Single imputation is a collection of techniques which involve the replacement of missing 
values with plausible values. Using the newly complete dataset, the analyses are 
completed as if there were no unobserved data. A wide range of single imputation 
techniques are available such as arithmetic mean imputation, last observation carried 




Though these approaches have a number of strengths including their simple execution 
and their ability to account for the observed data, the use of single imputation 
techniques can very rarely be recommended. Under MCAR, MAR and MNAR 
conditions, single imputation techniques are likely to produce biased estimates and over-
estimate the precision of estimates by ignoring the uncertainty of the imputed values. 
They can also distort relationships within the data and make implausible assumptions 
(He, 2010).  
2.2.2.1 MEAN IMPUTATION 
Mean imputation involves the replacement of missing values with the arithmetic mean 
value of the variable of interest. In analyses with repeated measurements, this involves 
imputing the mean value for all non-missing subjects for that specific time-point 
(Gadbury et al., 2003).  
Despite its quick and easy execution, the use of mean imputation is difficult to justify 
due to a number of shortcomings (Baraldi & Enders, 2010). Firstly, under all missing 
data mechanisms mean imputation produces biased estimates. Secondly, mean 
imputation under-represents extreme values leading to the underestimation of variance. 
This in turn incorrectly attenuates standard errors and increases the risk of observing a 
type 1 error (Schafer & Graham, 2002). Thirdly, this approach inserts values that are 
uncorrelated with any other variable, and so correlations between imputed variables and 
other variables are diluted (Baraldi & Enders, 2010). This problem is illustrated in Figure 
2.1 (from Schafer & Graham, 2002).  Here the imputed values fall on a straight 
horizontal line suggesting no relationship between x and y, while the real values show 




















Finally, where data are non-Normally distributed, the mean may not be the best measure 
of central tendency of the data and therefore parameter estimates are under or over 
estimated.  
These limitations have been demonstrated in numerous simulation studies (Engels et al, 
2003; Schafer & Graham, 2002). In one example, the performance of mean imputation 
in producing parameter estimates which concur with true population values was 
compared to that of three other single imputation methods (Schafer & Graham, 2002). 
Here, mean imputation performed consistently worse than all other methods under all 
mechanisms of missingness. Indeed, Graham (2012) commented that this is perhaps the 
worst missing data approach available.  
2.2.2.2 REGRESSION IMPUTATION (CONDITIONAL MEAN IMPUTATION) 
Regression imputation is a technique which replaces missing observations with values 
obtained from regression equations. This approach uses the observed data to create 
regression models to predict values of the missing variable(s) (Little & Rubin, 1987). For 
example, when the y variable has missing values and the x variable does not, conditional 
mean imputation fits a model for predicting y given x. Inserting corresponding values of 
(Imputed values fall on straight line) 




x into the newly-formed regression equation will therefore identify predicted values for 
y. The resulting predictive regression equation is as follows  
yᵢ =   β̂0 + β̂1 (xᵢ) 
where yᵢ is the predicted value of y for case i.  Like other single imputation techniques, 
the main virtue of this approach is that all information is preserved and study sample 
size remains intact. However, regression imputation has several limitations which have 
restricted its utility in medical research. As well as underestimating standard errors, this 
approach overstates relationships in univariate analyses leading to imputed value falling 
on a straight regression line creating overly correlated scores (Figure 2.2) (Baraldi & 
Enders, 2010). In multivariate analyses, this problem is present but to a lesser extent 
(Enders, 2010). 
 
Figure 2.2: Regression imputation scatterplot of x and y. (From Schafer & Graham, 
2002) 
 
A variant of regression imputation exists for missing repeated measures data. This 
technique predicts missing values using a regression equation which models the 
relationship between variable scores from two separate time-points in subjects with 





at one of these time-points. Unfortunately, this technique suffers from the same 
problems as standard regression imputation for cross-sectional data.  
2.2.2.3 STOCHASTIC IMPUTATION  
Stochastic imputation attempts to overcome the problem of underestimated variability 
in regression imputation by adding random error to predicted values (Baraldi & Enders, 
2010). The method is identical to regression imputation, but for the addition of a 
Normally-distributed residual term with a mean of zero and a variance equal to the 
residual variance. The regression equation would therefore become: 
yᵢ =   β̂0 + β̂1 (xᵢ) + zᵢ 
where zᵢ is the residual term. By including this residual term this method is capable of 



















Figure 2.3 shows a stochastic regression imputation scatterplot of x and y where the 
missing data are MAR. Clearly, the imputed values no longer follow a straight line 
therefore stochastic regression imputation successfully restores lost variability whilst 
preserving the relationship between the x and y variables. The scatterplot closely 
Figure 2.3. Stochastic regression imputat ion scatterplot of x and y. 




resembles the original scatterplot with complete data. Stochastic imputation is 
frequently the best performing of each of the single imputation techniques due to its 
ability to yield unbiased parameter estimates with MAR data (Little & Rubin, 2002; 
Newman, 2003). Though simulation studies have reported similar estimates to those 
from more advanced techniques, this technique still incorrectly attenuates standard 
errors.  
2.2.2.4 HOT DECK IMPUTATION 
Hot deck imputation is the name of a series of imputation techniques which use 
responses from similar respondents to fill in missing values (Enders, 2010). In its most 
basic form, hot-deck imputation will randomly replace missing values with the scores of 
other respondents. In this form, the likelihood of selecting a single value will depend on 
the rate of its occurrence amongst respondents. More typically however, hot-deck 
imputation involves the replacement of missing values with a random value drawn from 
a subsample of similar respondents. This technique is often referred to as closest match 
and is easily applied to repeated measurements by using values obtained from one or 
more participants who have similar scores on the same measure assessed at other time-
points (Elliott & Hawthorne, 2005). Alternatively, missing data may be replaced with the 
‘average closest match’ by identifying participants with the lowest sum of absolute 
differences and using the mean value from these participants for the variable of interest.  
With hot deck imputation, the variability of the imputed data can be attenuated but not 
to the extent shown by other single imputation techniques (Figure 2.4). The approaches 
may also distort the relationship between variables and Figure 2.4 clearly demonstrates 
this feature (Schafer & Graham, 2002). Here, the scatterplot should resemble a positive 
correlation but does not.  
Despite this, one simulation study comparing the efficacy of closest match, average 
closest match, list-wise deletion and last observation carried forward for imputing 
repeated measures data reported better performances from the two variants of hot-deck 






Figure 2.4: Hot-deck imputation scatterplot of x an d y. (From Schafer & Graham, 2002) 
 
2.2.2.5 LAST OBSERVATION CARRIED FORWARD 
A popular technique for handling missing data in longitudinal studies is last observation 
carried forward (LOCF). To achieve a complete dataset, LOCF replaces missing values 
with previous observations. This technique therefore makes the unlikely assumption 
that the most recent observation for each individual is the best guess for any subsequent 
unobserved values (Carpenter & Kenward, 2007). This assumption seldom holds and 
resultant estimates are generally biased (Mallinckrodt et al., 2003). For example, in 
analyses of treatment effects on progressive diseases, LOCF will produce overly 
optimistic results for each treatment group. Where missing data occur in an outcome of 
interest that is likely to deteriorate through time, such as in Alzheimer’s, replacing values 
with previous observations will cause patients to seem healthier than they actually are. If 
more withdrawals occur in the active treatment arm there will be a larger bias in favour 
of this group and so an incorrect treatment effect will be identified (European 
Medicines Agency, 2010).  
Variants of the LOCF approach designed to handle unobserved values in the middle of 
a set of longitudinal data also exist. These techniques are able to take advantage of 
recorded values taken before and after the missing value. In one example, Engels and 
Diehr (2003) compared the use of 14 separate single imputation techniques. These 14 




complete the imputations; ‘Population’, ‘Baseline’, ‘Before’ and ‘Before and After’. The 
population methods used data from the whole population such as population median or 
mean values to fill in missing values in a specific year. The baseline techniques used 
other covariates to group individuals into classes before using group mean/median to 
impute missing values. This group of techniques included hot-deck imputation and 
regression imputation. The before methods included LOCF and mean or median of the 
subjects previous known values. Before and after methods used data available from 
before and after the missing value for imputation. Here, next observation carried 
backward, mean of the last known and next known values, mean/median of the 
participant’s values before and after missing value were used. 
Each imputation technique was found to produce biased results and underestimated 
variances, regardless of the imputation technique used. However, some techniques such 
as the population-based methods performed worse than others. The study concluded 
that those methods which used person-specific longitudinal information were superior 
to those that did not. More specifically, the authors recommended the use of the 
method that use the mean or median from the last and next available values for each 
individual. Despite promising results taken from this simulation study which did not 
compare these techniques to more advanced approaches, most methodologists actively 
discourage the use of all forms of LOCF due to its previously discussed unrealistic 
assumptions (Mallinckrodt et al., 2003; Carpenter et al., 2004; Kenward & Molenberghs, 
2009). 
 METHODS FOR MAR DATA 2.3
There are a number of methods that assume data are MAR; whereby the probability of 
missing data is conditional on observed data only. The two main methods which are 
effective when data MAR are multiple imputation and maximum likelihood approaches. 
These methods are described below.  
 MULTIPLE IMPUTATION  2.3.1
Multiple imputation is an important modern statistical technique that is rapidly 





(Schafer & Graham, 2002). Unlike single imputation, multiple imputation is able to take 
into account the uncertainty of the imputed values, whilst producing unbiased 
parameter estimates. It predominantly assumes MAR data, though there is potential for 
its use in datasets with MCAR and MNAR data when the MNAR mechanism is known 
(White & Carlin, 2010).  
The technique is multi-step and involves the creation of several plausible datasets using 
the distribution of observed values, the analysis of each individual imputed dataset and 
finally the combining of results obtained from each dataset (Sterne et al., 2009). This 
approach therefore maintains the natural variability of the data whilst preserving 
relationships between variables (Wayman, 2003). There are a number of advantages of 
this technique including its ability to produce complete datasets which can be 
subsequently analysed using familiar data analysis techniques. It is also a fairly general 
approach whose basic steps may be applied in a number of contexts (Kenward & 
Carpenter, 2007). Indeed, imputed datasets may even be used for multiple different 
analyses.   
Despite multiple imputation being considered ‘state of the art’ amongst most 
methodologists, its use remains low in comparison to CCA. Upon searching 4 high 
impact journals from 2002 and 2007, Sterne et al (2009), found only 59 articles in which 
multiple imputation had been used in original research. Similarly, MacKinnon (2010) 
searched the same 4 high impact journals from their earliest searchable full text articles 
until the end of 2008 and found only limited use of multiple imputation. It is suggested 
that this pattern of use could reflect the perceived complexity and multi-step nature of 
multiple imputation which can prove too time-consuming for some researchers. 
Nonetheless, the recent advent of statistical software capable of performing multiple 
imputation has allowed the method to become more accessible to researchers. 
2.3.1.1 STAGES OF MULTIPLE IMPUTATION 
To produce estimates from incomplete data, multiple imputation involves three distinct 
stages, often referred to as the imputation phase, analysis phase and the pooling phase 




Imputation Stage  
The imputation phase involves the use of statistical models to obtain plausible 
substitutes for the missing values using the MAR assumption. There are two chief 
imputation models that have been implemented in standard statistical software, these 
are the multivariate normal model and the imputation using chained equation 
approaches.  
The multivariate normal (MVN) modelling approach, also named data augmentation 
and joint modelling was first popularised by Schafer (1997). This approach assumes all 
variables in the model exhibit a multivariate normal distribution. When imputation 
models include different types of variables such as continuous and categorical variables 
the construction of a joint model is difficult. 
The MVN imputation model is an iterative procedure which has two distinct steps, an 
imputation step (I-step) and a posterior step (P-step). The I-step begins by generating 
starting values for data parameters including means, variances and covariances using the 
expectation maximisation (EM) algorithm. Briefly and simply, this algorithm attempts to 
find the maximum likelihood estimates of parameters and uses observed values to 
generate an initial guess of the parameters. Using the observed data and these initial 
guesses, the EM algorithm then re-estimates the missing values. This process continues 
until the estimates converge upon a stable set of estimates. The I-step then regresses 
variables containing missing values on the complete variables and from these equations 
missing values are replaced with predicted scored. A random draw from the normal 
distribution of residuals is augmented to these predicted scores to restore variability. In 
the P-step, new values of the parameters are simulated by drawing from their posterior 
distribution and random residual terms are added to each of the resulting estimates. 
These new parameters are then used to recalculate the regression model in the I-step. 
This process is repeated until convergence is achieved.  
The second most widely used imputation model is the multiple imputation using 
chained equations (MICE) approach. This method, also termed fully conditional 
specification, sequential regression and multiple imputation with regression switching 
was first developed by van Buuren (1999). MICE is a variable by variable approach with 





values are replaced with observed values using a simple random sampling with 
replacement approach (White et al., 2011). The variable with the least missing data is 
then regressed on all other variables and missing values for this variable are replaced 
with simulated draws from the corresponding posterior predictive distribution. This is 
repeated for each incomplete variable to form one cycle. To stabilise results, this 
procedure is repeated for several cycles to produce a single imputed dataset. The whole 
procedure is then repeated to produce several imputed datasets. When missing data 
occur in only one variable, iterations are not required.  
Unlike in the MVN approach, MICE can use the most appropriate regression model for 
imputing different variable types. For example, linear regression may be used in 
imputation models for normally distributed continuous variables, logistic regression for 
binary variables and multinomial logistic regression for nominal or ordinal categorical 
variables. MICE is therefore a more flexible approach that does not make the 
assumption that data exhibit a multivariate normal distribution. The downside of this 
approach is that MICE lacks the theoretical basis that MVN imputation has. 
Accordingly, the conditional distributions may be incompatible making convergence 
difficult to achieve (White et al., 2011). Both approaches have been found to produce 
unbiased estimates in a wide range of settings and therefore no general consensus 
regarding the appropriateness of each imputation model has been reached (Kropko et 
al., 2014).  
A slight alternative to this imputation approach is predictive mean matching (PMM). 
This approach mimics MICE but instead of replacing missing values with random draws 
from the corresponding posterior predictive distribution, PMM matches unobserved 
cases with a pre-specified number of nearest neighbours, known as donors, whose 
predictive means are closest to that of the unobserved case. Missing values are replaced 
with observed values from one of the randomly selected donors (Schenker & Taylor, 
1996). In this way PMM is similar to hot-deck imputation since it imputes values from 
nearby complete cases. As a result, PMM imputes realistic values with greater validity 
but imputed values are limited to the range of observed data. PMM has been proposed 
as a method which provides a greater degree of robustness against model 
misspecification. For example, this method may be appropriate when data are non-




this technique is not recommended when the sample size is small since this will result in 
almost identical imputations in each imputed dataset. 
Each of these imputation approaches are widely implemented in standard statistical 
software including R, STATA and SAS (Horton & Kleinman, 2007). 
Analysis Phase 
The second stage of multiple imputation is the separate analysis of each imputed 
dataset. This step is straightforward and requires only traditional complete-case analysis 
approaches. Each imputed dataset will produce distinct parameter estimates due to 
imputed data differing in each newly created dataset (White et al., 2011).  
Pooling Phase 
The final step involves the aggregation of estimates from each imputed dataset 
according to Rubin’s combining rules (1987). To obtain the point estimate for the 
parameter of interest, such as a regression coefficient, the arithmetic average of 
parameter estimates obtained from each imputed dataset is calculated. Calculating 
pooled standard errors is slightly more complicated. Standard errors from multiple 
imputation combine two sources of sampling fluctuation; firstly the within-imputation 
variance and secondly the between-imputation variance. The within-imputation variance 
reflects the uncertainty of the results from a single imputed datasets whilst between-
imputation variance allows for the additional uncertainty due to the missing 
observations. It is the between-imputation variance which simple imputation 
approaches are unable to account for since they treat imputed values as real data and do 
not account for the additional uncertainty of the imputations.  
To calculate the within-imputation variance, the arithmetic average of the sampling 
variances, (i.e. squared sample errors) from each imputed dataset is taken. 






Where represents the within-imputation variance, m denotes the number of imputed 
datasets and 	





The between-imputation variance is equal to the sample variance of the parameter 
estimates across the m datasets and quantifies the uncertainty due to the missing data. 
The formula is as follows:  





Where  denotes the between-imputation variance 	 is the parameter estimate from 
dataset t and ̅ is the average point estimate (Enders, 2010). To obtain the multiple 
imputation standard error,  and 	are summed, with the addition of a correction 
factor to  due to the average parameter estimate being subject to sampling error too. 
The square root of the sum of these values is then taken, as shown below:  
 = 	 +	 +   
where SE denotes the standard error. From the between-imputation variance, it is also 
possible to calculate the fraction of missing imputation which is able to quantify the 
missing data’s influence on the sampling variance of a parameter estimate.   
Most statistics may be combined using Rubin’s rules. However, some statistics may need 
to be transformed to achieve Normality such as odds ratios and hazard ratios. Statistics 
that may not be combined using Rubin’s rules are those whose values change with the 
sample size such as measures of strength including P-values (White et al., 2011). Most 
software packages which implement multiple imputation have built-in processes which 
automate the pooling process.  
2.3.1.2 MODEL SPECIFICATION 
Incorrectly specified imputation models are the source of the majority of problems 
associated with multiple imputation. Important considerations when specifying the 
imputation model include the number of and choice of variables, the number of 
imputed datasets created and the compatibility of the imputation model and the model 




Variable Selection & Form  
To obtain unbiased parameter estimates, variable selection is a vital step of imputation 
model specification. Despite the risk of over-fitting and the resulting potential for 
reduced precision, the general consensus is that the inclusion of more variables is better 
(Rubin, 1996; Kenward & Carpenter, 2007). Briefly, it is important that the imputation 
model includes the following:  
- All variables to be included in the model of substantive interest  
- All variables that are predictive of missingness in the unobserved variable  
- All variables associated with the unobserved variable 
To avoid bias, the imputation model should include all variables that are in the model of 
substantive interest. To preserve relationships of interest, imputation models should 
include predictors and outcomes that are involved in these later analyses (Schafer & 
Graham, 2002). Failure to do so will weaken the association between these variables, as 
was unfortunately illustrated in the development of the QRISK tool for cardiovascular 
disease prediction (Hippisley-Cox et al., 2007). In this high-profile mistake, researchers 
excluded their cardiovascular disease outcome from their imputation model for 
imputing cholesterol values and subsequently reported a null association between 
cholesterol value and cardiovascular disease risk. The inclusion of all variables to be 
included in analysis models may be difficult to achieve in settings where the imputed 
datasets are to be used for multiple analyses (White et al., 2011). 
The imputation model must also include these variables in their correct functional form. 
For example, if the model of substantive interest contains transformed variables, 
interaction terms or higher-order terms to account for non-linearity, the imputation 
model also needs to include these terms.  
However, there is currently no consensus regarding the best way of incorporating non-
linear and interaction terms. A number of approaches have been suggested, such as 
passive imputation, just another variable (JAV), PMM and polynomial combination 
(Von Hippel, 2009; White et al., 2011; Seaman et al., 2012; Vink & van Buuren, 2013; 
Bartlett et al., 2014). In passive imputation, all non-linear and interaction terms are 
excluded from the imputation model and are then calculated from the imputed value. 





Unfortunately, both of these approaches and PMM have been found to produce biased 
estimates when data are MAR, particularly for logistic regression (Seaman et al., 2012). 
These approaches have yet to be investigated in a survival analysis setting. Alternative 
means of handling higher terms such as polynomial combination are in their infancy and 
have not been applied in a wide range of settings (Vink & van Buuren, 2013).  
The appropriate method for incorporating ratio variables, such as BMI and total 
cholesterol in multiple imputation also remains unclear. Only one study was identified 
which explored this issue (Morris et al., 2014). This study advises against the use of a 
passive imputation approach, whereby the denominator and numerator are imputed and 
then the ratio is calculated using imputed data. Further work is required on this topic.  
Similarly, there has been uncertainty regarding the most appropriate means of 
incorporating outcome variables when the model of substantive interest is a survival 
analyses. In this setting, the outcome comprises of both the time (t) and the censoring 
indicator variable (D) and failure to incorporate these in imputation models may dilute 
the association between the covariate and survival. Previously these variables have been 
included in imputation models as D, t and log t with little justification (van Buuren et al., 
1999). However, White and Royston (2009) found that this approach biased associations 
between covariates and survival towards the null and instead proposed the inclusion of 
D and the Nelson-Aalen estimator of the cumulative baseline hazard. This approach 
had the lowest bias and highest precision in the majority of simulations carried out. 
The imputation model should also include those variables which are predictive of 
missingness in the unobserved variable. This makes the MAR assumption more 
plausible (Sterne et al., 2009). The MAR mechanism assumption made my multiple 
imputation only holds if the variables which are predictive of missing data are included 
in the imputation model (Enders, 2010). 
Variables which are correlated with the missing variables to be imputed should be 
included in the imputation model too. These variables will not necessarily be included in 
the final analysis but can provide valuable information for the imputation process. 
Selecting these variables will be based around the biological plausibility of any 




include height (since these variables are likely to be correlated) even if height is not to be 
included in the final analysis. 
This fully inclusive analysis strategy has been widely recommended to avoid bias. 
Reduced precision through over-fitting has been observed, though in practice these 
reductions are typically small and unlikely to be a problem in large datasets (Kenward & 
Carpenter, 2007).  
Handling non-Normally distributed variables  
Appropriately handling non-Normally distributed continuous variables is a further 
important step in model specification. Both MICE and the MVN imputation model 
assume incomplete continuous variables are Normally-distributed. There is currently no 
agreement regarding the impact of including non-Normal variables in imputation 
models. A number of studies have suggested that their inclusion may bias results and 
imputed data will not resemble that of the observed values (Sterne et al., 2009; White et 
al., 2011; Lee & Carlin, 2012). For example, in their empirical study Lee and Carlin 
(2012) observed considerable bias when estimating the effect of a skewed continuous 
covariate even when missingness was moderate.  On the other hand, other studies have 
shown that normality violations do not pose a threat to the accuracy of parameter 
estimates from multiple imputation (Schafer & Graham, 2002; Demirtas et al., 2008)   
To mitigate the potential for bias, transformations may be used prior to imputation 
before back-transforming afterwards. Proposed transformations include the Box-Cox 
transformation, a procedure which identifies an appropriate exponent to add to 
observed values until the value which best removes the skew is identified and the 
shifted-log transformation which involve taking the log of the observed values and 
subtracting a positive or negative value dependent on whether the distribution is right or 
left skewed. Alternatively, PMM may be used (White et al., 2011).  
Number of imputations 
The number of imputed datasets to include is an important consideration when 
specifying the imputation model. Earlier work suggested that a small number of imputes 
(e.g. m=3 to 5) would suffice, though more recently there has been a shift in opinion 
towards larger number of imputations. White et al. (2011) have argued that considerably 





the authors recommend that the number of imputations should be similar to the 
percentage of incomplete cases. This recommendation comes from simulation studies 
which have explored Monte Carlo errors and identified that more imputations are better 
for improving reproducibility along with providing good statistical efficiency and 
limiting loss of power. 
2.3.1.3 SITUATIONS WHEN MULTIPLE IMPUTATION MAY BE BENEFICIAL  
Multiple imputation is widely advocated as a better missing data handling approach than 
CCA. Whilst this is true for a wide range of settings, there are a number of settings in 
which more traditional approaches may be more appropriate. This is an important 
consideration which is rarely emphasised in the missing data literature (White & Carlin, 
2010).  
Both multiple imputation and CCA produce valid estimates when data are MCAR. In 
this setting, the use of multiple imputation may be advocated in preference of CCA 
since it is able to use all available information and therefore may improve precision. 
However, it is important to note that when missing data levels are high, the impact of 
model misspecification is likely to increase with increasing fractions of imputed data. 
There are no current guidelines regarding how much missing data may be imputed. For 
example, Marshall et al. (2010) identified that multiple imputation can produce biased 
estimates with more than 50% MAR missingness in binary or continuous variables 
where the outcome is survival. White et al. (2011) meanwhile suggest caution is required 
when more than 30% of data are to be imputed.  
When missing data occur in the outcome variable only and no additional variables can 
be included in the imputation model that are not in the model of substantive interest, 
CCA and multiple imputation will yield almost identical results (Enders, 2010). If there 
are auxiliary variables which are associated with the unobserved outcome that are not 
included in the model of substantive interest then multiple imputation may be better.   
When missing data occur in covariates, the additional benefit gained from using multiple 
imputation is dependent on the role of the covariate in the analysis. According to recent 
simulation studies, if the incomplete covariate is included in the analysis model for 
confounding adjustment only, multiple imputation may be beneficial since it is able to 




outcome (White & Carlin, 2010; Lee & Carlin, 2012). However, when missingness 
occurred in the predictor variable of interest only, the benefits of using multiple 
imputation were minimal, especially where there are no strongly correlated auxiliary 
variables. It remains uncertain if this effect would be observed across a wider range of 
settings in real-life data.  
The use of multiple imputation therefore requires a careful consideration of the 
mechanism of missingness, the patterns of missing data and the context of the study. 
Clearly, its potential for information recovery needs to be balanced against the 
numerous sources of bias which may be introduced when the imputation model is 
misspecified.  
 MAXIMUM LIKELIHOOD ESTIMATION (MLE) 2.3.2
Maximum likelihood estimation (MLE) is a broad set of approaches which attempt to 
identify the population parameter estimates that have the highest probability of 
producing the sample data, using all available data (Peugh & Enders, 2004). 
Consequently, this technique can be applied to both complete and incomplete data with 
minimal alterations. Two main approaches to MLE with missing data are commonly 
applied; Full-information maximum likelihood, also known as direct maximum 
likelihood and the EM algorithm. Both approaches assume data are multivariate normal 
and are MAR.  
To achieve their goal, MLE approaches use a log likelihood function to identify the 
parameter estimates which minimise the standardised distance between the observed 
data points and the parameters of interest (Enders, 2010). The method uses an iterative 
process to ‘audition’ different values for the parameter of interest until the best fit of the 
data is identified. When MLE approaches are applied, no data are discarded whilst no 
data are permanently imputed either.  
Since its development, numerous real-data and generated-data simulation studies have 
demonstrated that MLE approaches will produce unbiased estimated with analyses 
using MAR data, especially where sample sizes are large (Barnard & Meng, 1999; 





MCAR, maximum likelihood approaches are more powerful than traditional techniques 
since they make use of all the observed data (Horton & Kleinman, 2007).  
Current options for using MLE approaches for missing data analysis are limited. 
Though software are available, often the model requires manual specification especially 
when auxiliary variables are to be included (Enders, 2010). The unavailability of 
accessible software may have contributed to the limited uptake of MLE methods.  
 INVERSE PROBABILITY WEIGHTING (IPW)  2.3.3
An alternative means of dealing with MAR data is IPW. This approach involves 
weighting complete cases by the inverse of their probability of being a complete case 
(Horton & Kleinman, 2007). This weighting system gives greater weight in the CCA to 
cases who had the lowest probability of being a complete case, and less weight to those 
who had higher probabilities. This therefore aims to rebalance the complete cases so 
that they become representative of the population of interest. Theoretically this 
approach is considerably more straightforward than the MAR methods previously 
discussed. In practical terms, IPW is easier to apply using standard statistical software 
and unlike multiple imputation, involves specifying a comparatively simple model. 
Unfortunately, a serious drawback of this approach is the requirement for data to 
exhibit monotone missingness when occurring in multiple variables. In large clinical 
databases, data are typically non-monotone and therefore IPW’s utility is limited in these 
datasets. There are extensions to allow IPW for non-monotone data though these are 
complicated and not currently available in statistical packages. In addition, IPW is less 
efficient than multiple imputation and MLE approaches since it only uses complete 
cases  and obtains no other information from incomplete records (Seaman & White, 
2013). Due to these important limitations, the use of this approach was not considered 
appropriate for this large dataset and not pursued further.  
 COMPARISON OF MAR METHODS 2.3.4
Three general methods for handling data that are MAR have been presented, each with 




Multiple imputation has a number of strengths over MLE and weighting methods. 
Firstly, multiple imputation is considerably more flexible and is not model specific. This 
means the basic steps may be applied very generally and regardless of the analysis of 
substantive interest, the specification of the imputation model is the same. Each 
complete dataset may then be used to conduct any analytic model. In contrast, the 
specification of a MLE model is problem specific since the handling of missing data is 
in-built into the final analysis model. Specialised software is required to conduct these 
model-specific analyses. For example whilst MLE methods for linear models may be 
available in certain software, this same software may not be able to conduct MLE for 
logistic regression analyses (Allison, 2012).     
Secondly, since multiple imputation is based upon two distinct models, it is more 
straightforward to incorporate auxiliary variables into the missing data model (Johnson 
& Young, 2011). Unlike in MLE approaches, these auxiliary variables need not be 
included in the final analysis model. In MLE the inclusion of these auxiliary variables 
may alter the parameter estimates obtained from the model of interest (Peugh & 
Enders, 2004).  Furthermore, some findings have suggested multiple imputation may 
give more accurate standard errors than MLE (Abraham & Russell, 2004).  
However, whilst multiple imputations will produce slightly different results each time it 
is applied, thus raising concerns that different investigators could plausibly reach 
different conclusions, MLE approaches will always produce the same result given the 
set of data. The complexity of multiple imputation also means this approach is 
considerably more labour intensive than the other MAR methods. To apply multiple 
imputation a number of issues require considerable forethought. For example, thorough 
consideration of the imputation model to be used, the number of datasets to produce 
and the handling of interactions is required. In addition, the imputation and final 
analysis model need to be compatible to prevent bias. Failure to include variables to be 
included in the final model in the imputation model is likely to dilute associations of 
interest. In comparison, the specification of MLE models is much more straightforward 
(providing the software is available) since all analyses are confined to a single analysis. 
Providing the same set of cases and variables are used and the number of imputed 





estimates. The practical considerations described above are therefore likely to influence 
their relative utility by researchers 
 METHODS FOR MNAR DATA 2.4
Missing data may also be MNAR meaning that given the observed data, the missingness 
mechanism depends on the unobserved data. Selection models and pattern-mixture 
models are two proposed methods for handling MNAR data and whilst a great deal of 
literature is devoted to these approaches, much of it remains inaccessible to non-
statisticians. These approaches attempt to jointly model both the distribution of the data 
and the probability of missing data but in very different ways. Selection models combine 
the substantive analysis with an additional regression equation that predicts response 
probabilities whilst pattern mixture models produce sub-samples of cases with similar 
missing data patterns and estimates the substantive analysis model for each pattern 
(Abraham & Russell, 2004). Unfortunately, in practice these models are difficult to 
specify and are not currently implemented in standard statistical software.  
Basic sensitivity analyses have therefore been proposed which use the general principles 
of the above approaches but are considerably more accessible in standard statistical 
software. Rather than producing joint MMAR models, these sensitivity analyses 
investigate the robustness of estimates obtained from multiple imputation under the 
MAR assumption.  
 SELECTION-BASED SENSITIVITY ANALYSES 2.4.1
One selection-based approach is the reweighting method, first proposed by Carpenter et 
al. (2007). This technique reweights parameter estimates obtained from the imputed 
datasets to reflect the distribution of imputations under a MNAR mechanism. In 
ordinary multiple imputation, the point estimates from each imputed dataset are simply 
averaged, whilst in this approach, weighted averages are used. Here, estimates acquired 
from imputations that are more likely under MNAR are up-weighted relative to the 
others. The value of the weight, often referred to as δ may be elicited from experts’ 




(2007), δ may reflect how much the probability of observing the incomplete variable 
increases for a one unit increase in that variable, given the other variables. Accordingly, 
this method is a local sensitivity analysis approach which assumes the true MNAR 
inference lies within the range of estimates from MAR. Furthermore, if the number of 
imputations is small, one imputation may receive a disproportionally large weight and 
therefore dominate the pooled estimate. However, Carpenter and colleagues suggest 
that this will not necessarily mean the estimate is poor. At the time of writing, this latter 
approach had only been reported in a single observational study (Heraud-Bousquet et 
al., 2012). In this approach, Heraud-Bousquet and colleagues applied this approach to 
an investigation of the risk factors that were predictive of severe liver disease, in which 
data for a number of risk factors were missing. The authors were able to explore the 
application of this approach and encouraged its use where there are non-trivial 
proportions of missing data.  
 PATTERN MIXTURE-BASED APPROACH 2.4.2
An alternative approach is the pattern-mixture sensitivity analysis which involves 
changing imputations obtained under the MAR assumption to reflect a MNAR 
assumption. This approach was first proposed by Rubin who described it as an ad-hoc 
imputation approach (Rubin, 1987). In this simple model, Rubin proposes that 
imputations are generated under an MAR mechanism and then a constant term is added 
to 50% of these imputed values to compensate for the possibility that these may be too 
high or low. Alternatively, a prior distribution of the differences between the observed 
and unobserved values for the incomplete variable could be elicited from experts (White 
et al., 2007). From this prior distribution, values are drawn and added to the imputed 
values.  In practice eliciting this prior distribution is not straightforward and may not be 
possible in routine data sources where there may be no experts on the likely distribution 
of the unobserved variable.  
 SUMMARY  2.4.3
In summary, both of these approaches rely on potentially poorly estimated MNAR 
models and make assumptions that are not only tenuous but also cannot be verified. 





estimates (Enders, 2010). Schafer (2002) suggested that it would be preferable to specify 
a richer imputation model under the MAR assumption with more auxiliary variables that 
were related to missingness. By doing so, the MAR assumption is made more plausible.   
 CONCLUSIONS 2.5
There are currently an abundance of methods for handling unobserved data, each with a 
number of strengths and limitations which will make them more or less appropriate in a 
given setting. Ultimately, the use of a given method is dependent on a number of 
important considerations: 
1. Extent of missing data 
It has been repeatedly shown that the level of bias is likely to increase with 
increasing proportions of unobserved data. However it is not sufficient to base the 
decision on the appropriateness of a missing data method on the extent of missing 
data alone.  
2. Pattern of missing data 
Some methods are more readily suited to specific patterns of missing data, though 
this is becoming less important with the advent of flexible missing data techniques. 
The appropriateness of a method will also depend on whether the missing data 
occurs in a covariate or in the outcome variable. For example, multiple imputation is 
not worthwhile in settings where only the outcome variable has unobserved data 
and there are no auxiliary variables predictive of the probability of missingness in 
this variable.   
3. Method assumptions 
The most important assumption made my missing data methods is the missingness 
mechanism. Violation of this assumption will result in biased estimates. A thorough 
exploration of the mechanisms of missingness is therefore recommended. 
Furthermore, some methods make distributional assumptions that may not be 





A further consideration is the accessibility of the method. Many of the approaches 
detailed above remain inaccessible to non-statisticians and may not be implemented 
in standard statistical software. However, a number of recent developments have 
reduced this problem. Unfortunately, maximum likelihood approaches and MNAR 






3. LITERATURE REVIEW OF THE RELATIONSHIP 





 REVIEW AIMS 3.1.1
To illustrate the techniques for handling missing data, an analysis of the relationship of 
both cross-sectional and longitudinal patterns of BMI on all-cause mortality was 
undertaken. In an effort to determine the current approaches to measuring this 
relationship and the current understanding of the association between patterns of BMI 
and all-cause mortality, a small-scale literature review was carried out. The chosen 
method for handling missing data in each of the relevant studies was also documented.  
 SEARCH STRATEGY 3.1.2
To identify relevant articles, Medline, EMBASE, and the Web of Knowledge were 
searched through August 2011. Searches of papers investigating the association between 
BMI and all-cause mortality were not limited to diabetes populations. In addition to 
those identified using these searches, reference lists from relevant articles including 
systematic reviews were examined. This literature review was continually updated with 
new studies.  
 BMI AND MORTALITY IN NON-DM PATIENTS 3.2
The association between cross-sectional BMI and mortality has been extensively 
explored in the general population. A number of large-scale studies have demonstrated a 
U or J-shaped association between BMI and all-cause mortality (Pischon et al., 2008; 
Prospective Studies Collaboration, 2009; Berrington de Gonzalez et al., 2010; Hotchkiss 
& Leyland, 2011; Zheng et al., 2011). Figure 3.1 illustrates a convincing U-shaped 
relationship in a population of 900,000 adults from 57 prospective studies. The large 
sample size of this and many other studies investigating this association have enabled 





Figure 3.1 All-cause mortality versus BMI for each sex in the range 15–50kg/m² 
(excluding the first 5 years of follow-up). (From P rospective Studies Collaboration, 
(2009)) 
Typically the lowest risk of mortality is observed in the 22.5 to 30kg/m² BMI ranges 
with progressively increased risk in higher and lower BMI categories. Whilst the risk of 
mortality is consistent in the upper BMI categories, a great deal of uncertainty remains 
in the lower BMIs. The uncertainty of the relationship at these BMIs likely reflects the 
complicated nature of this association. More specifically, the overall association may be 
confused by the risk of residual confounding by smoking and reverse causation by 
chronic pre-existing disease (Nilsson, 2008).  
Smoking is strongly associated with both weight loss and premature mortality and 
therefore excess mortality in below-normal BMI groups may be a consequence of 
smoking rather than a mechanism of low BMI. Adequately controlling for smoking and 
smoking intensity is difficult, especially where the quality of smoking data is poor. 
Where smoking data are available, it may be possible to exclude current or former 





dismissed elsewhere (The BMI in Diverse Populations Collaborative Group, 1999). One 
argument against the exclusion of smokers is that results from non-smokers are not 
generalizable.  
In instances where analyses have been limited to non-smokers, the relationship between 
BMI and mortality has become increasingly J-shaped. For example, in a pooled analysis 
of 19 prospective studies from the National Cancer Institute Cohort Consortium, the 
hazard ratio (HR) for all-cause mortality in the 20 to 22.5kg/m² BMI category decreased 
from 1.60 to 1.01 amongst healthy male participants when smokers were excluded 
(Berrington de Gonzalez et al., 2010). The decrease was less apparent amongst females. 
Similarly, in a cohort of U.S. men and women aged between 50 and 71 years, the 
association between BMIs below 23.5kg/m² and mortality was strongest amongst 
current smokers than never or former smokers (Adams et al., 2006). This association 
was weakened in former smokers and further still amongst never smokers. Whilst this 
study had a number of strengths including a large sample size which allowed for detailed 
exploration of the relationship in various subgroups, the use of self-reported weight was 
a clear limitation of this research. Self-reported weights have been demonstrated to be 
under-estimated amongst overweight and obese patients, though it seems unlikely that 
the level of underestimation would differ by the patients smoking status. Evidence of 
reduced mortality in the lowest BMI categories amongst never smokers compared to 
never smokers has also been reported in a population of elderly patients (ages ≥65 
years) participating in the Leisure World Cohort Study in California and in the large 
scale European Prospective Investigation into Cancer and Nutrition (EPIC) study 
(Corrada et al., 2006; Pischon et al., 2008).  In each of these studies, obesity was more 
strongly associated with mortality risk in never smokers than ever smokers.  
Nonetheless, Hotchkiss and Leyland (2011) observed the opposite when performing a 
sensitivity analysis using sequential exclusions in their study based in Scotland. This 
study used cross sectional surveys linked to NHS administrative databases and had a 
sample size of 20,117 people. Hazard ratios (HR) for mortality in the less than 
18.5kg/m² BMI category initially decreased from 2.63 [95% Confidence interval (CI): 
1.95-3.55] to 2.54 [95% CI: 1.82-3.55] with the exclusion of patients with cancer or 
cardiovascular disease, before increasing to 2.71 [95% CI: 0.84-8.70] following the 




exclusions resulted in the exclusion of over 60% of the sample and therefore the 
precision of estimates was considerably reduced.  
Research using the California Teachers Study also did not identify a difference in the 
relationship between BMI and mortality between smokers and non-smokers (Bessonova 
et al., 2011). The method of categorisation may have contributed to this finding, with 
former smokers being grouped with current smokers. Of the patients in this group, 85% 
were former smokers and therefore the effect of smoking was likely to be diluted in this 
analysis. When the relative risks of mortality in the lowest BMI categories of BMI were 
observed for all participants and never smokers only, the risk of mortality was lowest 
for never smokers. This study also relied upon self-reported weights and the sample was 
made up of California women in the teaching profession only. These may be possible 
sources of bias.  
The presence of chronic pre-existing disease in patients may also act to complicate the 
relationship between lower BMIs and mortality through reverse causation. Patients with 
chronic diseases may lose weight through a number of biological processes or may 
intentionally lose weight in response to the disease diagnosis. Lower BMI values could 
therefore be indicative of disease rather than a direct cause of mortality. To overcome 
this problem, most researchers opt to exclude deaths that occur in the first few years 
after follow-up. Though this approach will limit the risk of reverse causation, some 
conditions such as depression and lung disease have a longer duration and may proceed 
undiagnosed. This problem was illustrated by Berrington de Gonzalez et al. (2010) 
whereby they were able to show that the association between underweight (BMI below 
18.5kg/m²) and risk of mortality was weaker amongst patients with a follow-up of 15 
years compared to patients with a follow-up of 5 years (HR: 1.21 vs. 1.73). Nonetheless, 
weight gain amongst underweight participants during this lengthy follow-up could bias 
these results. Likewise, the Prospective Studies Collaboration (2009) demonstrated that 
the inverse association between lower BMI levels (<25kg/m²) and mortality weakened 
upon exclusion of patients who died within 10 years of follow-up.   
An alternative approach to preventing reverse causation through chronic disease has 
been the exclusion of patients with pre-existing disease. Adams et al. (2010) reported a 





analyses to participants without pre-existing disease. This is despite this method being 
unable to account for undiagnosed illnesses.  
Stratifying analyses by age has also been used to address reverse causation since younger 
patients are less likely to be afflicted with underlying chronic diseases (Pischon et al., 
2008). Pischon and colleagues (2008) stratified age by <55 years, 55 to <65 years and 
≥65 years and surprisingly reported a higher risk of mortality in the BMI categories 
below 23.5kg/m² amongst men aged below 55 years (HR for risk of mortality in 18.5 to 
<21kg/m² vs. 23.5 to <25kg/m²: 1.69). In contrast, risk of mortality in men with BMIs 
of 18.5 to < 21kg/m² aged 65 and above was 1.32. Interestingly, this finding was not 
demonstrated amongst women.   
Using a slightly different approach to handle reverse causation, Adams and colleagues 
investigated the association between BMI and mortality by using patients recalled weight 
at the age of 50 (2010). In this analysis, the relative risks of death in the BMI categories 
below 23.5kg/m² based on recalled BMI were lower than observed in the analyses using 
the current BMI values.   
In contrast, excess body fat is a well-established risk factor for premature mortality. For 
example, the Prospective Studies Collaboration demonstrated that mortality was 
approximately 30% higher for every increase in BMI of 5kg/m2 above the optimal BMI 
range (22.5-25 kg/m2), after adjustment for age at BMI determination, smoking and 
study. Most of the excess deaths associated with raised BMI were attributable to 
vascular diseases. This is a likely impact of the association between elevated adiposity 
and increased blood pressure, lipoprotein particles and type 2 DM incidence. 
Nonetheless, whilst excess death is generally attributed to people classed as severely 
obese (BMI ≥35kg/m²), there remains uncertainty whether moderate elevations in BMI 
confer a survival advantage over normal weight, particularly amongst patients with 
chronic diseases such as type 2 DM and heart failure (Fonarow et al., 2007). This has 
been termed the obesity paradox.  In the general population, a recent systematic review 
reported a potential survival advantage for being overweight but not obese relative to 
normal weight(HR overweight vs. normal weight: 0.92 [95% CI: 0.88/0.96])  (Flegal et 
al., 2013). The meta-analysis conducted in this review used data from over 80 papers, 




was self-report or measured weight. The findings were the same even after stratification 
and therefore misclassification bias is unlikely to have contributed to this observation. It 
did not investigate the association between BMIs lower than 18.5kg/m² and mortality. 
Flegal and authors (2013) postulated that possible explanations for these findings 
include improved management of obesity-related chronic disease such as type 2 DM, 
earlier presentation, greater likelihood of receiving intensive treatment and potential 
benefits of raised metabolic reserves. Evidence which supports the notion that 
improved treatment may explain this trend comes from results from older cohort 
studies. In these studies, the association between obesity and mortality were much 
stronger than observed in more contemporary studies. Using data from National Health 
and Nutrition Examination Survey (NHANES) I, II and III, Flegal et al., (2005) 
demonstrated that relative risks of mortality were less strongly associated with obesity in 
NHANES II and III relative to NHANES I. These reduced associations possibly reflect 
better treatment for cardiovascular disease and its risk factors, particularly amongst 
obese patients (Preis et al., 2009).   
Unfortunately, most of the aforementioned studies do not provide much detail 
regarding the approach to handling missing data utilised. Typically, CCA was applied 
without providing a justification for its selection (Adams et al., 2006; Corrada et al., 
2006; Pischon et al., 2008; Berrington de Gonzalez et al., 2010; Bessonova et al., 2011; 
Zheng et al., 2011; Chen et al., 2012). For example, the EPIC study excluded over 
100,000 (23% of sample) participants due to the presence of missing data (Pischon et 
al., 2008). None of the studies presented provided a comparison of included and 
excluded patients making it difficult to ascertain the risk of bias in each of these studies. 
Nevertheless, Hotchkiss and colleagues (2011) did investigate the differences in 
estimates generated from multiple imputation and CCA and reported similar estimates 
from both approaches. The authors demonstrated an increasing risk of missingness in 






 BMI AND MORTALITY IN PATIENTS WITH TYPE 2 DM 3.3
Of the studies addressing this topic amongst patients with DM, only one study explored 
the potential impact of missing data on estimates of the association between BMI and 
mortality (Logue et al., 2013). In all other articles identified, patients with missing data 
were excluded regardless of the proportion of missing data. For example, Zoppini et al. 
(2003) excluded over 50% of their sample and did not provide any comparison of 
patients with and without missing data. It was therefore not possible to assess whether 
the use of CCA was likely to affect this study’s findings in this study and many others 
addressing this topic.   
The association between BMI at diagnosis and all-cause mortality remains uncertain 
amongst patients with type 2 DM. While findings have consistently observed a U-
shaped relationship in patients with DM, there remains uncertainty whether an obesity 
paradox is present (Zoppini et al., 2003; Khalangot et al., 2009; Carnethon et al., 2012; 
Logue & Sattar, 2013; Thomas et al., 2014; Tobias et al., 2014).  
Nevertheless, the vast majority report reduced mortality in overweight and obese 
individuals relative to normal weight patients. For example, using data from 37,000 
patients with type 2 DM on the General Practice Research Database, Thomas et al. 
(2014) reported a HR of 1.47 (95% CI: 1.29, 1.69) for patients with normal weight 
(defined as <25kg/m²) relative to obese patients (defined as ≥30kg/m²). This is despite 
the grouping together of moderately and severely obese patients. Similarly, findings 
from a pooled analysis of five US-based longitudinal studies indicated a considerably 
higher risk of mortality in the normal weight group at diagnosis relative to the obese 
group (HR: 2.08 [95% CI: 1.52, 2.85]) (Carnethon et al., 2012). The risk of mortality was 
similar between obese and overweight patients. Using data from the Scottish DM 
register, Logue and colleagues (2013) demonstrated the presence of an obesity paradox, 
primarily amongst men. Relative to overweight BMI status (25 to <30kg/m²) men with 
obesity had better survival (HR: 0.97 [0.91-1.04]) whilst obese women had worse 
survival (HR: 1.04 [0.96-1.12]), though differences between these BMI categories were 
not statistically significant. Meanwhile, patients with normal weight had considerably 
worse all-cause mortality, relative to overweight patients and this was observed amongst 




conducted on over 80,000 Ukrainian, conflicting findings by sex were again observed 
(Khalangot et al., 2009). Amongst men, risk of mortality was higher in the 23 to 
24.9kg/m² relative to the 25 to 29.9kg/m² group (HR: 1.11 [1.01-1.22]) but similar 
amongst women (0.99 [0.90 to 1.08]), after adjustment for age, smoking, alcohol 
consumption, systolic blood pressure, total cholesterol, history of cardiovascular disease, 
DM treatments and duration of DM. Evidence of  an obesity paradox was also 
observed in a population of type 2 DM patients in Finland (Hu et al., 2005). However, 
the use of sex-specific tertiles hindered the interpretation of HRs in this study. Relative 
to BMI tertile 1 (<27.1kg/m² for men and <28.0 for women), risk of mortality was 
lower in patients with a BMI in tertile 2 (27.1 to <30.4kg/m² for men and 28.0 to 
32.6kg/m² for women) (HR: 0.94 [0.80-1.10]). However, these estimates were not 
significant due to small sample sizes (n=3,708).  
The authors of the above studies have offered multiple explanations for this obesity 
paradox. Firstly, failure to adequately addressing missing values may have led to biased 
estimates. Secondly, as described previously, failure to adequately control against reverse 
causation and confounding by pre-existing disease and smoking status, respectively. 
Thirdly, the paradox could reflect the poor performance of BMI as a general marker for 
adiposity. Finally, patients who are diagnosed with DM at a lower BMI may have a more 
damaging disease phenotype which ultimately leads to premature mortality. Should the 
paradox be real and not simply an artefact of poor study design, then there may be large 
implications for DM treatment. Currently, recommendations suggest newly-diagnosed 
type 2 DM patients should be encouraged to lose weight (Scottish Intercollegiate 
Guidelines Network, 2010). This advice may not be appropriate for thin patients with 
increased risk of mortality. 
Conversely, a number of studies have reported no evidence to support the existence of 
an obesity paradox. Most recently, Tobias et al (2014) found no reduced mortality 
among overweight or obese patients at time of diagnosis compared to normal-weight 
patients using data from the Nurses’ Health Study and the Health Professionals Follow-
up Study. Likewise, an observational study using data from 13,000 patients with type 2 
DM on the Swedish National Diabetes Register reported that obesity in increased the 





of hyperglycaemic treatment, DM duration, smoking (Eeg-Olofsson et al., 2009). 
Explanations for these discrepant findings may include limited power and other 
practical differences such as inconsistent approaches for controlling for reverse 
causation and confounding.  
 CONFOUNDERS & EFFECT MODIFIERS  3.3.1
Along with smoking status and the presence of comorbidities, a number of other 
characteristics are typically controlled for in studies addressing the topic of BMI and 
mortality. Unsurprisingly, all studies typically adjust for age at diagnosis. Increasing age 
is associated with increasing mortality and patient BMI tends to increase with age, 
before gradually decreasing amongst elderly patients. Some studies have also identified 
potential effect modification of BMI by age at diagnosis. For example, using data from 
participants in the Verona Diabetes Study, Zoppini et al., (2003) demonstrated that 
amongst older patients (>65 years) obesity was protective against death, whilst obesity 
was related to poorer outcomes amongst younger patients. This observation was 
consistent with findings from other large-scale studies (Thomas et al., 2014; Tobias et 
al., 2014). This interaction effect has been suggested to reflect the inability of BMI to 
distinguish between lean muscle mass and adiposity. In elderly patients, decreased BMIs 
may reflect muscle wasting through sarcopenia rather than reductions in body fat. As a 
result, normal weight elderly patients may appear to have worse outcomes than obese 
patients. In the EPIC study conducted in the general population, this effect 
modification by age was stronger amongst men than women (Pischon et al., 2008). 
Nonetheless, this relationship was not observed in the study conducted by Carnethon et 
al. (2012).  
Sex is also an important confounder of this relationship. Women tend to have higher 
BMIs at diagnosis than men whilst having lower mortality levels (Logue et al., 2011). 
Though the majority of studies have combined analyses with men and women there are 
some evidence to suggest effect modification by sex. For example, Logue al. (2013) 
observed a BMI of 30 to 35kg/m² to be protective against mortality amongst men but 
not women. Khalangot and colleagues reported similar findings, though no differences 
in relative risks of death by BMI were observed between men and women in the study 




increased more mortality in high BMIs and suggested this may be since BMI is more 
closely related to abdominal fat amongst men than in women. Deprivation status may 
also be an important confounder of this association. BMI tends to be higher in more 
deprived categories and risk of mortality (Connolly & Kesson, 1996). Treatment type is 
another potential confounder as some anti-hyperglycaemic agents have been found to 
affect weight changes and the use of these agents may also affect overall mortality.  
A number of biochemical characteristics may confound or mediate the association 
between BMI and mortality. For example, raised BMIs are widely associated with raised 
total cholesterol and blood pressure values, whilst also being risk factors for a number 
of adverse health outcomes, particularly cardiovascular disease and mortality.  
Glycated haemoglobin may affect the observed relationship. Logue et al. (2013) 
observed higher glycated haemoglobin levels amongst leaner individuals whilst poorly 
controlled glycated haemoglobin is associated with higher levels of DM complications. 
This may offer an additional explanation for the increased risk of mortality in leaner 
patients relative to overweight patients. However, upon additionally adjusting for 
glycated haemoglobin, total cholesterol, LDL-cholesterol and systolic blood pressure, 
the authors did not report any differences in estimates.  Though these variables had a lot 
of incomplete data and therefore a large number of participants were excluded.  
Meanwhile, Hu et al (2005) reported an attenuation in the risk of mortality in obese 
patients relative to normal weight patients upon additionally adjusting for systolic blood 
pressure and total cholesterol (obese vs normal HR: 1.24 [1.09, 1.41] vs. 1.14 [1.00-1.30] 
for fully adjusted model). A similar attenuation of the risk of total mortality in obese 
patients was observed in the Swedish National Diabetes Register study (Eeg-Olofsson et 
al., 2009). 
However, the practice of adjusting for factors such as blood pressure and total 
cholesterol has been actively discouraged (Manson et al., 1987; World Health 
Organisation, 2000). These factors are direct effects of raised adiposity and are therefore 
on the causal pathway between BMI and mortality. Controlling for these factors will 





This may lead to the erroneous conclusion that BMI is not associated with increased 
mortality.      
 TRENDS IN BMI IN PATIENTS WITH TYPE 2 DM 3.4
As it was likely that measurement data recorded before and after diagnosis date would 
be used to fill-in missing BMI at diagnosis data, it was deemed worthwhile to investigate 
current knowledge regarding trends in BMI amongst patients with type 2 DM. 
Unfortunately, data describing patterns of BMI in patients with DM are less widely 
available and tend to originate from studies assessing the impact of various glycaemic 
control therapies. The UK Prospective Diabetes Study (1998) is a good example of this. 
In this study, changes in BMI in recently diagnosed type 2 DM patients were measured 
and related to different glycaemic control interventions. Patients on the most intensively 
treated arm gained considerably more weight than those who were not. In particular, 
patients assigned insulin-therapy were especially at risk of weight gain. This pattern of 
weight gain in patients prescribed insulin-therapy has been observed in numerous other 
studies (Adams et al., 2006; Nichols & Gomez-Caminero, 2007; Westphal & Palumbo, 
2007; Janghorbani & Amini, 2009). One study even estimated that during the first year 
of insulin-treatment, a 1 per cent deduction in glycated haemoglobin came at the 
expense of a weight gain of approximately 2kg (Yki-Jarvinen, 2001). Meanwhile, 
treatment with metformin has been demonstrated to be the most weight-neutral 
glycaemic control therapy (UK Prospective Diabetes Study Group, 1998).  
One observational study described trends in BMI prior to and after diagnosis of type 2 
DM for a cohort of Pima Indians (Looker et al., 2001). The results from this study 
conflicted with results from intervention studies. Here, the authors observed a tendency 
for patients to lose weight post-diagnosis, with the mean change varying between -0.6 
and +0.2kg/m2 per year. However, following stratification by glycaemia control 
medication type, those patients who were not receiving treatment lost weight most 
rapidly, whilst in keeping with other studies, patients prescribed insulin lost weight least 
rapidly or even gained weight. It is unlikely that these results are readily generalisable to 




1.7) were also reported in an Iranian population with type 2 DM with a mean follow-up 
period of 9.1 years (Janghorbani & Amini, 2009). 
Similarly, De Fine Olivarius et al. (2006) reported an average weight change of -3.3kg in 
the first 5 years of follow-up amongst 711 patients participating in the Diabetes Care in 
General Practice study. Most of this weight loss occurred within the first five months 
following diagnosis. Weight loss was largely dependent on treatment type. Patients 
receiving insulin gained on average 0.5kg whilst patients receiving metformin lost on 
average 4.3kg and patients receiving dietary advice only lost 5.4kg on average. A larger 
study conducted in Sweden (n=8,486) noted no change in BMIs (within 1 unit change) 
in 53% of newly-diagnosed patients with DM (Bodegard et al., 2013). Data from the 
Health and Retirement Study in the US indicated that 75% of newly-diagnosed DM 
patients exhibited stable weight trajectories and 18% lost weight before gaining weight 
during 10 years of follow-up, after adjustment for treatment type (Chiu et al., 2013). In 
contrast, a US-based study which followed patients for an average of 9.4 years identified 
small weight increases in patients with DM independent of age at baseline, though these 
increases were small (mean change 0.23 ± 0.2 kg/year) (Chaudhry et al., 2006). 
However, these analyses were restricted to only 205 newly diagnosed DM patients.  
Data describing trends in BMI prior to diagnosis with type 2 DM are also limited and 
differences in methods for measuring weight changes make comparisons difficult. 
Generally studies have reported a steady rise in weight prior to diagnosis with DM 
(Looker et al., 2001; De Fine Olivarius et al., 2008; Vistisen et al., 2014). Though De 
Fine Olivarius and colleagues (2008) reported an average weight gain of 1kg per year 
prior to diagnosis, significant weight loss was reported in the year immediately preceding 
diagnosis, a possible consequence of hyperglycaemia. In their study of weight changes 
amongst Pima Indians with DM, Looker et al. (2001) reported an average increase of 
0.43 and 0.71kg/m² per year before diagnosis. Meanwhile, using data from the 
Whitehall II study and latent class trajectory analyses, it was reported that 94% of 
patients exhibited an average weight gain of 2.3 BMI units between baseline and 













This chapter provides a detailed explanation of the datasets used throughout the entirety 
of this project. The extent of the missing data problem is documented and the 
demographic and clinical characteristics of the cohort are described.  
 DESCRIPTION OF DATASET 4.2
 DATASETS  4.2.1
Data were obtained in the form of 13 separate datasets from a pseudonymised, 2008 
research extract of the SCI-DC database. As previously described, this is a dynamic 
national register of people with diagnosed diabetes. The SCI-DC database captures 
demographic and key DM-related clinical data on a daily basis from the majority of 
hospital DM clinics (all adult clinics but a smaller proportion of paediatric clinics) and 
all but 5 of 1003 GPs in Scotland.  
The datasets held information on 274,364 patients with any form of DM. Data 
extraction of these datasets took place in July 2008 and the generation of linked datasets 
took almost two years. These datasets held information on fixed demographic and 
repeat biochemical results, including dates of measurement. Datasets were combined 
using a unique patient identifier, the community health index. Patients’ names, 
addresses, or dates of birth were not included in any dataset.  
A hospital admissions dataset, the Scottish Morbidity Records (SMR-01), and mortality 
data were linked to the SCI-DC database by Information Services Division (ISD), a 
division of NHS Scotland using the Scottish unique health record identifier, the 
Community Health Index and probabilistic linkage. SMR-01 contains information of 
date of admission, date of discharge and the relevant International Classification of 
Disease (ICD) diagnosis codes. Date of death data were obtained in 2012 from the 
National Records of Scotland (NRS). This register captures all deaths occurring in 




Permission for the generation of the linked dataset was obtained from the Scottish 
multi-centre research ethics committee, the Caldicott guardians of each Health Board 
and ISD’s Privacy Advisory Committee. Details of each dataset, including their 
respective number of observations and number of variables can be found in Table 4.1 
 DESCRIPTION OF VARIABLES  4.2.2
A description of available variables in the SCI-DC register is presented in Table 4.2.  
The first half of the table describes variables that are measured once in each person, 
whilst the second section describes variables that are measured multiple times. Notes are 
provided which outline each variable’s method of collection and the recommended 
measurement practice for each clinical characteristic as described by the 2010/2011 
QOF and the Scottish Intercollegiate Guidelines Network (SIGN) (2010).  
Although the majority of these variables are unlikely to be of substantive interest in the 
final analysis model (which investigates the association between BMI and all-cause 
mortality), auxiliary variables may provide information regarding the potential reasons 
for missingness or may help to predict the missing values themselves. In missing data 
analyses where data are MAR, it has been recognised that the inclusion of auxiliary 
variables which are correlated with the variable with missing data will improve 
imputations, whilst including variables which are correlated with the probability of the 












Table 4.1: Details of 13 datasets extracted from SC I-DC from 2008 onwards. 
Dataset name Total no. 
observations 
Available Variables  




Date of measurement 
BP 8,980,146 Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Date of measurement 
Creat 3,472,238 Creatinine (umol/L) 
Date of measurement 
Ethnic 273,690 Year of birth 
Sex 
Ethnic Group 
Date of Death 
Vital status (True/False) 
Health Board Area (HBA) 
HbA1c 3,300,130 Percentage Glycated Haemoglobin 
Date of measurement 
Hdl 1,576,348 High-density lipoprotein (HDL) cholest rol level (mmol/L) 
Date of measurement 




272,268 Rank on the SIMD 
SIMD score 
SIMD quintile 
Trig 796,077 Triglyceride level (mmol/L) 
Date of measurement 
TotalChol 2,856,858 Total cholesterol level (mmol/L) 
Date of measurement 
Diagdate 274,363 Date of diagnosis 
DMtypeMay10 273,756 DM type (generated from algorithm) 
Scottish Morbidity 
Records (SMR01) 
2,541,690 Admission date 
Discharge date 
Primary condition 
Secondary conditions (up to five conditions) 
GROA  90,957 Date of death 






Table 4.2: Description of variables extracted from SCI-DC to be used in analyses.   












Year of birth Year Used in conjunction with year of diagnosis to  
calculate patient age at diagnosis 
Date of death Date   
Sex 0 = female, 1 = male  
Health Board Area 
(HBA) 
A = Ayrshire & Arran, B = Borders, F = Fife, G = Greater Glasgow, H = 
Highlands, L = Lanarkshire, N = Grampian, R = Orkney, S = Lothian, T = 
Tayside, V = Forth Valley, W = Western Isles, Y = Dumfries and Galloway, Z = 
Shetland 
Assigned to each patient by determining within which 
HBA the patient’s registered GP is located. There are 
14 regional NHS boards across Scotland responsible 
for the delivery of frontline healthcare services within 
that locality. Prior to 2006, Argyll and Bute was an 
additional HBA in operation. However, in 2006, the 
responsibilities of the Argyll and Bute Health Board 
were shared between the Highland and Greater 
Glasgow HBAs. This thesis will discuss the post-2006 
HBAs only.  
Ethnicity 0 = Scottish, 1 = Caribbean, 2 = African, 3 = Indian, 4 = Pakistani, 5 = 
Bangladeshi, 6 = Chinese, 29 = Unknown, 30 = Any other ethnic origin, 31 = 
Irish, 32 = Other British, 33 = Other white background, 34 = Other black 
background, 35 = Other Asian background, 36 = Other mixed background, 40 = 
Not known, 50 = Not disclosed.    
Patient ethnicity is traditionally, a poorly recorded 
demographic characteristic. Fortunately, over 95% of 
people in Scotland are White British and therefore 
failure to include this variable in analyses due to high 
rates of unobserved data should have a negligible 
effect (Office of the Chief Statistician, 2004) . 
Diabetes  type 0 = Not diabetic, 1 = type 1, 2 = type 2, 3 = Maturity onset DM of the young, 4 
= Other DM type 
DM type was derived using an algorithm generated by 
Dr Shona Livingstone and Professor Helen Colhoun 
in Dundee which utilised data for age at diagnosis, the 
use of and the timing of treatment with oral 
hypoglycaemic agents and insulin. Presence of type 1 
DM was ascertained by a diagnosis before 30 years of 
age, prescribing history showing continuous insulin 
prescription from diagnosis of DM and clinically 
defined type of DM.  
Scottish Index of 
Multiple Deprivation 
1 = Most deprived  5= Least deprived The SIMD is an area-based measure of socio-






       Variables Coding Notes 
(SIMD) quintile considered important predictors of deprivation 
including; income, education, employment, health, 
housing, crime and geographic access to services. The 
index score for each data-zone is formed through the 
weighted summing of scores from each domain. 
There are 6,505 data-zones across Scotland which 
have a median population size of 769 and nest within 
local authorities. The data-zones are then divided into 
quintiles based upon their rank. Individuals are 
assigned a deprivation quintile by determining within 
which data-zone their postcode lies. 
Date of diagnosis  “Best-guess” date of diagnosis estimated from timing 














Body mass index (BMI) Measured in kg/m² Calculated using standard approach of 
weight/height². The QOF recommends that BMI is 
measured and recorded  in patients with DM at least 
every 15 months  
Height Height in m  (rounded to the nearest centimetre) Recorded while patients are without shoes. 
Weight Weight in kg Recorded while patients are without shoes or outdoor 
clothing. 
Smoking Status 0 = Unknown, 1 = Current, 2 = Ex-smoker, 3 = Never smoker 
Recoded: 0 = Never, 1 = Ever 
The QOF recommends that smoking status of DM 
patients is measured and recorded every 15 months.  
Diastolic and systolic 
blood pressure (BP) 
mmHg Resting blood pressure recorded using a 
sphygmomanometer. The QOF encourages general 
practices to record BP at least every 15 months. 
Practices are rewarded for achieving high percentages 
of patients with DM with a last blood pressure 
measurement of 145/85 or less. SIGN recommends 
patients should aim to achieve a diastolic BP of 80 or 
less and a systolic BP of less than 130.  
Glycated haemoglobin 
(HbA1c) 
Percentage of total haemoglobin. Provides an estimate of average blood glucose 
level during the preceding 10-12 weeks.    
High levels of HbA1c are indicative of poor control 
of blood glucose levels. The QOF recommends 






       Variables Coding Notes 
DM. SIGN recommends patients with type 2 DM 
should aim to achieve a HbA1c value of 7.0% or 
below but good control is often defined as HbA1c 
<7.5%.   
Serum creatinine umol/L Indicator of renal function. The QOF recommends 
patients with type 2 DM have serum creatinine 
measurements recorded every 15 months. 
Serum total cholesterol Mmol/L Fasting total cholesterol value. The QOF 
recommends patients with type 2 DM have their total 
cholesterol recorded every 15 months and should aim 
to be at 5.0mmol/L or less.  
Serum HDL-cholesterol Mmol/L Fasting HDL-cholesterol value. HDL-cholesterol is 
considered the ‘good cholesterol’ and therefore a 
HDL-cholesterol below 1.03mmol/L for men and 
below 1.29mmol/L for women is considered 
undesirable.  
Serum triglycerides Mmol/L Fasting serum triglycerides level. A triglyceride level 




Diseases recorded using the International Classification of Diseases (ICD) – 9th 






 DATA CLEANING 4.3
A data cleaning exercise was undertaken with the aim of creating a single dataset upon 
which various missing data methods could be tested and applied. Analyses were 
restricted to patients with type 2 DM and who had a date of diagnosis prior to 
01/07/2008.  
The presence of type 2 DM was ascertained using an algorithm which used age at date 
of diagnosis (under 30 years) and the use and timing of treatment with oral 
hypoglycaemic agents and insulin to identify people with type 1 DM for exclusion. After 
exclusion of patients with any other form of DM (n=33,035), and who were diagnosed 
after study-endpoint (n=238) there were 241,091 patients with type 2 DM in the sample. 
A separate cohort of patients diagnosed with type 2 DM between 2004 and July 2008 
was also generated (n=77,948). 
Data cleaning was undertaken for the original cohort of 241,091 patients by checking 
for invalid readings. Within each dataset, each continuous variable was examined for 
implausible values (see Table 4.3), and these were set to missing. The upper and lower 
bounds were set in accordance with the SCI-DC data quality audit. Measurement dates 
were also examined for plausibility. All measurements taken prior to 02/01/1910 or 
after 01/07/2008 were considered implausible and were set to missing.  Since data 
extraction for separate variables occurred at different times, the plausibility cut-off point 
was set to 01/07/2008 to obtain a snapshot of the data. Vital status was determined at 
31/12/2012 to obtain a longer duration of follow-up. Measurements before 1910 were 
assumed implausible since these measurements were considered unlikely to still be 
available.  Values taken before a patient’s year of birth or after their date of death were 
also considered implausible.  
The percentage of missing values was calculated for each variable to ascertain the extent 






Table 4.3: Plausibility cut-offs for available cont inuous variables (obtained from SCI-
DC data quality audit) 
Variable Lower Bound Upper Bound 
Age at diagnosis (years)  0 105 
Diagnosis Date 02/01/1910 01/07/2008 
Height (m) 1.0 2.1 
Weight (kg) 15 200 
BMI kg/m² 15 75 
Systolic Blood Pressure (mm Hg) 80 400 
Diastolic Blood Pressure (mm Hg) 40 300 
Glycated Haemoglobin (%) 4 30 
Serum Creatinine (umol/L) 40 1999 
Total Cholesterol (mmol/L) 1.0 15 
Triglycerides (mmol/L) 0.5 100 
HDL-cholesterol (mmol/L) 0.5 6.0 
 FIXED VARIABLES 4.3.1
Datasets containing information on fixed demographic characteristics were examined 
for implausible or missing observations first. These variables were only measured once 
for each patient, e.g. age at diagnosis, sex, deprivation status and were likely to be key 
covariates in the final analysis model. 
There were few implausible measurements in fixed variables but there were missing 
observations. Table 4.4 shows the level of completeness for each fixed variable after 
removal of implausible values in both the full sample and the 2004 to 2008 cohort. With 
the exception of ethnicity, all variables exhibited a completeness of over 96%. Ethnicity 
was poorly recorded (32% complete in full sample; 26% in the reduced 2004-2008 
cohort) and so its inclusion in a CCA would substantially decrease sample size. 
However, since 95% of people in Scotland are White British and of the people with a 
recorded ethnicity, 95% were recorded as White British, it was deemed unlikely that the 






Table 4.4: Data completeness of fixed variables in patients with type 2 DM 
Variables Full Cohort (n=241,091) Reduced cohort, 2004-2008 
(n=77,948) 
Observed (%) Missing (%) Observed (%) Missing (%) 
Age at diagnosis 238,568 (98.95) 2,523 (1.05) 75,429 (96.77) 2,519 (3.23) 
Sex 241,031 (99.98) 60 (0.02) 77,892 (99.93) 56 (0.07) 
Ethnicity 78,006 (32.36) 163,085 (67.64) 20,587 (26.41) 57,361 (73.59) 
Vital Status 241,091 (100.00) 0 (0.00) 77,948 (100.00) 0 (0.00) 
Health Board Area 241,031 (99.98) 60 (0.02) 77,937 (99.99) 11 (0.01) 
Deprivation status 239,425 (99.38) 1,666 (0.69) 77,407 (99.31) 541 (0.69) 
Date of diagnosis 238,585 (98.96) 2,506 (1.04) 75,472 (96.82) 2,476 (3.18) 
 
Age at diagnosis could not be calculated for 2,523 patients, predominantly because they 
were missing a DM diagnosis date. There were only 60 patients whose year of birth was 
unavailable, 56 of these patients were diagnosed with type 2 DM between 2004 and 
2008. Upon further exploration, it was observed that the 60 patients with missing data 
for date of birth were the same 60 patients who had missing data for sex and Health 
board area. Of the 241,091 patients in the full sample, 236,973 (98%) had complete data 
for these fixed variables, excluding ethnicity. In the reduced sample this number 
equalled 74,933 (96%). Missingness in individual variables therefore did not combine to 
produce missingness in a large number of cases. There were 12 patients for whom all 
fixed variables except vital status were missing.  
4.3.1.1 CHARLSON COMORBIDITY INDEX  
To assess comorbidity levels and therefore relative ‘healthiness’ of each patient at date 
of diagnosis with type 2 DM, the Scottish Morbidity Records (SMR01) data were used 
to calculate a Charlson Comorbidity Index (CCI) for each patient on the DM register 
(Charlson et al., 1987). This score uses 19 pre-defined comorbid conditions to develop a 
weighted score which is then typically used to calculate the cumulative increased risk of 







Table 4.5: Charlson Comorbidity Index (CCI) Scoring  System by condition 
Score* Condition 
1 Myocardial infarction  
 Congestive heart failure 
 Peripheral vascular disease 
 Cerebrovascular disease 
 Dementia 
 Chronic pulmonary disease 
 Connective tissue disease 
 Peptic ulcer disease 
 Mild liver disease (without portal hypertension, includes chronic hepatitis) 
 DM without end-organ damage  
2 Hemiplegia 
 Moderate or severe renal disease 
 DM with end-organ damage (retinopathy, neuropathy, nethropathy, or brittle DM) 
 Tumour without metastases  
 Leukemia 
 Lymphoma 
3 Moderate or severe liver disease 
6 Metastatic solid tumour 
 AIDS (not just HIV positive) 
*Summed to calculate overall comorbidity index 
To calculate a CCI at diagnosis for each patient the SMR-01 dataset, containing data on 
hospital admission, discharge dates and the patient’s main condition and up to five other 
conditions was used. Hospital admissions occurring after date of diagnosis of type 2 
DM were not considered. No restrictions on the length of look-back were in place since 
it was deemed unlikely that patients would be considered cured of these conditions 
without a significant amount of time passing – e.g. the majority of cancer patients 
require 10 years of remission to be adjudged cured. Admissions occurring prior to 1992 
had disease codes corresponding to version 9 of the International Classification of 
Disease (ICD-9), whilst admissions after this date corresponded to ICD-10. 
Comorbidities were defined using ICD-9 and ICD-10 coding algorithms generated by 





patient had both a mild and a more severe form of a condition, only the most severe 
form was counted. This hierarchical structure ensures that a single type of comorbidity 
is not counted more than once in each patient. The weighted scores were summed to 
provide a final CCI, where higher scores reflect a more severe burden of comorbidity. 
Data were not available for people admitted to hospitals outside Scotland, though this 
number is likely to be small and should have a limited impact on scores.  
Table 4.6: Frequency distribution of Charlson comor bidity index scores at diagnosis 
Charlson Comorbidity 
Index (CCI) 
Full Sample (n=238,585) 
Frequency (%) 
Reduced Cohort (n=75,442) 
Frequency (%) 
1 173,284 (72.63) 49,990 (66.26) 
2 21,058 (8.83) 8,694 (11.52) 
3 29,239 (12.26) 10,168 (13.48) 
4 7,626 (3.20) 3,372 (4.47) 
5 3,037 (1.27) 1,451 (1.92) 
6 1,222 (0.51) 595 (0.79) 
7 1,962 (0.82) 673 (0.89) 
8 696 (0.29) 284 (0.38) 
9 287 (0.12) 137 (0.18) 
10 105 (0.04) 42 (0.06) 
11 38 (0.02) 20 (0.03) 
12 13 (0.01) 6 (0.01) 
13 15 (0.01) 9 (0.01) 
14 3 (0.00) 1 (0.00) 
 
Of the 241,091 patients with DM, the hospital admissions dataset held records for 
211,769 (93%) of them. For those patients without a hospital admission, they were 
assigned a CCI of 1 due to their diagnosis of DM. A CCI at diagnosis was not calculated 
for the 2,506 patients whose date of diagnosis was not available. Table 4.6 shows the 
frequency distribution of patient scores in both cohorts. In the full sample 72% of 
patients had a CCI of one, indicating that most patients had DM alone, with no other 




score. This number reduced to 66% in the cohort of patients diagnosed between 2004 
and 2008.  
 REPEAT VARIABLES 4.3.2
Datasets containing information on biochemical levels were examined next for 
problems and implausible measurements. A flow-chart of the data cleaning process for 
these repeatedly measured variables is presented in Figure 4.1. Within this process, each 
dataset was examined for duplicates, defined as either identical or non-identical. 
Identical duplicates were defined as readings that were identical to other readings in the 
dataset in terms of their identifier, date of measurement and measurement value. Non-
identical duplicates occurred when there were multiple measurement values were 
available on a common date for the same individual. Where this was the case, the 
median value was used. 
The data cleaning process outlined in Figure 4.1 was applied to each repeatedly 
measured variable, excluding BMI. Additional problems were encountered during data 
cleaning of the BMI variable. Details of the data cleaning process for the BMI variable 






Identify number of observations in 
dataset 
Identify number of missing values in 
variable of interest 
Remove implausible values using variable 
implausibility bounds 
Remove values where year of 
measurement occurred before year of 
birth 
Remove values where year of 
measurement occurred after year of death 
Remove identical duplicates defined as 
measurements with the same patient 
identifier, date of measurement and 
measurement value  
Replace non-identical duplicates defined 
as measurements with the same patient 
identifier, date of measurement (with 
median value) 
Figure 4.1: Data cleaning process for repeatedly measured bio chemical 





For each biochemical measurement, a baseline (at date of diagnosis) measurement 
variable was constructed. Baseline characteristics were defined as measurements taken 
closest to date of diagnosis rather than a measurement taken within a year of diagnosis. 
The decision to use this definition for baseline measurement was based upon balancing 
the likely harms of using either a measurement taken a considerable time after diagnosis 
to reflect baseline value or having a definition which was likely to result in large amounts 
of missing data. Table 4.7 presents the extent of the missing data problem when using 
the closest measurement compared to a measurement taken within one year of 
diagnosis. Table 4.8 presents the median time until measurement when the 
measurement taken closest to diagnosis with type 2 DM is used.  
In general, completeness was considerably lower amongst repeatedly measured variables 
compared to fixed variables. Unsurprisingly, levels of completeness were highest 
amongst the traditional risk factors for CVD such as blood pressure and smoking status. 
In the full sample completeness of repeated measurements recorded within a year 
diagnosis was poor. Only systolic and diastolic blood pressure recordings surpassed 60% 
completeness. For example, only 53% of patients had a measurement of glycated 
haemoglobin recorded within a year of diagnosis. Amongst patients diagnosed between 
2004 and 2008, completeness levels in measurements recorded within a year of 
diagnosis were much better than those observed in the full cohort. Variable 
completeness was typically over 85% between 2004 and 2008. Regardless of the defined 
time period, triglycerides and HDL-cholesterol values were relatively poorly recorded. 
In the full sample only 22% of patients had a recording of triglycerides within one year 
of diagnosis and this only improved to 33% in the 2004 to 2008 cohort.  
In the full sample, 19% of patients had recordings for all biochemical measurements 
taken within one year of diagnosis. In contrast, 53% of patients had at least one 
recording of all repeatedly measured variables. Thirty five percent of patients diagnosed 
between 2004 and 2008 had complete data for all these repeated variables within a year 





 Table 4.7: Completeness of repeat variables based on measurements taken closest to date of diagnosis and within a year of diagnosis date  
 Full sample (n=241,041) 2004-2008 sample (n=77,948)  
Variables  Closest measurements (%) Measurements taken within 1 year 
of diagnosis (%) 
Closest measurements (%) Measurements taken within 1 year 
of diagnosis (%) 
Observed Missing Observed Missing Observed Missing Observed Missing 
Smoking status 223,631 (93.75) 17,460      (6.25) 135,761 (56.32) 105,330 (43.68) 72,943  (93.58) 
5,005             
(6.42) 
70,043         
(89.56) 





11,123       
(3.59) 
153,107 (63.52) 
87,984      
(36.48) 
73,509       
(94.31) 
4,439               
(5.69) 
71,405        
(91.61) 




230,012 (96.43) 11,079     (3.57) 153148  (63.54) 
87,943      
(36.46) 
73,508  (94.30) 
4,440             
(5.70) 
71,402       
(91.60) 




217,027 (90.98) 24,064     (9.02) 128,998 (53.52) 112,093 (46.48) 71,533  (91.77) 
6,415           
(8.23) 
69,137        
(88.70) 
8,811         
(11.30) 
Serum Creatinine 218,265 (91.50) 22,826     (8.50) 125,49   (52.61) 115,601 (47.39) 72,644  (93.20) 
5,304             
(6.80) 
70,125         
(89.96) 
7,823           
(10.04) 
Total cholesterol 215,379 (93.29) 25,712     (6.71) 126,274 (52.39) 114,817 (47.61) 72,838  (94.44) 
5,110            
(6.56) 
70,635        
(90.62) 
7,313          
(9.38) 
Triglycerides 129,553 (54.31) 111,538 (55.69) 
53,674      
(22.27) 
187,417 (77.73) 35,112  (45.05) 
42,836           
(54.95) 
26,021          
(33.38) 
51,927              
(66.62) 
HDL-cholesterol 183,042 (76.73) 
58, 049     
(23.27) 
86,771     
(36.00) 
154,320 (64.00) 61,802  (79.29) 
16,146                
(20.71) 
54,721   (70.20) 







Inspection of the median time between closest measurement and diagnosis revealed 
wide variations in length of time until measurement (Table 4.8). The median time until 
measurement was considerably longer amongst patients in the full cohort compared to 
the median times in the reduced cohort. For example, in the full cohort the median time 
until measurement of blood pressure was just over two months, whilst in the reduced 
cohort the median time was 15 days. The time until HDL-cholesterol and triglyceride 
measurement was over a year amongst the full cohort but again much reduced in the 
reduced cohort (<80 days). Clearly, a measurement taken a number of years before or 
after diagnosis with type 2 DM is unlikely to accurately reflect values at baseline. 
However, the median-time until measurement was deemed reasonable for the majority 
of the biochemical measurements and therefore these closest measurements were 
chosen to reflect these variables at diagnosis. Using these measurements also reduced 
the amount of incomplete data. Nonetheless, this definition of the time-frame for 
measurement is a potential source of bias which must be acknowledged when 
interpreting later analyses with these measurements.  
Table 4.8: Median time between diagnosis and closes t measurement date for 
repeatedly measured variables. 
Variables  
(closest to date of diagnosis) 
Median time between date of diagnosis and variable recording, 
days (IQR) 
Full Sample 2004-2008 sample 
Smoking status 144 (24, 943) 27 (6, 77) 
Systolic blood pressure 74 (12, 714) 15 (2, 44) 
Diastolic blood pressure 74 (13, 714) 15 (2, 44) 
Glycated Haemoglobin 142 (22, 1,255) 22 (6, 72) 
Serum Creatinine 161 (21, 1,344) 20 (6, 58) 
Total cholesterol 141 (20, 1,324) 20 (6, 55) 
Triglycerides 624 (81, 2,139) 79 (20, 381) 
HDL-cholesterol 441 (42, 1,923) 35 (9, 128) 
 BMI  4.3.3
4.3.3.1 CLEANING BMI 
Within the BMI dataset there were a large number of problems. This dataset had 
9,925,067 rows of observations for patients with type 2 DM, with large proportions of 




First, the dataset was checked for implausible height and weight values, defined in Table 
4.3. A graph of height against weight was produced to check for further implausible 
values. In some instances, measurements of patient’s respective height and weight on a 
single date were recorded on separate rows in the dataset. Accordingly, automated 
calculations of BMI had not been completed on these dates resulting in high 
missingness in the BMI variable (74%; 7,364,832 of 9,925,067), whilst missingness in 
height and weight was lower, 68% and 49%, respectively. The dataset therefore needed 
to be restructured so that all heights and weights recorded for a patient on a single date 
could be found on a single row.  Once on a common row, height and weight 
measurements were used to calculate the patient’s BMI for that date. Where patients 
had more than one measure of height or weight on a common date, the median value 
was used. For patients with weight measurements but no height measurement on a 
common date, the patient’s median height from available height data was imputed, since 
height is unlikely to vary considerably over time in this adult population. BMI values 
falling below 15kg/m2 or above 75kg/m2 were considered implausible and set to 
missing, a process which reduced the number of rows to 3,254,193.  
The number of measurements per patient is presented in Table 4.9. Of the 241,091 
patients, there were 20,656 (9%) patients without a single measure of BMI. Over 35% of 
patients had more than ten measurements. Similar patterns were observed in the 
reduced cohort. However, fewer patients had more than ten measurements of BMI 
(14% vs. 36% in full cohort). This probably reflects a shorter follow-up time in the 
reduced cohort of patients diagnosed with type 2 DM between 2004 and 2008.    




Full sample        2004-2008 sample 
0 20,656 (8.57) 5,951 (7.63) 
1 12,411 (5.15) 3,876 (4.97) 
2 11,550 (4.79) 5,404 (6.93) 
3-10 110,503 (45.83) 51,564 (66.15) 
11-20 64,459 (26.74) 10,087 (12.94) 




4.3.3.2 BMI AT DATE OF DIAGNOSIS  
The aim of this project was to illustrate the use of missing data on an analysis of the 
association between BMI at diagnosis with type 2 DM and all-cause mortality. Using 
BMI measurements recorded on diagnosis date was not viable since only 8% of patients 
in the full sample had a valid BMI at diagnosis. It was therefore necessary to create a 
time-window during which BMI measurements could be used which accurately reflected 
the predictor of interest at diagnosis. To define this BMI time-window, a balance 
between limiting the potential impact of weight changes and limiting the proportion of 
unobserved data was sought.  
Definitions which included measurements taken a considerable time after diagnosis 
were likely to be biased by treatment effects and the potential development and 
progression of comorbid conditions. Following a diagnosis of type 2 DM, patients are 
encouraged to make lifestyle changes e.g. healthier eating, smoking cessation) and may 
be prescribed glycaemic control therapies that have been demonstrated to be associated 
with weight change. To restrict the impact of these biases, researchers investigating the 
relationship between BMI and all-cause mortality have used BMI recordings measured 
within one year prior to diagnosis. Unfortunately, using this definition would result in 
complete data for only 22% of patients in the full sample. To achieve greater data 
completeness, it was necessary to use measurements recorded after diagnosis to reflect 
patient BMI at diagnosis. Of the full sample, 83% of patients had a BMI recording after 
diagnosis thus representing a significant proportion of patients.  
To assess how accurately BMI measurements recorded before or after diagnosis date 
reflected BMI at diagnosis, patient measurements recorded within 2 weeks of diagnosis 
were compared to the respective patients measurement outside this time-period (Table 
4.10).. Mean differences presented in Table 4.10 indicate measurements recorded before 
diagnosis more accurately reflected BMI measurements at diagnosis than measurements 
recorded after diagnosis. However, the overall correlation between measurements 
recorded before or after diagnosis was high and generally, as time from diagnosis 
decreased the level of correlation increased.  
There were two major limitations of this assessment. Firstly, only 18% of patients from 




likely that patients with available recordings within these time-intervals are different to 
those that do not. For example, patients with more recordings may have more variable 
BMI patterns due to weight loss attempts. Patient weight changes may therefore prompt 
increased frequency of measurements.   
Table 4.10. Comparison of measurements recorded at diagnosis and measurements 
recorded before or after diagnosis 
Measurement time-frames  N Mean difference between 
measurements (SD)  
Pearsons 
correlation 
Diagnosis vs. 1 month before diagnosis 2,268 - 0.15 (1.52) 0.974 
Diagnosis vs. 2 months before diagnosis 4,828 - 0.15 (1.64) 0.969 
Diagnosis vs. 3 months before diagnosis 6,512 - 0.16 (1.86) 0.960 
Diagnosis vs. 6 months before diagnosis 9,767 - 0.16 (1.95) 0.956 
Diagnosis vs. 1 year before diagnosis 14,655 - 0.12 (2.04) 0.954 
Diagnosis vs. 1 month following diagnosis 4,962 0.23 (1.66) 0.970 
Diagnosis vs. 2 months following diagnosis 12,174 0.29 (1.71) 0.967 
Diagnosis vs. 3 months following diagnosis 17,776 0.33 (1.75) 0.965 
Diagnosis vs. 6 months following diagnosis 27,464 0.35 (1.84) 0.960 
Diagnosis vs. 12 month following diagnosis 35,100 0.34 (1.90) 0.956 
 
Due to the inherent limitations of this exploratory work, it was difficult to ascertain an 
appropriate time-frame to use as a definition for BMI at diagnosis. Furthermore, data 
from previous studies have reported mixed BMI trends in the year prior to diagnosis 
(see Section 3.4). Whilst Looker et al. (2001) suggested patient BMI generally increases 
within one year prior to diagnosis, Vistisen et al. (2014) and De Fine Olivarius et al. 
(2008) observed rapid weight losses in the year prior to diagnosis. Similarly, data from 
previous work for weight changes following diagnosis with type 2 DM do not show a 
consistent trend (Looker et al., 2001; de Fine Olivarius et al., 2006; Chiu et al., 2013). A 
suitable definition for BMI at diagnosis was therefore arbitrarily defined as a 
measurement taken 10 months prior to or 2 months after diagnosis with type 2 DM 
date. Where multiple measurements were available within this time-frame, the 
measurement taken closest to the date of diagnosis was used.  This definition provided a 
year-long window for measurement whilst also limiting the amount of unobserved data 
and the potential for bias. The impact of using this definition for BMI at diagnosis is 




Of the 241,091 type 2 DM patients in the full sample, there were 100,979 (42%) with a 
valid BMI measurement at date of diagnosis, leaving 140,112 patients (58%) without a 
valid measurement of BMI. In the reduced cohort 56,990 (73%) patients had an 
observed BMI at diagnosis and 20,958 (27%) patients were without.  
4.3.3.3 PREDICTED BMI AT DATE OF DIAGNOSIS 
The majority of patients had 2 or more measurements and therefore it was possible to 
use these measurements to obtain an extrapolated or interpolated estimate BMI at 
diagnosis. This new variable could be used to ascertain the potential for missingness in 
BMI at diagnosis being MNAR, dependent on the missing BMI values themselves. To 
create the variable individual level-linear regressions were applied using individual BMI 
measurement values and timing of measurement from diagnosis with DM. The value of 
this variable was the intercept of the regression equation estimated for each patient. 
Figure 4.2 presents this process for a patient with 11 available measurements.  
 
Figure 4.2: Production of predicted BMI in a patien t with type 2 DM 
 
This method had a number of problems. For example, this approach led to the 
development of implausible BMI estimates, especially where measurements were 
extrapolated from earlier or later measurements. This issue was particularly severe 
















-100 0 100 200 300 400
Time from diagnosis with diabetes, days
BMI, kg/m² Regression Line




or after diagnosis date. If these measurements showed a slight incline or decline in BMI, 
the estimated BMI value at date of diagnosis was considerably different from the 
observed values. Indeed, some predicted BMI values were negative. Figure 4.3 presents 
this problem for a patient whose three measurements were taken over six months after 
diagnosis with DM. For this patient, the predicted BMI at diagnosis (23.9kg/m²) was 
considerably lower than the patient’s observed measurements. This figure also presents 
a large amount of variability in BMI measurements over a short period of time, 
suggesting possible measurement error.  
 
Figure 4.3: Illustration of potential problems asso ciated with using individual level 
linear regression to predict BMI at date of diagnos is. 
 
There were also 20,656 patients in the full cohort that were without any BMI 
measurements and therefore a BMI at diagnosis with DM could not be estimated. A 
further 9,273 patients only had one BMI measurement and so their predicted BMI value 
was the same as their observed value. For people with an observed BMI at diagnosis 
with DM, the mean difference between observed BMI values at date of diagnosis and 
predicted BMI from the individual-level regression models was 0.23kg/m2 (SD: 1.56). 
This difference is relatively small and therefore this method appears to provide 
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uncertain whether this difference would be the same for patients without a BMI 
measurement at diagnosis.  
4.3.3.4 CREATION OF MEDIAN BMI 
Since there were numerous problems with the creation of a predicted BMI using linear 
regression, a variable which used the median BMI value across measurements was 
created. This variable had the advantage of creating plausible measurements. However it 
could not reflect changes in BMI over time. This variable will be described as Median 
Ever-recorded BMI in later discussions.  
 COHORT CHARACTERISTICS    4.4
Table 4.11 provides a description of the baseline characteristics of the full cohort and 
for those patients diagnosed between 2004 and 2008 after data cleaning. The mean age 
at diagnosis with DM was 61.5 years in the full sample, but slightly higher in the 2004 - 
2008 cohort. This finding in the most up-to-date cohort is surprising given that the 
typical age at which patients are diagnosed with DM is declining (Alberti et al., 2004). 
There were a higher proportion of males (56%) with DM than females (46%), a trend 
that has been observed in several different DM populations (Lipscombe & Hux, 2007; 
Sarwar et al., 2010). A higher prevalence of DM was observed in the most deprived 
groups. The mean BMI at diagnosis was 31.6kg/m² in the full cohort, while it was 
slightly higher in the reduced cohort (31.9kg/m²). This is perhaps an indication that 
people are being diagnosed at heavier weights in recent times. The prevalence of ever-
smokers at time of diagnosis was high at 57% in the full cohort and 42% in the reduced 
cohort. The distribution of DM prevalence by HBA was similar to the general 
population distribution (Table 4.12) (National Records of Scotland, 2013). However, the 
number of people with DM in Lothian was slightly smaller (13%) than its population 







Table 4.11: Characteristics of people within full s ample and 2004 to 2008 cohort  
Characteristic Full sample 
2004-2008 
sample 
Mean age at diagnosis, yrs (SD) 61.48 (12.57) 62.21 (1 .65) 
Male sex (%) 129,177 (53.59) 42,410 (54.45) 
Deaths prior to 31/12/11 (%) 62,339 (25.86) 14,317 (18.37) 
SIMD (%) 1 (Most deprived) 56,953 (23.79) 18,435 (23.82) 
 2 54,914 (22.94) 17,621 (22.76) 
 3 49,519 (20.68) 15,990 (20.66) 
 4 43,670 (18.24) 14,053 (18.15) 
 5 (Least deprived) 34,369 (14.35) 11,308 (14.61) 
Year of diagnosis, (%) Before 1995 52,419 (21.74) - 
 1995 – 1999 45,648 (18.93) - 
 2000 – 2004 86,576 (35.91) - 
 After 2004 56,448 (23.41) - 
BMI at date of diagnosis,  kg/m2 (SD)  31.60 (6.43) 31.92 (6.52) 
Mean of (median) ever-recorded BMI, kg/m2 (SD) † 30.75 (6.11) 31.48 (6.27) 
Mean of predicted BMI, kg/m2 (SD) 30.89 (29.48) 31.57 (7.99) 
Median Follow-up time, years (IQR) 5.92 (2.91, 10.44) 5.55 (4.41, 6.77) 
With additional comorbidity (%)   27,958 (35.87) 
Measurements taken at closest time to diagnosis with DM 
Ever-smokers (%) 128,159 (57.31) 30,513 (41.83) 
Mean Systolic BP, mmHg (SD) 143 (21.04) 139 (18.89) 
Mean Diastolic BP, mmHg (SD) 82 (12.19) 80 (10.98) 
Mean Glycated Haemoglobin, % (SD) 7.93 (2.00) 8.00 (2.10) 
Mean serum creatinine, umol/L (SD)  94.58 (34.56) 91.11 (27.77) 
Mean total cholesterol, mmol/L (SD) 5.25 (1.27) 5.15 ( .30) 
Mean triglycerides, mmol/L (SD) 2.58 (2.51) 2.52 (2.60) 








Table 4.12: Distribution of patients with DM in Sco tland by HBA 
Health Board Area Full sample Reduced cohort  
(2004 – 2008) 
Ayrshire & Arran 18,814 (7.81) 7,031 (9.02) 
Borders 5,388 (2.24) 1,613 (2.07) 
Dumfries & Galloway 7,971  (3.31) 2,297 (2.95) 
Fife 17,795 (7.38) 5,423 (6.96) 
Forth Valley 13,980 (5.80) 4,291 (5.51) 
Grampian 22,567  (9.36) 8,029 (10.30) 
Greater Glasgow 56,189 (23.31) 18,303 (23.48) 
Highlands 13,259 (5.50) 4,224 (5.42) 
Lanarkshire 26,114 (10.83) 9,580 (12.29) 
Lothian 32,784 (13.60) 10,183 (13.07) 
Orkney 945 (0.39) 334 (0.43) 
Shetland 977 (0.41) 298 (0.38) 
Tayside 23,111 (9.59) 5,977 (7.67) 















In large, routinely-collected clinical databases there is often limited information available 
on the mechanisms giving rise to missing data; especially when data are collected on a 
national scale. Geographical variations in recording practices across large areas make it 
difficult to surmise or predict reasons for missingness. Changing recording practices and 
motivations for recording information add additional complexity to this problem. 
Furthermore, unlike in studies where data collection is conducted by members of a 
research team, gathering specific reasons for missingness, such as lack of patient 
motivation is untenable in studies which use routinely collected health records. There 
are also few opportunities to collect additional covariates which may later be useful for 
predicting missing values. 
The mechanism of missingness dictates the appropriateness of any given method for 
handling partially observed datasets. From a practical perspective, it is not possible to 
verify with any certainty the mechanism giving rise to missing data; as to do so requires 
knowledge of the unobserved values. Despite this, prior knowledge of the data 
collection methods and data exploration exercises are useful in identifying the likely 
mechanisms by which missing data occurred. This chapter presents an assessment of the 
potential mechanisms giving rise to missing BMI. Findings from this chapter are then 
used in the assessment of the appropriateness of different missing data methods applied 
in later chapters.  
In addition, this chapter also presents findings from investigations into the possible 
predictors of the BMI at diagnosis variable. These analyses were used to identify 
important variables to be included in missing data models to help impute plausible 
values for BMI.  
 MECHANISMS OF MISSINGNESS & THE SCI-DC DATA 5.2
In this population-based register, it is likely that all three mechanisms of missingness 
were present to varying degrees. Definitions of each mechanism are provided in section 




mechanism. Here, examples of potential missing data mechanisms specific to the BMI 
at diagnosis variable within the SCI-DC dataset are presented.  
 MCAR DATA 5.2.1
For BMI data at diagnosis with DM to be MCAR, defined as missingness which does 
not depend on observed or unobserved measurements, missingness in BMI would have 
been dependent on chance alone. Although it was probable that there may have been 
instances whereby BMI at diagnosis was not recorded through chance occurrences, such 
as broken weighing scales, it seemed unlikely that these occurrences accounted for such 
high levels of incomplete data (58% of BMI records around time of diagnosis of type 2 
DM were missing). 
 MNAR DATA 5.2.2
For data to have been MNAR, missingness in BMI at diagnosis would have been 
dependent on some unobserved data; either the missing BMI value itself or on other 
unobserved variables. For example, it seemed plausible that patient’s whose weight was 
deemed normal would not have been weighed or that even if they were weighed, the 
measurement was not recorded. Meanwhile, people who were perceived to be under- or 
overweight may have been monitored more closely. In some cases the patient’s weight 
may even have been above the maximum weight recorded on scales.  Nonetheless, the 
availability of multiple repeated measures of BMI could be protective against the risk of 
missingness at diagnosis with DM being dependent on the missing value itself. For 
example, BMI values before or after the date of diagnosis may be used to indicate 
whether patients with ‘healthier’ weights before or after diagnosis were more likely to 
have missing BMIs at the diagnosis date. Data would therefore be MAR dependent on 
BMI at earlier or later time-points. 
The risk of MNAR data was likely to have been reduced through the implementation of 
the QOF in 2004, when GPs began receiving financial incentives for the improved 
recording of risk factors. Prior to 2004, BMI data was primarily measured and recorded 




MAR. For patients diagnosed after this time, the mechanism of missingness may have 
been different.   
It was also possible that unobserved variables may have played a role in missingness in 
the BMI at date of diagnosis variable. For example, missing BMI at diagnosis data may 
have been dependent on the GP to which the patient attended as different practices are 
likely to have different procedures. Since we only have data on health board areas and 
not individual practices, these data would be MNAR. In addition, when the dataset was 
set up in 2000, data were retrieved retrospectively, where they were available. Different 
general practices/health board areas may have had different look-back periods. 
Consequently, the mechanisms of missingness may be different before and after SCI-
DC’s development. For patients diagnosed prior to the development of SCI-DC, 
missingness may be related to GP surgery; whilst for those diagnosed after its 
development, other factors may have governed missingness.  
 MAR DATA  5.2.3
Given the number of variables available in this linked dataset, it seemed plausible that 
data were MAR, whereby missingness in the BMI variable was related to the observed 
data. As an example, the proportion of data on BMI at diagnosis that were missing 
could have varied with patient age, sex or socio-economic status. Previous studies have 
identified associations between failure to attend appointments and younger age and 
lower socio-economic status (Waller & Hodgkin, 2000). If these relationships were 
found to hold in the type 2 DM cohort therefore resulting in higher proportions of 
missing data in these groups, the MAR assumption would hold. In addition health status 
at date of diagnosis could impact on missingness. Patients who are too ill at the time of 
diagnosis may be less likely to attend appointments. Information on the burden of 
comorbid conditions was available and therefore the likelihood of MAR dependent on 
‘healthiness’ could be crudely assessed using this.  It could not, however, account for 
mild and transient illness, such as a cold or a bad back or people with limited mobility 
whose height or weight could not be measured with the available equipment. 
An additional variable that missingness in BMI could be dependent on was year of 




occurred before or after the implementation of the QOF. Missingness may be highest 
amongst patients who were diagnosed prior to its implementation.  
 CLINICIANS’ VIEWS ON EXPLANATIONS FOR MISSING DATA 5.3
 INTRODUCTION & METHODS 5.3.1
In an effort to understand the potential reasons for missing BMI data at diagnosis in the 
SCI-DC register, I carried out five informal interviews with four clinicians and a data-
entry clerk within primary and secondary care clinics. These interviews were undertaken 
within a GP in West Lothian and within an out-patient DM clinic at the Western 
General Hospital, Edinburgh. The interviews were structured with two aims: firstly to 
obtain an understanding of the processes by which clinicians collected and recorded key 
DM information, and secondly to understand why some patients may be missing data. 
To achieve these aims I conducted five face-to-face semi-structured interviews ranging 
from 15 minutes to 1 hour long in duration. Interviews were recorded and were later 
transcribed. 
 RECORDING PROCEDURES 5.3.2
From the interviews it was apparent that strict recording procedures are in place to 
ensure patients with DM are seen regularly and important risk factors are measured. 
Within each setting, patients are seen at least annually. During these review 
appointments, important health indicators specified by the QOF are measured. This 
ensures that patients have at least one recording of each important risk factor every year.  
In both settings, patients whose glycated haemoglobin is considered to be poorly 
controlled (defined by QOF as above 7.5% in the 2011/2012 revision, although 
individual targets are frequently set) may be recalled regularly until their glycated 
haemoglobin lies at a satisfactory level. At the GP, the practice nurse stated that, at the 
patient’s follow-up, no further readings of other recordings are taken unless a computer 
prompt informs them of due measurements. In comparison, each time a patient attends 




To guarantee patients are seen by a clinician at least annually, each setting has a recall 
system which ensures letters are sent out to patients one month prior to their review 
date. These letters specify an appointment time or advise patients to call the surgery to 
arrange an appointment. If patients miss an appointment three reminders are sent out. 
In the outpatient clinic, the consultant will send a letter to the patient’s GP if there is 
still no response. The practice nurse stated that patients rarely miss their appointments 
and there are no discerning characteristics of those that do.  
Within each setting, a defined process of data recording is undertaken when a patient is 
given a diagnosis of DM. When patients are initially diagnosed within the GP setting, 
they are asked to return to the surgery within 2 weeks to measure important risk factors. 
If a patient’s glycated haemoglobin level is considerably higher than the recommended 
level, the patient would be seen within 1 to 2 days of diagnosis. 
To measure BMI, the patient is weighed and this recording is entered into the patient’s 
electronic health record. In neither setting would a self-reported weight be entered. BMI 
is calculated automatically using height. According to guidelines, weight measurement 
should be standardised; shoes and outdoor clothing should be removed. However, upon 
observation of this process it seems there are wide variations in measurement practices, 
increasing the risk of substantial measurement error. Within the out-patient clinic height 
is only repeatedly recorded when there is a clear shrinking in size or when a patient is 
under 21 years of age. Each setting had a feature on the electronic system to highlight 
implausible BMI values. 
There had been no noticeable changes in recording practices (even after the 
introduction of the QOF) whilst the interviewees had been employed in their roles, a 
period which stretched to 12 years for one interviewee.  
 REASONS FOR MISSING DATA 5.3.3
Some clinicians surmised that potential reasons for missing data around date of 
diagnosis could reflect uncertainty surrounding the accuracy of the date of diagnosis, 
rather than the failure to record important key indicators at this time point. As 
previously discussed, a strict recording process for each newly diagnosed patient is in 




2 weeks of date of diagnosis. Indeed, the practice nurse stated that upon diagnosis the 
vast majority of patients are quite concerned about their new diagnosis and are typically 
very compliant.  
The practice nurse could not think of any reason for patients to have missing BMI 
recordings. In hindsight, this response may have been due to a misunderstanding of the 
question posed. The aim of this question was to attempt to understand why missing 
data may occur in general, whilst the practice nurse may have interpreted it as why she, 
personally may not have recorded BMI data. To offer suggestions may have been 
perceived to be an admission of her not doing her job correctly.  Other clinicians were 
unable to provide possible explanations for the presence of missing data.   
 PLAUSIBILITY OF MCAR & MAR ASSUMPTIONS - FINDINGS FROM 5.4
DATA  
 INTRODUCTION  5.4.1
An assessment of the likely mechanisms of missingness in the SCI-DC register was 
conducted using all available data. Through an exploration of the data, this subsection 
aimed to identify the most likely mechanisms of missingness for BMI at diagnosis.   
 METHODS 5.4.2
To assess the plausibility of the MCAR assumption, comparisons between patients with 
and without observed BMI measurements at diagnosis with type 2 DM were made. 
Systematic differences in demographic and clinical characteristics between these groups 
would indicate a likely violation of the MCAR assumption. Analyses based on patients 
with complete data would therefore be undertaken on a sample which would not be 
representative of the true population.  
To compare groups, a missing indicator variable was created which was equal to zero if 
the patient had a BMI recording at diagnosis and one if the patient did not. Means are 
presented for normally distributed continuous variables and percentages for categorical 
variables by missing BMI status. Where continuous variables were not normally 




tests were not undertaken for these comparisons due to large sample sizes. Even small 
changes between the groups would be statistically significant but not necessarily 
clinically relevant.  
To assess the plausibility of the MAR assumption, univariate and multivariate logistic 
regression analyses were carried out using a missing indicator variable. The aim of these 
regressions was to determine which variables were associated with missingness in the 
BMI variable. Identification of such variables would then inform their likely inclusion in 
missing data models. To assess the plausibility of data being MNAR, within-patient 
summary measures of available BMI measurements (median ever-recorded BMI and 
linear regression predicted BMI) were included in univariate and multivariate logistic 
regression analyses. These variables were used to indicate possible BMI ranges at which 
rates of missingness were the highest. 
Putting age into models as a continuous linear effect was considered potentially 
misleading as treatment patterns and healthcare-seeking practices were likely to differ 
across age in a non-linear fashion. For this reason, it was decided to include age as a 
categorical variable. Age at diagnosis of DM was divided into the following 5 age 
groups: under 50 years, 50 to 59 years, 60 to 69 years, 70 to 79 years and 80 years or 
over. There were 43,746, 58,959, 69,307, 49,085 and 17,471 patients in each respective 
age group. The under 50 years age group was chosen as the reference category because 
it was the extreme value with the largest numbers of people in it. 
Year of diagnosis was also categorised. The introduction of the QOF in 2004 and the 
formation of SCI-DC in 2000 onwards were likely to produce non-monotonic changes 
in risk of missingness by year of diagnosis. Categories were formed to ensure odds ratios 
effectively described these distinct time-points whilst ensuring group sizes were not 
overly unbalanced.  These categories were: Before 1995, 1995 to 1999, 2000-2004 and 
after 2004.  
Charlson comorbidity index (CCI) is presented as both a continuous and a 
dichotomised variable. To form the binary variable patients were divided into two 
groups: CCI=1 ‘No comorbidities’, CCI > 1 ‘Comorbidities’. Patients in the ‘no 
comorbidities’ category therefore had DM only, whilst patients in the other category had 




categories, we were able to assess the risk of missingness in relatively unhealthy DM 
patients and a comparatively healthy DM population.  
Reference categories for other categorical variables were chosen on the basis of having 
large numbers and/or lowest perceived risk of missingness in BMI at date of diagnosis.  
STATA, version 11.2, College Station, Texas, StataCorp LP was used to run all analyses 
(StataCorp, 2009).  
The variables that were included in the multivariate model were:  
- Age at diagnosis (categorical) - Smoking status (binary: never/ever) 
- Sex (binary) - Health Board Area (HBA) (categorical) 
- Vital status (binary) - Deprivation status (categorical) 
- Year of diagnosis (categorical) - CCI (categorical) 
- Within-patient Median ever-
recorded BMI (continuous) 
- HDL-cholesterol around date of diagnosis 
(continuous) 
- Diastolic blood pressure around 
date of diagnosis (continuous) 
- Total cholesterol around date of diagnosis 
(continuous) 
- Glycated haemoglobin around 
date of diagnosis (continuous) 
 
 
Since the logistic regression models used CCA as the method for handling missing data, 
triglycerides and serum creatinine were not included in the multivariate model since 
their inclusion would result in a sample size reduction of almost 50%. It was deemed 
unlikely that these variables would be meaningful in terms of their ability to affect 
missingness in the BMI variable. Diastolic blood pressure (BP) and predicted BMI were 
also excluded from the multivariate model due to concerns regarding collinearity with 
systolic BP and median ever-recorded BMI, respectively.  
The following interactions were also investigated graphically and by the inclusion of 
interaction terms in logistic regression models. 
− Age at diagnosis vs. Sex 




− Deprivation status vs. Sex 
− Charlson comorbidity index vs. Age at diagnosis 
− Charlson comorbidity index vs. Vital status 
The relationship between survival and missing BMI data was also explored using a Cox 
proportional hazards model, adjusted for age, sex, smoking status and deprivation 
status. The validity of the proportional hazards assumption was checked using Kaplan-
Meier and log-log plots. Censoring was assumed to be non-informative. Informative 
censoring occurs when the censoring process is dependent on the event occurrence 
leading to biased estimates of survival. Censored patients in this study were deemed to 
have similar survival to those that were not censored. Age standardised mortality rates 
by BMI missingness were calculated using the Standard European population.   
 RESULTS I: PREDICTORS OF MISSINGNESS  5.4.3
In this cohort of patients with type 2 DM, 140,112 (58.12%) of the 241,091 patients did 
not have a BMI measurement recorded around date of diagnosis with DM. Table 5.1 
presents some important differences between patients with and without a BMI recorded 


















Table 5.1. Factors influencing missingness in BMI a t diagnosis in patients with type 2 
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(0.74, 0.77) 
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† Calculated by averaging median patient BMI. SD: Standard Deviation, IQR: Interquartile Range 
 
Missingness in BMI at diagnosis was strongly associated with year of diagnosis, with 
missingness being highest amongst patients who were diagnosed prior to 1995 (5.4% 
with data available if diagnosis before 1995 compared with 76.8% if diagnosis was after 
2004). In the multivariate logistic regression model, earlier year of diagnosis remained 
independently associated with the probability of having missing BMI at diagnosis than 
later diagnoses (Before 1995 vs. After 2004 multivariate (mv) odds ratio (OR): 58.74 
[95% CI: 55.20-62.50])  




People who had died prior to the date of data extraction in January 2012 were 
considerably more likely to be missing a BMI at diagnosis than patients who were still 
alive at that time-point (deceased vs. alive: univariate (uni) OR 3.03 [95% CI: 2.62, 
3.80]). This association reduced considerably after adjustment (deceased vs. alive: mv 
OR 2.22 [2.14, 2.30]) suggesting possible confounding by year of diagnosis or age. Men 
were slightly less likely to be missing a BMI at diagnosis than women (males vs. females: 
mv OR 0.93 [0.91, 0.95]).   
 
Figure 5.1: Unadjusted odds ratios (& 95% confidenc e intervals) of having missing 
BMI at diagnosis by HBA.  
 
Missingness in BMI at diagnosis was related to the Health Board Area (HBA) in which 
the patient resided (Table 5.1 & Figure 5.1). With the exception of the Western Isles, 
patients attending healthcare services within the most sparsely populated HBAs were 
more likely to be missing a BMI at date of diagnosis measurement. Patients within the 
Highlands or the Shetland HBA, whose population density were 10 & 15 persons per 
square kilometre respectively, were considerably more likely to have missing data than 
attending patients within the Greater Glasgow HBA (1,052 persons per square 
kilometre) (Highlands vs. Greater Glasgow: mv OR 1.41 [95% CI: 1.32-1.50], Shetland 
vs. Greater Glasgow: mv OR 2.07 [1.73, 2.47]), though this was based on smaller 
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BMI at diagnosis than patients from Greater Glasgow (Tayside vs. Greater Glasgow: mv 
OR 0.59 [0.57, 0.62]).  
Median ever-recorded patient BMIs were lower amongst patients with missing BMI at 
diagnosis than for patients without missing BMI (observed 31.31kg/m2 vs. missing: 
30.27kg/m2). Upon categorisation of ever-recorded median BMI using the World 
Health Organisation’s BMI classification system (BMI below 18.5kg/m2 underweight, 
18.5-24.99kg/m2 normal weight, 25-29.99kg/m2 overweight, 30-34.99kg/m2 moderately 
obese, 35-39.99kg/m2 severely obese, 40kg/m2 or over very severely obese), the highest 
rates of missingness of BMI at diagnosis was observed in the underweight and normal 
weight categories (Figure 5.2). Patients with severe or very severe obesity were more 
likely to have observed recordings of BMI at diagnosis than patients who had a ever-
recorded median BMI in the moderately obese category.   
 
Figure 5.2: Adjusted ORs for having missing BMI val ues at date of diagnosis by 
categories of BMI group (from median ever-recorded BMI). Estimates adjusted for age, 
sex and smoking status 
 
Though the median level of comorbidity was the same for patients with and without 
complete data, a greater proportion of patients with missing data had no other 
comorbid conditions defined in the Charlson Comorbidity Index. The proportion of 




















































of patients with comorbidities. Ever smokers had lower odds of having a missing BMI 
measurement at diagnosis than never smokers (Ever vs. Never mv OR 0.91 [95% CI: 
0.89, 0.93]). Lower glycated haemoglobin, lower total cholesterol and higher HDL-
cholesterol were all associated with increased odds of missing BMI at diagnosis.  
No evidence of multiplicative interactions was observed in the multivariable model.  
 RESULTS II: SURVIVAL AND MISSINGNESS  5.4.4
Patients with missing data had a median follow-up time of 11.00 years compared with 
6.72 years for patients without missing BMI data (Table 5.1). Patients without a date of 
diagnosis were not included as follow-up time could not be calculated (n=2,511). 
A Kaplan-Meier plot showed some further interesting features of patient follow-up and 
survival (Figure 5.3). Firstly, while the maximum follow-up time amongst patients with 
missing data was just below 60 years, maximum follow-up time was less than 37 years 
amongst patients with an observed BMI. Nonetheless, median survival times were 
comparatively similar for patients with and without missing data with 17.72 years and 
16.90 years, respectively.  
During the course of follow-up the survival curves for the missingness groups cross 
over. In the early years of follow-up, patients without missing data have better survival 
than patients with missing BMI data. In the later years of follow-up, survival seems to 
be poorest amongst patients with observed data; however this apparent difference was 
based on small numbers.  
The crossing-over of the curves in the Kaplan-Meier plot indicate a likely violation of 
the proportional hazards assumptions made by the Cox proportional hazards model. 
This notion correlates with the log-log plot, shown in Figure 5.4 whereby the curves do 






Figure 5.3: Kaplan Meier plot of the probability of  survival by groups of missingness 
 
Figure 5.4: Log-log plot for testing the proportion al hazards assumption 
 
Table 5.2 presents the unadjusted and age and sex adjusted HRs for all-cause mortality 
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relative measures for mortality contradict one another; relative measures indicate that 
patients with missing BMI had better survival (missing vs. observed  mvHR: 0.95 [0.93. 
0.97]), whilst absolute measures suggest patients with missing BMIs had worse survival 
compared with patients with observed BMI data (22.5 deaths per 1,000 person-years vs 
33.6 deaths). These contradictory results remained after stratification by sex (See 
Appendix Table A5.1). These findings can be assumed to have arisen through the 
violation of the proportional hazards assumption. Accordingly, relative measures of 
survival calculated using the Cox proportional hazards model did not accurately describe 
the true survival experience of the groups. 
Table 5.2: Relative and absolute measures of surviv al by groups of missingness 
 Complete BMI Missing BMI 
Crude HR (95% CI) 1 0.97 (0.95, 0.98) 
Age and sex adjusted HR (95% 
CI) 
1 0.95 (0.93, 0.97) 
   
Deaths 22,383 62,574 
Person-years 716,608 1,619,412 
Crude mortality, deaths per 1,000 
person-years 
31.2 38.6 
Age-standardised mortality, per 
1,000 person years (95% CI) 
22.5 (22.2, 22.8) 33.7 (33.4, 33.9) 
 
To investigate this problem further, time was divided into discrete time periods. The 
first five years in which the majority of patients were either censored or died were 
divided into yearly intervals whilst the remaining follow-up time was divided into 5-year 
intervals. The proportionality assumption was checked within each discrete time interval 
and deemed reasonable in all intervals.  
Absolute and relative measures of survival for each time interval by missingness are 
presented in Table 5.3. Age-standardised mortality rates could not be calculated in the 
last two categories for patients with an observed BMI due to low numbers. Across each 
time-interval, absolute and relative measures of survival were in agreement. In the first 
year of follow-up, patients with missing data had worse survival than patients without, 
though this pattern was reversed from one year of follow-up onwards. In both groups 




During the exploration of this problem of contradictory findings, an irregularity in the 
dataset was observed that had not before been considered. Upon investigating mortality 
by missingness, it was observed that in the early years of the dataset there is artificially 
low mortality. Figure 5.5 presents this problem. Numbers of deaths gradually increased 
as calendar year increased; a pattern indicative of uneven retrospective look back. The 
majority of patients diagnosed with DM prior to the formation of SCI-DC only 
appeared on the register if they were still alive at the time of its formation. This feature 
was likely to introduce considerable survival bias to the study and therefore needed to 





Table 5.3: Absolute and relative measures of surviv al within defined time-intervals by missingness in BMI at diagnosis 
 Intervals for follow-up time, years 
0 to < 1 1 to < 2 2 to <3 3 to < 4 4 to <5 5 to< 10 10 to <15 15 to <20 20 to < 25 25 to <30 
Observed Deaths 2,086 2,441 2,503 2,520 2,566 7,756 2,054 426 30 1 
Person-years 98,729 96,381 93,915 90,883 80,177 208,672 40,849 6,587 382 30 
Crude 
mortality 




 13.7  (13.0, 
14.4) 
16.7  (16.0, 
17.5) 
18.1  (17.3, 
18.9) 
19.0  (18.2, 
19.9) 
22.5  (21.5, 
23.4) 
29.1  (28.3, 
29.8) 
49.1  (46.0, 
52.1) 
74.4  (71.6, 
77.2) 
- - 
Missing Deaths 3,588 3,254 3,350 3,401 3,550 17,021 12,983 8,118  4,163 1,866 
Person-years 133,491 130,173 126,884 123,351 117,384 483,513 278,840 134,724 57,022 21,857 
Crude 
mortality 




16.5   (16.0, 
17.1) 
16.2  (15.6, 
16.8) 
17.7  (17.1, 
18.4) 
18.2  (18.0, 
19.4) 
21.4  (20.8, 
22.1) 
29.5  (29.1, 
30.0) 
48.4  (47.1, 
49.6) 
76.3  (60.0, 
92.5) 






Crude HR, missing vs. 
observed (95% CI) 
1.27   (1.20, 
1.34) 
0.99  (0.94, 
1.04) 
0.99  (0.94, 
1.04) 
0.99  (0.94, 
1.07) 
0.94  (0.90, 
0.99) 
0.92  (0.90, 
0.95) 
0.91  (0.86, 
0.95) 
0.90  (0.82, 
1.00) 
0.90  (0.63, 
1.30) 
1.61  (0.09, 
4.34) 
Age and sex adjusted HR, 
missing vs. observed (95% 
CI) 
1.26    
(1.20, 1.33) 
 0.97 (0.92, 
1.02) 
1.01  (0.96, 
1.07) 
1.01  (0.93, 
1.09) 
1.00  (0.95, 
1.05) 
0.99  (0.96, 
1.01) 
0.95  (0.91, 
0.99) 
 0.96 (0.87, 
1.06) 
0.96          
(0.67, 1.38) 
1.77  (0.12, 
5.46) 





Figure 5.5: Frequency of deaths amongst patients wi th DM by calendar year 
 DISCUSSION OF RESULTS FROM FULL DATASET 5.4.5
This section was able to discern some interesting features of the completeness of the 
SCI-DC register. Generally it was clear that the dataset’s completeness improved 
through time. The largest improvements occurred in BMI completeness after 2004 
following the introduction of the QOF. Improvements such as these have been 
reported in a number of routine healthcare databases in the UK (Bhaskaran et al., 2013; 
Marston et al., 2014). For example, Bhaskaran et al., (2013) reported that between 2000 
and 2004, 34% of patients on the Clinical Practice Research Datalink (CPRD) had a 
BMI measurement recorded in the previous three years and this increased to 51% 
between 2005 and 2011. 
The purpose of this thesis was to investigate methods for dealing with missing data. 
Early years of the dataset were missing deceased patients and therefore it made sense to 
restrict our efforts to incident cases between 2004 and 2008, when death data was more 
complete. Though this process acted to reduce the sample size considerably, unbiased, 
but less precise results are of more value than more precise but biased estimates. 
Methods could be repeated on earlier data, but there was not sufficient time to do this 




















Aside from the elucidated problems in the dataset, interesting findings were observed in 
relation to the missingness mechanism that may be a useful guide in later analyses of 
missing data mechanisms. In the full cohort and indeed in the reduced sample, it is likely 
that the three missing data mechanisms coexist. That is, some of the missing data were 
MCAR, some were MAR and others were MNAR. Nonetheless, systematic differences 
between patients with and without a BMI at diagnosis were suggestive of a possible 
violation of the MCAR assumption. 
The finding that missingness was highest amongst patients diagnosed before 1995 is 
unsurprising and probably reflects widespread improvements in risk factor recording 
through initiatives such as the QOF. Through the introduction of financial incentives, 
type 2 DM care and risk factor recording has become more standardised. As a result, 
BMI should now be recorded at least annually in patients with type 2 DM, regardless of 
its clinical relevance.  
Patients residing in sparsely populated areas were also more likely to have missing data. 
This finding could be a reflection of the increased rurality of these areas and the 
subsequent issues surrounding patient access to and the availability of healthcare 
services. Meanwhile, completeness in the Tayside register was considerably better than 
elsewhere, possibly because SCI-DC was initially developed and implemented in this 
health board area. 
A number of crude indicators of relative healthiness, such as total cholesterol, HDL-
cholesterol and glycated haemoglobin suggested that healthier patients were more likely 
to have missing BMI at diagnosis measurements than unhealthy patients. Lower total 
cholesterol values and higher HDL-cholesterol values typically reflect lower 
cardiovascular disease risk and these were found to be associated with an increased risk 
of missingness of BMI. Similarly, lower glycated haemoglobin levels, which are 
indicative of better DM control, were associated with lower completeness of BMI 
recording around date of diagnosis of DM. This finding coincides with what was 
discovered in discussions with clinicians. Patients with poorly controlled glycated 
haemoglobin are prioritised and recalled regularly, thus providing more opportunities to 




were also more likely to have no comorbidities and be never smokers. This finding 
could be due to lower attendance rates of comparatively healthier patients.  
Nonetheless, analyses investigating the survival experience of the groups indicated that 
patients with observed data had better short-term (≤1 year) survival than patients with 
missing data. The recording of patient BMI upon the diagnosis of DM may not be 
relevant or indeed possible in dying patients. Long-term survival was better amongst 
patients with missing data compared with patients with observed data, reflecting a 
change in the factor driving missingness in BMI.  
Median ever-recorded BMI appeared to be a strong predictor of missingness. Patients 
whose median-ever recorded BMI fell within the underweight or normal categories were 
found to be more likely to be without a BMI at diagnosis measurement. This may relate 
to a lower inclination of clinicians to measure patients whose weight was deemed to be 
‘healthy’. Meanwhile obese and severely obese patients whose weight was of clinical 
concern may have been monitored closely. Failure to include further BMI recordings in 
imputation models could therefore lead to data being MNAR. 
Some clinicians indicated that missing BMI data around diagnosis date could reflect 
incorrect recording of diagnosis date. This is an interesting notion but is difficult to 
validate. In order to ascertain DM type an algorithm is used which involves validating 
the date of diagnosis. This process uses timing of first DM mention, timing of treatment 
and age at diagnosis. Using these different sources of information should ensure a 
reliable “best-guess” of DM diagnosis date. Although this algorithm has not been 
validated, it is likely that the performance of it has improved with the introduction of 
QOF and the subsequent increased recording of DM-related indicators. Where there are 
errors in the diagnosis date, there is no reason to believe these are differential and biased 
in a particular direction. The use of a BMI value recorded within a one-year time interval 
(10 months before and 2 months after) to reflect BMI at diagnosis should provide some 
protection should diagnosis date be incorrect and the true diagnosis date lies within this 
one-year time-interval.  
The mechanisms by which missing BMI data came about in this large cohort are 




reasons by which missing data came about, though many more possibly exist. These 
possibilities will need to be considered when applying missing data methods.   
 2004 - 2008 COHORT 5.5
 INTRODUCTION 5.5.1
As discussed in the previous section, despite the register’s introduction in 2001, 
universal coverage of the SCI-DC register was not achieved until 2004.  Consequently, 
completeness of the register before this time was poor. Whilst patients who were alive at 
the time of the formation of SCI-DC would be included in the register, patients who 
died before this time may or may not have been included in the register, depending on 
the availability of retrospective data. Accordingly, this produces artificially low mortality 
in the early years of the register. It was therefore necessary to divide the cohort into 
sections to deal with differential survivor bias. This section reports on the group 
diagnosed between 2004 and 2008. 
Limiting the cohort to incident cases within this time period was likely to have a 
profound impact on both the amount of missing data and the likely mechanisms by 
which missing data came about. For example, 2004 was when the QOF was introduced 
and therefore risk factor recording was intensified and became more universal. Failure 
to record BMI should therefore have been primarily due to chance alone after 2004, 
meaning that data are MCAR. Prior to QOF, risk factor recording was at least partly 
clinically driven.  
 METHODS  5.5.2
The methods used to identify potential reasons for missingness were the same as those 
applied in section 5.4.2, but applied to the smaller sample of people who were diagnosed 





Of the 241,041 patients in the cohort, 77,948 patients were diagnosed with type 2 DM 
between 2004 and 2008. The proportion of missingness in the BMI at diagnosis variable 
was considerably lower (26.9%) in this subsample than was observed for the whole 
sample (58.1%).  
Table 5.4 presents the characteristics of patients with and without missing data for this 
subsample. Odds ratios from univariate and multivariate models for the risk of 
missingness in BMI are presented. Trends in missingness were similar to those observed 
in Section 5.4.3.  
People with type 2 DM who were deceased at the end of follow-up were considerably 
more likely to be missing BMI at diagnosis than patients who were still alive in 2008 
(deceased vs. alive: mv OR 1.65 [1.52, 1.78]). Older age at diagnosis was protective 
against missingness until the over 80 years of age group. In this age-group, the odds of 
missingness were 9% higher than that observed in the under 50 year old age group 
(Over 80s vs under 50s: mv OR 1.09 [1.01, 1.19]). Male sex and ever-smoking were 
protective against missingness. The presence of comorbid conditions also conferred an 
increased risk of missingness in BMI. Of the clinical characteristics, only elevated 
glycated haemoglobin levels were moderately associated with a lowered risk of 











Table 5.4: Factors influencing missingness in BMI a t diagnosis with type 2 DM 












OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years (%) 
< 50  9,807 (75.50) 3,182 (24.50) 1                    
(Ref) 
1                          
(Ref) 
50 – 59  13,859 
(76.48) 
4,263 (23.52) 0.95                    
(0.90, 1.00) 
0.90                     
(0.85, 0.96) 
60 – 69  16,566 
(77.59) 
4,785 (22.41) 0.89                    
(0.85, 0.94) 
0.79                     
(0.74, 0.84) 
70 – 79  12,701 
(76.34) 
3,937 (23.66) 0.96                   
(0.91, 0.73) 
0.77                  
(0.72, 0.82) 
≥80 4,027 (63.63) 2,302 (36.37) 1.76                 
(1.62, 1.88) 
1.09                     
(1.01, 1.19) 




1                 
(Ref) 




9,890 (27.87) 0.91                     
(0.88, 0.94) 
0.93                    
(0.91, 0.95) 




1                 
(Ref) 
1                           
(Ref) 
Deceased 8,121 (56.72) 6,196 (43.28) 2.53                     
(2.43, 2.62) 
1.65                       
(1.52, 1.78) 




4,763 (25.84) 1.02                       
(0.96, 1.07) 




4,911 (26.74) 1.06                   
(1.01, 1.12) 




4,354 (27.23) 1.09                     
(1.03, 1.15) 




4,042 (28.76) 1.18              
(1.11, 1.25) 




8,421 (74.47) 2,887 (25.53) 1                 
(Ref) 






5,346 (28.15) 1                       
(Ref) 




4,137 (23.64) 0.79                    
(0.75, 0.83) 




3,828 (22.16) 0.73                    
(0.69, 0.76) 




3,917 (23.23) 0.77                   
(0.74, 0.81) 
0.83                
(0.79, 0.87) 
2008 3,569 (74.15) 1,244 (25.85) 0.89                     
(0.83, 0.96) 
0.97                 
(0.90, 1.04) 
Mean ever-recorded BMI, kg/m2 
(SD) † 
31.61              
(6.21) 
30.99         
(6.48) 
0.984                 
(0.981, 0.987) 
















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Mean predicted BMI at diagnosis, 
kg/m2 (SD) 




0.991                
(0.988, 0.994) 
- 
Median Follow-up time, years 
(IQR) 
5.58       
(4.49, 6.74) 
5.45     (4.17, 
6.86) 
0.94             
(0.93, 0.95) 
1.02                
(0.96,1.08) 










1                 
(Ref) 
1                  
(Ref) 
One or more 18,717 
(66.95) 
9,241 (33.05) 1.38            
(1.36, 1.40) 








7,200 (23.60) 1                 
(Ref) 
1                            
(Ref) 
Ever smoker  33,418 
(78.76) 
9,012 (21.24) 0.85                
(0.81, 0.89) 
0.91                           
(0.89, 0.93) 




1.000        
(0.999, 1.001) 
- 
Mean Diastolic BP, mmHg (SD)  80.59 (10.94) 80.13  
(11.14) 
0.996               
(0.995, 0.998) 
- 
Mean Glycated haemoglobin, % 
(SD)  
8.04       
(2.13) 
7.89       
(2.03) 
0.96               
(0.95, 0.97) 
0.965   
(0.956,0.975) 






1.001         
(1.000, 1.002) 
- 
Mean total cholesterol, mmol/L 
(SD)  
5.16      
(1.30) 
5.12      
(1.31) 
0.98           (0.96, 
0.99) 
0.98              
(0.97, 1.00) 
Mean triglycerides, mmol/L (SD)  2.53        
(2.61) 
2.54       
(2.54) 
0.99           (0.98, 
1.00) 
- 
Mean HDL cholesterol, mmol/L 
(SD)  
1.24        
(0.40) 
1.26      
(0.42) 
1.12                  
(1.07, 1.18) 
- 
Health Board Area 
Ayrshire & Arran 4,950 (70.40) 2,081 (29.60) 1.33           (1.24, 
1.42) 
1.07           (0.99, 
1.16) 
Borders 1,212 (75.14) 401    (24.86) 1.03                      
(0.91, 1.16) 
1.00           (0.86, 
1.56) 
Dumfries & Galloway 1,709 (74.40) 588      
(25.60) 
1.08           (0.98, 
1.20) 
1.21                 
(1.08, 1.36) 
Fife 3,949 (72.82) 1,474 (27.18) 1.17                 
(1.09, 1.25) 
1.18                
(1.08, 1.36)  
Forth Valley 3,196 (74.48) 1,095 (25.52) 1.07           (0.99, 
1.17) 
1.02           (0.93, 
1.12) 
Grampian 5,902 (73.60) 2,127 (26.40) 1.13           (1.06, 
1.20) 
0.94              
(0.86, 1.02) 















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Greater Glasgow 13,755 
(75.15) 
4,548 (24.85) 1                 
(Ref) 
1                 
(Ref) 
Highlands 2,747 (65.03) 1,477 (34.97) 1.72               
(1.57, 1.87) 
1.44                
(1.29, 1.60) 
Lanarkshire 6,998 (73.05) 2,582 (26.95) 1.16                    
(1.09, 1.23) 
0.97           (0.90, 
1.04) 
Lothian 7,409 (72.76) 2,774 (27.24) 1.18                   
(1.11, 1.25) 
1.21              
(1.13, 1.30) 
Orkney 205    (61.38) 129    (38.62) 2.04                     
(1.63, 2.56) 
1.69                  
(1.26, 2.25) 
Shetland 212    (71.14) 86       
(28.86) 
1.26                   
(0.98, 1.63) 
1.30             
(0.97, 1.75) 
Tayside 4,491 (75.14) 1,486 (24.86) 1.04                  
(0.97, 1.12) 
1.06              
(0.97, 1.75) 
Western Isles 255    (72.03) 99      (27.97) 1.24                  
(0.98, 1.56) 
1.12                
(0.84, 1.49) 
† Calculated by averaging median patient BMI. SD: Standard Deviation, IQR: Interquartile Range 
 
According to both absolute and relative measures, all-cause mortality risk was 
significantly greater amongst patients with missing data than amongst patients without 
missing data (Complete vs. Missing age and sex adjusted HR: 1.47 [1.42, 1.53]) (Table 
5.5). The proportional hazards assumption was checked using log-log plots and deemed 
reasonable.  
Table 5.5: Relative and absolute measures of surviv al by groups of missingness in 
cohort of patients diagnosed with DM between 2004 a nd 2008. 
 Complete BMI Missing BMI 
Crude HR (95% CI) 1 1.61 (1.55, 1.67) 
Age and sex adjusted HR (95% CI)  1 1.47 (1.42, 1.53) 
   
Deaths 8,068 4,072 
Person-years 307,816 95,739 
Crude mortality, deaths per 1,000 
person-years 
26.2 42.5 
Age-standardised mortality, per 
1,000 person years (95% CI)  
17.8 (17.3, 18.2) 26.3 (25.3, 27.1) 
 




 DISCUSSION OF RESULTS FROM 2004-2008 SUBSAMPLE  5.5.4
In this subsample of patients diagnosed between 2004 and 2008, there were still 
important differences between patients with and without missing data, despite the 
introduction of the QOF. Patient survival was perhaps the biggest predictor of 
missingness, though the presence of comorbid conditions and being an ever-smoker 
were protective against missingness. 
Patients with missing BMI data had considerably worse survival than patients without 
missing BMI at diagnosis. This finding has large implications for missing data analyses 
since failure to include patients with missing data would markedly over estimate overall 
survival in the population.  
The reason behind poorer survival in patients with missing data is unknown; it may be 
that it is not a priority to record BMI in individuals who are approaching end of life. 
Alternatively, there may be fewer opportunities in which to record this measurement 
before death.  
The observation that raised glycated haemoglobin levels conferred a reduced risk of 
having missing BMI data probably reflected the need for patients with poorly controlled 
DM to attend their healthcare provider on a regular basis. Nonetheless, the observed 
effect was quite small in this sample.   
HBA also remained a considerable predictor of missingness in BMI at diagnosis 
suggesting that improvements in recording practices were not universal.  
To summarise, within this subsample the MAR assumption seems relatively plausible 
for at least some of the data. The use of missing data methods which make the MAR 
assumption should therefore yield valid results. However, it would be beneficial to 




 PREDICTORS OF BMI AT DATE OF DIAGNOSIS 5.6
 INTRODUCTION 5.6.1
Many missing data approaches require robust predictive models to identify ‘best-
guesses’ of the missing values. For example, to produce unbiased estimates using 
multiple imputaiton, it is necessary to include variables which reliably predict the 
missing values in the imputation model. This section outlines the process of identifying 
variables that are predictive of BMI at diagnosis. These predictors were later included in 
models for handling partially observed data. 
 METHODS 5.6.2
For continuous variables, patterns of BMI at diagnosis were examined visually using 
scatterplots with added regression lines. BMI at diagnosis was grouped into 5kg/m2 
categories to enable the observation of non-linear trends. Patients with a BMI between 
15kg/m2 (the lower plausibility bound) and 25kg/m2 were grouped together as were 
those with a BMI above 45kg/m² to 75kg/m² (upper plausibility bound).  Means and 
standard deviations by BMI categories were calculated. Significance tests for mean 
differences were not carried out due to large numbers. 
Linear regression was used to assess the association between BMI at diagnosis 
(continuous variable) and available demographic and clinical characteristics. Crude and 
adjusted regression coefficients are presented. Diastolic BP and serum creatinine were 
log-transformed due to evidence of non-linear relationships with BMI around diagnosis 
of DM. Triglycerides and HDL-cholesterol were not included in multivariate models 
due to high proportions of incompleteness. Since initial analyses were attempting to 
assess the performance of missing data methods in the absence of repeat recordings of 
BMI, neither within-patient median nor regressed BMI were included in the final model. 
 RESULTS  5.6.3
In the study population of patients diagnosed with DM between 2004 and 2008, there 
were 56,990 patients who had an available BMI at diagnosis. Figures 5.6, 5.7 and 5.8 




presents binary and categorical characteristics by categories of BMI at diagnosis. 
Univariate and multivariate regression coefficients for the association between BMI at 
diagnosis and available variables are also presented in Table 5.6.     
According to the scatterplots and summary statistics, few variables were strongly 
associated with BMI at diagnosis. Nonetheless, patient BMI appeared to decrease with 
increasing age at diagnosis and there were a lower proportion of deceased patients in the 
highest BMI categories. Men tended to have a lower BMI at diagnosis than women 
(men vs.women: mv. regression coefficient -2.01 [95% CI: -2.11, -1.91]) and patients in 
the most deprived quintile were more likely to have higher BMIs at diagnosis than 
patients in the least deprived quintile (Q1 vs. Q5: mv. Regression coefficient 1.62 [95% 
CI: 1.44, 1.79]) (Table 5.7).   
The number of patients with comorbid conditions decreased with increasing  BMI and 
there were a smaller proportion of ever smokers in the higher BMI categories. Patients 
residing in certain HBAs were also more likely to fall into the highest BMI categories 
(Table 5.8). For example, patients in Shetland (33.0 kg/m²) and Orkney (32.11kg/m²) 









Figure 5.6. Scatterplots of BMI at diagnosis with D M against (a) Age at diagnosis, (b) Follow-up time,  (c) Charlson Comorbidity Index, (d) 


























Table 5.6: Clinical and demographic characteristics  of study population by categories of BMI at diagno sis with DM 
 BMI category, kg/m²  Crude Linear 
regression 
coefficients        
(95% CI) 
Multivariate  linear 
regression coefficients 
(95% CI) 
<25 25 to < 
30 
30 to < 
35 
35 to < 
40 
40 to < 
45 
≥ 45 ALL 





























-0.16 (-0.17, -0.15) -0.163 (-0.167, -0.158) 














-1.49 (-1.60, -1.38) 
vs. female 
- 2.01 (- 2.11, - 1.91) vs. 
female 






864 (9.54) 325 (8.46) 211 (9.11) 8,121 
(14.25) 
-2.51 (-2.66, -2.36) 
vs. alive 
-0.89 (-1.12, -0.66) vs. 
alive 
Median year of diagnosis 
(IQR) 
2005 2006 2006 2006 2006 2006 2006 - - 
















-0.54 (-0.66, - 0.43) 
vs. no additional 
-0.37 (-0.48, -0.26) vs. 
no additional 














-0.65 (-0.76, -0.55) 
vs. Never smoker 






















5.55      
(4.41, 6.77) 
-0.05                     
(-0.07, -0.04) 
- 














139   
(18.65) 
0.02                  
(0.01, 0.03) 
- 




79 (10.54) 81 (10.67) 83 (10.93) 84 (10.82) 85 (11.51) 81     
(10.94) 
0.12                           
(0.11, 0.12) 
0.085 (0.080, 0.089) 
Mean Glycated haemoglobin, 













8.04          
(2.13) 
-0.05                       
(-0.08, -0.03) 





 BMI category, kg/m²  Crude Linear 
regression 
Multivariate  linear 
regression coefficients 
Mean serum creatinine, 















-0.023                 
(-0.025, -0.209) 
- 
Mean Total cholesterol, 













5.16   (1.30) 0.08                             
(0.04, 0.12) 
- 0.30 (-0.33, -0.27) 














2.53     
(2.61) 

















1.19      
(0.38) 
-2.39                       
(-2.53, -2.24) 
- 




Table 5.7: Mean BMI at diagnosis with DM by depriva tion status (from SIMD) 




coefficients        
(95% CI) 




1 (most deprived) 32.56 (6.98) 1.70 (1.52, 1.87) 1.62  (1.44, 1.79) 
2 32.15 (6.62) 1.28 (1.11, 1.46) 1.22 (1.05, 1.39) 
3 32.03 (6.44) 1.16 (0.98, 1.34) 1.11  (0.94, 1.29) 
4 31.51 (6.21) 0.65 (0.46, 0.84) 0.65 (0.47, 0.83) 
5 (least deprived) 30.86 (5.89) Ref Ref 
a Adjusted for age, sex, vital status, comorbidity status, smoking status, diastolic BP, glycated haemoglobin 
and total cholesterol and HBA 
 
Table 5.8: Mean BMI at diagnosis with DM by HBA 





coefficients        
(95% CI) 
Multivariate  linear 
regression coefficients 
(95% CI) a 
Ayrshire & Arran 31.73 (6.55) 0.05 (-0.17, 0.27) 0.32 (0.11, 0.53) 
Borders 31.62 (6.33) -0.09  (-0.48, 0.30) 0.90 (0.52, 1.29) 
Dumfries & Galloway 32.35 (6.56) 0.65 (0.31, 0.98) 0.83 (0.61, 1.25) 
Fife 32.31 (6.55) 0.59 (0.35, 0.83) 0.72 (0.48, 0.94) 
Forth Valley 32.21 (6.64) 0.52 (0.26, 0.78) 0.81 (0.57, 1.06) 
Grampian 31.95 (6.53) 0.25  (0.04, 0.46) 0.84 (0.63, 1.04) 
Greater Glasgow 31.69 (6.49) Ref Ref 
Highlands 31.55 (6.34) 0.00 (-0.32, 0.32) 0.48 (0.17, 0.79) 
Lanarkshire 32.00 (6.55) 0.30  (0.10, 0.50) 0.31 (0.12, 0.50) 
Lothian 32.04 (6.67) 0.33 (0.14, 0.53) 0.63 (0.45, 0.82) 
Orkney 32.11 (6.34) 0.29 (-0.63, 1.21) 0.91 (0.00, 1.82) 
Shetland 33.00 (6.17) 1.20 (0.31, 2.09) 1.47 (0.63, 2.32) 
Tayside 31.95 (6.38) 0.25 (0.02, 0.48) 0.74 (0.52, 0.96) 
Western Isles 32.16 (5.60) 0.50 (-0.31, 1.31) 1.06 (0.29, 1.83) 
a Adjusted for age, sex, vital status, deprivation status, comorbidity status, smoking status, diastolic BP, 
glycated haemoglobin and total cholesterol 
 
 
Both systolic and diastolic BP increased with increasing BMI group, though at the 
highest DBP values, this association disappears (Figure 5.6b). Similarly Figure 5.6d 
indicates that BMI tends to decrease with increasing blood creatinine level up until a 
creatinine level of 350umol/L. After this level there does not appear to be a relationship 




A U-shaped relationship was observed between glycated haemoglobin (Table 5.6) and 
BMI. HDL-cholesterol increased with increasing BMI, though this association was not 
apparent in patients with a HDL-cholesterol above 4mmol/L. This relationship was 
possibly confounded by sex. Women have on average, higher HDL-cholesterol values 
than men (1.33mmol/L vs. 1.17mmol/L) and are over-represented in the very high BMI 
groups. A similar pattern was observed for total cholesterol. No relationship was 
observed between BMI and follow-up time nor year of diagnosis. Mean BMIs increased 
slightly by year of diagnosis (Figure 5.9) 
 
Figure 5.9: Box and whiskers plot of BMI at diagnos is by year of diagnosis 
 
The R-squared statistic from the multivariate model was 0.1578, thus indicating that less 
than 16% of the variance in BMI at date of diagnosis was explained by available 
characteristics. 
 SUMMARY  5.6.4
This section identified several important predictors of BMI at diagnosis, including age at 
diagnosis, sex, health board area, year of diagnosis and deprivation status. These 

































The tendency for people to lose weight when they become elderly is well-documented 
and reflects, amongst other things, losses in muscle mass and changes in metabolic rates. 
The finding that older patients had lower BMIs may have been slightly overstated 
through a cohort effect. Younger people tend to be more overweight than currently 
older people were at the same age (Roubenoff, 1999). Since these data are not 
describing weight changes amongst individuals caution needs to be used when 
interpreting these findings. Nonetheless, this relationship may also go some way in 
explaining the finding that deceased patients tended to have lower BMIs than still-alive 
patients. Patients approaching the end of their life are more likely to be older, thus 
explaining their lower BMIs at diagnosis. However, this relationship remained after 
adjustment for age at diagnosis and other variables indicating that vital status may be 
independently associated with BMI. Indeed, this finding signals the potential for reverse 
causality in which the disease process that increases the risk of death also causes weight 
loss. The finding of a higher prevalence of comorbid conditions in the lowest BMI 
categories may also reflect this process.  
Patients in the most deprived category were more likely to be heavier than patients in 
the least deprived category. This finding corresponds well with previously conducted 
studies on both general and DM populations in developed countries (McLaren, 2007; 
Wild et al., 2008). Indeed, this association is considered to be an important factor in 
determining the known association between deprivation and type 2 DM prevalence. It 
might be expected that this relationship may also account for the finding that patients 
residing in certain HBAs were more likely to be heavier than patients residing elsewhere. 
However, places such as Shetland and the Orkney have some of the lowest levels of 
deprivation yet had the highest mean BMIs at diagnosis. Indeed, no patients residing in 
Shetland or Orkney lived in an area found to be in the most deprived category so 
factors other than deprivation are clearly important.    
There were a lower proportion of ever smokers in the highest BMI category, thus 
reflecting the fact that smokers tend to weigh less than non-smokers. This association 
may have been diluted due to our classification system which does not take into account 
that amongst ever-smokers some patients are former smokers. Many previous studies 




therefore the classification system used here may have diluted the effect of smoking on 
BMI at diagnosis (Cao et al., 2012).  
There was a slight indication that newly-diagnosed patients were heavier, or perhaps 
shorter in later years than they were in previous years. This, in part, may reflect secular 
trends in BMI distribution. In samples of the general population in Scotland 
participating in Health Surveys, mean BMI has increased from 26.8kg/m² in 1998 to 
27.9kg/m² in 2008 (Lean et al., 2012). In addition, there is now a growing trend for 
much younger patients to be diagnosed with type 2 DM and these patients tend to have 
much higher BMIs than people whose DM is diagnosed at a later age (Logue et al., 
2011).  
Many of the observed trends in biochemical characteristics must be interpreted 
carefully. The measurements used were those recorded closest to diagnosis with DM 
and therefore may have been recorded a considerable time after or before diagnosis. 
These measurements may not accurately reflect the true reading at diagnosis. It is 
difficult to interpret what impact this may have on observed associations. However, the 
association between increasing BMI and increasing BP is well known (Kannel et al., 
1967).  
Unfortunately, common to most epidemiological studies, the prediction of BMI was 
poor when cross-sectional data was used (van Buuren et al., 1999; Hardt et al., 2012). 
This feature of the dataset may be detrimental to later imputation models which will 
attempt to use these variables to provide a best-guess of the missing values. Where 
fewer predictors of BMI are available, the fraction of missing information increases. 
This describes the proportion of missing data values and the correlation between the 
missing data and the observed data. As the fraction of missing information increases, 
the uncertainty in the imputed values increases, thus resulting in longer imputation 
model convergence times and wider confidence intervals.  Furthermore, when the 
fraction of missing information is large, problems associated with misspecified 
imputation models are amplified (White et al., 2011). To overcome this problem and 
generate robust parameter estimates, Graham et al. (2007) recommend increasing the 




  CONCLUSIONS 5.7
The aim of this section was firstly to assess the plausibility of the separate missing data 
mechanisms and secondly to identify variables that were predictive of the BMI variable. 
This process was complicated by the finding that mortality was erroneously low in the 
full cohort and therefore the cohort was reduced to incident DM cases between 2004 
and 2008.  
In this newly formed cohort, systematic differences between persons with and without 
missing BMI data were observed. In consequence, the MCAR assumption made by 
numerous approaches for handling missing data is unrealistic and any resulting estimates 
from these approaches are likely to be biased.  More specifically, this section has 
indicated that the probability of BMI at diagnosis measurements being observed is 
dependent on survival suggesting data are MAR. Persons with shorter-survival times 
were more likely to have missing data than those with longer survival times. This factor 
must therefore be included in imputation models when correcting for missingness. The 
probability of missingness in BMI was also found to be conditional on year of diagnosis 
and health board area. These variables are unlikely to be important in the model of 
substantive interest but will need to be included in the missing data model to improve 
imputations.  
Despite these findings, it remains possible that a considerable amount of data were 
MNAR. Alternative methods will therefore need to account for the possibility that data 
are MNAR. To achieve this, ad-hoc sensitivity analyses will be displayed to investigate 
the robustness of estimates to departures from the MAR assumptions.  
Table 5.9 summarises the observed relationships between available variables and BMI at 
diagnosis and also missingness in BMI. It also presents the variables that will be used in 
the missing data model. Selection of these variables was based on their ability to predict 
BMI and/or missingness in BMI. Despite its identification as a variable capable of 
potentially describing the variance in BMI at diagnosis, HDL-cholesterol was not 




Table 5.9: Summary of relationship of baseline char acteristics with BMI at diagnosis 
and missingness in BMI at date of diagnosis 














↓ with ↑age Quite strong ↓ with ↑age Quite strong  
Sex ↑ for women Quite strong ↑ for women Quite strong  









↓ with later year of 
diagnosis 
Strong 
↑with later year 
of diagnosis 
Weak  














Quite strong  
Systolic BP None - ↑ with ↑SBP Quite strong  
Diastolic BP None - ↑ with ↑DBP Weak  
Glycated 
haemoglobin 
↓ with ↑HbA1c Quite strong None   






↓ with ↑total 
cholesterol 
Quite strong 





































This chapter describes the association between BMI at diagnosis and all-cause mortality 
in patients diagnosed with type 2 DM between 2004 and 2008. Several approaches for 
handling unobserved BMI data were applied. Analyses were restricted to patients with 
missing data in a single variable (BMI) to illustrate available methodology when there is 
a univariate pattern of missingness. At this stage, repeated BMI variables are not used to 
estimate plausible values of BMI at diagnosis. More complicated missing data scenarios 
are explored in later chapters.  
Information regarding the likely missing data mechanism is used to explain observed 
estimates and to inform a discussion of the problems associated with selecting an 
inappropriate method for handling missing data.   
For each missing data mechanism, at least one approach for handling missing data is 
presented. The chosen methods were selected on the basis of their availability in 
popular statistical packages and their accessibility to non-statisticians. The following 
methods were chosen:  
1. For MCAR data - CCA and population mean imputation;  
2. For MAR data - the single imputation approach, stochastic imputation and 
two varieties of multiple imputation, namely multiple imputation using chained 
equations (MICE) and predictive mean matching (PMM).  
3. For MNAR data – a pattern mixture sensitivity analysis were applied to 
investigate the robustness of estimates to departures from the MAR assumption.  
 METHODS  6.2
This methods section is divided into three subsections; the first describes the initial 
exclusion criteria, the second outlines the methods used for handling missing data and 




 EXCLUSION CRITERIA 6.2.1
Initial analyses were performed upon a sub-sample of patients with a univariate pattern 
of missingness. It was therefore necessary to restrict the sample to patients with 
complete data for all variables (other than BMI) to be included in both the missing data 
model and the final model of interest. Variables to be included in the final model were 
chosen on the basis of being known to influence and confound the relationship between 
BMI and all-cause mortality. These variables were age, sex, Charlson comorbidity index, 
smoking status and deprivation status. The variables to be included in the missing data 
model were selected from the exploratory analyses detailed in Chapter 5. These variables 
were included in the missing data models for two reasons. First, the inclusion of 
variables which are associated with the probability that BMI data are missing will reduce 
bias and will make the MAR assumption more plausible. Second, the inclusion of 
variables which are at least moderately correlated with BMI at date of diagnosis will help 
to reduce the uncertainty of the imputations. The selected variables to be included in the 
missing data model were age at diagnosis, sex, vital status, year of diagnosis, follow-up 
time, Charlson comorbidity index, HBA, systolic BP, glycated haemoglobin and total 
cholesterol. Patients with missing data in any of the above variables were therefore 
removed.  
Patients who had died within two years of follow-up were also excluded from analyses 
to limit the risk of biases through reverse causation. Inclusion of these individuals could 
bias associations in the lowest BMI categories as their low BMIs may be in response to 
chronic disease. Risk of mortality in these categories would therefore be exaggerated.  
The final, full case-flow is presented in section 6.3.1.    
 METHODS FOR HANDLING MISSING DATA 6.2.2
Six methods for handling missing BMI data were applied.  This section describes the 
application of each approach.  
6.2.2.1 MCAR: CCA 




6.2.2.2 MCAR: POPULATION MEAN ANALYSIS 
Missing values were replaced with the calculated mean BMI of the non-missing 
observations at diagnosis (32kg/m²).  
6.2.2.3 MAR: STOCHASTIC IMPUTATION 
Stochastic imputation is a single imputation approach which involves the replacement of 
missing values with a predicted value from a regression model with an added error term. 
The addition of this random error term gives this single imputation approach its name.   
The uvis command in the ICE suite (imputation by chained equations) for STATA was 
used to predict missing values for BMI at date of diagnosis (Royston, 2004). This user-
written program is typically used for multiple imputation models but in its application 
here was used to create a single complete dataset only. Briefly, ICE is an iterative 
procedure which uses a series of conditional distributions to impute missing data. For 
each variable with missing data, a regression model is formulated conditional upon other 
selected variables. Therefore binary variables with missing data are modelled using 
logistic regression, continuous variables are modelled using linear regression and so on. 
Random draws are then taken from the resulting posterior distribution of the missing 
data to form the final imputations. Where multiple variables have missing data, this 
procedure is iterated a number of times (the default is 10 in ICE) to obtain final 
estimates of the missing values. In this analysis only the BMI at diagnosis variable 
required imputing and therefore only one regression model was used and no iterations 
were required. Only one complete dataset was produced using this approach.  
The imputation model comprised of the following variables: age at diagnosis, sex, year 
of diagnosis, deprivation status, smoking status, Charlson comorbidity index, diastolic 
BP, total cholesterol and HBA. To avoid biasing relationships towards the null, it is 
crucial to include all variables whose associations will be assessed in the later analysis 
model. It was therefore necessary to include the outcome variables, survival time and 
vital status in the imputation model to help predict the missing covariate.  
Previous studies have indicated a non-linear relationship between BMI and survival in 
both the general population and populations of DM patients. The presence of a non-
linear relationship between the covariate to be imputed (BMI) and other variables could 




are resolved using polynomials, splines or the categorisation of the continuous variable. 
In accordance with previous studies which categorised BMI to overcome non-linearity 
issues, our final model did the same. To ensure the imputation model and the final 
model were compatible, BMI was also categorised in the imputation model. Though the 
categorisation of this quantitative exposure is inefficient, there remains no general 
consensus on which approach is best for handling non-linearity problems in imputation 
models (See section 2.3.1.2 for more details). Available methods are currently under-
developed and largely untested on real data. Categorisation of BMI is therefore a 
straightforward technique which will also enable us to present easily-interpretable 
absolute and relative estimates by BMI category. In addition, it will reduce the risk of 
obtaining implausible values for BMI (below 15kg/m2 or above 75kg/m2). 
BMI was grouped into 5kg/m² categories between 20kg/m² and 40kg/m². Those 
patients whose BMI fell outside this range were included in the lowest and highest BMI 
categories.  
6.2.2.4 MAR: MULTIPLE IMPUTATION USING CHAINED EQUATIONS 
uvis for STATA was used to create 25 multiply imputed data sets. Despite early research 
indicating 5-10 imputed datasets were sufficient, recent studies have indicated that as a 
rule of thumb, the number of imputed datasets should be at least as large as the 
proportion of missing data (White et al., 2011).  
The multiple imputation using chained equations approach was chosen since it does not 
assume multivariate normality and was therefore more able to efficiently handle the 
incomplete ordinal BMI variable (This was further examined in Chapter 8).  
Initial estimates were generated using an imputation model comprising of all variables 
included in the previous stochastic imputation model.  
Following the creation of 25 complete data sets, ICE’s mim command was used to 
analyse each dataset separately and to combine parameter estimates to form a single 




6.2.2.5 MAR: MULTIPLE IMPUTATION USING PREDICTIVE MEAN MATCHING 
The ice command in STATA with the additional ppm option was used to create 25 
multiply imputed datasets. PMM involves imputing an observed value which is amongst 
the closest values to the predicted value from the respective regression model. In ice, the 
default number of neighbours from which imputed values are randomly chosen from is 
3. PMM is capable of maintaining the observed relationships in variables included in the 
imputation model and has therefore been proposed as a valuable means of overcoming 
problems surrounding non-linear relationships and non-normality.   
The imputation model was specified in the same way as in the above multiple 
imputation approaches. 
6.2.2.6 MNAR: SENSITIVITY ANALYSIS USING A PATTERN-MIXTURE BASED 
APPROACH 
A pattern mixture sensitivity analysis was used to assess the robustness of estimates 
obtained from multiple imputation, when the MAR assumption is violated. This MNAR 
approach  was proposed by Donald Rubin (1987) at a time when software options for 
MNAR data were severely limited.  
It was hypothesised that 50% of patients with missing data were without a BMI 
measurement because their BMI was not considered clinically relevant and therefore 
was not recorded. This would occur if the practitioner did not believe the patients BMI 
was of concern, i.e. it lay in the ‘normal’ BMI range. Accordingly, a random selection of 
50% of patients with imputed data had their BMI category reduced by one unit in each 
of the 25 datasets formed using MICE. Therefore if a patient was coded in the 35 to 
<40kg/m² category they would be placed into the 30 to <35kg/m². Where patients 
were already in the lowest BMI category they remained in this category. At the time of 
writing, there was no accessible guidance for conducting more advanced approaches to 
exploring the sensitivity of MAR assumptions.  
 ANALYSIS MODEL  6.2.3
Associations between BMI at date of diagnosis and all-cause mortality were investigated 
using Cox proportional hazards regression. BMI at diagnosis, defined as a BMI 




predictor of interest. Given the findings of previous studies which have convincingly 
demonstrated that mortality has a J- or U-shaped pattern with BMI, it was deemed 
inappropriate to summarise the effect of BMI using a single hazard ratio. For this 
reason, BMI was grouped into 5kg/m² categories between 20kg/m² and 40kg/m². 
Those patients whose BMI fell outside this range were included in the lowest and 
highest BMI categories as appropriate.  
Hazard ratios (HR) were estimated relative to a reference category of 25 to< 30kg/m2 
due to containing a large number of people and having the lowest perceived risk of 
mortality (Logue et al., 2013). The timescale was calculated from the time of diagnosis 
until death or the end of follow-up (31/12/2012), whichever came first. Models were 
adjusted for age at diagnosis, sex, smoking status at diagnosis, deprivation status and 
Charlson comorbidity index. Previous studies have indicated that these variables are 
potential confounders of the relationship between BMI and mortality. The inclusion of 
these variables was therefore important to ensure the true relationship of interest was 
preserved. Violations to the proportional hazards assumption were investigated 
graphically using Kaplan Meier plots and log-log survival plots. Evidence of effect 
modification by sex was also investigated by stratifying analyses.   
Age-standardised mortality rates for each category of BMI were calculated using the 
European standard population so that both absolute and relative measures could be 
used to compare the effect of missing data methods on mortality estimates. 
 RESULTS 6.3
 EXCLUSION CRITERIA 6.3.1
The initial data cleaning procedure reduced the full cohort from 274,363 to 77,948 
patients. The exclusion criteria for these analyses further reduced the sample size to 
66,372 patients. Figure 6.1 presents the full case-flow schedule.  
The main reason for exclusion of patients was the presence of incomplete data for 
variables included in the missing data or final analysis models (n=8,487). Proportions of 




the foremost reason for exclusion amongst the 8,487 patients was the unavailability of 
smoking status, glycated haemoglobin or total cholesterol values. There were 12 patients 
who did not have data for any variable of interest (not shown in Table 6.2). A further 
3,089 patients were excluded due to having died within two years of the date of 
diagnosis of DM. Amongst the final sample, 13,775 (20%) patients were missing a BMI 
record at diagnosis. There were a total of 7,592 deaths occurring more than two years 
after diagnosis of DM in the sample between 2004 and 2012. 
Table 6.1. Proportions of missing data for variable s to be included in missing data 
models  (n=77,948) 
 
 
Variable Observed (%) Missing (%) 
Age at diagnosis 75,429 (96.77) 2,519 (3.23) 
Sex 77,892 (99.93) 56 (0.07) 
Vital status 77,948 (100.00) 0 (0.00) 
Deprivation status 77,407 (99.31) 541 (0.69) 
Year of diagnosis 75,442 (96.79) 2,506 (3.21) 
Follow-up time 75,472 (96.82) 2,476 (3.18) 
Smoking status 72,943 (93.58) 5,005 (6.42) 
Charlson comorbidity index 75,442 (96.79) 2,506 (3.21) 
Systolic BP 73,509 (94.31) 4,439 (5.69) 
Glycated haemoglobin 71,533 (91.77) 6,415 (8.23) 
Total cholesterol 72,838 (93.44) 5,110 (6.56) 





Table 6.2. Top 10 patterns of data completeness in variables to be included in imputation models and a nalysis models  (n=77,948) 
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   .         1 430 (0.55) 
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Figure 6.1: Full case-flow of excluded patients  
Full cohort 
n = 274,363 
n = 241,328 
n = 241,091 
Removed patients without 
type 2 DM  
(n=33,035) 
Excluded patients who had 
died within 2 years of date 
of diagnosis  
(n=3,089) 
n = 77,948 
Final sample 
n = 66,372 
Excluded patients with 
missing data on variables to 
be included in analysis or 
missing data model 
(n=8,487)  
Excluded patients who were 
diagnosed with type 2 DM 
after July 2008 
(n=238) 
Excluded patients who were 
diagnosed with type 2 DM 
before January 2004 
(n=163,143) 





 MCAR: COMPLETE CASE ANALYSIS (CCA) 6.3.2
Analyses were based on 52,597 eligible patients (67% of patients diagnosed with type 2 
DM between 2004 and 2008) having excluded patients with missing BMI data 
(n=13,775). The final sample included 28,930 men and 23,667 women, among whom a 
total of 5,491 deaths from all causes occurred. The median follow up time was 5.71 
years, with a maximum follow-up time of 7.99 years (2004-2012).   
Baseline characteristics by BMI category for the study sample are presented in Table 6.3. 
Characteristics by category of BMI were similar to those observed in the original whole 
sample. Age at diagnosis and the proportion of male patients decreased with increasing 
BMI. The proportion of patients alive at end of follow-up increased with increasing 
BMI, though this may be a result of a younger age at diagnosis amongst patients in the 
highest BMI categories. The proportion of patients in the most deprived category 
increased as did the median number of days of follow-up with increasing BMI. The 
prevalence of smoking also decreased with increasing BMI. As expected, elevated total 




Table 6.3. Baseline characteristics of patients inc luded in final CCA by BMI category  
(n=52,597) 
a Closest recorded measurement to date of diagnosis, SD: Standard Deviation, IQR: Interquartile Range  
HR estimates described a U-shaped relationship between BMI at diagnosis and all-cause 
mortality, after adjustment for age at diagnosis, sex, smoking status, deprivation status 
and Charlson comorbidity index (Table 6.4 & Figure 6.2). Patients with a BMI within 
the desirable weight category (< 25kg/m2), as defined by the World Health Organisation 
 BMI category, kg/m² 
<25 25 to < 
30 
30 to < 
35 
35 to < 
40 
≥ 40 Total 
N (%) 












Mean age at diagnosis of 













% Male 52.22 61.38 59.00 49.08 37.18 55.00 
% Alive at end of follow-up 80.49 88.22 90.96 92.80 93.45 89.56 

























23.03 21.83 23.46 26.07 29.99 24.05 
2 21.76 22.27 22.32 23.99 24.32 22.74 
3 19.07 19.93 21.16 21.24 20.31 20.48 
4 18.29 18.56 18.46 16.21 15.23 17.75 
5 (Least 
deprived) 
17.85 17.41 14.60 12.49 10.15 14.99 
Median Charlson 
Comorbidity Score (IQR) 
1 (1,2) 1 (1,2) 1  (1,2) 1  (1,2) 1 (1,2) 1 (1,2) 
% Never smoker 40.60 40.32 39.64 43.30 47.68 41.43 














Mean Diastolic BP, mmHg 
(SD) a 
77 (10.69) 79 (10.49) 81 (10.65) 83 (10.90) 84 (10.80) 81  (10.88) 
Mean glycated 
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cut-off points, were found to be at an elevated risk of mortality compared to patients in 
the 25 to <30kg/m2 group (HR: 1.51 [1.40, 1.63]). Compared with a BMI of 25 to < 
30kg/m2, risk of mortality was also higher amongst patients with a BMI of 40kg/m² or 
above. Standard errors were largest amongst the highest and lowest BMI categories 
reflecting smaller numbers in these groups. Obese patients (30 to <35kg/m2) had a 
slightly lower relative risk of mortality than overweight patients (25 to <35kg/m2) (HR: 
0.98 [0.92, 1.06]). Crude mortality rates indicated that those patients in the highest BMI 
groups had the lowest rates of death of all BMI categories (11.6 deaths per 1,000 
person-years), a trend that was reversed when results were age-standardised. Even after 
age-standardisation, mortality rates in the lowest BMI category remained highest (19.1 
deaths per 1,000 person-years) compared with mid-range BMI categories (around 11 per 
1,000 person years).  
Table 6.4: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using CCA.  
 BMI category (kg/m²) 
 < 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  






8,503 (16.17) 5,785 (11.00) 
      
Multivariable 
adjusted HR ab 
1.51      
(1.40, 1.63) 
1.00 
0.98       
(0.92, 1.06)  
1.04       
(0.94, 1.14) 
1.37         
(1.22, 1.53) 
Standard Error 
0.057 - 0.035 0.049 0.080 
      
No. deaths 1,101 1,918 1,478 610 374 
Person years 31,218 92,509 92,471 47,925 32,461 
Crude mortality c 35.3 20.7 16.0 12.7 11.6 
Age-standardised 
mortality b c 
19.1          
(17.3, 20.9) 
11.6          
(11.0, 12.3)  
11.2          
(10.5, 11.9) 
11.4         
(10.3, 12.5) 
14.3          
(11.5, 17.0) 
a Adjusted for age, sex, smoking status, deprivation status and Charlson comorbidity index, b with 95% CI, c deaths 





Figure 6.2. a) Hazard ratio estimates for risk of a ll-cause mortality and b) deaths per 
1,000 person-years by categories of BMI at diagnosi s of type 2 DM in CCA after 
exclusion for deaths in the first two years after d iagnosis. Reference category is 25 to 
less than 30kg/m² in a.  
 
When analyses were stratified separately by sex there was no change in the observed 
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 MCAR: POPULATION MEAN IMPUTATION  6.3.3
Within this sample, 13,775 patients had their missing BMI value replaced with the mean 
BMI at date of diagnosis, 32 kg/m².  Therefore, 45 per cent of patients were now 
grouped into the 30 to <35kg/m² category. Amongst the cohort of 66,372 patients 
included in these analyses, there were 36,223 men and 30,149 women. There were 7,592 
deaths from all-causes during follow-up and the median follow-up time was 5.76 years.  
Baseline characteristics of patients included in the analysis are presented in the appendix 
(Appendix Table A6.3). Briefly, the addition of these patients into the 30 to < 35kg/m2 
BMI category had little impact on the patterns of clinical and demographic 
characteristics by categories of BMI, but did increase the follow-up time, lower the 
proportion of males and increase the proportion of smokers in the 30 to 35kg/m² 
group. 
Table 6.5 presents both the HR estimates for risk of mortality and age-standardised 
mortality rates by BMI category after adjustment for age, sex, smoking status, 
deprivation status and Charlson comorbidity index. Figure 6.3 displays a comparison of 
HR estimates and age-standardised mortality rates obtained after the implementation of 
population mean-imputation and CCA. Adding patients with missing data into the 30 to 
<35kg/m2 category had the effect of raising mortality in this group (HR 1.23 [1.17, 
1.31]) compared to when CCA was used (HR: 0.98 [0.92, 1.06]).  In agreement with this 
finding, the age-standardised mortality rate for this group also increased from 11.2 
deaths per 1,000 person-years to 14.1 deaths per 1,000 person-years using population 









Table 6.5: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using population mea n imputation.  
 BMI category (kg/m²) 
 < 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  




8,503 (12.81) 5,785  (8.72) 
Increase in N from 





      
Multivariable 
adjusted HR (95% 
CI)  b c 
1.49      
(1.39, 1.61) 
1.00 
1.23       
(1.17, 1.31)  
1.04       
(0.95, 1.14) 
1.37         
(1.23, 1.54) 
Standard Error 
0.057  0.035 0.049 0.079 
      
No. deaths 1,101 1,918 3,577 610 375 
Person years 31,218 92,509 171,538 47,925 32,461 
Crude mortality rate 
d 
35.3 20.7 20.9 12.7 11.6 
Age-standardised 
mortality rate c  d 
19.1             
(17.3, 20.9) 
11.6               
(11.0, 12.3) 
14.1           
(13.5, 14.6) 
11.4              
(10.3, 12.5) 
14.3             
(11.5, 17.0) 
a Percentage of missing data, b Adjusted for age, sex, smoking status, deprivation status and Charlson comorbidity 















Figure 6.3: Comparison of a) adjusted hazard ratio estimates for risk of all-cause 
mortality and b) deaths per 1,000 person-years by c ategories of BMI using CCA and 
population mean imputation.  Deaths in first two ye ars of after diagnosis of type 2 DM 
































 <25 25 to < 30 30 to <35 35 to < 40 =>40












































 <25 25 to < 30 30 to <35 35 to < 40 =>40







 MAR: STOCHASTIC IMPUTATION  6.3.4
Using data from the 52,597 patients with complete observations, stochastic imputation 
replaced missing BMI categories in 13,775 patients. Estimates obtained from the 
adjusted Cox proportional hazards model and age-standardised mortality rates are 
presented in Table 6.6 and Figure 6.4. The U-shaped relationship observed using CCA 
was flattened with relative estimates of mortality decreasing across all BMI categories 
when stochastic imputation was applied. 
HR estimates from stochastic imputation indicated that patients in the 30 to <35kg/m² 
and 35 to 40kg/m² had similar mortality to patients in the referent category. Confidence 
intervals were also narrower than observed when CCA was the method for handling 
missing data.  
As previously stated, relative risk of mortality decreased in all categories of BMI upon 
the use of stochastic imputation and this is despite the inclusion of patients with missing 
data whose survival is known to be poorer. Absolute mortality values indicated that 
stochastic imputation placed a large number of comparatively unhealthy patients with 
missing data into the reference category and therefore had the effect of raising mortality 
risk in this group (Age-standardised mortality rate in 25 to less than 30kg/m² category: 
CCA 11.2 deaths per 1,000 person-years vs. 12.4 using stochastic imputation). Relative 
comparisons of estimates from stochastic imputation are therefore made between this 
reference category with higher mortality risk to other BMI categories for which absolute 
mortality has not increased to the same extent.  
Interestingly, absolute measures of mortality for the highest BMI category were identical 
for CCA and stochastic imputation suggesting stochastic imputation placed individuals 









Table 6.6: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using stochastic imp utation.  
 BMI category (kg/m²) 
< 25 25 to < 30  30 to < 35 35 to < 40 ≥ 45 
N (%) 
7,201   
(10.85) 
20,475 (30.85) 20,642 (31.10) 10,781 (16.24) 7,273  (10.96) 
Increase in N 
from CCA (%) a 
1,548  
(11.25) 
4,187  (30.44) 4,274  (31.07) 2,278  (16.56) 1,488  (10.82) 
      
Multivariable 
adjusted HR b c 
1.42                
(1.34, 1.52) 
1.00 
0.97               
(0.91, 1.02) 
0.98              
(0.91, 1.06) 
1.22              
(1.10, 1.34) 
Standard Error 0.046  0.029 0.040 0.060 
      
No. deaths 1,527 2,696 2,032 832 505 
Person years 40,122 117,321 118,676 62,246 42,244 
Crude mortality 
rate c d 
38.1 23.0 17.1 13.4 12.0 
Age-standardised 
mortality rate c d 
20.3              
(18.6, 22.0) 
12.9                 
(12.3, 13.6) 
12.4                  
(11.7, 13.0) 
12.2                     
(11.2, 13.2) 
14.3                 
(12.9, 15.9) 
a Percentage of missing data, b Adjusted for age, sex and smoking status, deprivation status and Charlson comorbidity 





Figure 6.4: Comparison of a) adjusted hazard ratio estimates for risk of all-cause 
mortality and b) deaths per 1,000 person-years by c ategories of BMI using CCA and 
stochastic imputation.  Deaths in first two years o f after diagnosis of type 2 DM are 
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 MAR: MULTIPLE IMPUTATION USING CHAINED EQUATIONS (MICE) 6.3.5
Twenty five datasets were created using observed data from the 52,969 patients with 
complete data. The process of imputing 25 datasets was computationally intensive and 
took considerable time.  
Table 6.7: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using MICE.  
 BMI category (kg/m²) 
 < 25 25 to < 30  30 to < 35 35 to < 40 ≥ 40  







Average increase in 
N from CCA (%)a 
1,520 (11.04) 4,193 (30.43) 4,273 (31.02) 2,254 (16.36) 1,534 (11.14) 
      
Multivariable 
adjusted HRbc 
1.38           
(1.28, 1.48) 
1.00  
0.97          
(0.91, 1.04) 
1.00            
(0.90, 1.09) 
1.21              
(1.08, 1.34) 
Standard Error 
0.049  0.032 0.046 0.07 
      
No. deaths 1,483 2,713 2,049 842 505 
Person years 40,100 117,256 118,615 62,098 42,541 
Crude mortality rate 
d 
37.0 23.1 17.3 13.6 11.9 
Age-standardised 
mortality rate c d 
19.3               
(17.7, 20.9) 
12.9             
(12.4, 13.7) 
12.4               
(11.7, 13.0) 
12.4         
(11.4, 13.4) 
14.2            
(12.6, 15.9) 
a Percentage of missing data, b Adjusted for age, sex and smoking status, deprivation status and Charlson comorbidity 
index c with 95% CI, d deaths per 1,000 person-years. CCA: CCA  
 
Table 6.7 and Figure 6.5 display both relative and absolute measures of mortality risk by 
BMI category at time of DM diagnosis. To calculate average numbers in each BMI 
group, along with age-standardised mortality in the presence of multiple datasets, 








Figure 6.5: Comparison of a) hazard ratio estimates  for risk of all-cause mortality and 
b) deaths per 1,000 person-years by categories of B MI using CCA and MICE.  Deaths 
in first two years after diagnosis of type 2 DM are  excluded. Reference category is 25 
to less than 30kg/m² group in a).  
 
Like stochastic imputation, MICE acted to flatten out the observed U-shaped 
relationship in HRs for risk of mortality when CCA was applied. Relative risk of 
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applied. The differences in mortality in the lowest and highest BMI categories compared 
to the reference category were statistically significant.  
In absolute terms, mortality rates increased across all BMI groups apart from in the 
highest BMI category when MICE was applied. Figure 6.6 presents absolute mortality 
by BMI categories for each imputed dataset. These estimates consistently exhibit a U-
shaped relationship. Patients in the ≥40kg/m² BMI category experienced a markedly 
reduced mortality using this method than when CCA was used (MICE: 7.2 deaths per 
1,000 person-years vs. CCA: 8.8).  
Despite estimates from stochastic imputation and MICE being largely similar, 
comparison of the respective assigned BMI categories for each patient and the mode 
assigned category from MICE, the BMI categories were in agreement in only 4,586 of 
13,925 patients with an imputed BMI.  
Interestingly, the width of confidence intervals for both the relative and absolute 
estimates was smaller using multiple imputation than CCA.




































































































































































































































 MAR: MULTIPLE IMPUTATION USING PREDICTIVE MEAN MATCHING (PMM) 6.3.6
Multiple imputation using PMM was used to create 25 datasets. The distribution of BMI 
categories for each imputed dataset were observed against the observed data and 
deemed reasonable. Gross discrepancies may have indicated problems with the 
imputation model. 
Results from MICE and multiple imputation using PMM were similar. Compared to 
results from CCA, multiple imputation using PMM flattened out the U-shaped 
relationship between BMI and all-cause mortality (Table 6.8, Figure 6.7). Patients in the 
highest and lowest BMI categories had lowered HRs for risk of mortality than were 
observed when CCA was used. Compared to results from CCA, multiple imputation 
using PMM slightly raised the HR for mortality in the 30 to <35kg/m2 category, this 
BMI category was associated with lower mortality compared to the reference category 
(30 to <35kg/m2 vs. 25 to <30kg/m2 mv HR: 0.96 [95% CI: 0.83, 1.10]). Table 6.8 also 
presents the age-standardised mortality results for each BMI category. The absolute risk 
of mortality was higher in the mid-BMI categories compared to CCA when multiple 
imputation using PPM was applied. The lowest rates of mortality were observed in the 
30 to <35kg/m2 group. The absolute measure of mortality did not change in the 












Table 6.8: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using PMM. 
 BMI category (kg/m²) 
 < 25 25 to < 30  30 to < 35 35 to < 40 ≥ 40  







Average increase in 
N from CCA (%) a 
1,496 (10.75) 4,280 (31.10) 4,240 (31.13) 2,209 (16.16) 1,550 (10.87) 
      
Multivariable 
adjusted HRb c 
1.19         
(1.02, 1.40) 
1.00     
(REF) 
0.96          
(0.83, 1.10) 
1.08            
(0.89, 1.31) 
1.30       
(1.02, 1.64) 
Standard Error 
0.0878  0.0713 0.1075 0.1842 
      
No. deaths 1,428 2,732 2,093 848 491 
Person years 40,073 117,753 118,289 61,844 42,654 
Crude mortality rate 
d 
35.6 23.2 17.7 13.7 11.5 
Age-standardised 
mortality rate c d 
18.8         
(16.4., 21.2) 
12.9         
(12.3, 13.5) 
12.5            
(11.8, 13.4) 
12.5             
(11.8, 13.4) 
14.5              
(12.0, 17.0) 
a Percentage of missing data, b Adjusted for age, sex, smoking status, deprivation status and Charlson comorbidity 









Figure 6.7: Comparison of a) hazard ratio estimates  for risk of all-cause mortality and 
b) deaths per 1,000 person-years by categories of B MI using CCA and multiple 
imputation using PMM. Deaths in first two years of after diagnosis of type 2 DM are 
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 MNAR: SENSITIVITY ANALYSIS USING A PATTERN-MIXTURE BASED 6.3.7
APPROACH 
A pattern-mixture based sensitivity analysis was conducted on the 25 imputed datasets. 
Table 6.9 displays the average number of patients in each BMI category, along with HR 
estimates for all-cause mortality and age-standardised mortality rates. Unsurprisingly, 
there is a clear left shift in numbers of persons in each category with higher percentages 
now in the lowest BMI categories. Over 26% of patients with missing data were 
categorised into the under 25kg/m² group using this pattern-mixture based approach.  
Table 6.9: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using a pattern-mixt ure based sensitivity analysis. 
 BMI category (kg/m²) 
 < 25 25 to < 30  30 to < 35 35 to < 40 ≥ 40  






6,551  (9.86) 
Average increase in 
N from CCA (%) a 
3,628 (26.34) 4,221 (30.64) 3,271 (23.74) 1,927 (13.84) 
786       
(5.64) 
      
Multivariable 
adjusted HRb c 
1.41       
(1.31, 1.52) 
1.00     
(REF) 
0.97         
(0.90, 1.03) 
1.00            
(0.91, 1.09) 
1.23       
(1.09, 1.37)  
Standard Error 
0.054  0.033 0.045 0.072 
      
No. deaths 1,885 2,598 1,880 789 440 
Person years 51,791 116,846 111,383 58,797 36,834 
Crude mortality rate 
d 
36.3 22.2 16.9 13.4 11.9 
Age-standardised 
mortality rate c d 
18.9             
(17.7, 20.1) 
12.8          
(12.1, 13.5) 
12.1                
(11.3, 12.9) 
12.2             
(11.1, 13.3) 
14.1           
(12.0, 16.3) 
a Percentage of missing data, b Adjusted for age, sex, smoking status, deprivation status and Charlson comorbidity 
index, c with 95% CI . CCA: CCA  
 
 
Figure 6.8a displays a comparison of both HR estimates for all-cause mortality by BMI 
categories between CCA and this pattern-mixture based sensitivity analysis. The two 
curves are largely similar, with a slightly flattening of the U-shaped relationship. In 
particular, the risk of mortality in the highest BMI group (≥40kg/m²) was considerably 
attenuated where this pattern-mixture based sensitivity analysis was applied.  
In absolute terms, risk of mortality was slightly raised in BMI categories between 




BMI category, absolute risk of mortality was lowered using this approach compared to 
CCA. 
 
Figure 6.8: Comparison of a) hazard ratio estimates  for risk of all-cause mortality and 
b) deaths per 1,000 person-years by categories of B MI using CCA and a pattern-
mixture based sensitivity analysis. Deaths in first  two years of after diagnosis of type 
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Dynamic clinical registers offer huge potential for epidemiological research. Clearly, as 
more large population-based registers become available for research purposes, a key 
component of all analyses will be the chosen method for handling partially observed 
data. Unfortunately, the nature of these datasets mean that researchers are typically far 
removed from the data collection process. Options for improving data quality and 
minimising the occurrence of missing data are therefore limited. One proposed method 
which has received considerable attention recently is the use of record linkage to 
enhance patient records using equivalent data in alternative available datasets (Norris et 
al., 2000; Faris et al., 2002). Unfortunately no other alternative sources of BMI data were 
available and therefore this approach was not feasible for this dataset. This problem, 
whereby data cannot be enhanced with information from other data sources is likely to 
be common across epidemiology, particularly in health indicators that are not regularly 
recorded in routine clinical care. Researchers therefore need to apply appropriate 
statistical techniques to handle the unobserved data. To do so requires knowledge of the 
likely mechanism through which missing data came about; a complicated process when 
researchers are not directly involved in the data collection process and data are 
population-based. Investigators cannot speak to everyone responsible for data 
collection, and even if they did, those responsible for data collection might not know 
why data were missing. Furthermore, motivations of clinicians to record risk factors 
such as BMI are likely to change over time, a feature that was true of our data. It is 
therefore often necessary to depend instead upon the data itself to explain the probable 
reasons for missing data. This cannot be achieved with any certainty and therefore the 
robustness of findings should be assessed by carrying out sensitivity analyses.  
 RELATIONSHIP BETWEEN BMI AND ALL-CAUSE MORTALITY 6.4.1
Using this large population-based register of persons with type 2 DM in Scotland, the 
impact of various techniques for handling partially observed data on parameter 
estimates was investigated. 
Six separate methods for handling missing data in the BMI at diagnosis variable were 




would have been acceptable (10 months prior or 2 months after) in relation to diagnosis 
date, the proportion of missing data remained high (>20%). 
Regardless of the method used for handling missing data, an approximately U-shaped 
relationship between all-cause mortality and BMI at date of diagnosis was demonstrated. 
Patients with BMIs in the ≤25kg/m² or ≥40kg/m² category consistently had the highest 
all-cause mortality. Interestingly, risk of mortality was similar in BMI groups between 25 
to <40kg/m² though lowest risk of mortality was consistently observed in the 
moderately obese (30 to<35kg/m²) category.  
These findings correspond well with other studies which have investigated this 
relationship amongst type 2 DM patients (Church et al., 2005; Hu et al., 2005; Mulnier 
et al., 2006; Carnethon et al., 2012; Thomas et al., 2014). The problems surrounding 
missing data were rarely discussed in this body of literature and often approaches 
chosen to handle missing data were not stated. In fact, rarely did the studies describe the 
extent of missing data therefore making it difficult to ascertain their potential impact on 
the respective study’s conclusions. Only one study investigating the relationship 
between BMI and mortality in the general population applied multiple imputation to 
handle partially observed data (Hotchkiss & Leyland, 2011).  
Nonetheless, these studies have identified an apparent protective effect of being 
overweight or obese, an observation that has also been reported amongst patients with 
other chronic conditions such as heart disease, COPD and stroke (Oreopoulos et al., 
2008; Ovbiagele et al., 2011; Cao et al., 2012). This finding has been restricted to 
moderately obese patients only, not severely obese.  
The finding that obese or overweight patients have a survival advantage over normal 
weight patients has been termed the obesity paradox and this topic has received 
considerable attention in recent years as epidemiologists have sought an explanation 
(Hainer & Aldhoon-Hainerová, 2013; Standl et al., 2013). Typically, it is postulated that 
this paradox is a consequence of poor study design and methodological flaws (Ferreira 
& Stehouwer, 2012; Banack & Kaufman, 2013; Hughes, 2013). Residual confounding 
and selection bias are often cited as potential explanations for the obesity paradox, along 
with insufficient handling of potential sickness-related weight loss. Smoking history is 




validity of estimates for the relationship between BMI and all-cause mortality. In our 
study, former and current smokers are grouped together which may have diluted the 
effect of smoking status on estimates.   
The largest problem for analyses addressing this topic is potential reverse causation by 
underlying conditions resulting in high mortality in leaner individuals. In our study, it is 
possible that this could explain the observation that patients with a BMI in the normal 
BMI or below category (≤25kg/m²)  experienced higher mortality than those in the 
overweight or obese category. Unfortunately, the short duration of follow-up in our 
cohort means that this study is particularly prone to reverse causation. To control for 
this possibility, patients who died within 2 years of diagnosis were excluded and analyses 
were adjusted for patient Charlson comorbidity index. However, these approaches had a 
number of problems which may have limited their ability to control against reverse 
causation. Firstly, patients with some chronic conditions often live more than two years 
after diagnosis of DM. Secondly, the Charlson comorbidity index only accounts for 
diagnosed serious comorbid conditions that resulted in hospital admission. Undiagnosed 
conditions could therefore confuse the observed relationship.  
One large study using two prospective cohorts investigating this relationship in DM 
patients did not identify this effect in their data (Tobias et al., 2014). This study 
observed a J-shaped association with the lowest mortality occurring in the normal 
weight category. In a response to this paper, Logue et al, (2014) suggested that this 
discrepancy may be a consequence of an older cohort. Analyses conducted by Tobias 
and colleagues included incident DM cases dating back to 1976 and since this time there 
have been large rises in BMIs whilst improvements in DM management have led to 
increased life expectancies. These changes may have occurred disproportionately across 
BMI ranges. Their study also relied on self-reported weight which are typically under-
estimated in questionnaires (Gorber et al., 2007). This could therefore lead to attenuated 
mortality in the normal BMI category.    
Given the uncertainty of the true relationship due to conflicting studies and the 
methodological difficulties in measuring this association, it is difficult to assess whether 
results obtained from these analyses accurately reflect the real association between BMI 




studies capable of discerning intentional weight loss from non-intentional weight loss 
are required.   
 PERFORMANCE OF MISSING DATA METHODS 6.4.2
6.4.2.1 CCA 
Given the findings from earlier studies and information from the data itself, it appears 
that some methods for handling missing data were more appropriate for this specific 
analysis than others, and thus gave more valid estimates. For instance, initial 
investigations into the probable mechanism of missingness indicated that a substantial 
quantity of missing BMI data were MAR conditional primarily on survival. For this 
reason, methods which assumed MCAR were unlikely to produce appropriate estimates 
since the complete cases were no longer representative of the full sample. Consequently, 
whilst this method was quick and easy to implement, absolute estimates from CCA were 
likely to have been over-estimated in this cohort. 
The exclusion of 13,775 patients with missing data was clearly inefficient and reduced 
the number of events in the sample from 1,593 deaths to 1,096, reflecting a significant 
loss of information.  
6.4.2.2 POPULATION MEAN IMPUTATION 
The second method employed to handle the missing data was mean imputation. Here, 
the risk of mortality in the BMI category (30 to <35kg/m²) where all patients with 
missing data were placed was considerably attenuated relative to the reference group. 
Clearly, this method’s implicit assumption is hugely restrictive, namely that the unseen 
data all fall in the same category. The method therefore reduced the variability of the 
observations, a problem which is considerably more problematic when proportions of 
missing data are high. Despite this method being wholly inappropriate for the problem 
at hand, it was able to illustrate our finding that patients with missing data had 
considerably worse survival than those with unobserved data. In some circumstances, 
this method may therefore be useful as an exploratory analysis, but certainly cannot be 





6.4.2.3 IMPUTATION APPROACHES FOR MAR DATA 
Estimates from stochastic and multiple imputation approaches were largely similar. 
Compared to CCA, these techniques acted to increase absolute mortality in all but the 
highest BMI category. In relative terms this resulted in the flattening of the U-shaped 
relationship. The finding that the highest BMI category experienced lower absolute 
mortality when these imputation approaches were implemented indicates that these 
methods acted to place the healthiest patients with missing data into this category.  
Changes in relative estimates from those obtained from CCA would not affect overall 
inferences. This was in agreement with findings from a simulation study which 
compared estimates from CCA and multiple imputation (Lee & Carlin, 2012). This 
study reported that when missing data occurred in the exposure of interest, the benefits 
of using multiple imputation was minimal. The authors found that multiple imputation 
was most useful when missing data occurred in confounding variables as then multiple 
imputation is able to recover information about the relationship between the predictor 
of interest and the outcome. However, these analyses were restricted to logistic 
regression analyses. Another simulation study conducted in the context of a survival 
analysis with unobserved covariate data found that multiple imputation approaches 
yielded estimates with large bias when the censoring time depended on missing 
covariates (Qi et al., 2010). The authors therefore suggested that in order to get 
consistent estimates from multiple imputation, missing data in covariates should be 
independent of censoring times. Clearly this was not the case in our study and therefore 
the applied multiple imputation approaches may have produced biased estimates. Qi and 
colleagues suggest that weighted analyses may perform better in these scenarios. 
Unfortunately, this approach is less straightforward to apply in standard statistical 
software.  
White and Carlin (2010) also identified that multiple imputation was not always superior 
to CCA for missing covariate problems. For example when missingness in covariates 
was independent of the outcome given other covariates, CCA had negligible bias whilst 
estimates from multiple imputation were biased away from the null. Nonetheless, the 
authors found that multiple imputation performed better than CCA in a wider range of 
settings and ought to be preferred due to its greater efficiency. However, it was 




models are likely to introduce additional bias that is absent in CCA. This potential 
limitation of multiple imputation has been observed elsewhere whereby incompatible 
imputation and analysis models have led to biased parameter estimates in the latter 
(White et al., 2011; Bartlett et al., 2014).   
In accordance with the approach proposed by Royston and White (2009), the Nelson 
Aalen estimate of cumulative hazard instead of the survival time was included in a 
separate imputation model. It has been suggested that the inclusion of this variable in 
the imputation model will reduce the amount of bias in the later Cox proportional 
hazards model. Despite this being tested in a single simulation study, it has now become 
widely accepted as the best approach for including the outcome in missing data analyses 
for survival analyses. When used here, the model produced largely similar results to 
those presented in 6.3.5 (See Appendix Table A6.4). 
Meanwhile, confidence intervals from multiple imputation were narrower than those 
from CCA. This observation  therefore suggests that even when taking into account 
between-imputation variance, multiple imputation produced smaller standard errors. 
Most critically perhaps, was the poor prediction of the BMI at diagnosis variable 
(r2=0.15). Unfortunately, few of the available variables were strongly correlated with the 
BMI at diagnosis variable and therefore the predictive power of the imputation model 
was poor, leading to uncertain imputed values. This process may have led to patients 
being placed into the incorrect BMI category, resulting in random misclassification bias. 
It is uncertain what effect this random misclassification may have had on estimates but 
it is possible that findings were biased towards the null as demonstrated by the 
flattening of the U-shaped curve.  
The problem of poor predictive power of the imputation model was possibly attenuated 
through the categorisation of BMI in the imputation model. Categorisation of BMI was 
carried out to reduce the risk of dilution of the association between BMI and all-cause 
mortality since the imputation model would assume this relationship was linear. 
However, categorisation of BMI was likely to have led to significant loss of information. 
Interestingly, upon the imputation of BMI as a continuous variable, the resulting HRs 
exhibited a greater curve than was observed when BMI was imputed as a categorical 




to handle non-linear relationships and interactions in multiple imputation models 
(Seaman et al., 2012; Vink & van Buuren, 2013). In order to produce valid estimates, the 
imputation model should preserve all relationships of interest in the final model. This 
becomes difficult when the analysis model contains squares and interaction terms and 
these variables need to be accounted for in the imputation model. At present a number 
of methods to include variables with more than one functional form have been 
investigated including passive imputation and the just another variable approach  (Von 
Hippel, 2009). However, these approaches have been shown to produce biased 
estimates when data are MAR and have not yet been tested in a survival analyses setting 
(Seaman et al., 2012). Due to this lack of agreement regarding the best approach, BMI at 
diagnosis was categorised in these analyses. This had the additional benefit of easing 
comparisons with other studies investigating the association between BMI and all-cause 
mortality.  
Without using BMI data obtained prior to or after diagnosis, there are limited options 
for improving the imputations. Unfortunately, some potentially reasonable predictors of 
BMI at diagnosis could not be included in the imputation model due to concerns 
surrounding collinearity issues and high levels of unobserved data. Nonetheless, in their 
recent study exploring the inclusion of auxiliary variables, Hardt et al. (2012) concluded 
that the use of too many auxiliary variables could be disadvantageous unless correlations 
were high. In order to achieve better predictions using this dataset, it was necessary to 
utilise the available repeated measurements (Chapter 7). This may not always be possible 
in other datasets. 
Secondly, even with a modest number of predictors and only a single variable to impute, 
multiple imputation was computationally intensive and time-consuming. In real-life 
analyses involving routine data, it is unlikely that the pattern of missingness is univariate, 
and therefore multiple variables will need to be imputed. Consequently, real-life 
imputation processes are likely to be even more intensive due to the need for multiple 
iterations. Furthermore, compared to the conventional methods, its application required 
considerable thought and prior exploratory analyses to correctly specify the imputation 
model. A thorough understanding of the missing data problem and the subsequent 
analysis model is required to produce congenial models capable of producing proper 




involved with handling the missing data are separate from those who subsequently 
analyse the data, as Rubin (1987) initially proposed when he developed multiple 
imputation. 
Therefore, whilst multiple imputation has become more popular, with all mainstream 
statistical packages now offering multiple imputation software and numerous review 
articles providing considerable guidance on its implementation, the aforementioned 
difficulties may contribute to its low uptake across epidemiological research (Klebanoff 
& Cole, 2008). 
6.4.2.4 IMPUTATION APPROACHES FOR MNAR DATA 
Regularly, researchers are encouraged to display sensitivity analyses of their results when 
it is likely that data could be MNAR. However, not a great deal of guidance is available 
on how to go about doing this. Most literature relating to this problem concerns MNAR 
data in clinical trials where differential attrition by treatment arm has occurred. 
Unfortunately, there are few instances whereby MNAR methods have been applied in 
the non-clinical trial setting. Indeed, software options for these methods are currently 
limited in standard statistical packages.  
Figure 4.2 highlighted that missingness was highest amongst patients whose median 
ever-recorded BMI were in the under- or normal-weight categories. Since repeat 
measurements were not included in this chapter’s analyses, the risk of MNAR data was 
high. It was therefore necessary to explore the sensitivity of estimates to departures 
from MAR. Upon the application of a basic sensitivity analysis, inferences did not 
change dramatically, with relative risk of mortality increasing in only the <25kg/m² BMI 
category compared to the 25 to 30kg/m² group. This finding suggests that multiple 
imputation estimates were robust to possible departures to the MAR assumption. The 
present analysis used arbitrarily defined assumptions, whereby 50% of patients were 
considered to have missing data that were MNAR. It was assumed that these patients’ 
BMI were not recorded as it was considered clinically irrelevant. Accordingly we 
assumed that multiple imputation over-estimated imputed BMI values. Of course, these 
assumptions are completely unverifiable in these data. It would therefore have been 
beneficial to explore the sensitivity of MAR-based estimates through further analyses 




missingness. Unfortunately, time constraints prevented further exploration of this issue. 
However, Chapter 7 investigates the inclusion of longitudinal BMI data which should 
reduce the risk of data being MNAR.   
 PROBLEMS & LIMITATIONS  6.4.3
In addition to some of the problems already mentioned, there were a few other 
potential limitations to these analyses. One complicating factor of these analyses was the 
fact that patients with missing BMI at diagnosis were also missing a date of 
measurement. Accordingly, it was necessary to use date of diagnosis as the starting point 
to calculate follow-up time, rather than measurement date. It is difficult to ascertain the 
likely effect, if any, this would have on analyses. It is possible that there were differences 
in survival time by time of measurement from date of diagnosis. For example, if patients 
were unwell at date of diagnosis, the only available BMI measurement may have been 
taken long in advance of this date. These un-well patients may therefore have a shorter 
survival time if they subsequently died during follow-up. Nonetheless, a CCA which 
used measurement date as the starting point for survival time produced very similar 
results to those presented earlier which used date of diagnosis as the starting point (not 
shown).  
The method of categorisation of BMI may be a further limitation to this work. More 
specifically, defining the lowest BMI group as below 25kg/m² may have obscured the 
dose-response relationship. As a result, it was not possible to obtain an accurate 
understanding of the effect of low BMI on all-cause mortality. It is possible that the 
inclusion of patients with a BMI below 20kg/m² in this category considerably inflated 
the risk of mortality in the below 25kg/m² group. Patients with a BMI below 20kg/m² 
are likely to be significantly different to patients with a BMI of 25kg/m² in respect to 
their health status. Similarly, using a BMI of above 40kg/m² as the definition for the 
highest BMI category may have obscured the association between high BMI and all-
cause mortality. Indeed, upon the re-categorisation of BMI with the lowest BMI 
category becoming below 20kg/m² and the highest BMI group becoming 45kg/m² or 
above, an analysis of the association between BMI and all-cause mortality using CCA 
produced a more pronounced U-shaped relationship (see Appendix Figure A6.1). This 




to the reference category was lowered from 1.51 using the original classification system 
to 1.44. Excluding patients with a BMI below 20kg/m² from this category therefore 
attenuated the risk of mortality in this group. The creation of an additional category for 
patients with a BMI above or equal to 45kg/m² also led to the attenuation of the risk of 
mortality in the 40 to less than 45kg/m² group (from 1.37 to 1.23). However, this 
categorisation scheme was defined prior to conducting the analysis and was used due to 
concerns surrounding small numbers of patients with a BMI below 20kg/m² and 
subsequent risk of low power. The number of patients with a BMI below 20kg/m² was 
464, of which there were 133 deaths. Of these, 193 patients had a BMI below 
18.5kg/m², the “healthy weight” BMI definition. Furthermore, this definition assisted in 
the comparison of estimates with those obtained from earlier analyses using this dataset. 
Future work using this dataset will have larger sample sizes and therefore can describe 
the relationship between low BMIs and all-cause mortality in greater detail.  
A further potential problem with these analyses may be missing outcomes. This could 
arise where patients have emigrated and possibly died elsewhere creating an immortal 
time bias. This may be of particular concern if patients without a BMI at date of 
diagnosis may be more likely to be lost to follow-up, thus leading to the belief that they 
are alive when they are not. Nonetheless, it seems unlikely that this would account for 
such large differences in survival by missingness.  
 CONCLUSIONS  6.4.4
Though recording practices in clinical care are improving through initiatives such as 
QOF, missing data are always going to be a concern where population-registers are 
used. Despite data being recorded more regularly, the timing of measurements may not 
occur within the time-frame of interest in any given analysis. This is a unique feature of 
data analyses using routine data and means that appropriate methods for overcoming 
missing data need to be used to avoid bias and inefficiency.  
In our study we have illustrated the difficulties in assessing the performance of each 
missing data method without knowing the true associations. However, careful 
consideration of the plausibility of the assumptions made by each respective method 




of each method. In these analyses, given the aforementioned problems associated with 
CCA and the poor prediction of BMI at diagnosis for multiple imputation approaches, it 
seems probable that the true relationship lies somewhere between estimates observed 
for CCA and either multiple imputation approach, providing data are MAR. The true 
relationship in our data is therefore likely to exhibit an approximate U-shaped curve.   
These analyses have emphasised the importance of presenting a primary analysis whose 
assumptions regarding the missing data mechanism are most plausible, followed by a 
second analysis which investigates the robustness of estimates to departures from the 
proposed missing data mechanism. Results from these analyses should be compared and 












 INTRODUCTION  7.1
In the previous chapter, missing data methods which utilised cross-sectional data to 
predict missing values were applied. It was shown that any additional efficiency benefits 
obtained by using multiple imputation could be hindered by the limited availability of 
strong predictors of the missing BMI variable. To overcome this problem, it may be 
possible to utilise longitudinal patient data to reduce uncertainty in imputed values. 
Within-patient measurements are likely to be correlated and therefore should provide a 
powerful guide to plausible values for the missing data. Additionally, conditioning 
imputation models on longitudinal data may also strengthen the plausibility of the MAR 
assumption (Welch et al., 2014). 
The incorporation of longitudinal data from routinely collected data sources is not 
straightforward. In these databases, important health indicators are typically recorded as 
part of a patient’s routine clinical care and therefore tend to be recorded on the basis of 
their clinical relevance. Consequently, recordings of important health indicators occur at 
irregular time-intervals resulting in wide differences in the number of available 
measurements per patient. This form of data are termed unbalanced and introduce 
several additional complexities into statistical analyses with missing data, such as the 
necessity to arbitrarily define missing data. 
This chapter will present and document the extent of unbalanced data in the SCI-DC 
register. Later, a series of imputation models capable of incorporating longitudinal data 
will be applied to an analysis of the association between BMI at diagnosis and all-cause 
mortality. 
 DESCRIPTION OF DATA PROBLEM  7.2
 INTRODUCTION 7.2.1
The key problem with incorporating longitudinal data from the SCI-DC register into 




in the timing of measurements. This problem is illustrated in Figure 7.1 which presents 
the pattern of BMI measurements of a typical sample of ten patients without a BMI at 
date of diagnosis. Within this sample of ten patients, three patients had BMI 
measurements recorded both before and after the BMI timeframe, two patients only 
had BMI values taken before the diagnosis timeframe whilst all other patients only had 
values taken after the diagnosis timeframe. The timing of available measurements was 
markedly different too. Patient 1 did not have a BMI recording until two years after 
their diagnosis with DM whilst Patient 9’s closest BMI measurement was only a few 
days outside of the diagnosis time-frame. The number of available measurements by 
patient fluctuated considerably. For example, patient 2 only had one available BMI 
measurement, whilst patient 7 had 14 measurements.  
Figure 7.1 also highlights large differences in BMI trends over time in patients. Some 
patient’s BMI remained similar across large periods of time and others varied widely in 
relatively short periods of time. In the context of this study this is important since it is 
easier to predict patient BMI when individual-level measurements exhibit a stable 












Figure 7.1: Pattern of BMI measurements in relation  to date of diagnosis in a random selection of 10 p atients. Black dotted reference lines 
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 NUMBER OF OBSERVATIONS PER PERSON 7.2.2
With the widespread use of annual DM review appointments during which key health 
indicators are recorded, it might be expected that patients would have multiple 
measurements of BMI available over several years, provided their diagnosis occurred 
sufficiently long ago. Table 7.1 presents both the number of measurements per patient 
in the overall sample of patients diagnosed between 2004 and 2008 and in those patients 
without a BMI at diagnosis. Number of measurements per person were categorised into 
6 distinct groups; no measurements, 1, 2, 3 to 10, 11 to 20 and more than 20. The 
choice of these groups was arbitrary, but allowed the inspection and comparison of 
patients with vastly different recording patterns. The number of patient BMI 
measurements ranged between 0 and 79, with a median of 6 measurements per person.     
Table 7.1: Number of BMI observations per patient 
 
The table above shows a large amount of variability in the number of BMI 
measurements per patient in the SCI-DC register for those patients meeting the 
eligibility criteria described in Section 6.2. As a reminder, this included patients who 
were diagnosed with type 2 DM between 2004 and 2008, who had not died within two 
years of diagnosis and who had complete data for variables to be included in either the 
analysis or missing data model. In the whole sample, 1,401 did not have any BMI 
measurements and 2,241 patients had only one BMI recording. Of the patients with 
only a single measurement, 1,302 of these measurements were outside of the date of 
diagnosis timeframe, defined as a measurement recorded 10 months prior to or 2 
Number of 
measurements 
N in whole sample (% of 66,372) N in patients without a BMI at diagnosis 
value (% of 13,775) 
0 1,401 (2.11) 1,401 (10.13) 
1 2,241 (3.38) 1,302 (9.44) 
2 4,244 (6.39) 1,712 (12.42) 
3-10 47,713 (71.89) 8,569 (62.20) 
11-20 9,753 (14.69) 763 (5.52) 




months after diagnosis. Identifying a BMI at date of diagnosis for these individuals 
would therefore mean extrapolating information from a single BMI measurement 
recorded some time from diagnosis. 
In patients without a recording of BMI at diagnosis, 67% had three or more BMI 
measurements. A substantial quantity of information from which a BMI at diagnosis 
could be estimated was therefore available.  
 CHARACTERISTICS OF PATIENTS BY NUMBER OF OBSERVATIONS  7.2.3
To acquire a greater understanding of attendance rates and potential reasons for 
differences in patterns of missing data, baseline characteristics of patients by their 
respective number of available BMI recordings were examined (Table 7.2). The number 
of measurements per person was categorised as in Section 7.2.2. To display patterns of 
measurements for year of diagnosis and deprivation status, box and whisker plots are 
presented in Figure 7.2. According to Figure 7.2, patient year of diagnosis was a major 
determinant of number of BMI measurements per person. Patients diagnosed in 2008 
had many fewer measurements than patients diagnosed in 2004. Since BMI data were 
extracted in 2008, the amount of data collected after diagnosis amongst patients 
diagnosed with DM in 2008 was severely limited. This may also partly explain the 
observation that the median years of follow-up increased with increasing available 
measurements per patient (Table 7.2).  
Patients with fewer measurements were older (0 measurements: 64.36 years vs. >20 
measurements: 55.64 years) and were less likely to be alive at the end of the study period 
(0 measurements: 81% vs. >20 measurements 88%). The older age of patients without a 
single measurement of BMI could be a reflection of the perceived lack of need to 
measure BMI in elderly patients as weight control may not be prioritised in these 
patients. Meanwhile, since patients diagnosed at an early age tend to be considerably 
more overweight than patients diagnosed at a later stage in life, these patients may be 
monitored more closely for a longer period.   
A strong association between number of BMI measurements and median BMI values 
was observed (1 measurement: Median overall BMI 31.0kg/m² vs. 35.3kg/m² for people 
with >20 measurements:), indicating patients with higher, more clinically-concerning 





previously stated, patients diagnosed at an earlier age tend to be heavier whilst also 
tending to have more available BMI recordings. The prevalence of never smokers 
decreased with increasing number of available measurements indicating more intensive 
monitoring of smokers. A U-shaped relationship was observed between number of 
measurements of BMI and the presence of comorbid conditions. BMI measurement 
may not be a priority for very unwell patients, thus accounting for high levels of 
comorbidity amongst patients without an available BMI. Conversely, patients with 
additional comorbidities may have higher GP attendance levels, thus resulting in more 
opportunities to record BMI measurements.   
Mean glycated haemoglobin levels exhibited a general positive association with number 
of BMI measurements, suggesting patients with poorly controlled diabetes had higher 
attendance rates, a finding supported by discussions with clinicians (Section 5.3). Upon 
restricting these comparisons to patients without a BMI at diagnosis only, similar 
patterns were observed (See appendix Table A7.1 and Figure A7.1). To conclude, there 
are large differences between patients by number of available BMI measurements, 
though it is uncertain whether these differences are reflective of shorter periods of 
follow-up for those patients diagnosed in 2008. Nonetheless, observed differences in 
median patient BMI by number of measurements were noteworthy and could reflect 







Table 7.2: Characteristics of patients by number of  BMI measurement per person 
a Closest recording to date of diagnosis with DM 
 Number of BMI measurements per patient 
TOTAL 
0 1 2 3-10 11-20 >20 
N (%) 1,401 (2.11) 2,241 (3.38) 4,244  (6.39) 47,713 (71.89) 9,753 (14.69) 1,020 (1.54) 66,372 
Mean age at diagnosis, years (SD) 64.36 (14.18) 60.99 (13.82) 60.44 (13.33) 61.65 (12.22) 61.79 (11.72) 60.31 (11.72) 61.61 (12.34) 
% Male 51.96 56.49 57.49 55.38 50.50 43.24 54.58 
% Alive at end of follow-up 80.94 87.10 88.97 88.89 88.24 88.24 88.56 
Median no. of years follow-up (IQR) 4.61                
(4.07, 5.39) 
4.59          
(4.05, 5.50) 
4.72            
(4.15, 5.62) 
5.75             
(4.74, 6.81) 
6.72         (5.62, 
7.50) 
6.62         (5.31, 
7.48) 
6.04               
(4.89, 7.09) 
% With comorbidities 37.26 29.54 28.06 31.18 37.05 41.96 32.08 
% Never smoker 47.11 45.65 44.34 42.08 40.27 40.39 42.16 
Median ever-recorded BMI, kg/m2 (SD) - 30.99 (6.48) 31.16 (6.27) 31.44 (6.08) 32.68 (6.45) 35.27 (7.12) 31.65 (6.22) 
Mean Systolic BP, mmHg (SD)  a 140 (20.25) 139 (19.51) 139 (19.13) 140 (18.77) 139 (18.54) 138 (18.62) 140 (18.82) 
Mean Diastolic BP, mmHg (SD)  a 80 (11.51) 81 (11.07) 81 (10.96) 81 (10.92) 80 (10.77) 80 (10.56) 81 (10.91) 
Mean Glycated haemoglobin, % (SD)  a 8.08 (2.14) 8.10 (2.20) 8.16 (2.16) 8.00 (2.10) 7.97 (2.06) 7.87 (1.99) 8.01 (2.10) 
Mean Serum creatinine, umol/L (SD)  a 90.16 (25.78) 88.94 (29.79) 87.18 (23.71) 90.49 (26.81) 92.34 (26.87) 93.06 (29.11) 90.53 (26. 
Mean Total cholesterol, mmol/L (SD)  a 5.08 (1.29) 5.15 (1.38) 5.23 (1.33) 5.19 (1.30) 5.10 (1.27) 4.94 (1.27) 5.17 (1.30) 
Median Triglycerides, mmol/L (IQR)  a 2.01             
(1.34, 2.96) 
2.00             
(1.43, 2.90) 
2.05               
(1.40, 2.86) 
2.00                 
(1.40, 2.91) 
2.00              
(1.42, 2.90) 
2.08                          
(1.45, 2.93) 
2.00                 
(1.41, 2.93) 












 TIMING OF MEASUREMENTS  7.2.4
The timing of available measurements relative to the diagnosis time-frame was examined 
(Table 7.3). For patients without a BMI at diagnosis (n=13,775) who could potentially 
benefit from data imputation, only 7,557 patients had a valid BMI recorded prior to the 
date of diagnosis timeframe (Patterns A + C). This would therefore limit the feasibility 
of applying a Last Observation Carried Forward (LOCF) method to handle the missing 
data. There were 6,684 patients without an observed BMI who had BMI records either 
side of diagnosis with DM (Pattern C). Accordingly, interpolation of BMI could not be 
applied to estimate an approximate BMI value at diagnosis for all patients.  
Table 7.3: Patterns of observations in relation to date of diagnosis timeframe. 
 Pattern 
Pattern of observations 
Frequency 











A  . . 873 (1.32) 
B . .  4,817 (7.26) 
C  .  6,684 (10.08) 






E    34,445 (51.90) 
F .   12,298 (18.53) 
G   . 4,377 (6.59) 
H .  . 1,477 (2.22) 
 
In addition, the median number of years that the last measurement was taken prior to 
date of diagnosis was 2.94 years, with an IQR of 1.45 to 6.97 years (or 2.12 years 
[IQR:0.63, 6.15] from diagnosis timeframe), reflecting a considerable time before time 
of diagnosis. Indeed, only 7% of patients had a valid BMI reading in the preceding year 
before the date of diagnosis timeframe. 
Following a diagnosis with type 2 DM, BMI appears to be monitored more closely with 
87% of patients having an available measurement taken after the defined date of 





patients without a BMI at diagnosis value was equal to 0.37 years with 50% of 
measurements occurring between 0.24 and 0.73 years (or 0.21 years after defined 
diagnosis timeframe [IQR: 0.08, 0.57]).  
The number of available measurements before and after the diagnosis time-frame 
highlights the intensification of risk factor monitoring upon diagnosis with DM; the 
median number of within-patient measurements before diagnosis: 1 (IQR: 0, 2) vs. after 
diagnosis: 3 (IQR: 1, 5).  
 INCORPORATING LONGITUDINAL DATA TO IMPROVE IMPUTATIONS  7.3
 INTRODUCTION 7.3.1
There are various options for incorporating longitudinal data into missing data analyses, 
each of which have features that make them more or less appropriate to apply to this 
routinely collected dataset. This section illustrates the use of these methods in an 
analysis of the association between BMI at diagnosis with DM and all-cause mortality.   
 METHODS  7.3.2
This subsection will describe the methods applied to handle missing data in the SCI-DC 
register and is divided into single imputation and multiple imputation approaches. 
Results from each approach will be compared to results from CCA.  
7.3.2.1 EXCLUSION CRITERIA 
The exclusion criteria are displayed in Figure 7.3. Unfortunately, some of the selected 
methods for handling missing data could not identify a suitable value for the missing 
data point when patients did not have any BMI measurements at all. Therefore to ease 
the comparison of estimates from each method, a further 1,401 patients with no BMI 





Figure 7.3: Exclusion criteria for analysis involvi ng use of longitudinal data to impute 
missing data 
FULL COHORT     
n = 274,363 
n = 241,328 
n = 241,091 
Removed patients without 
type 2 DM  
(n=33,035) 
Excluded patients who had 
died within 2 years of date 
of diagnosis  
(n=3,089) 
n = 77,948 
n = 66,372 
Excluded patients with 
missing data on variables to 
be included in analysis or 
missing data model 
(n=8,487)  
Excluded patients who were 
diagnosed with diabetes 
after July 2008 
(n=238) 
Excluded patients who were 
diagnosed with diabetes 
before January 2004 
(n=163,143) 
n = 69,461 
Excluded patients who did 
not have any BMI 
measurements 
(n=1,401) 






7.3.2.2 DELETION APPROACH 
COMPLETE CASE ANALYSIS 
Analyses were conducted only on patients with complete data. This analysis will serve as 
a comparison to the other analyses using alternative methods of handling unobserved 
data. 
7.3.2.3 SINGLE IMPUTATION APPROACHES  
CLOSEST OBSERVATION IMPUTATION 
Missing values were replaced with those observations that lay closest to the date of 
diagnosis timeframe. In essence, this method simply extends the diagnosis time-frame.  
EXTRAPOLATED BMI IMPUTATION 
Missing BMI values at diagnosis were replaced with predicted values from individual-
level linear regressions using all available BMI measurements. Where patients only had a 
single BMI measurement, this single BMI measurement was used.  
7.3.2.4 MULTIPLE IMPUTATION APPROACHES 
INCLUDING EXTRAPOLATED BMI IN IMPUTATION MODELS 
uvis for STATA was used to create 25 multiply imputed datasets to coincide with the 
proportion of missing data, as recommended by Bodner (2008). The imputation model 
included the following variables BMI at diagnosis (categorical), age at diagnosis 
(continuous), sex (binary), year of diagnosis (categorical), deprivation status (categorical), 
vital status (binary), smoking status (binary), follow-up time (continuous), Charlson 
comorbidity index (binary), diastolic BP (continuous), total cholesterol (continuous), 
HBA (categorical) and extrapolated BMI (categorical). Extrapolated BMI was divided 
into 5kg/m2 intervals (<25kg/m², 25 to < 30kg/m², 30 to <35kg/m2, 35 to 40kg/m2 
and ≥40kg/m²).  
INCLUDING MEASUREMENTS RECORDED BEFORE AND AFTER DIAGNOSIS 
The ice command in STATA was used to include measurements taken one (t-1), two (t-2) 
and three years (t-3) before and one (t+1), two (t+2) and three (t+3) years after the 
diagnosis time-block. Where more than one measurement was available in the year 
block, the nearest measurement to diagnosis chronologically was used. The inclusion of 




therefore necessitated the use of the ice command rather than uvis (Royston, 2005). uvis is 
primarily designed for imputing missing values in a single variable based on multiple 
regression on fully observed variables in the imputation model.  
Briefly, ice imputes missing values in a number of variables by using regression 
switching. This involves the generation of conditional distributions for each variable 
with missing data using observed data on all variables included in the imputation model. 
Imputed values are generated by taking simulated draws from the respective posterior 
predictive distribution (more detail may be found in Section 2.3.1.1). This process is 
repeated for several cycles or iterations in order to stabilise results.   
In its application here, ice was used to impute 60 datasets. This number of imputed 
datasets was selected following the inclusion of further incomplete variables. The model 
included the follow variables BMI at diagnosis, age at diagnosis, sex, year of diagnosis, 
deprivation status, vital status, smoking status, Charlson comorbidity index, follow-up 
time, diastolic BP, total cholesterol, HBA, BMI (t-1, t-2, t-3, t+1, t+2, t+3). These BMI 
measurements were included as categorical variables and were imputed using 
multinomial logistic regression. The imputation process was iterated through 10 cycles, 
the default in STATA.  
TWO FOLD FULLY CONDITIONAL SPECIFICATION (FCS) 
Two-fold FCS is an extension of the MICE model and was proposed by Nevalainen et 
al, (2009) to handle intermittent patterns of missing longitudinal data. To achieve this, 
two fold FCS only conditions on variables at the time-point of interest and 
measurements in immediately adjacent time-blocks only. It has been proposed that this 
approach has two chief benefits over the inclusion of all time-blocks in the same model. 
Firstly, this approach reduces the risk of over-fitting and therefore collinearity problems 
by reducing the number of variables conditioned on in each regression. Secondly, this 
approach allows for the temporal ordering of the measurements to be taken into 
account. 
The STATA command twofold was used to implement this technique (Welch et al., In 
print 2014). Available BMI measurements were again divided into yearly time-blocks 
outside of the BMI at diagnosis time-frame up to 3 years before and after. BMI was 





As per the default settings, the number of among-time iterations was set to 10 and the 
number of within-time iterations was set to 5. Twenty-five imputed datasets were 
created. The following fully observed time-independent variables were included; age at 
diagnosis, sex, year of diagnosis, deprivation status, Charlson comorbidity index, HBA, 
systolic blood pressure and total cholesterol. Since smoking status was the most 
correlated variable with BMI and multiple measurements were available, this was 
included as a binary time-dependent variable.  The outcomes for the substantive model, 
vital status and follow-up time were also included. 
 RESULTS 7.3.3
After exclusion of patients without any BMI measurement, there were a total of 64,971 
patients in the cohort, of whom 12,380 patients were without a recorded BMI at 
diagnosis. Patients without missing data contributed 300,334 person years of follow up 
during which there were 5,491 deaths at a rate of 18.3 deaths/1,000 person-years. 
Patients with missing BMI data contributed 73,559 person-years during which there 
were 1,834 deaths at a rate of 24.9 deaths per 1,000 person-years.  
7.3.3.1 CCA 
CCA resulted in the exclusion of 12,380 patients without a BMI at date of diagnosis. 
Obtained results were the same as presented in Section 6.3.2. 
7.3.3.2 CLOSEST OBSERVATION IMPUTATION 
Closest observation imputation was applied to impute values for the 12,380 patients 
who were without a BMI at diagnosis. Table 7.4 presents the multivariate HRs, adjusted 
for age at diagnosis, sex, smoking status, deprivation status and Charlson comorbidity 
index, along with absolute age-standardised mortality rates. Figure 7.4 presents a 
comparison of relative and absolute estimates from CCA and closest observation 
imputation. 
Compared with estimates from CCA, replacing missing values with the closest available 
measurement had very little impact on the observed relationship between BMI at 
diagnosis and mortality. Relative risk of mortality was slightly lowered in the 30 to 
35kg/m² group and raised in the less than 25kg/m² group when compared to CCA 




increased across all BMI categories upon using this imputation approach. Mortality in 
the less than 25kg/m² group was raised from 19.1 deaths per 1,000 person-years using 
CCA to 20.9 deaths per 1,000 person-years when closest observation imputation was 
applied. These results were almost identical to estimates obtained when replacing 
individual-level median BMIs to replace missing values (results not shown).  
Table 7.4: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using closest observ ation imputation. 
 BMI category (kg/m²) 
 < 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  







Increase in N from 
CCA (%)a 
1,776 (14.35) 4,056 (32.76) 3,498 (28.26) 1,811 (14.63) 1,239 (10.01) 
      
Multivariable 
adjusted HR (95% 
CI)bc 
1.54            
(1.45, 1.64) 
1.00 
0.98             
(0.92, 1.04) 
1.05               
(0.97, 1.14) 
1.36             
(1.23, 1.51) 
Standard Error 
0.050  0.030 0.043 0.070 
      
No. deaths 1,592 2,545 1,891 797 490 
Person years 41,181 115,437 113,133 58,567 39,722 
Crude mortality rate 
c 
38.6 21.9 16.7 13.6 12.3 
Age-standardised 
mortality ratec  
20.9            
(19.3, 22.5) 
12.2           
(11.5, 12.8) 
11.8         
(11.1, 12.2) 
12.1           
(11.1, 13.2) 
15.8         
(13.5, 18.1) 
a Adjusted for age, sex, smoking status, deprivation status and Charlson comorbidity index, b with 95% 






Figure 7.4: Comparison of a) Estimates of relative hazard of all-cause mortality and b) 
deaths per 1,000 person-years by categories of BMI at diagnosis of diabetes after 
using closest observation imputation and CCA.  Deaths in the first two years after 
diagnosis of type 2 DM were excluded. Reference cat egory is 25 to less than 30kg/m² 
group in a).  
 
Overall, the median time from diagnosis at which a BMI was available was 23 days 









































 <25 25 to < 30 30 to <35 35 to < 40 =>40

































 <25 25 to < 30 30 to <35 35 to < 40 =>40
BMI at date of diagnosis, kg/m²
Complete case analysis
Closest observation imputation





days of diagnosis and 99% had a measurement within 969 days of measurement. 
Amongst imputed values, the median time from diagnosis at which measurements were 
recorded was 148 days (IQR: 91, 324). Ninety-one percent of imputed measurements 
were recorded after diagnosis at a time when DM treatments were likely to have affected 
measurements.  
To ascertain how well measurements recorded outside of the BMI time-frame described 
BMI at diagnosis measurements, a series of comparisons were made between 
measurements recorded at diagnosis and closest available measurements. In order to do 
this, it was necessary to firstly identify patients with a BMI at diagnosis and a BMI 
measurement recorded before diagnosis (Patterns E & G in Table 7.3) and secondly 
patients with a BMI at diagnosis and a BMI measurement recorded after diagnosis 
(Patterns E & F in Table 7.3). The validity of using patients with observed BMI data and 
additional records prior to or after diagnosis to assess the likely performance of using 
measurements recorded before and after diagnosis is questionable. Patients without data 
at diagnosis may have very differing trends in BMI around diagnosis than those with 
BMI data at diagnosis. Caution is therefore required when interpreting these results.  
To compare measurements, Pearson’s correlation coefficients and linear regression 
coefficients were calculated. Mean differences between measurements taken before and 
at diagnosis with DM were also calculated. Both measurements of BMI were then 
categorised and the percentage concordance between categories was examined. All 
results are stratified by time at which measurements recorded before were available. 
Measurements taken before diagnosis time-period 
Overall, 38,820 patients had an available measurement recorded before the diagnosis 
timeframe, Table 7.5 displays the correlation and concordance between measurements 
recorded before and measurements recorded within the diagnosis timeframe. Results are 
stratified by years before diagnosis. Fifty percent of closest measurements recorded 
before diagnoses were measured within two years prior to the diagnosis time-frame. A 
further 25% of closest measurements were recorded five years or more before diagnosis.  
Overall, the Pearson’s Correlation coefficient for closest measurements recorded before 





diagnosis timeframe – BMI at diagnosis) was equal to 0.51kg/m² (SD: 3.15), indicating a 
slight weight gain before diagnosis with DM. The overall concordance between 
measurements recorded before and at diagnosis was reasonable. Sixty-seven percent of 
patients would not change BMI category if the closest BMI measurement was used, with 
33% of patients changing categories. Of the patients whose categories were not in 
agreement, the vast majority differed only by a single higher or lower level of BMI (See 
Appendix Table A7.2).  
The level of agreement between measurements decreased as the time between 
measurement and diagnosis increased. Measurements recorded one year prior to the 
diagnosis timeframe were more strongly correlated with measurements at diagnosis 
(Pearson’s correlation 0.93) than measurements recorded over five years before 
diagnosis (Pearson’s correlation 0.77).  
Table 7.5: Agreement between closest measurement re corded before diagnosis and 



















% Concordance  
in BMI category  
0 to <1 
4,221 
(10.87)  




1 to <2 
15,096 
(38.89) 




2 to <3 
5,072  
(13.07) 




3 to <4 
2,696 
(6.94) 




4 to <5 
2,006 
(5.17) 











Overall 38,820 0.51 (3.15) 0.88 










Measurements taken after diagnosis time-period  
There were 46,741 patients with both a BMI at diagnosis and a BMI recorded after 
diagnosis. Table 7.6 displays the correlation and concordance between these 
measurements. Results were stratified into much smaller time intervals than in Table 7.5 
due to the high availability of recordings in the first few years following diagnosis.   
Overall, the correlation between available measurements was strong (Pearson’s 
correlation: 0.95). The correlation between closest measurements and BMI at diagnosis 
was strongest amongst measurements recorded 0.25 years after diagnosis (Pearson’s 
correlation: 0.96) and gradually declined with increasing time from diagnosis. Percentage 
concordance also decreased with increasing time, despite the use of very narrow time-
frames. Overall concordance of measurements used after the diagnosis time-frame was 
78%. This value is higher than observed in Table 7.5 for measurements recorded before 
diagnosis but this possibly reflects the shorter time-frame. For those measurements 
which were not in agreement, 12% of BMI measurements recorded after diagnosis were 
in higher BMI categories and 10% were lower than those measurements recorded at 
diagnosis (Appendix Table A7.3).   
The mean difference between measurements recorded at diagnosis and the closest 
measurement recorded after diagnosis was -0.45kg/m², thus reflecting an overall 
decrease in BMI after diagnosis. Interestingly, the mean difference in measurements 
decreased with increasing time (Mean difference in BMI measurements at 0 to 
<0.25years: 0.47kg/m² vs. Mean difference in BMI measurements at ≥1.25 years: 
0.28kg/m²). This could reflect weight loss followed by weight gain over the longer 
period of time or perhaps biased recording of weight for people that lost weight soon 










Table 7.6: Agreement between closest measurement re corded after diagnosis and 
measurement recorded at diagnosis with DM. 
7.3.3.3 EXTRAPOLATED BMI IMPUTATION  
Absolute and relative risks of all-cause mortality by category of BMI are presented in 
Table 7.9. These estimates are presented along with estimates from CCA in Figure 7.5. 
Compared with CCA, extrapolated BMI imputation produced a more marked U-shaped 
relationship with the lowest risk of death occurring in the 30 to <35kg/m² category. 
The risk of mortality in this group dropped from 0.98 to 0.87 upon using extrapolated 
BMI imputation. Similarly, compared to when CCA was used, the risk of mortality was 
considerably lowered in the <25kg/m² category (mv. HR using CCA: 1.56 vs. 1.35 using 
extrapolated BMI imputation), whilst the HR remained the same in the two highest BMI 
categories. Absolute risk of mortality increased across all BMI categories using 
extrapolated BMI category. The smallest changes in absolute mortality were observed in 
the 30 to <35kg/m² category. 
 
 





















0.47 (1.85) 0.96 
0.984             
(0.979, 0.990) 
80.70 
0.25 to < 0.50 
17,310 
(37.03) 
0.51 (1.94) 0.96 
0.976         
(0.971, 0.980) 
77.82 
0.50 to <0.75 
8,361 
(17.89) 
0.47 (2.09) 0.95 
0.952           
(0.945, 0.959 
76.56 
0.75 to <1.00 
4,257 
(9.11) 
0.39 (0.26) 0.94 
0.952            
(0.941, 0.962) 
75.47 
1.00 to <1.25 
3,752 
(8.03) 
0.32 (2.41) 0.93 






0.28 (6.25) 0.93 






0.45 (2.05) 0.95 






Table 7.7: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using extrapolated B MI imputation 
 BMI category (kg/m²) 
 < 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  







Increase in N from 
CCA (%)a 
1,778 (14,36) 4,109 (33.19) 3,475 (28.07) 1,759 (14.21) 1,259 (10.17) 
      
Multivariable 
adjusted HR (95% 
CI)bc 
1.35        
(1.18, 1.54) 
1.00 
0.87           
(0.76, 0.99) 
1.04         
(0.87, 1.24) 
1.39         
(1.13, 1.73) 
Standard Error 
0.092  0.059 0.094 0.154 
      
No. deaths 1,583 2,577 1,859 789 507 
Person years 41,197 116,774 113,049 58,231 39,784 
Crude mortality rate 
d 
38.4 22.1 16.4 13.5 12.2 
Age-standardised 
mortality rate c d 
20.7            
(19.1, 22.4) 
12.4           
(11.8, 13.0) 
11.6         
(10.9, 12.2) 
12.2           
(11.0, 13.2) 
16.1         
(14.1, 18.1) 
a Percentage of missing data, b Adjusted for age, sex and smoking status, deprivation status and Charlson comorbidity 











Figure 7.5:  Comparison of a) hazard ratio estimate s for risk of all-cause mortality and 
b) deaths per 1,000 person-years by categories of B MI after using CCA and 
extrapolated BMI imputation. Deaths in first two ye ars of after diagnosis of type 2 DM 
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Table 7.8: Agreement between categories of extrapol ated BMI and BMI at diagnosis 
 BMI at date of diagnosis (kg/m²) Diagonal 
Total (% of 
52,591) 

















< 25 4,856  
(85.93) 
759                
(4.66) 
7             
(0.04) 
2            
(0.02) 











16           
(0.19) 














5 (0.09) 7 (0.04) 665 (4.06) 6,606 
(77.70) 
897        
(15.51) 
45 (0.09) 




Total (% of 
52,591) 
- 5 (0.01) 9 (0.02) 41 (0.08) 2,874 (5.46) 44,462 
(84.64) 
 
Upon categorisation of extrapolated BMI values and BMI at date of diagnosis levels, 
BMI groups were concordant for 85% of cases (Table 7.8). Where concordance was not 
achieved, the vast majority of patient’s BMI categories differed by only a single BMI 
category, with 10% of patients having an extrapolated BMI that was lower than the 
observed BMI at diagnosis and 5% having a value that was above the observed value. 
On average, extrapolated BMI values were 0.26kg/m² lower than observed BMI values 
at diagnosis.  
7.3.3.4 MULTIPLE IMPUTATION – INCLUDING EXTRAPOLATED BMI  
Multiple imputation was used to create 60 imputed datasets. The relative and absolute 
mortality risks are presented in Table 7.9, and a comparison of estimates from CCA and 
multiple imputation are displayed in Figure 7.6. Estimates for relative and absolute 
mortality have been pooled across the 25 datasets. The observed patterns of mortality 
risk by BMI category are largely similar to those observed when closest imputation was 
applied. Estimates from multiple imputation including BMI measurements taken before 
and after diagnosis were identical to estimates obtained including extrapolated BMI and 
are displayed in Appendix Table A7.4. Unfortunately, only measurements taken at time-
points t, t+1 t+2, t-1 and t-2 could be included in this imputation model due to issues 
with collinearity when further measurements outside this timeframe were incorporated 
into the multiple imputation model. The extent of the missing data in these variables is 





Table 7.9: Estimates of relative hazard of all-caus e mortality and age-standardised 
mortality by categories of BMI using multiple imput ation (+extrapolated BMI). 
a Percentage of missing data, b Adjusted for age, sex and smoking status, deprivation status and Charlson comorbidity 







 BMI category (kg/m²) 
 < 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  







Increase in N from 
CCA (%)a 
1,604 (12.96) 3,978 (32.13) 3,605 (29.12) 1,851 (14.95) 
1,342   
(10.84) 
      
Multivariable 
adjusted HR (95% 
CI)bc 
1.51           
(1.41, 1.60) 
1.00 
0.96        
(0.90, 1.02) 
1.01         
(0.93, 1.09) 
1.33               
(1.21, 1.47) 
Standard Error 
0.050  0.030 0.043 0.068 
      
No. deaths 1,543 2,583 1,900 789 500 
Person years 40,183 115,849 113,816 58,857 40,332 
Crude mortality rate 
d 
38.4 22.3 16.7 13.4 12.4 
Age-standardised 
mortality ratec d 
20.6          
(18.5, 22.7) 
12.5           
(11.4, 13.6)  
11.7            
(10.6, 13.0)  
12.0           
(10.5, 13.5) 






Figure 7.6: Comparison of a) hazard ratio estimates  for risk of all-cause mortality and 
b) deaths per 1,000 person-years by categories of B MI after using CCA and multiple 
imputation. Deaths in first two years after diagnos is of type 2 DM are excluded. 
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7.3.3.5 TWO FOLD FULLY CONDITIONAL SPECIFICATION (FCS) 
Two fold FCS was conducted to produce 25 imputed datasets. Minor problems with 
using this technique were quickly resolved upon corresponding with Catherine Welch, a 
member of the team which developed the two fold FCS tool in STATA. For example, 
unlike in the majority of other STATA commands the whole name of variables need to 
be specified to allow the model to run. Running the imputation model was time-
consuming and complicated. It was necessary to find a balance between incorporating 
more predictors, whilst attempting to limit the introduction of additional missing data. 
Using two-fold FCS did not affect the overall observed relationship between BMI at 
diagnosis and all-cause mortality (Table 7.10 & Figure 7.7). A U-shaped relationship 
between patient BMI was observed with the lowest risk of mortality occurring in the 25 
to <30kg/m² and 30 to <35kg/m² group. The relative risk of mortality in the highest 
and lowest BMI categories was again lowered using this multiple imputation approach. 
Table 7.10: Estimates of relative hazard of all-cau se mortality and age-standardised 
mortality by categories of BMI using two fold fully  conditional specification 
a Percentage of missing data, b Adjusted for age, sex and smoking status, deprivation status and Charlson comorbidity 
index c with 95% CI, d deaths per 1,000 person-years. CCA: CCA  
 
 
 BMI category (kg/m²) 
 < 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  







Increase in N from 
CCA (%)a 
1,548 (12.50) 4,115 (33.24) 3,776 (30.50) 1,746 (14.10) 1,195  (9.65) 
      
Multivariable 
adjusted HR (95% 
CI)bc 
1.37           
(1.27, 1.47) 
1.00 
1.00        
(0.93, 1.07) 
1.06         
(0.97, 1.16) 
1.30               
(1.16, 1.45) 
Standard Error 
0.052  0.035 0.050 0.076 
      
No. deaths 1,520 2,597 1,943 748 507 
Person years 40,943 116,201 114,008 58,351 39,510 
Crude mortality rate 
d 
37.1 22.3 17.0 12.9 12.8 
Age-standardised 
mortality ratec d 
18.7          
(17.1, 20.3) 
11.9           
(11.3, 12.5)  
11.8            
(11.1, 12.5)  
12.8           
(11.6, 14.0) 






Figure 7.7: Comparison of a) hazard ratio estimates  for risk of all-cause mortality and 
b) deaths per 1,000 person-years by categories of B MI after using CCA and two-fold 
fully-conditional specification.Deaths in first two  years after diagnosis of type 2 DM 
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 INTRODUCTION  7.4.1
In the previous chapter, the poor predictive value of available characteristics at diagnosis 
was a key limitation of the performance of multiple imputation. Available characteristics 
were only able to account for around 15% of the variation in the BMI at diagnosis 
measurements. This problem is not unusual in epidemiological studies (van Buuren et 
al., 1999). Fortunately, routine data sources commonly have longitudinal records of 
important health indicators which may be used to improve the prediction of missing 
values. Nevertheless, irregular patterns of risk factor recording make the incorporation 
of these measurements into statistical analyses difficult. This chapter attempted to 
summarise the use of a number of approaches for utilising repeatedly measured data to 
improve imputations and to highlight the strengths and weaknesses of respective 
methods.  
 RELATIONSHIP BETWEEN BMI AND ALL-CAUSE MORTALITY 7.4.2
Across all methods for handling missing data, risk estimates for mortality across BMI 
groups remained fairly stable. Each approach produced a U-shaped relationship in 
mortality with the highest risk of mortality occurring in the lowest BMI category 
(<25kg/m²). It is difficult to be certain about explanations for the stability in estimates. 
One reason may have been the relatively small amount of missing data occurring in the 
BMI at diagnosis variable (20%). Alternatively, there may well have been a lack of bias 
in the CCA approach.   
Despite age-standardised mortality rates between patients with and without (17.8 deaths 
per 1,000 person years vs. 26.3 deaths per 1,000 person years) BMI at diagnosis data 
appearing considerably different, these differences did not affect the relative 
relationships between BMI and all-cause mortality. Each method indicated that patients 
with missing data exhibited a similar distribution across the categories of BMI to those 
patients with observed data. Of the patients with imputed data, there did not appear to 
be a clustering of the patients at the highest risk of mortality into a single BMI group. 




fairly uniformly across all BMI categories after imputation regardless of the method for 
handling missing data.   
 PERFORMANCE OF MISSING DATA METHODS  7.4.3
7.4.3.1 CLOSEST OBSERVATION IMPUTATION 
Closest observation imputation was the first method utilised to handle missing data in 
BMI. Relative estimates from this method were virtually identical to those observed 
using CCA, whilst absolute estimates were raised fairly uniformly across all BMI 
categories. Marginally larger increases in absolute mortality were observed in the highest 
and lowest than in other BMI categories. The relationship remained U-shaped and 
therefore it is unlikely that these small changes would alter overall inferences. 
Of the imputed data, 90% of imputed values were derived from measurements taken 
after diagnosis with type 2 DM and 50% of these measurements were recorded 3 
months after the defined diagnosis timeframe.  
Closest observation imputation makes the assumption that closest observations 
accurately describe true BMI at diagnosis and therefore that BMI remains constant for 
considerable periods of time in some cases. This may not be a valid assumption, 
particularly where imputed data were derived from measurements recorded after 
diagnosis with DM. The diagnosis of type 2 DM is likely to trigger weight changes for 
two main reasons. Firstly, upon diagnosis with type 2 DM, current guidelines advise 
practitioners to offer individualised interventions, such as lifestyle changes and 
pharmacological therapies to encourage patient weight loss (Scottish Intercollegiate 
Guidelines Network, 2010). Secondly, the initiation of treatment with anti-
hyperglycaemic agents is well known to affect body weight. For example, the association 
between insulin therapy and weight gain is well-established (UK Prospective Diabetes 
Study Group, 1998). Nonetheless, metformin treatment is more usually the first line 
pharmacological treatment, whilst insulin treatment is usually only required in the longer 
term (UK Prospective Diabetes Study Group (UKPDS), 1998). Metformin has been 
shown, in some studies to cause small, yet long term weight losses (Stumvoll et al., 1995; 





Observational studies that have examined weight changes in newly diagnosed patients 
with type 2 DM have had mixed findings. De Fine Olivarius et al. (2006) reported 
sustained weight loss in newly diagnosed patients in Denmark, up to 5 years after 
diagnosis date, though this was largely dependent on treatment type. Weight loss was 
highest in patients whose treatment was advice on diet, whilst patient weight remained 
stable upon initiation of treatment with metformin or sulfonylureas. Across all treatment 
groups, weight changes were greatest in the first five months following diagnosis. In 
another study, Tuthill et al. (2008) observed that 60% of patients with type 2 DM 
identified in a hospital database in Ireland exhibited either a decrease or no change in 
weight in six months following treatment initiation. However, both of these studies 
were conducted on relatively small samples (<1,500 participants) and while the Danish 
study used CCA to handle unobserved data for 17 participants, there was no description 
of the chosen method for handling missing data in Tuthill et al.’s study.   
Another study observed that 53% of newly diagnosed type 2 DM patients in Sweden  
(n=8,486) had no change in their BMI (i.e. within 1 units) during the first 18 months 
after diagnosis (Bodegard et al., 2013). Thirty-two percent of patients had decreased 
BMI (defined as a fall of 1 or more units) and 14% had increased BMIs (gain of 1 or 
more units). Again, this study used CCA to handle unobserved data. Using trajectories 
to observe trends in BMI following diagnosis, Chiu et al. (2013) reported that 75% of 
participants in the Health and Retirement Study in the United States exhibited stable 
weight trajectories, whilst 18% of participants lost weight before regaining and 7% 
gained weight during 10 years of follow-up. The analyses in this study were conducted 
using maximum likelihood estimation and therefore were able to incorporate patients 
with missing data. Additionally, the authors reported results from those patients with 
CCA and the findings were similar. No studies were identified which provided data on 
weight change following diagnosis of DM from patients in the United Kingdom.  
Amongst patients with BMI recordings at diagnosis and after diagnosis in our study, 
closest measurements recorded after diagnosis were generally consistent with 
measurements within the diagnosis time-frame. Generally, patients exhibited a slight 
decline in BMI (-0.37kg/m²) after diagnosis, though these changes resulted in a change 




The median time between the diagnosis time-frame and the next closest measurement 
was 91 days amongst patients with a BMI recording at diagnosis. Amongst patients with 
imputed BMI values, the time between diagnosis time-frame and closest BMI 
measurement was 88 days. Providing the trends in BMI were similar between patients 
with and without a BMI at diagnosis, the imputation of closest measurements taken 
after diagnosis (91% of imputed values) to reflect BMI at diagnosis could be expected to 
provide a reliable estimate of BMI around diagnosis of DM. However, this is an 
unverifiable assumption.  
Similarly the accuracy of the nine percent of imputed values recorded prior to the 
diagnosis time-frame cannot be verified. Previous studies have indicated a steady rise in 
weight up until diagnosis of DM. One observational study has presented findings from 
incident type 2 patients indicating an average weight gain of 14.7kg from young 
adulthood until time of diagnosis (De Fine Olivarius et al., 2008). Overall, weight gain 
from 10 years prior to diagnosis was considerably smaller (+1kg), however significant 
weight loss was noted in the year immediately preceding diagnosis with DM. De Fine 
Olivarius et al. (2008) suggested that this may reflect the effect of hyperglycaemia and 
the resultant energy losses through glycosuria. Another study analysing data from 1965 
to 2000 in Central Arizona reported that patient BMI steadily climbed between 0.43 and 
0.71kg/m² per year before diagnosis but declined after diagnosis (Looker et al., 2001). 
However, using latent class trajectory analysis in a population of newly-diagnosed 
patients with diabetes in the Whitehall II study, Vistisen et al. (2014) found that 94% of 
patients could be categorised as ‘stable overweight’ prior to diagnosis with diabetes. 
These patients were characterised as having an average BMI in the overweight range for 
the period prior to diagnosis of diabetes (18 years), though exhibiting an average weight 
gain of 2.3 BMI units between baseline and end of follow-up. In a general population 
study, Bhaskaran et al. (2013) reported that previous BMI measurements (recorded 
within 3 years) were comparable to ‘most recent’ BMI values whilst measurements 
recorded more than 3 years prior to time of interest tended to underestimate later BMI 
values. This error was reduced by using a model-based imputation approach whereby a 
linear model for change in BMI over time was used to predict the most recent BMI. 
However, it is uncertain if these findings would be applicable to a population of type 2 





In our data, the correlation between patient measurements taken before and at diagnosis 
(Pearson’s Rank Correlation: 0.88) was weaker than the correlation between 
measurements taken after and at diagnosis (Pearson’s Rank Correlation: 0.95). This 
weaker correlation may reflect the longer period of time at which measurements taken 
before diagnosis are available, rather than true biological differences.  
Overall, in patients with a measurement taken at diagnosis, measurements recorded 
before and after diagnosis appear to be a reasonable estimate of BMI category at 
diagnosis. Unfortunately, whether these trends apply to patients without a BMI at 
diagnosis cannot be ascertained. It seems plausible that some practitioners may not have 
recorded patients whose weight was in agreement with previous recordings. In this 
scenario, closest observation imputation may produce unbiased estimates. Again 
though, this is an untestable theory using the data at hand. 
In previous analyses, BMI at diagnosis was defined as a measurement recorded within 
10 months prior to or 2 months after diagnosis. Here, this definition was expanded to 
include the closest BMI measurements and produced very similar results to those 
obtained from the CCA using the original definition of BMI at diagnosis. This work 
indicates that instead of using complicated modelling methods for handling unobserved 
repeatedly measured variables in routinely collected data sources, the expansion of the 
time-interval of interest may be sufficient to overcome problems associated with 
unobserved data. This approach to handling unobserved values is considerably more 
straight-forward and quicker to execute than more advanced approaches. Future work 
using routine data sources could investigate whether this approach produces valid 
estimates that are similar to those obtained using complicated methods.   
Closest observation imputation is largely similar to the traditionally used last observation 
carried forward (LOCF) approach. LOCF itself was not feasible in this dataset where 
some patients did not have BMI measurements prior to the diagnosis timeframe. 
However, LOCF and its derivatives have been widely criticised, especially in the clinical 
trial literature where dropout is likely to be related to the outcome or the assigned 
treatment group. In this dataset, missingness in BMI was strongly associated with the 
outcome of mortality and unintentional weight loss often precedes death. Depending on 




time before death. For example, weight loss in patients with cancer has been shown to 
accelerate significantly three years before death, regardless of age (Alley et al., 2010). 
This creates two problems. Firstly, using closest observation imputation may not have 
been valid if these patients had other chronic conditions as these conditions may have 
contributed to their observed weight taken outside the diagnosis timeframe. 
Comorbidity status was assessed at diagnosis and therefore may not reflect comorbidity 
status at BMI measurement date. Secondly, the exclusion of patients who had died 
within two years of diagnosis of type 2 DM may not have adequately controlled against 
reverse causation.  
A further criticism of this single imputation approach is its inability to take into account 
the uncertainty of the imputed data (Little & Rubin, 1987). Accordingly, closest 
observation imputation is likely to have produced standard errors which were too small 
and confidence intervals that were too narrow.    
7.4.3.2 EXTRAPOLATED BMI IMPUTATION  
Absolute estimates of the association between BMI at diagnosis and all-cause mortality 
obtained using extrapolated BMI imputation were almost identical to those obtained 
using CCA and closest observation imputation. The similarity between estimates using 
the two imputation methods is unsurprising given that assigned BMI categories from 
the two methods were in agreement for 10,423 (84% of 12,380) individuals. However 
1,302 of these were the same since only a single BMI measurement was available. 
Relative estimates however indicated that a higher proportion of relatively healthier 
patients were placed in the 30 to <35kg/m2 group using extrapolated BMI imputation. 
Estimates from extrapolated BMI imputation are likely to be more reliable than those 
obtained from closest observation imputation. Imputes using closest observations were 
generally available after diagnosis. Since patients with missing data had worse survival, 
the date of determination of their closest BMIs was likely to be closer to their date of 
death. This therefore increased the likely influence of reverse causation and therefore 
may have accounted for the increased risk of death in the <25kg/m2 category when 
using closest observation imputation.  
Nonetheless, the validity of using extrapolated BMI imputation to handle missing BMI 





individuals only had a single BMI measurement from which to calculate a BMI at 
diagnosis. This meant that the predicted BMI at diagnosis was equal to the available 
measurement, regardless of time from diagnosis. Secondly, the use of this technique did 
not allow for within subject variability. Thirdly, this method led to the production of 
implausible BMI measurements (above 75kg/m2 or below 15kg/m2) where recordings 
were available a long time prior to or after diagnosis (See section 4.3.3.3 for more detail). 
These individuals were included in the highest and lowest BMI categories to avoid the 
exclusion of further patients. Interpolation of missing values, whereby measurements 
taken before and after are used to predict the unobserved measurement may have 
helped to overcome this problem. Unfortunately, this approach was not feasible in this 
dataset where not every patient had measurements available before and after the 
diagnosis timeframe. Finally, amongst individuals with few measurements, extrapolated 
BMI values were likely to have been heavily affected by BMI outliers. 
Nonetheless, according to findings where extrapolated BMI and observed BMI at 
diagnosis measurements were compared, the performance of extrapolated BMI was 
good. Categories of extrapolated BMIs and observed BMIs at diagnosis were in 
agreement 87% of the time, and the mean difference was equal to only 0.24kg/m2. This 
difference indicates that extrapolated BMI underestimated BMI at diagnosis, though this 
difference was small enough that it would rarely result in a change of BMI category. 
Unfortunately, these findings may not be representative of the performance of this 
measure amongst patients with missing BMI data.  
Furthermore, this is another single imputation approach and therefore the uncertainty in 
imputations was not reflected in the calculated standard errors.  
7.4.3.3 MULTIPLE IMPUTATION APPROACHES 
A number of options for incorporating longitudinal data into multiple imputation are 
available. One approach involves the inclusion of a derived summary measure of the 
available longitudinal measurements. An alternative approach involves the inclusion of 
measurements recorded in a number of distinct time-blocks into a single multiple 
imputation model. Most recently, the two-fold fully conditional specification (FCS) 
multiple imputation approach has been proposed to handle longitudinal missing data 




Derivatives of these three approaches were applied and were each found to result in 
very similar estimates. In the first approach, a multiple imputation model including 
extrapolated BMI was used. In the second approach, measurements recorded before 
and after the diagnosis time-frame were included in the imputation model. 
Unfortunately, this approach was not able to account for the temporal ordering of the 
data and therefore gave equal weight to BMI measurements regardless of the timing of 
the recording. This assumption is unlikely to be correct. Unfortunately, collinearity 
issues prevented the inclusion of further BMI measurements. These issues have been 
observed in previous studies incorporating longitudinal data in standard multiple 
imputation approaches (Welch et al., 2014). In their simulation study, Welch et al. (2014) 
reported that their imputation model which conditioned on weight measurements from 
numerous time-blocks failed to run successfully in 25% of datasets due to collinearity 
problems.  
An additional problem for this technique, and indeed the two-fold FCS approach is the 
need to arbitrarily define the width of the time intervals. The specification of the time-
window width is a balance between available measurements within time-periods and the 
limiting of missing data in each window. For example, ideally the width of the time 
blocks would be small in order to incorporate a number of measurements that are likely 
to be highly correlated to the value of interest. However this would result in large 
proportions of missing data within time-windows. It is possible that estimates could 
change depending on the width of the time-interval. Time constraints restricted the 
further exploration of this issue, though it does appear that estimates have been fairly 
robust to changes in the specification of the imputation model.   
The final approach applied was the two-fold FCS method. Again, this method produced 
similar estimates for the relationship between BMI at diagnosis and all-cause mortality, 
despite being considerably more time-consuming. 
This approach is comparatively new and has only recently became available as a STATA 
command (Welch et al., In print 2014). Due to the relative newness of this approach, it 
has yet to be evaluated in a wide range of settings. Despite this, Welch et al. (2014) were 
able to present largely unbiased estimates using two-fold FCS in a simulation study 





this approach was observed when imputing weight compared to the imputation of BP 
and smoking status measurements. This was probably due to the high within-patient 
correlation between weight measurements. However, these analyses were performed on 
generated data which had MCAR data and therefore this approach may yield biased 
estimates when data are MAR. Accordingly the use of this approach requires further 
investigation in a wider range of settings.   
Relative to the other multiple imputation approaches, two fold FCS was considerably 
more computationally intensive, taking a considerably longer time to complete the 
imputation process than previous multiple imputation methods. This problem is likely 
to increase in larger, more complicated models (Nevalainen et al., 2009).  
Despite this, it is clear that this technique has some very attractive features which may 
ensure its widespread use in the future. Indeed, it is likely that this approach might be 
used to improve investigations describing patterns of change in BMI after diagnosis of 
DM in Scotland. Current research investigating weight changes after diagnosis with type 
2 DM and their effect on metabolic and cardiovascular outcomes has been hindered by 
the presence of missing data at different time-points (Aucott et al., 2013). Using CCA, 
the researchers have identified that the majority of patients (>50%) of patients exhibited 
a stable pattern of weight (-2.5% to 2.5% weight change) in the first year following 
diagnosis with DM. Unfortunately, these analyses included only 29,316 cases out of 
81,990 cases due to the presence of missing data. Two-fold FCS could therefore be 
more useful in imputing missing values at these different time-points, rather than being 
limited to imputing BMI at a single time-point.  
Each multiple imputation approach had the benefit of overcoming the problem 
associated with underestimated standard errors. Nonetheless they produced largely 
comparable results to single imputation approaches, despite taking a considerably time 
longer to implement.  
 LIMITATIONS 7.4.4
This investigation of available approaches for incorporating longitudinal measurements 
to improve imputations had a number of potential limitations. Firstly, patients 




after 2008 at the time of writing up. Therefore these patients typically will have had less 
information from which to estimate missing values with. However, the numbers of 
patients diagnosed in 2008 were low since data extraction occurred in June 2008, and 
amongst these patients BMI at diagnosis completeness was higher than observed in 
earlier years (88%). Secondly, these approaches heavily depend on the definition of cut-
off points that may or may not be correct. For example, the width and definition of the 
time-window for measurements of BMI at diagnosis was arbitrarily defined and may not 
truly reflect BMI at diagnosis. It may well have been beneficial to explore how much 
estimates for the association between BMI and mortality changed by altering the 
definition of BMI at diagnosis. This could certainly be investigated in the future. 
Similarly, the width of the time-blocks for the BMI measurements was also arbitrarily 
defined. Unfortunately the width of the time-blocks needed to be the same in two-fold 
FCS whether the measurements were recorded before or after diagnosis. This is despite 
there being considerable more available measurements after diagnosis during shorter 
time-frames. However, using smaller time-frames would have resulted in considerably 
more missing data in the BMI variables recorded before diagnosis (t-3, t-2, t-1).    
Adjustment for hyperglycaemic treatment is a further limiting factor of these analyses. 
BMI measurements recorded after diagnosis were likely to have been affected by hyper-
glycaemic therapy (Yki-Jarvinen, 2001; Aucott et al., 2004; Wing et al., 2013).  
 CONCLUSIONS 7.4.5
Incorporating longitudinal data into analyses with missing data has the potential to 
increase the precision of imputed values whilst also reducing the risk of MNAR. 
Unfortunately, this process is not straightforward using routine data where data tends to 
have intermittent patterns of missing data.  
Several missing data methods which were able to incorporate longitudinal data were 
applied. Despite each respective method making different assumptions, estimates of the 
association between BMI and mortality were robust. Though the absolute risk of 
mortality increased across all BMI categories upon inclusion of patients with missing 
data, it is unlikely that these increases would affect overall inferences of the strength of 





methods for handling unobserved data did not provide any additional benefit. However, 
these results may not be generalisable to different settings with different patterns of 













In previous sections, the pattern of missingness was univariate with only one variable, 
BMI at diagnosis containing missing data. Patients with missing data on any other 
variable to be included in either the imputation model or the model of substantive 
interest were excluded. However, missing data are rarely clustered in a single variable in 
epidemiological research. More usually, missing data are present in multiple variables 
and exhibit a non-monotone pattern of missingness, whereby the configuration of 
missing data are in no clear pattern. Additionally, it is not uncommon for the form of 
the analysis model to be unknown, particularly which variables should be included and 
their functional form. In previous chapters, only variables that have been established as 
important confounders of the relationship between BMI and mortality have been 
included in survival models in an effort to simplify the issues. However, it is probable 
that other available variables may confound this relationship and ought to be included in 
the analysis model to prevent biased estimates. Typically, variable selection for 
unestablished analysis models is implemented using backwards, forwards or stepwise 
selection among the complete cases. Unfortunately, these methods are impractical in 
this dataset for two reasons. Firstly, the sample size is so large that the presence of even 
very small differences away from the null lead to highly significant p-values (p<0.000). 
Secondly, the identification of predictors in the presence of missing data may lead to the 
selection of unimportant variables or the failure to select important variables due to 
biased parameter estimates when data are not MCAR. Fortunately, the relationship 
investigated here has been explored extensively and therefore it was possible to identify 
appropriate confounders using these studies rather than data exploration exercises. 
When researchers are confronted with a missing data problem, they are faced with a 
number of decisions regarding the method for handling missing data. If the researcher is 
concerned that CCA may result in biased estimates or reduce the sample size to an 
unacceptable level then alternative methods for handling missing data are required. Due 
to its accessibility in popular statistical software, multiple imputation is often used when 
data are thought to be MAR (Horton & Kleinman, 2007). There are a number of 





normal model (MVN), the imputation using chained equations (MICE) method first 
implemented by van Buuren et al. (1999) and predictive mean matching (PMM). Each 
of these approaches has been recommended for use in the presence of non-monotone 
missing data. These approaches rest on different theoretical assumptions yet it remains 
unclear how these differences may affect a study’s overall findings.  
The following chapter presents a comparison of results obtained from the three multiple 
imputation models mentioned above. A comparison of the issues raised by using each 
of these methods is presented. Unlike in previous sections, this section will demonstrate 
the use of these techniques in a considerably more realistic setting whereby an 
investigation into the association between BMI and mortality is complicated by the 
presence of multiple incomplete variables. Two separate analysis models will be 
presented. The first will be adjusted for well-known confounders, whilst the second will 
be further adjusted for additional confounders that have been included in analysis 
models in previous studies. 
 METHODS 8.2
 DATA  8.2.1
The data used will be the cohort of patients who were diagnosed with type 2 DM 
between 2004 and 2008 and were alive two years after diagnosis (n=73,890).  
In previous sections, biochemical measurements observed closest to diagnosis date were 
used to describe patient characteristic at diagnosis. In this section, to ensure 
measurements accurately reflect biochemical measurements at diagnosis, recordings 
taken within 1 year of diagnosis (10 months prior to or 2 months after) were used. 
Changes to the definition of biochemical measurements at diagnosis were applied to: 
smoking status, systolic BP, diastolic BP, glycated haemoglobin, creatinine, total 
cholesterol, HDL-cholesterol and triglycerides.  
Additionally, smoking status at diagnosis was divided into three groups; current, former 
and never smokers. In previous sections smoking had been grouped into two distinct 




estimates for the association between BMI at diagnosis and all-cause mortality. Weight 
gain is known to be strongly associated with smoking cessation (Williamson et al., 1991). 
Grouping together former and current smokers together may therefore have diluted the 
relationship between BMI and smoking status.  
 DATA AND EXTENT OF MISSINGNESS 8.2.2
Amongst the cohort of patients diagnosed with DM between 2004 and 2008, the extent 
of and patterns of completeness in variables to be included in the models of substantive 
interest were observed.  
 PREDICTORS OF MISSINGNESS 8.2.3
To ascertain whether patients with missing data were a random subsample of the full 
cohort, a comparison of demographic and biochemical characteristics between patients 
with and without complete data was conducted. To achieve this, a missing indicator 
variable was generated to indicate presence of missing data in any variable to be 
included in the final model. Using this variable, mean and percentage differences 
between patients with and without complete data for all variables were observed. 
Logistic regression analyses were used to identify characteristics that were predictive of 
missing data. The presence of multiplicative interactions was investigated graphically 
and by the inclusion of interaction terms in logistic regression models. To reduce the 
risk of identifying spurious interaction effects, only those interactions considered 
plausible were investigated. These are listed below: 
a. Age at diagnosis vs. Sex 
b. Age at diagnosis vs. Deprivation status 
c. Deprivation status vs. Sex 
d. Charlson comorbidity index vs. Age at diagnosis 
e. Charlson comorbidity index vs. Vital status 
Cox proportional hazards models were used to identify differences in survival between 





person-years) by missing data indicator were also produced. This process was then 
repeated for each incomplete variable individually.  
 ANALYSIS MODEL  8.2.4
Cox proportional hazards models were used to assess the association between categories 
of BMI and all-cause mortality. In Model I, estimates were adjusted for age, sex, 
deprivation status, Charlson comorbidity index and smoking status. In Model II, 
estimates were adjusted for, in addition to those variables listed above, systolic BP, 
glycated haemoglobin, total cholesterol and HDL-cholesterol. Due to the large sample 
size, typical methods for predictor selection such as backward selection would lead to 
the inclusion of unimportant predictor variables. These additional variables included in 
Model II were chosen on the basis of having the propensity to confound the observed 
relationship and have regularly been included in adjusted models in previous studies. 
The proportional hazards assumption was examined using log minus log plots. 
Hypothesis tests for proportionality were not used due to the large sample size. HRs 
and 95% confidence intervals are presented. Estimates were stratified according to 
smoking status to assess potential residual confounding and by Charlson comorbidity 
index (No comorbidity vs. Comorbidity) to reduce the potential for reverse causation. 
Effect modification was investigated by the inclusion of the multiplicative interaction 
term between BMI at diagnosis and the effect modifier in the main effects model. The 
proposed effect modifiers were age at diagnosis (<65 vs. ≥ 65years) and smoking status.  
 MISSING DATA METHODS 8.2.5
CCA were conducted to serve as comparison estimates. Three separate multiple 
imputation approaches were then applied; MICE, multivariate normal model and 
predictive mean matching. The theoretical underpinnings of these techniques are 
described in Section 2.3. 
The imputation of smoking status posed unique challenges. The variable smoking status 
cannot transition from either being a current smoker or an ex-smoker to being a never 
smoker. This feature of the categorical variable was difficult to accommodate in missing 
data methods. To overcome this problem in part, patients with more than one mention 




diagnosis. This was deemed a reasonable assumption given that smoking initiation 
typically occurs in adolescents and young adults, whilst levels of initiation are low 
amongst people over 30 years of age (Oh et al., 2010). In this sample, the mean age at 
diagnosis was 62 years. In addition, for patients who were missing a smoking status at 
diagnosis but had consistent smoking status records before and after diagnosis, it was 
assumed that their smoking status did not change during this time.   
8.2.5.1 MULTIPLE IMPUTATION USING CHAINED EQUATIONS 
STATA’S ice command was used to generate imputed datasets. This iterative procedure 
begins by replacing missing values with randomly selected observed values. It then 
imputes the variable with the least amount of missing data first using the appropriate 
imputation model (linear for continuous, logistic for binary, multinomial logistic 
regression for categorical), regressing on the other variables in the imputation model. 
The variable with the second least missing data is imputed next. This continues until all 
variables with missing data have had their values imputed. This concludes a cycle and in 
order to produce one multiply imputed dataset, the process is iterated for the pre-
selected number of cycles.  
Rubin (1996) recommends that imputation models should be at least as rich as the 
analysis model. Accordingly, an imputation model was developed with analysis Model II 
in mind. Model II is adjusted for age at diagnosis, sex, smoking status, deprivation 
status, Charlson Comorbidity Index, smoking status, systolic blood pressure, glycated 
haemoglobin, total cholesterol and HDL-cholesterol. The imputation model therefore 
included variables which were predictive of missing data and also variables that were 
predictive of missing values themselves.  
In chapter 7, it was observed that the inclusion of repeated variables of longitudinal may 
improve the predictive power of imputation models. For this reason, new variables were 
generated which represented closest measurement of the variable recorded after the 
diagnosis date. The following variables were therefore included in the imputation model:  
• Age at diagnosis (continuous) • BMI at date of diagnosis (ordinal) 






• Deprivation status (ordinal) • Systolic BP at diagnosis (continuous) 
• Vital status (binary) • Closest systolic BP recorded after diagnosis 
(continuous) 
• Follow-up time (log transformed  
continuous) 
• Glycated haemoglobin at diagnosis (log-
transformed continuous) 
• Smoking status at diagnosis 
(categorical) 
• Closest glycated haemoglobin recorded 
after diagnosis (log-transformed 
continuous) 
• Charlson comorbidity index 
(binary – [Comorbidities Y/N]) 
• Total Cholesterol at diagnosis (continuous) 
• Year of diagnosis (ordinal) • Closest Total Cholesterol recorded after 
diagnosis (continuous) 
• Health board area (categorical) • HDL-cholesterol at diagnosis (continuous) 
• Closest smoking status recorded 
after diagnosis (categorical) 
• Closest HDL-cholesterol recorded after 
diagnosis (continuous) 
 
In addition, the interaction terms investigated in the analysis model were included in the 
imputation model. This approach has been proposed to result in smaller downward bias 
than simply generating interaction terms from imputed values, i.e. passive imputation 
(Von Hippel, 2009).  
Evidence of non-normality was observed for follow-up time and glycated haemoglobin 
variables. Failure to correctly handle incomplete non-normal variables would result in 
the distribution of imputed values differing from the distribution of the observed values. 
These variables were therefore log-transformed and imputed values were back-
transformed to the original scale.  
Since missingness occurred in both smoking status at diagnosis and closest smoking 
status after diagnosis variables it was necessary to set rules to ensure patients who were 
smokers at diagnosis could not later become never smokers. To achieve this, the ice 
option conditional was specified. The interval command was used to ensure imputes for 
continuous variables remained within plausible bounds, i.e non-negative for biochemical 
measurements.  
White and Royston (2009) recommend the inclusion of the Nelson-Aalen estimator of 




feasible since the follow-up time variable was incomplete. In chapter 5 it was shown that 
the difference between estimates when using the Nelson-Aalen estimator and when 
using follow-up time in the imputation model was negligible in this large sample. For 
this reason, follow-up time was included in its basic form.  
To ensure convergence was achieved, the number of cycles was set to 20. This was 
more than the default 10 in STATA since there were a number of variables which were 
highly associated (e.g. BMI at diagnosis and closest BMI recorded after diagnosis). 
When this is the case, White et al. (2011) recommend increasing the number of cycles.  
The trace command was used to observe the mean of imputed values after each cycle 
and these were observed to stabilise after between 10 and 20 cycles.  
As recommended by Bodner (2008), the number of imputations was chosen based on 
the fraction of incomplete cases. Since analysis Model II includes only 40% complete 
cases, 60 imputed datasets were created.  
8.2.5.2 PREDICTIVE-MEAN MATCHING (PMM) 
PMM was used to impute missing values of continuous variables, whilst the regression 
models to impute missing values in ordinal, categorical and ordinal variables remained 
the same. The imputation model was specified as above using STATA’s ice command 
with the inclusion of the pmm option. Non-normal variables were not transformed since 
PMM is a suggested means of overcoming issues with non-Normality. Despite the 
default match-pool being 3 in ice, this was set to 10 in accordance with recent 
recommendations (Morris et al., 2014). Sixty imputed datasets were created.  
8.2.5.3 MULTIVARIATE NORMAL (MVN) MULTIPLE IMPUTATION  
STATA’S mi impute mvn was used to implement the multivariate normal model. The 
process of generating imputations using the MVN model is described in detail in 
Chapter 2. Briefly however, the MVN normal model uses an iterative Markov chain 
Monte Carlo (MCMC) method to impute missing values and assumes that all variables 
in the model jointly follow a multivariate distribution. There are two main phases of this 
model. The first phase involves obtaining initial values using the Expectation 







The imputation model was specified as above with the inclusion of the same variables. 
Since this approach assumes normality of continuous variables, non-normal variables 
were log-transformed. In this setting, binary and ordinal variables were imputed as 
dummy indicator variables and rounded to 0 or 1 based on the value of the other 
indicator variables. The number of iterations for the MCMC to converge was set to 200 
(default is 100) due to the high fraction of missing information. Convergence was 
assessed using trace plots of the MCMC parameter estimates. Sixty imputed datasets 
were created. 
 RESULTS 8.3
 EXTENT OF MISSINGNESS  8.3.1
Of the 73,890 patients, 52,980 patients were complete cases for Model I and 27,706 
patients were complete cases for Model II (Table 8.1). For patients with missing data for 
Model I, there were 5,099 patients who were without both values for BMI at diagnosis 
and smoking status, suggesting some clustering of missing values amongst patients. 
Three percent of patients were missing five variables, though these variables were those 
which required a valid date of diagnosis in their construction.  
For model II, there were 11,107 patients who were only without an HDL-cholesterol 
value alone. A further 4,430 patients were missing smoking status, BMI, systolic BP, 











Table 8.1: Completeness of variables included in mo dels of substantive interest  
(n=73,890) 
Variables to be included in 
substantive model 
Observed (%)  
Age at diagnosis 71,405 (96.64) 
Sex 73,834 (99.92) 
Deprivation status 73,365 (99.29) 
Vital status 73,890  (100.00) 
Follow-up time 71,414 (96.65) 
Smoking status at diagnosis 65,215 (88.26) 
Charlson comorbidity index 71,414 (96.65) 
BMI at diagnosis 54,534 (73.80) 
Systolic BP 62,674 (84.82) 
Glycated haemoglobin 49,992 (67.66) 
Total cholesterol 58,829 (79.62) 
HDL-cholesterol  39,785 (53.84) 
 PREDICTORS OF MISSINGNESS  8.3.2
8.3.2.1 ALL VARIABLES TO BE INCLUDED IN MODEL I  
Higher levels of comorbidity were associated with a lower probability of having 
complete data for any variable to be included in Model I (Comorbidities vs. no 
comorbidity: mv OR 1.08 [1.03, 1.12]) (Appendix Table A8.1). Similarly, dying before 
the end of follow up was associated with having missing data (Deceased vs. Alive: mv 
OR 1.25 [1.13, 1.39]). In general, there was no evidence to indicate any biochemical 
measurements were associated with the likelihood of patients being complete cases. 
Higher levels of total cholesterol were marginally protective against having missing data. 
When biochemical measurements were redefined to include only measurements taken 
10 months prior to or 2 months after diagnosis with DM, there remained no evidence 
that these biochemical measurements were associated with the likelihood of being a 
complete case (Appendix Table A8.2). HR estimates indicated that poorer survival was 
predictive of having incomplete data (mv HR missing vs. complete: 1.27 [1.22, 1.33]) 
(Appendix Table A8.3). Since missingness was dependent on the outcome of the 
analysis model, a CCA was likely to produce biased estimates. 
Divergent trends in the risk of missing data in variables to be included in Model I across 
Charlson comorbidity indices were observed by vital status at study endpoint. Among 
MODEL I: Overall 
completeness: 52,980 
(71.70%) 







patients with high levels of comorbid conditions, risk of missing data was highest 
amongst patients that died before the study endpoint than among survivors (Figure 8.1). 
This may reflect considerably poorer health statuses of patients with more comorbid 
conditions who later died compared with patients with more comorbid conditions who 
were still alive at study-endpoint. Accordingly, the recording of clinically unimportant 
variables may not have been prioritised in these extremely unwell patients.  
 
Figure 8.1: Probability of having missing data by C harlson Comorbidity index. 
Stratified by vital status. 
8.3.2.2 ALL VARIABLES TO BE INCLUDED IN MODEL II 
Logistic regressions to explore any differences between patients with (n= 27,706) and 
without (n=46,184) complete data identified similar trends in missingness to those 
observed for missingness in Model I variables (Appendix Table A8.4 & A8.5). As 
before, better survival was associated with complete cases, as was the absence of 
comorbidities. Interestingly, evidence pointed towards a relationship between year of 
diagnosis and the probability of being a complete case (2008 vs. 2004 mv OR: 0.42 
[0.36, 0.49]); an association that was not observed amongst complete cases for Model I. 
Since complete cases in this analysis included patients who had complete data for 
additional biochemical variables such as total cholesterol, this trend may reflect an 
increased emphasis on recording these variables between 2004 and 2008. This may 




completeness of total cholesterol is not considered. Lower glycated haemoglobin levels 
at diagnosis were associated with a higher probability of having missing data (mv OR: 
0.92 [0.91, 0.93]). No evidence of any multiplicative interaction was observed.  
8.3.2.3 IN INDIVIDUAL VARIABLES (INCLUDED IN MODEL I AND/OR MODEL II) 
Next, predictors of missingness in each individual variable with incomplete data were 
observed (Appendix tables A8.7, A8.9, A8.11, A8.13, A8.15, A8.17). The trends in 
missingness by demographic and clinical characteristics for each individual variable with 
incomplete data were largely similar. For example, vital status, survival (Appendix tables 
A8.8, A8.10, A8.12, A8.14, A8.16, A8.19) and HBA were all strongly associated with 
missingness in each individual variable. Being male was associated with lower levels of 
missing data in each distinct variables but the relationship was strongest for missingness 
in BMI (male vs. female mv OR: 0.89 [0.84, 0.93]) and total cholesterol (male vs. female 
mv OR: 0.86 [0.81, 0.92]).  Additionally, the probability of having missing smoking 
status, total cholesterol and HDL-cholesterol data increased with earlier calendar year of 
diagnosis, while a U-shaped relationship between year of diagnosis and missingness in 
BMI and systolic BP was also observed. Longer lengths of follow-up were associated 
with a higher probability of having unobserved data amongst the glycated haemoglobin, 
total cholesterol and HDL-cholesterol variables only. Meanwhile, the probability of 
having incomplete data in the BMI at diagnosis, smoking status and systolic BP 
variables were highest amongst patients with comorbidities.  
 COMPLETE CASE ANALYSIS (CCA) 8.3.3
CCA resulted in the exclusion of 20,910 patients for Model I (4,798 deaths and 104,560 
person-years, crude mortality: 45.9 deaths per 1,000 person-years) and 46,184 patients in 
Model II (7,582 deaths and 250,564 person-years, crude mortality: 30.3 deaths per 1,000 
person-years). Therefore there were 52,980 patients included in Model I analyses (5,484 
deaths and 300,592 person-years, crude mortality: 18.2 deaths per 1,000 person-years) 
and 27,706 patients included in Model II analyses (2,700 deaths and 154,589 person 
years, crude mortality: 17.5 deaths per 1,000 person-years).   
Estimates for the association between BMI and all-cause mortality are presented in 





relationship was observed with the highest risk of mortality being observed in the lowest 
and highest BMI categories. The lowest risk of mortality was observed amongst obese 
patients (30 to <35kg/m²).  
Results were stratified by smoking status to assess for residual confounding (Table 8.3). 
Estimates were similar for current, ex- and never smokers in Model I. However, relative 
mortality in the >40kg/m² group was higher amongst non-smokers mv OR: 1.59 [1.31, 
1.93]) than current smokers (mv OR 1.31 [1.05, 1.65]). In an effort to control for the 
potential effects of reverse causation by chronic diseases, results were stratified by 
presence of comorbidities (Figure 8.2 - panels E & F) (Table 8.3). Interestingly, 
compared with patients with comorbidities, patients without comorbidities had higher 
relative risk of mortality in the lower BMI categories. No interaction by age at diagnosis 
was observed. Estimates obtained from Model II (adjusted for age at diagnosis, sex, 
smoking status, deprivation status, Charlson comorbidity index, systolic BP, glycated 
haemoglobin, total cholesterol and glycated haemoglobin) were calculated using 
considerably fewer patients. Differences between estimates from Model I and Model II 
may therefore be due to these large changes in sample size, rather than the effect of the 






Figure 8.2: Model I estimates for the relationship between categories of BMI and all-
cause mortality with stratification.  Results for a ll participants are provided in Panel A. 
Relative estimates for current smokers are provided  in Panel B, for Ex-smokers in 
Panel C and Never smokers in Panel D.  Panel E pres ents estimates for patients with 







Figure 8.3: Model II estimates for the relationship  between categories of BMI and all-
cause mortality with stratification.Results for all  participants are provided in Panel A. 
Relative estimates for current smokers are provided  in Panel B, for Ex-smokers in 
Panel C and Never smokers in Panel D.  Panel E pres ents estimates for patients with 





Table 8.2: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing CCA (All participants) 
  BMI category (kg/m²) 









Deaths/Person-years 1,047 / 30,094 1,845 / 89,305 1,411 / 89,460 584 / 46,461 359 / 31,599 
Age-standardised mortality 18.9 (17.3, 20.6) 11.7 (11.0, 12.3) 11.1 (10.4, 11.8) 11.4 (10.3, 12.4) 14.9 (11.7, 18.1) 
Multivariable adjusted HR 1.48 (1.37, 1.60) 1.00 0.97 (0.91, 1.04) 1.02 (0.93, 1.13) 1.35 (1.20, 1.51) 









Deaths/Person-years 507 / 15,504 905 / 46,779 715 / 46,645 311 / 24,059 172 / 16,349 
Age-standardised mortality 17.9 (15.7, 20.1) 10.9 (10.1, 11.8) 10.6 (9.7, 11.5) 11.7 (10.2, 13.2) 16.7 (9.8, 23.6) 












Table 8.3: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing CCA, stratified by smoking status 
  BMI category (kg/m²) 









Deaths/Person-years 335 / 9,324 463 / 20,807 355 / 19,815 155 / 10,094 96 / 6,568 
Age-standardised mortality 27.4 (23.9, 31.0) 17.5 (15.5, 19.5) 15.5 (13.4, 17.6) 16.1 (12.1, 18.3) 17.0 (12.4, 21.6) 
Multivariable adjusted HR 1.56 (1.35, 1.79) 1.00 0.97 (0.84, 1.11) 1.05 (0.87, 1.26) 1.31 (1.05, 1.65) 









Deaths/Person-years 152 / 4,740 229 / 10,989 170 / 10,403 85 / 5,426 44 / 3,279 
Age-standardised mortality 25.9 (20.8, 31.1) 15.0 (12.7, 17.3) 14.3 (11.5, 17.0) 15.3 (12.3, 17.7) 16.2 (9.3, 23.0) 









Deaths/Person-years 361 / 8,784 798 / 32,887 636 / 34,519 236 / 16,531 123 / 10,177 
Age-standardised mortality 16.7 (13.6, 19.8) 12.0 (10.9, 13.0) 11.1 (10.0, 12.3) 11.1 (9.2, 12.9) 17.5 (6.6, 28.3) 
Multivariable adjusted HR 1.46 (1.28, 1.65) 1.00 0.98 (0.88, 1.09) 0.95 (0.82, 1.11) 1.22 (1.00, 1.48) 












Deaths/Person-years 179 / 4,485 401 / 17,407 345 / 18,144 127 / 8,544 63 / 5,397 
Age-standardised mortality 14.7 (11.8, 17.6) 11.8 (10.3, 13.4) 11.1 (9.6, 12.5) 11.7 (9.0, 14.3) 11.1 (8.1, 14.2) 









Deaths/Person-years 351 / 11,984 584 / 35,609 420 / 35,125 193 / 19,835 140 / 14,853 
Age-standardised mortality 11.7 (9.9, 13.5) 8.5 (7.6, 9.4) 8.4 (7.5, 9.4) 9.1 (7.7, 10.6) 14.2 (9.4, 19.1) 
Multivariable adjusted HR 1.44 (1.26, 1.64) 1.00 0.98 (0.86, 1.11) 1.11 (0.94, 1.32) 1.59 (1.31, 1.93) 













Deaths/Person-years 176 / 6,279 275 / 18,383 200 / 18,098 99 / 10,089 65 / 7,673 
Age-standardised mortality 11.4 (9.1, 13.8) 8.2 (7.0, 9.5) 7.8 (6.5, 9.1) 9.2 (7.2, 11.3) 14.4 (7.4, 21.5) 
















Table 8.4: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing CCA, stratified by presence of 
comorbid conditions 
  BMI category (kg/m²) 









Deaths/Person-years 562 / 20,650 901/61,153 672 /61,241 288 / 32,407 176 /22,893 
Age-standardised mortality 15.3 (13.7, 16.9) 9.2 (8.5, 10.0) 8.5 (7.7, 9.3) 8.4 (7.3, 9.6) 12.1 (8.1, 16.2) 
Multivariable adjusted HR 1.55 (1.39, 1.72) 1.00 0.99 (0.89, 1.09) 1.07 (0.94, 1.23) 1.32 (1.12, 1.56) 









Deaths/Person-years 281 / 10,884 424 /32,363 323 / 31,869 168  / 16,772 88  / 11,823 
Age-standardised mortality 14.3 (12.3, 16.4) 8.1 (7.2, 9.0) 7.8 (6.8, 8.9) 9.5 (7.8,11.2) 13.8 (6.8, 20.7) 









Deaths/Person-years 485 / 9,443 944 /28,150 739 / 28,219 296 / 14,053 183 / 8,706 
Age-standardised mortality 28.4 (23.4, 33.3) 17.0 (15.3, 18.8) 16.2 (14.6, 17.9) 17.4 (14.7, 20.1) 21.2 (15.3, 27.2) 
Multivariable adjusted HR 1.41 (1.26, 1.58) 1.00 0.96 (0.87, 1.06) 0.98 (0.86, 1.12) 1.38 (1.17, 1.63) 









Deaths/Person-years 226 / 4,620 481 /14,417 392 /17,776 143 /7,288 84 / 4,526 
Age-standardised mortality 28.6 (21.3, 35.8) 17.5 (14.7, 20.2) 16.4 (14.0, 18.8) 16.1 (12.5, 19.8) 17.5 (13.4, 21.7) 






 MULTIPLE IMPUTATION USING CHAINED EQUATIONS 8.3.4
MICE was used to create 60 datasets. Due to the number of auxiliary variables included 
in the imputation model and the size of the dataset, this took a considerable amount of 
time to run (>5 hours). The inclusion of predictor variables for incomplete variables 
introduced even more missing data into the analyses. For example, a closest glycated 
haemoglobin after diagnosis variable was included to improve imputations of glycated 
haemoglobin at diagnosis, however this new variable included missing data too.  
For each variable with missing data, the distribution of imputed and observed values 
was compared. Box-plots for each continuous imputed variable and bar charts for 
categorical variables were observed. Even summarising this data graphically was 
computationally intensive and took considerable time to generate. No gross 
discrepancies between observed and imputed data were observed and no implausible 
values were observed. Similarly, generating plotted residuals against fitted values for 
each imputed dataset was time-consuming. The pattern of residuals was similar across 
imputed datasets thus indicating no problems with the imputation model. 
Upon the inclusion of patients with incomplete data using multiple imputation, relative 
estimates for the association between categories of BMI and all-cause mortality were 
largely the same as those observed using CCA (Figure 8.4) (Table 8.5). A U-shaped 
relationship was observed with the lowest relative risk of mortality being observed in the 
overweight (25 to <30kg/m²) BMI category. Obese patients (30 to <35kg/m²) had a 
similar risk of mortality to overweight patients. Across all BMI categories absolute 
mortality rates were considerably larger upon the inclusion of patients with missing data 
using MICE suggesting considerably more mortality in patients with excluded data. 
However, mortality rates continued to exhibit a U-shaped relationship with categories of 
BMI.       
The results from Model I and Model II were almost identical suggesting that adjustment 
for systolic BP, glycated haemoglobin, cholesterol and HDL-cholesterol provided little 
additional benefit (Table 8.5). Stratification by smoking status had little impact on 
estimates (Table 8.6). Nonetheless, amongst never smokers, risk of all-cause mortality in 




smokers (mvHR: 1.42 [1.25, 1.62]) and ex-smokers (mv HR: 1.34 [1.19, 1.52]). Relative 
estimates of the association stratified by smoking status were similar when CCA and 
multiple imputation were used.   
Interestingly, upon stratification by presence of comorbidities, patients with no 
comorbidities in the lowest BMI group had higher risk of mortality (mv HR: 1.39 [1.25, 
1.53]) than patients with comorbidities in the lowest BMI category (mv HR: 1.30 [1.18, 
1.44]) (Table 8.7).  No evidence of multiplicative interaction between BMI and age at 
diagnosis was observed.  
The Monte Carlo errors were reasonably small for both the estimate and standard errors 
(<0.07), indicating that relative estimates were likely to be similar in repeat imputation 








Figure 8.4: A comparison of absolute and relative e stimates for the association 
between categories of BMI and all-cause mortality u sing CCA and multiple imputation 
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Figure 8.5: A comparison of relative estimates for the association between categories 
of BMI and all-cause mortality using CCA and multip le imputation using chained 
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Table 8.5: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing multiple imputation using chained 
equations (All participants) 
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
*Deaths/Person-years 1,639/42,887 3,404/125,328 2,955/126,160 1,382/65,753 902/45,025 
*Age-standardised mortality 23.2 (21.2, 25.2) 17.7 (17.0, 18.4) 17.7 (17.0, 18.5) 18.4 (17.1, 19.7) 20.5 (16.9, 23.1) 
Model I adjusted HR 1.35 (1.25, 1.44) 1.00 1.01 (0.95, 1.08) 1.06 (0.98, 1.15) 1.28 (1.17, 1.42) 
Model II adjusted HR 1.33 (1.24, 1.43) 1.00 1.01 (0.95, 1.08) 1.07 (0.98, 1.16) 1.29 (1.17, 1.42) 













Table 8.6: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing multiple imputation using chained 
equations. Estimates stratified by smoking status 
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
CURRENT SMOKERS 
*Deaths/Person-years 493/12,207 821/28,385  703/27,367 337/14,014 218/9,218 
*Age-standardised mortality 32.7 (31.0, 34.2) 24.5 (23.0, 26.0) 24.0 (23.1, 24.9) 26.6 (24.9, 28.9) 28.1 (25.0., 31.2) 
Model I adjusted HR 1.42 (1.25, 1.62) 1.00 1.00 (0.88, 1.13) 1.08 (0.92, 1.27) 1.28 (1.05, 1.56) 
Model II adjusted HR 1.40 (1.23, 1.61) 1.00 1.01 (0.89, 1.14) 1.08 (0.92, 1.27) 1.28 (1.05, 1.56) 
EX-SMOKERS 
*Deaths/Person-years 527/12,214  1,309/43,220 1,160/45,294 496/22,035 293/13,821 
*Age-standardised mortality 21.1 (18.9, 23.3) 17.7 (15.3, 20.1) 17.6 (15.4, 20.0) 18.2 (15.7, 20.7) 20.2 (16.6, 23.8) 
Model I adjusted HR 1.34 (1.19, 1.52) 1.00 1.01 (0.92, 1.11) 1.00 (0.89, 1.14) 1.20 (1.01, 1.42) 
Model II adjusted HR 1.33 (1.18, 1.50) 1.00 1.01 (0.92, 1.11) 1.00 (0.88, 1.15) 1.20 (1.01, 1.42) 
NEVER SMOKERS 
*Deaths/Person-years 619/18,466 1,273/53,724 1,092/53,499 549/29,705 392/21,986 
*Age-standardised mortality 17.2 (15.8, 18.6) 14.7 (13.0, 16.4) 14.9 (13.1, 16.7) 15.9 (14.5, 17.3) 18.0 (15.0, 21.1) 
Model I adjusted HR 1.29 (1.14, 1.46) 1.00 1.02 (0.92, 1.14) 1.12 (0.97, 1.30) 1.38 (1.17, 1.62) 
Model II adjusted HR 1.28 (1.13, 1.45) 1.00 1.03 (0.92, 1.15) 1.13 (0.98, 1.30) 1.38 (1.18, 1.63) 







Table 8.7: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing multiple imputation using chained 
equations. Estimates stratified by presence of como rbid conditions  
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
NO  COMORBIDITIES 
*Deaths/Person-years 730/29,351 1,320/85,841 1,069/86,208 488/45,616 320/32,191  
*Age-standardised mortality 14.5 (12.8, 16.2) 10.0 (8.6, 11.4) 9.7 (8.2, 11.2) 10.1 (8.7, 11.5) 11.9 (8.5, 15.3) 
Model I adjusted HR 1.39 (1.25, 1.53) 1.00 1.01 (0.92, 1.11) 1.08 (0.96, 1.22) 1.28 (1.11, 1.48) 
Model II adjusted HR 1.37 (1.24, 1.52) 1.00 1.02 (0.92, 1.12) 1.09 (0.96, 1.22) 1.29 (1.11, 1.48) 
COMORBIDITIES 
*Deaths/Person-years 909/13,535 2,083/39,487 1,887/39,953 895/20,137 582/12,834 
*Age-standardised mortality 47.8 (46.0, 49.6) 39.4 (37.6, 41.2) 38.8 (37.0, 40.6) 40.1 (39.1, 41.1) 42.7 (40.1, 45.3) 
Model I adjusted HR 1.30 (1.18, 1.44) 1.00 1.01 (0.93, 1.10) 1.05 (0.94, 1.17) 1.28 (1.11, 1.48) 
Model II adjusted HR 1.28 (1.16, 1.42) 1.00 1.01 (0.93, 1.10) 1.05 (0.94, 1.17) 1.29 (1.11, 1.48) 







 PREDICTIVE MEAN MATCHING (PMM) 8.3.5
PMM was used to generate 60 imputed datasets. This process took considerably longer 
than the MICE approach (>15 hours). The model contained twenty variables, of which 
seven were represented by dummy variables. This feature of the imputation model 
became problematic and the model failed to run. To overcome this problem, a subset of 
variables was selected to predict each incomplete variable. Within each custom 
imputation model, those variables to be included in analysis model II were included. 
Model diagnostics were carried out and deemed reasonable. Again, this was a lengthy 
process.  
Estimates from PMM were identical to those obtained from MICE. Compared with 
CCA, PMM resulted in a slight reduction in relative risk of mortality in the highest and 
lowest BMI categories (Table 8.8) (Figure 8.6). Nonetheless, highest relative mortality 
remained in the lowest BMI category (<25kg/m² vs. 25 to 30kg/m² mv HR: 1.36 [1.26, 
1.46]) compared with the reference category. Relative mortality risk was similar amongst 
overweight and obese patients (30 to 35kg/m²).  
Upon stratification, relative estimates for smokers, ex-smokers and never smokers were 
similar when obtained from CCA and PMM (Figure 8.7 & Table 8.9). The flattening out 
of the U-shaped relationship upon using PMM was observed in each stratified analysis 
with the risk of mortality attenuating in the lowest and highest BMI categories. Similarly, 
few differences were observed between estimates obtained from CCA and PMM upon 
stratification by comorbidity status, defined using the Charlson comorbidity index 
(Figure 8.8 & Table 8.10). Model II produced identical estimates to those obtained in 
Model II indicating that systolic BP, total cholesterol, glycated haemoglobin and HDL-
cholesterol did not confound this relationship.  
Changing the size of the match-pool in the imputation model from ten to three made 





Table 8.8: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing PMM (All participants) 
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
*Deaths/Person-years 1,650 / 42,915 3,401 / 125,384 2,955 / 126,072 1,374 / 65,826 902 / 44,957 
*Age-standardised mortality 23.6 (21.4, 25.8) 17.9 (16.4, 19.4) 17.9 (16.5, 19.4) 18.3 (16.7, 19.9) 20.6 (17.7, 23.5) 
Model I adjusted HR 1.36 (1.26, 1.46) 1.00 1.01 (0.95, 1.07) 1.05 (0.97, 1.14) 1.27 (1.14, 1.41) 
Model II adjusted HR 1.34 (1.25, 1.45) 1.00 1.01 (0.95, 1.08) 1.05 (0.97, 1.14) 1.27 (1.14, 1.41) 






Table 8.9: Estimates for relationship between categ ories of BMI at diagnosis and all-cause mortality u sing PMM, estimates stratified by 
smoking status 
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
CURRENT SMOKERS 
*Deaths/Person-years 473 / 12,031 809 / 28,308 703 / 27,447 336 / 14,025 219 / 9,244 
*Age-standardised mortality 31.6 (30.1, 33.1) 23.8 (22.6, 25.0) 23.5 (21.2, 25.8) 25.0 (23.5, 26.5) 27.1 (23.7, 30.5) 
Model I adjusted HR 1.44 (1.26, 1.65) 1.00 1.00 (0.87, 1.15) 1.07 (0.90, 1.28) 1.25 (1.01, 1.54) 
Model II adjusted HR 1.42 (1.24, 1.63) 1.00 1.01 (0.88, 1.15) 1.07 (0.90, 1.28) 1.25 (1.01, 1.54) 
EX-SMOKERS 
*Deaths/Person-years 545 / 12,400 1,295 / 43,224 1,126 / 45,078 484 / 22,085 293 / 13,856  
*Age-standardised mortality 23.0 (21.5, 24.6) 18.0 (16.8, 19.3) 17.6 (16.3, 18.8) 18.0 (16.6, 19.3) 20.9 (17.5, 22.3) 
Model I adjusted HR 1.35 (1.20, 1.52) 1.00 0.99 (0.90, 1.10) 0.98 (0.86, 1.13) 1.17 (0.99, 1.39) 
Model II adjusted HR 1.33 (1.18, 1.50) 1.00 1.00 (0.90, 1.10) 0.99 (0.86, 1.13) 1.17 (0.99, 1.39) 
NEVER SMOKERS 
*Deaths/Person-years 632 / 18,484 1,297 / 53,852 1,126 / 53,547 554 / 29,815 390 / 21,857 
*Age-standardised mortality 18.1 (16.8, 19.4) 15.2 (14.1, 16.4) 15.4 (14.3, 16.6) 16.1 (14.9, 15.3) 18.1 (15.8, 21.4) 
Model I adjusted HR 1.30 (1.15, 1.48) 1.00 1.04 (0.93, 1.15) 1.12 (0.98, 1.28) 1.39 (1.18, 1.64) 






Table 8.10: Estimates for relationship between cate gories of BMI at diagnosis and all-cause mortality using PMM, estimates stratified by 
presence of comorbid conditions. 
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
NO COMORBIDITIES 
*Deaths/Person-years 727 / 29,331 1,318 / 85,902 1,074 / 11,163 490 / 45,655 319 / 32,157 
*Age-standardised mortality 14.4 (12.5, 16.3) 10.0 (8.9, 11.1) 9.8 (8.7, 10.9) 10.1 (8.7, 11.5) 11.8 (8.7, 14.9) 
Model I adjusted HR 1.39 (1.26, 1.54) 1.00 1.01 (0.93, 1.11) 1.08 (0.96, 1.22) 1.27 (1.09, 1.48) 
Model II adjusted HR 1.38 (1.24, 1.52) 1.00 1.02 (0.93, 1.12) 1.09 (0.96, 1.23) 1.28 (1.10, 1.48) 
COMORBIDITIES 
*Deaths/Person-years 923 / 13,584 2,083 / 39,481 1,882 / 39,909 884 / 20,171 583 / 12,800  
*Age-standardised mortality 50.2 (48.2, 52.1) 41.7 (40.5, 42.9) 40.0 (38.8, 41.2) 40.4 (39.0, 41.8) 44.1 (41.4, 47.7) 
Model I adjusted HR 1.32 (1.19, 1.46) 1.00 1.00 (0.92, 1.09) 1.03 (0.92, 1.15) 1.27 (1.09, 1.47) 





Figure 8.6: A comparison of relative and absolute e stimates for the association 
between categories of BMI and all-cause mortality u sing CCA and multiple imputation 
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Figure 8.7: A comparison of relative estimates for the association between categories 
of BMI and all-cause mortality using CCA and multip le imputation using PMM, 
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Figure 8.8: A comparison of relative estimates for the association between categories 
of BMI and all-cause mortality using CCA and multip le imputation using PMM, 
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 MULTIVARIATE NORMAL (MVN) MULTIPLE IMPUTATION  8.3.6
The MVN model was used to create 60 imputed datasets. This model ran considerably 
quicker than the previous two imputation models.  
However, additional steps were required to successfully run the analysis model on each 
imputed dataset. To impute categorical variables it was necessary to include each 
dummy variable excluding the referent category and these were imputed assuming they 
were continuous. Accordingly imputed values fell between 0 and 1.  After imputation, to 
calculate the predicted value for the referent category the values from the dummy 
variables were subtracted from one, as recommended by Enders (2010). Rounding was 
then used in each imputed dummy variable to replace values with zero or one.  
Table 8.11 presents the results when the MVN method was applied. Relative and 
absolute estimates for all participants are presented in Figure 8.9. Relative estimates are 
almost identical to those obtained using CCA with only slight reductions in risk of all-
cause mortality being observed in the highest and lowest BMI categories.   
Upon stratification by smoking status, an error message stated that the estimation 
sample varied for each imputation model. When using the ice command for the chained 
equations and PPM matching approach, this potential problem went undetected. 
Differing estimation samples may occur when stratifying by an imputed variable and can 
be a source of bias. The distribution of smoking status was observed across imputed 
datasets and deemed reasonable (See appendix Table A8.18). Stratified relative results 
are presented in Figure 8.10 & Table 8.12 and were similar when obtained using CCA 
and the MVN model. Amongst never smokers however, the relative risk of mortality in 








Table 8.11: Estimates for relationship between cate gories of BMI at diagnosis and all-cause mortality using MVN model (All participants) 
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
*Deaths/Person-years 1,803 / 42,872 3,637 / 130,874 2,875 / 130,692 6,548 / 67,048 742 / 44,547 
*Age-standardised mortality 24.6 (22.5, 26.7) 17.3 (16.2, 18.4) 16.0 (15.9, 18.2) 17.7 (16.5, 18.9) 21.1 (17.8, 24.5) 
Model I adjusted HR 1.43 (1.33, 1.54) 1.00 0.98 (0.92, 1.05) 1.03 (0.94, 1.12) 1.33 (1.21, 1.47) 
Model II adjusted HR 1.41 (1.32, 1.52) 1.00 0.99 (0.92, 1.05) 1.03 (0.94, 1.13) 1.34 (1.21, 1.48) 






Table 8.12: Estimates for relationship between cate gories of BMI at diagnosis and all-cause mortality using MVN model, estimates are 
stratified by smoking status. 
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
CURRENT SMOKERS 
*Deaths/Person-years 533 / 12,393 893 / 29,621 700 / 28,408 307 / 14,304 189 / 9,087 
*Age-standardised mortality 32.1 (30.3, 34.8) 22.1 (20.8, 23.5) 22.1 (20.7, 23.5) 24.0 (22.3, 25.8) 27.4 (24.3, 30.4) 
Model I adjusted HR 1.55 (1.36, 1.77) 1.00 1.00 (0.87, 1.14) 1.07 (0.89, 1.28) 1.38 (1.04, 1.72) 
Model II adjusted HR 1.54 (1.35, 1.77) 1.00 0.99 (0.87, 1.13) 1.05 (0.87, 1.26) 1.39 (1.05, 1.73) 
EX-SMOKERS 
*Deaths/Person-years 595 / 12,232 1,425 / 45,341 1,163 / 47,257 458 / 22,415 247 / 13,556 
*Age-standardised mortality 21.2 (19.5, 22.9) 15.4 (14.1, 16.6) 14.8 (13.6, 16.1) 15.4 (14.0, 16.7) 19.0 (16.4, 22.6) 
Model I adjusted HR 1.40 (1.28, 1.51) 1.00 0.98 (0.88, 1.09) 1.00 (0.87, 1.14) 1.29 (1.04, 1.54) 
Model II adjusted HR 1.37 (1.26, 1.49) 1.00 0.98 (0.87, 1.09) 1.01 (0.87, 1.15) 1.28 (1.04, 1.55) 
NEVER SMOKERS 
*Deaths/Person-years 675 / 18,247 1,333 / 55,912 1,012 / 55,027 461 / 30,329 306 / 21,905 
*Age-standardised mortality 15.9 (13.6, 18.3) 12.1 (10.9, 13.2) 12.0 (10.8, 13.2) 13.0 (11.8, 14.3) 16.3 (13.8, 19.7) 
Model I adjusted HR 1.30 (1.17, 1.43) 1.00 1.00 (0.89, 1.12) 1.04 (0.93, 1.15) 1.26 (1.01, 1.49) 
Model II adjusted HR 1.30 (1.16, 1.43) 1.00 1.00 (0.89, 1.12) 1.05 (0.96, 1.17) 1.25 (1.01, 1.48) 







Table 8.13: Estimates for relationship between cate gories of BMI at diagnosis and all-cause mortality using MVN model, estimates are 
stratified by presence of comorbidities.  
  BMI category (kg/m²) 
  < 25 25 to < 30 30 to < 35 35 to < 40 ≥ 40 
NO COMORBIDITIES 
*Deaths/Person-years 767 / 28,210 1,333 / 55,912 1,012 / 55,027 461 / 30,329 306 / 21,905 
*Age-standardised mortality 15.4 (13.1, 17.7) 10.0 (8.9, 11.2) 9.5 (8.3, 10.6) 9.8 (8.6, 11.0)  12.6 (9.1, 15.0) 
Model I adjusted HR 1.45 (1.31, 1.61) 1.00 0.98 (0.89, 1.08) 1.06 (0.93, 1.20) 1.33 (1.15, 1.53) 
Model II adjusted HR 1.44 (1.30, 1.59) 1.00 0.99 (0.89, 1.09) 1.06 (0.94, 1.21) 1.33 (1.15, 1.54) 
COMORBIDITIES 
*Deaths/Person-years 1,036 / 14,663 2,255 / 44,024 1,832 / 43,657 774 / 21,407 458 / 13,018 
*Age-standardised mortality 39.7 (37.6, 41.8) 25.8 (24.4, 27.2) 24.8 (23.4, 26.1) 25.9 (24.3, 25.4) 30.3 (27.6, 33.9) 
Model I adjusted HR 1.40 (1.26, 1.55) 1.00 0.98 (0.90, 1.07) 1.00 (0.88, 1.14) 1.33 (1.14, 1.54) 
Model II adjusted HR 1.38 (1.25, 1.53) 1.00 0.99 (0.90, 1.08) 1.01 (0.89, 1.15) 1.34 (1.15, 1.56) 







Figure 8.9: comparison of relative and absolute est imates for the association between 
categories of BMI and all-cause mortality using CCA  and MVN model. Relative 
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Figure 8.10: A comparison of relative estimates for  the association between 
categories of BMI and all-cause mortality using CCA  and multiple imputation using 
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 ALL METHODS 8.3.7
Differences in relative differences between the four methods utilised are presented in 
Figure 8.11. From this Figure it is clear that estimates obtained when using MICE and 
PMM are very similar whilst estimates from the MVN model were most similar to 
estimates from CCA. Figure 8.12 presents absolute estimates from each method for 
handling missing data. Each multiple imputation model produced largely comparable 
results and observed differences would be unlikely to affect overall inferences. Clearly, 
failure to include patients who had unobserved data in the variables of interest would 
produce invalid absolute estimates.  
 
Figure 8.11: A comparison of relative estimates for  the association between 
categories of BMI and all-cause mortality using fou r different methods for handling 
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Figure 8.12: A comparison of absolute estimates for  the association between 
categories of BMI and all-cause mortality using fou r different methods for handling 
incomplete data.  All estimates were obtained from Model I.  
 DISCUSSION 8.4
 INTRODUCTION 8.4.1
The use of a number of multiple imputation approaches has been demonstrated in this 
large retrospective cohort study investigating the association between BMI at diagnosis 
and all-cause mortality amongst patients with incident type 2 DM. Regardless of the 
imputation method used, the observed relationship was U-shaped. This section is 
subdivided into two sections with the first presenting details on the missing data issues 
investigated whilst the second presents details on the findings from the analysis model.  
 MISSING DATA IN SCI-DC 8.4.2
Unobserved data in each of the variables to be included in Model I and Model II 
analysis model combined to result in complete data for only seventy and thirty-seven 
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than earlier years (See Section 5.4), suggesting a positive impact by the QOF on risk 
factor recording. Improvements in the recording of important risk factor recording, 
such as smoking status (Taggar et al., 2012), ethnicity (Mathur et al., 2013) and BMI 
(Bhaskaran et al., 2013) have been observed in multiple other UK-based electronic 
health databases. Despite these improvements, clinician work-load, irregular GP 
attendance and the respective study’s definition of complete data mean that missing data 
are an inevitable problem in medical research using routine data.    
Missing data occurred in a non-monotone pattern, though the presence of incomplete 
data in some variables was more likely amongst patients with unobserved data in other 
variables. Data appeared to be, but not definitely, MAR with the main predictor of 
missing data in all variables being patient survival. Patients with missing data had 
considerably poorer survival than those with complete data resulting in the 
underestimation of absolute mortality in categories of BMI. This setting whereby 
completeness of covariates is related to the outcome of interest has been reported in 
other observational studies (van Buuren et al., 1999; Hotchkiss & Leyland, 2011). 
Clearly, the risk of bias in this setting is high and therefore the choice of appropriate 
methods for handling missing data is essential in ensuring the study’s validity.  
Due to its ability to generate unbiased parameter estimates when data are MAR, multiple 
imputation was selected as a potentially appropriate method for handling the 
unobserved data. In this study three separate multiple imputation models were applied; 
MICE, PMM and the MVN model. These methods can be implemented in commonly 
used statistical software packages, yet there remains little practical guidance as to which 
imputation model is the most appropriate for any given missing data problem. Those 
studies which have provided guidance have done so using simulation studies and few 
have presented comparisons using real-data with real missing data problems (van 
Buuren, 2007; Lee & Carlin, 2010; Kropko et al., 2014). Furthermore, only one study 
was identified which compared the use of PMM with MICE and MVN (Lee & Carlin, 
2010). No study was identified which compared the performance of these approaches in 
survival analyses.  
Typically the two main concerns regarding the use of MVN is the assumption regarding 




data.  The MVN model assumes a joint normal distribution of the data, an assumption 
that is regularly violated in the presence of binary or categorical variables. Nonetheless, 
it has been observed that this model is relatively robust to departures from the normal 
distribution (Schafer & Graham, 2002; Demirtas et al., 2008; Kropko et al., 2014). In 
their study which tested MVN and MICE in a political research setting, Kropko et al., 
(2014) observed that MVN and MICE performed similarly well when continuous 
variables were imputed which did not exhibit a MVN distribution. Demirtas et al., 
(2008) also reported reasonable performance of MVN even when the normality 
assumption did not hold, particularly when the sample size was large. In the analysis 
presented here, non-normal variables were transformed in the MVN analysis and back-
transformed when included in the imputation model. PMM was used as an alternative 
means of handling non-Normal variables within the MICE framework. However, results 
obtained from MICE and PMM were almost identical suggesting that the 
transformation of variables in MICE was an adequate method for handling non-
Normality. Nonetheless, the performance of MICE may not be comparable to PMM in 
all contexts. For example, in the presence of non-linear relationships the performance of 
PMM is likely to be superior to MICE (Morris et al., 2014).  
Using the MVN model, categorical variables can be imputed as a set of indicator 
variables whilst ordinal variables can be imputed in the same way or as a single 
continuous variable. However, it has been shown that imputing ordinal variables as 
continuous variables can distort non-linear relationships between imputed covariates 
variables and the outcome of interest (Lee et al., 2012). In this study, ordinal and 
categorical variables were imputed as a set of indicator variables and then rounded 
according to the combination of indicators (e.g. for each patient, the indicator with the 
highest imputed value was categorised as having the characteristic, so set to 1), an 
approach recommended by Enders (2010).  However, this approach to re-categorising 
imputed values into appropriate categories by simple rounding has been criticised and 
other approaches such as adaptive rounding and calibration have been suggested 
(Bernaards et al., 2007; Lee et al., 2012). The issue of rounding in MVN analyses has 
been extensively studied and it has been observed that inappropriate rounding 
approaches can introduce considerable bias (Horton et al., 2003; van Buuren, 2007). For 




distribution is not easily specified in the presence of missing data. Similarly, Kropko et., 
(2014) advised against using MVN for ordinal and categorical data. Nonetheless, even 
using a very simplistic rounding method in MVN, estimates from this study were not 
dissimilar to those obtained from MICE and PMM which have more natural means of 
handling non-continuous data. Similarly, Lee and Carlin (2010) presented results which 
indicated that comparable results can be expected from MICE and MVN approaches in 
the context of linear regression with a mixture of variable types. Due to time-
constraints, alternative means of rounding were not investigated. Clearly however, it 
would be worthwhile to check whether estimates were robust to changes in the 
rounding approach employed.  
In conclusion, three multiple imputation methods for handling unobserved data 
produced similar estimates. Despite strict assumptions made by the MVN model it 
appears that this model can be relatively robust to violations to the joint distribution 
assumption. However, this has yet to be vigorously investigated in the context of Cox 
regression analyses and therefore further work may be required. Ultimately the choice 
between the three is likely to be based upon practical considerations and potentially 
personal preference. In this large dataset, each approach took considerable time to run 
particularly PMM; a problem that is likely to be common in studies utilising large 
routinely collected databases. In addition, imputation model specification is a 
challenging undertaking and this in itself is an arduous activity. For example, in the 
context of a study with multiple incomplete variables, a balance needs to be struck as to 
how to improve the predictive power of the imputation model by including more 
variables whilst restricting the amount of missing data.      
Finally, the likely biggest source of bias when using these methods is incorrect model 
specification. Some of the issues faced upon specifying imputation models are presented 
in Chapter 8.  
 ANALYSIS OF ASSOCIATION BETWEEN BMI AND ALL-CAUSE MORTALITY  8.4.3
Relative estimates of the association between BMI and all-cause mortality did not differ 




the multiple imputation approaches were considerably different, highlighting the 
problems of estimating absolute estimates when patients are excluded from analyses.  
The relationship between BMI and all-cause mortality remained U-shaped, providing 
more evidence of an obesity paradox amongst patients with chronic disease. 
When analyses were restricted to patients who had never-smoked, the relationship 
between BMI and all-cause mortality remained U-shaped, though the risk of mortality 
did lower slightly for patients in the <25kg/m² group. This finding indicates that at least 
some of the excess risk of mortality in the <25kg/m² group may be explained by 
smoking status. The reliability of smoking status records may also be questionable. Self-
reported smoking status records have regularly been shown to be inaccurate with the 
under-reporting of tobacco-use, particularly when reporting to clinicians (Gorber et al., 
2009). If this were the case in this dataset then misclassification bias may have masked 
the true relationship amongst non-smokers.  A previous study conducted by Tobias et 
al. (2014) in the Nurses’ Health Study identified that upon exclusion of current and 
former smokers, the U-shaped relationship diminished considerably and became a 
monotonically increasing trend. This effect may have been a result of the inverse 
relation between BMI and smoking and the increased mortality risk amongst smokers.  
Nonetheless, many other studies have not observed any differences in trends among 
smokers and non-smokers (Khalangot et al., 2009; Carnethon et al., 2012). In fact, the 
practice of excluding patients to investigate the relationship between BMI and mortality 
is becoming more controversial as large-scale exclusions may result in changes in 
findings that may simply be due to chance (Cooper, 2008) In addition, these findings 
cannot be extrapolated to the whole population with DM.   
Upon stratification by the presence of comorbidities, estimates for all-cause mortality in 
the lowest BMI category were highest amongst patients without comorbidities. This is 
an interesting finding given that the presence of comorbid conditions is likely to 
contribute to both weight loss and increased mortality. For this reason, upon 
stratification it was thought that relative risk of mortality in this BMI category would 
actually decrease. There are a few potential explanations for this finding. Firstly, this 
may reflect the presence of undiagnosed disease amongst patient with no comorbid 




change in relative estimates and absolute estimates of mortality in this group remain 
low.  
It has been suggested that the validity of BMI as a measure of adiposity decreases 
amongst elderly people through sarcopenia. This process lowers body weight through 
the reduction in lean muscle mass but not body adiposity. In addition, older age confers 
an increased prevalence of comorbid conditions thus resulting in an increased likelihood 
of reverse causation amongst older patients. Accordingly, it has been observed 
elsewhere that amongst patients below 65 years the relationship between BMI and all-
cause mortality is comparatively linear whilst U-shaped amongst patients over 65 years 
(Zoppini et al., 2003; Tobias et al., 2014).  Nonetheless, age (<65 vs. ≥ 65years) was not 
an effect modifier of the relationship between BMI and all-cause mortality in this study, 
nor in a recent pooled analysis of five longitudinal studies (Carnethon et al., 2012). 
Future analyses could investigate higher cut-offs since 65 years may be too low in 
patients with type 2 DM as the effect may appear at later ages. 
Despite the World Health Organisation advising against adjustment for additional 
confounders that are closely related to BMI such as hypertension and hyperlipidaemia 
due to the potential for downward bias, additionally adjusting for systolic BP, total 
cholesterol and glycated haemoglobin had very little impact on relative estimates (World 
Health Organisation, 2000). This may be since this study was amongst people with DM 
and therefore the differences in lipids and blood pressures between obese and non-
obese patients may not be as marked than for people without DM. Mulnier et al., (2006) 
suggested that the finding of increased mortality amongst patients with low BMIs could 
be a consequence of poorly controlled DM. Although this potential explanation was not 
investigated in this study, controlling for glycated haemoglobin at diagnosis had no 
effect on estimates.  
In conclusion, this study provides additional evidence of the existence of an obesity 
paradox. Even after controlling for residual confounding by excluding smokers and 
controlling for reverse causation by excluding patients who had died within two years of 
diagnosis and restricting analyses to patient with no comorbid conditions, risk of 
mortality remained lowest in overweight or obese participants. The presence of an 




practice. Currently, patients with DM are encouraged to lose weight, however these 
findings suggest that this may not be appropriate for all patients.  
Further work is required to assess whether patients diagnosed at a lower BMI have a 
greater disease severity than patients diagnosed with higher BMI categories. This could 
be assessed by comparing occurrence of diabetes complications such as retinopathy and 
nephropathy by BMI at diagnosis. This may assist in the interpretation of the 
relationship between BMI and mortality.  
Furthermore, a trial which observes weight changes following diagnosis with type 2 DM 
and their association with a number of health outcomes may also be beneficial.   Given 
the observational nature of the studies conducted to date, it has not been possible to 
distinguish between intentional and unintentional weight loss, a trial could overcome 
this problem. This trial could provide justification for weight loss advice following 










Missing data are an inevitable problem across epidemiological research and their 
presence can lead to inefficient and sometimes biased analyses. The most effective way 
of managing missing data is to collect complete data in the first place. Unfortunately, 
this approach is not tenable when data are obtained from electronic healthcare records 
whose recording is typically clinically driven. These sources of data are information-rich 
and offer numerous opportunities for clinical research including the long-term follow-
up of traditionally hard-to-reach populations. Despite these obvious benefits, concerns 
surrounding data quality are unavoidable and so appropriate methods for handling 
missing data are required to ensure analyses remain valid despite the presence of missing 
data.   
Various approaches have been developed and utilised to handle missing data. Complete 
case analysis, the practice of excluding incomplete cases is the most commonly applied 
method despite some well-established limitations. Other approaches include single 
imputation methods whereby missing values are replaced with some value obtained 
from the observed data such as the variable mean. Most recently, multiple imputation 
methods have been incorporated into most standard statistical software packages. 
Compared to CCA, multiple imputation makes more relaxed assumptions regarding the 
mechanism of missingness and mitigates the limited efficiency of CCA. This approach 
aims to generate several plausible imputed datasets using the observed data and then 
results from each imputed dataset are appropriately combined to produce final 
estimates. The appropriateness of any given method for handling unobserved data is 
largely dependent on the mechanism by which the missing data came about. 
Accordingly, any analysis with missing data should be supplemented with a sensitivity 
analysis which tests the robustness of the methods assumptions regarding the 
mechanism of missingness.  
This discussion is subdivided into two sections. The first presents a review of the 
missing data methods applied and the second section assesses the findings from the 
investigation of the association between BMI at diagnosis and mortality in patients with 




 FINDINGS FROM MISSING DATA 9.2
In this large population-based register of patients with DM in Scotland, unobserved data 
have presented difficult challenges for research. Despite high levels of completeness in 
demographic characteristics, problems persist in repeatedly measured health indicators 
such as BMI, BP and cholesterol.  
In this study we were interested in the completeness of health indicators, particularly 
BMI recorded at date of diagnosis with type 2 DM. Apart from fixed variables such as 
ethnicity and sex, missing data patterns vary through time, and the precise proportion of 
missing data depends on the definition used in its calculation. Typically, a time-frame is 
specified around an event of interest, such as date of registration at a GP, and it is 
observed whether patients have a measurement within this time-frame. Since our 
analyses were concerned with estimating the effect of BMI at diagnosis, it was necessary 
to specify a time-frame during which BMI recordings would accurately reflect BMI at 
diagnosis. Since missing data issues in routine data have not been widely explored, little 
guidance has been provided in choosing the width of these time-frames. In this study, a 
time-frame was chosen that was wide enough to limit the extent of missing data but was 
narrow enough to provide recordings of BMI that reasonably accurately reflected BMI 
at diagnosis. 
Even with a relatively wide time-interval, the proportion of patients diagnosed with type 
2 DM without a BMI at diagnosis was high (58%). When analyses were restricted to 
patients diagnosed between 2004 and 2008, BMI incompleteness reduced to 27% but 
this was still moderately high. This attenuation in missingness was observed in other 
important health indicators and possibly reflects the introduction of the QOF. 
Improvements in completeness levels in routine clinical databases have been reported 
elsewhere (Bhaskaran et al., 2013; Mathur et al., 2013). However, since most health 
indicators are recorded based on their clinical relevance and may not be available during 
the time-period of interest, missing data problems are likely to persist in analyses using 
the SCI-DC dataset.  
Whilst it was not possible to speak to every clinician and data-entry clerk involved with 




workers provided useful information regarding recording practices and data entry 
processes. This information was used to postulate the potential reasons for missing data. 
Data exploration activities identified key differences between patients with and without 
missing data. Patients with missing data had considerably worse survival, had an earlier 
year of diagnosis and were less likely to have comorbid conditions than patients without 
missing data. This therefore indicated that data were MAR conditional primarily on 
survival, a finding that has been reported in observational data before (van Buuren et al., 
1999; Hippisley-Cox et al., 2007). In the development of the QRISK score using the 
QRESEARCH database, Hippisley-Cox and colleagues (2007) reported that men with 
missing cholesterol ratios had a 10 year risk of a cardiovascular event of 10.9% 
compared to 4.9% for patients with a recording. This observation possibly reflects 
patients who are very unwell at the date of measurement and so the recording of health 
indicators such as BMI may not be possible or a priority for these patients. There may 
be important implications for future research which use this and other routinely 
collected databases as a result of this finding. Many studies are interested in the impact 
of an exposure on survival. The exclusion of a large number of events may mean the 
study will lack power, absolute estimates may be underestimated and relative estimates 
could be biased if the missing data are clustered around particular values of the 
exposure.  
Nevertheless, using data exploration techniques, it was not possible to rule out the 
possibility that missing data in the SCI-DC register were MNAR, dependent on the 
missing value. However, the introduction of QOF in 2004 and the subsequent 
standardisation of patient care should have ensured the regular recording of health 
indicators in patients with type 2 DM. Furthermore, interviewed clinicians stated that 
the recording of health indicators was universal, irrespective of their perceived value.   
In Chapter 6, CCA was used to handle incompleteness in the BMI at diagnosis variable 
only. This approach reduced the sample size by 25% and the number of events by 32%. 
In this large dataset, exclusions such as these had limited impact on the study’s power 
since the sample size remained very large. It is unlikely that the exclusion of this 
proportion of patients would be acceptable in many other studies, particularly if the 




We could find little evidence that this approach introduced substantial bias in this case. 
Population imputation illustrated the problem of underestimated survival by increasing 
the absolute and relative risk of mortality in the category in which patients with missing 
data were added, but cannot be advocated as a method for handling unobserved data as 
it relies on highly unrealistic assumptions.  
Estimates from stochastic imputation and multiple imputation using chained equations 
produced almost identical estimates. Compared to CCA, absolute estimates of mortality 
from stochastic imputation and multiple imputation increased uniformly across all 
categories of BMI, whilst relative estimates indicated a weakening of the association 
between BMI and all-cause mortality, with the HR decreasing across all categories of 
BMI towards the null. Standard errors were smaller using stochastic imputation than 
multiple imputation though this difference was negligible, potentially due to the sample 
size. In this setting, it was less time-consuming than using multiple imputation to run 
the model in STATA. Handling 25 datasets for 72,000 patients was computationally 
demanding and modelling diagnostics took a significant length of time to run. This may 
deter epidemiologists with time constraints from applying multiple imputation in large 
routine clinical databases. 
The finding that multiple imputation approaches may produce similar results to single 
imputation approaches and CCA is not uncommon. For example, multiple imputation 
was used to impute >10% (exact percentage not provided) unobserved data and 
produced estimates comparable to those obtained using CCA in a case-control study 
investigating the association between obesity and myocardial infarction in the routinely 
collected General Practice Research Database (Delaney et al., 2007). Similarly, a study 
using the same database to investigate the effect of hormone therapy on coronary heart 
disease reported estimates that were similar to CCA estimates when multiple imputation 
was applied to handle incomplete BMI, Systolic BP and smoking data for 20% of cases 
(Weiner et al., 2008).  
Meanwhile, evidence from a study which used a range of imputation methods to handle 
unobserved serum cholesterol in 28 cohort studies indicated that single imputation 
approaches, including stochastic imputation produced similar results to multiple 




2004). For studies with more than 10% missing data, large differences in estimated 
mean cholesterol values and HRs for risk of coronary heart disease were reported for 
single and multiple imputation approaches. In a simulation study, estimates from 
stochastic imputation and multiple imputation were generally consistent until the 
proportion of missing data exceeded 15% (Marshall et al., 2010). However, stochastic 
imputation underestimated the variability even with 10% missingness. In our study, over 
20% of cases had missing data, thus supporting the notion that the results from 
different studies cannot be generalised to other studies. The performance of these 
methods will not only depend on the proportion of unobserved data but also on the 
distribution of the covariates, the mechanisms of missingness and the relationship 
between the covariates and outcomes.   
A selection-based sensitivity analysis was also applied to explore the robustness of 
estimates obtained from multiple imputation. Results from this approach were 
remarkably similar to those observed using stochastic imputation, suggesting estimates 
were robust to departures from the MAR assumption.  
In Chapter 7 a range of methods were used to incorporate earlier or later patient BMI 
measurements in an effort to improve predictions of BMI at diagnosis. The majority of 
patients (83%) with missing BMI data at diagnosis had BMI measurements taken after 
the BMI time-frame. These measurements were used to improve the prediction of 
missing data at diagnosis and also minimise the risk that BMI recording was dependent 
on the value of BMI itself. The identification of approaches capable of imputing BMI 
values will be hugely beneficial to colleagues in Aberdeen who are currently investigating 
the effect of BMI trajectories after diagnosis on a number of health outcomes such as 
cardiovascular disease events. Despite the increasing complexity of each imputation 
approach, relative estimates of the effect of BMI on total mortality remained similar.   
In Chapter 8, missing data methods were applied to a more complicated setting where 
missing data occurred in multiple variables. The proportion of patients with complete 
data for all variables to be included in the model of substantive interest was low (37%). 
Despite having different statistical underpinnings, three separate imputation models 
were applied and produced similar results. Like previous imputation models, the 




categories. The multivariate normal multiple imputation model had the lowest effect on 
the observed estimates from CCA.  
A study by Lee and Carlin (2012) reported that multiple imputation has the greatest 
value when missing data occur in confounders rather than the predictor of interest. 
When missing data occur in confounding variables only, the exclusion of these cases will 
lead to the loss of available information regarding the association of interest. However, 
when missing data occurred in the potential confounders in this analysis, estimates did 
not change considerably and results from multiple imputation approaches were largely 
similar for the risk of mortality whether missing data occurred in the predictor of 
interest only or missing data occurred in confounders and the risk of mortality.  
 STRENGTHS & LIMITATIONS  9.2.1
There are a number of strengths to this work. This project was able to use a large, 
population-based register of patients with DM which contain a large number of 
variables which can be used to provide explanations for the missing data and also to 
impute the unobserved data. Methods were applied to a real clinical database with real 
missing data problems and therefore the encountered issues are likely to be applicable to 
analyses using other clinical databases.   
The primary limitation of this work is the fact that the true values of the observed data 
were unknown. Accordingly it was not possible to ascertain which method produced 
estimates that were closest to the truth. However, this approach ensured that problems 
faced were realistic and typical of those faced by epidemiologists. Nonetheless, access to 
a contemporary external dataset of patients with DM with complete data would have 
been beneficial to identify whether the distribution of BMI and other incomplete 
variables following imputation were comparable to distributions in this external dataset. 
Instead, comparisons were made with similar studies investigating this relationship. 
In these analyses, the choice of missing data method was based upon each method’s 
accessibility in standard statistical software and the availability of practical guidance in 
the literature. For this reason maximum likelihood methods for missing data were not 
applied in this project. Some authors recommend these approaches over multiple 




analysis. Unfortunately, maximum likelihood techniques require problem specific 
programmes and are therefore not readily available. As a consequence, these methods 
remain inaccessible to many epidemiologists and are rarely applied.  
Similarly, the accessibility of MNAR methods prevented the thorough exploration of 
the robustness of MAR estimates to departures from this assumption. Unfortunately, it 
is not possible to rule out the possibility of data being MNAR using the data alone. 
Nonetheless, the inclusion of earlier and later measurements of BMI at diagnosis in 
multiple imputation approaches in Chapters 7 and 8 may have reduced the potential for 
missing data to be dependent on the value of the data point itself. Furthermore, 
according to the clinicians spoken to, there were no common characteristics of patients 
who failed to attend appointments. However, these clinicians were based in the Lothian 
HBA only and therefore this observation may not be generalisable to all patients with 
DM in Scotland.  
 IMPLICATIONS & FUTURE RESEARCH  9.2.2
Regardless of the complexity of the method used for handling missing data, relative 
estimates did not change substantially. Where relative estimates did change, the changes 
were generally not large enough to affect the overall conclusions.  
Within this dataset, patients with unobserved values for important biochemical variables 
such as blood pressure, BMI and glycated haemoglobin had considerably worse survival 
than those who had observed data. This finding could have important implications for 
future research using the SCI-DC dataset. In particular, CCA may not be an appropriate 
method for handling unobserved data when absolute measures are reported. Though 
this finding is likely to have the largest impact on analyses investigating mortality trends, 
it may also introduce survival bias in analyses investigating other health outcomes. 
Furthermore, STROBEs reporting guidelines encourage the reporting of both absolute 
and relative measures of association and therefore this finding may have wider 
implications (Altman et al., 2007). 
Whilst missing data occurring in variables involved in the relationship between BMI and 
all-cause mortality did not affect relative estimates, this may not be true for all analyses 




problem and the likelihood that data are not MCAR, it remains sensible to explore the 
missing data problem and report a secondary analysis investigating the robustness of 
estimates. This could be in the form of expanding the time-frame for measurement, as 
shown in Chapter 7 or by applying a more advanced approach for handling missing data 
such as imputation.  
Expanding the time-frame for measurements of interest may be a simple and viable 
approach for handling unobserved data in repeatedly recorded variables but not for 
variables that are recorded once only or are only typically recorded due to their clinical 
relevance. This approach is also unlikely to be appropriate where measurements are 
likely to change considerably and will also over-estimate the precision of estimates.  
Further research is required to assess whether this approach may be an appropriate and 
applicable method that may be used as an alternative to more complicated missing data 
methods. Simulations within routinely collected datasets may be useful in informing the 
applicability of this approach for repeatedly measured variables.  
Where this approach is not feasible or where there are concerns regarding precision 
estimates, more advanced approaches to handling unobserved data such as multiple 
imputation may be applied. Unfortunately, there remains a series of evidence gaps 
regarding the implementation of multiple imputation that may limit their use. Further 
work needs to assess the appropriateness of different imputation models in routine data. 
For example, two-fold FCS was designed to handle the complicated missing data 
problems observed in routine datasets. This approach has only recently been 
implemented in standard statistical software and the reliability of estimates from this 
approach requires further assessment, particularly whether this approach produces valid 
estimates when data are MAR. Data from this research has indicated that two-fold FCS 
produces largely similar estimates to MICE, MVN and PMM. It is necessary to identify 
whether this finding is typical of research using large routinely collected datasets.  
Clarity also needs to be sought regarding the best practice for handling non-linear 
relationships and interactions in imputation models.  In the analyses presented here, the 
continuous variable BMI was categorised prior to imputation to prevent bias due to 
non-linearity issues. In analyses investigating the association between BMI and 




classification system and therefore categorisation was deemed acceptable in this setting. 
In many other analyses, categorisation of an imputed variable may not be appropriate. 
There is currently no consensus on the method for handling non-linearities which will 
result in the least amount of downward bias. Currently, the Just Another Variable 
method has been proposed as the best approach for handling non-linear data but has 
been shown to produce invalid estimates when data are MAR (Seaman et al., 2012).  
Further simulation work is necessary to identify the most appropriate method.  
 SUMMARY 9.2.3
In this large routinely collected dataset, the choice of method for handling missing data 
had limited effect on the overall relative estimates. However, though alternative 
methods for CCA can be computationally intensive with many important practical 
considerations, it remains valuable to explore the robustness of estimates to departures 
from assumptions made by CCA. Where correctly applied, these methods are able to 
preserve the sample size whilst also reducing bias.  
 FINDINGS FROM THE ASSOCIATION BETWEEN BMI & ALL-CAUSE 9.3
MORTALITY 
In 2012, data from the Scottish Health Survey suggested that 62% of people in Scotland 
aged between 16 to 64 years were overweight or obese. Excess adiposity is an 
established risk factor for a number of adverse health outcomes including cardiovascular 
disease and type 2 DM. In the general population, obesity is associated with increased 
all-cause mortality (Adams et al., 2006; Pischon et al., 2008; Prospective Studies 
Collaboration, 2009; Chen et al., 2012). The relationship between BMI and mortality is 
far less well-established amongst patients with type 2 DM. Whilst most recent studies 
have reported an increased risk of mortality in people with BMI above 35 kg/m² 
(Carnethon et al., 2012; Logue et al., 2013), a number of early studies found no 
association between BMI and all-cause mortality (Morrish et al., 1990; Knuiman et al., 





The analyses presented in this thesis, after applying multiple different methods for 
handling unobserved data, are generally consistent with previous observations of lower 
mortality among overweight and obese patients relative to normal weight, thus 
providing further evidence of an obesity paradox. After adjustment for smoking status, 
presence of comorbid conditions, age at diagnosis, sex and deprivation status, risk of 
mortality in overweight and moderately obese patients were generally lower relative to 
normal weight patients, even after the exclusion of deaths occurring in the first two 
years of follow-up. These findings were consistent regardless of the method applied for 
handling missing data.  
 THE OBESITY PARADOX 9.3.1
The obesity paradox refers to the situation whereby normal weight patients have higher 
mortality than overweight and moderately obese patients (those with BMI of 25 to 
35kg/m²), in spite of the well-known association between elevated BMI and a number 
of adverse health outcomes. It has primarily been reported amongst adults with pre-
existing chronic diseases such as heart failure, though a recent systematic review 
described decreased mortality in overweight people relative to normal weight in the 
general population (Flegal et al., 2013). In this review of prospective, observation cohort 
studies, overweight patients had lower all-cause mortality than normal weight 
participants (summary HR: 0.94 [0.91-0.96]). The main explanations for this observation 
included earlier presentation of overweight and obese patients and more rigorous 
medical treatment for non-normal weight patients. However, it may also reflect secular 
trends in BMI distribution and typically mortality is lowest in the group that forms the 
largest proportion of any population (Mehta & Chang, 2011).   
In patients with DM, there is growing evidence of an obesity paradox (Hu et al., 2005; 
Mulnier et al., 2006; Carnethon et al., 2012; Logue et al., 2013; Thomas et al., 2014).  
Whilst plausible mechanisms for the obesity paradox in patients with some chronic 
diseases have been put forward including that for chronic kidney failure whereby weight 
losses are common as this disease progresses, a plausible mechanism for the observation 
amongst patients with DM is less obvious (Carnethon et al., 2014). Nonetheless, there 




- Triggers for type 2 DM diagnosis 
The current procedures for the identification and diagnosis of people with Type 2 DM 
may play a role in the presence of the obesity paradox. Within the current NICE 
guidance document “Preventing type 2 diabetes: risk identification and interventions for 
individuals at high risk” it is recommended that GPs and other health professionals use 
a risk assessment to identify people of high risk of type 2 diabetes. According to this 
document, this risk assessment should be offered to: 
• Adults aged 40 and above (excluding pregnant women) 
• People aged 25-39 of South Asian, Chinese, African-Caribbean, black 
African and other high risk black and minority ethnic groups 
• Adults with conditions that increase the risk of type 2 diabetes, 
including cardiovascular disease, hypertension, obesity, stroke, 
polycystic ovarian syndrome, a history of gestational diabetes and 
mental health problems.    
The risk assessment is conducted using a validated risk assessment tool, such as the 
Diabetes UK risk score. This risk score uses information regarding patient age, sex, 
ethnicity, family history of DM, waist circumference, BMI and history of hypertension. 
Patients with a high risk score are then offered either a fasting blood glucose test or a 
glycated haemoglobin blood test to determine type 2 DM status. This strategy for 
identifying patients with type 2 DM, and in particular the recommendation that patients 
with obesity should be offered a risk assessment is likely to ensure overweight or obese 
patients to be diagnosed early. Whilst it is recommended that all adults aged 40 and 
above should be offered a risk assessment, GP time-constraints make it unlikely that 
this recommendation is routinely applied. Individuals with a lower BMI and without the 
risk factors described above would therefore only be offered an assessment and 
diagnostic tests if they were exhibiting symptoms suggestive of type 2 DM. As a 
consequence, patients diagnosed at lower BMIs may have a more severe form of DM or 
may have been diagnosed at a later stage of DM. These patients may therefore have a 
worse prognosis. For example, it has been shown that longer duration of type 2 DM is 
independently associated with elevated mortality and non-fatal DM complications 




undiagnosed DM or more severe disease amongst low BMI patients. To test this 
hypothesis and to help in the interpretation of this relationship, the development of a 
tool for measuring DM severity at diagnosis may be beneficial. Accordingly, this score 
would identify those patients with the worst prognosis at diagnosis and analyses of the 
association between BMI and all-cause mortality could be adjusted for disease severity. 
Currently, there are several scores which attempt to classify DM severity, however these 
tools were not designed to measure disease severity at diagnosis and therefore may not 
include important factors, such as prescription data (Selby et al., 2001; Clarke et al., 
2004; Young et al., 2008). Alternatively, the identification of patients with a more 
progressive form of type 2 DM may be achieved by observing rates of DM 
complications by BMI at diagnosis. 
- Heterogeneous DM 
Firstly, patients with type 2 DM are phenotypically heterogeneous. Previous studies 
have identified that lean and normal-weight patients with DM have different genetic 
profiles to overweight or obese patients with DM (Perry et al., 2012). These genetic 
profiles or other disease processes may predispose these individuals to DM at lower 
BMIs through a number of mechanisms including more rapid visceral fat accumulation, 
increased insulin resistance and earlier beta cell failure (Logue et al., 2013). If these 
genetic differences also confer increased susceptibility to other diseases or are a more 
aggressive form of DM, patients may exhibit worse survival. One such phenotype that 
has been identified is the metabolically obese normal weight (MONW) phenotype 
(Ruderman et al., 1998). MONW individuals have been observed to have higher visceral 
adiposity, higher blood pressure, lower physical activity expenditure, altered insulin 
sensitivity and are predisposed to cardiovascular diseases (Conus et al., 2007). Similarly, 
it is possible that some type 2 DM patients may have been misdiagnosed and actually 
have late onset autoimmune diabetes (LADA) which is phenotypically similar to type 1 
DM. In a population of Swedish patients with clinically determined type 2 DM, it was 
observed that between 8 to 10% of patients may have LADA.  The presence of these 
more aggressive pathophysiologies may have important management implications for 
people with newly-diagnosed DM. Treatment advice for normal-weight but 




- Body composition & poor performance of BMI as a measure of obesity 
Secondly, patient body composition and the distribution of fat may be important 
contributors to the obesity paradox. BMI is a crude anthropometric measure of obesity 
which is unable to discriminate between adiposity and lean body mass. Though some 
patients may have low BMIs, these patients may have low muscle mass and high fat 
mass. Lean muscle mass is more insulin sensitive than fat mass and therefore sarcopenic 
obesity is metabolically disadvantageous (Hainer & Aldhoon-Hainerová, 2013).  
Sarcopenia also increases the frailty of patients which in turn is heavily associated with 
poor health outcomes including survival (Shamliyan et al., 2013). Therefore the use of 
BMI as a measure of adiposity may not be suitable amongst elderly populations as used 
here. Indeed, Zoppini et al. (2003) observed an obesity paradox only when analyses 
were restricted to patients over 65 years of age in a cohort of type 2 DM patients (n= 
3,398) in Italy. However, no evidence of an interaction by age was observed in our study 
or in a pooled analysis of five longitudinal studies by Carnethon et al. (2012). 
A related issue is BMIs inability to reflect the distribution of body fat. Visceral fat is 
known to be more strongly associated with insulin resistance than subcutaneous fat. 
When Carmethon et al. (2012) used waist circumference as the measure of visceral fat, 
the obesity paradox was no longer apparent, suggesting that the obesity paradox may, in 
part be explained by the limitations of BMI as a measure of adiposity. Similarly, a recent 
meta-analysis of studies investigating mortality amongst patients with coronary heart 
disease identified an obesity paradox when using BMI as a predictor but not when waist 
circumference was used (Coutinho et al., 2011). Unfortunately, waist circumference 
measurements are not routinely collected in SCI-DC (or in clinical practice and many 
routine datasets) and therefore this alternative hypothesis could not be explored using 
the current data.  
BMI also does not provide any indication of physical fitness. A previous study from the 
Aerobics Center Longitudinal Study observed that obese but fit men with DM had 
lower cardiovascular disease mortality than lean and unfit patients (Church et al., 2005). 
Furthermore, an earlier study by the same group noted that cardiorespiratory fitness is a 
stronger determinant of mortality than weight status (Church et al., 2004). However, this 




lifestyles and fitness. Nonetheless, Kokkinos et al (2012) found that fitness was a strong 
predictor of all-cause mortality in patients with DM independent of BMI. Again, as for 
waist circumference, this information was not available in the SCI-DC register and is 
rarely available in clinical databases.   
Other explanations of the obesity paradox have centred on methodological flaws of the 
studies investigating this relationship. These flaws include the likelihood of selection 
bias, treatment bias, residual confounding and reverse causation.  
- Treatment Bias 
Intensive DM management amongst overweight and obese patients may be contributing 
to a treatment bias which may contribute to reduced mortality in these groups (Standl et 
al., 2013). This form of bias is difficult to control for and may have arisen through a 
greater emphasis on stringent DM management of cardiovascular risk factors in 
overweight or obese patients. Unfortunately, assessing the potential for treatment bias is 
not straightforward. For example, using prescription data as an indicator of intensive 
risk factor recording is likely to produce biased estimates since prescriptions for statins 
or anti-hypertensive agents by categories of BMI are more likely to relate to the 
increased prevalence of hypertension or dyslipidemia in higher BMI categories.  
- Selection bias 
Collider stratification bias is a form of selection bias which has also been proposed as a 
potential explanation for the apparent protective influence of obesity amongst patients 
with chronic diseases (Dahabreh & Kent, 2011). Collider bias occurs when an 
association between two variables is distorted by conditioning on a common effect or 
collider, in this case, DM. By restricting analyses to patients with DM, a collision 
between obesity and smoking status occurs leading to a strengthening of the inverse 
association between smoking and obesity in this subpopulation. This in turn increases 
the likelihood that the association between obesity and mortality will be underestimated 
because of a failure to fully control for the effect of smoking. Preston and Stokes (2014) 
used data from the National Health and Nutritional Examination Survey to test this 
hypothesis in a population of DM patients. The authors presented an obesity paradox 




when former or current smokers were excluded. In my analyses presented in Chapter 8, 
when analyses were conducted on never smokers the obesity paradox was not 
eliminated when either CCA or multiple imputation were applied.  
- Residual confounding by poorly controlled smoking status 
Smoking status is strongly, inversely related to BMI and mortality (positively) and 
adjusting for this important confounder is difficult. Information on dose such as 
number of cigarettes smoked per day was not available and information regarding time 
since smoking cessation or smoking initiation amongst former and current smokers, 
respectively could not be incorporated into analyses. However, restricting analyses to 
people described as never smokers should have helped to overcome this problem.  
- Cross Sectional Studies  
Another proposed explanation for the paradox and a clear limitation of our study here is 
the cross-sectional nature of the exposure variable. This study and many others before it 
ignored the time-varying nature of the exposure and make the unlikely assumption that 
BMI remains constant throughout the entirety of follow-up. Upon diagnosis with DM, 
overweight and obese patients are more likely to make beneficial weight changes than 
normal weight patients and therefore exhibit healthier trajectories (Ferreira & 
Stehouwer, 2012). By making these changes, mortality risk may be underestimated for 
people who remain in the overweight and obese categories and fail to make such 
changes. Similarly, this approach of defining variables at a specific time-point meant that 
temporal changes in confounding factors such as patient smoking status could not be 
accounted for. Changes in these confounding factors may have contributed to the 
observed paradoxical finding in this study. Since repeated measurements are available in 
the SCI-DC dataset, further work using time-dependent variables should be focussed 
upon identifying trends in BMI following diagnosis with DM. Latent class trajectory 
analysis, as applied in the Whitehall II Cohort study to model pre-diagnosis BMI 
trajectories could be used to identify patterns of BMI change after diagnosis (Vistisen et 
al., 2014). The relationship between BMI trajectories and mortality could be explored. 
However, this may be difficult to achieve using data that are not measured at fixed 





As discussed previously, the presence of comorbid conditions may have influenced the 
findings of this study. Low BMI at diagnosis may have been a direct effect of co-
morbidity such as chronic kidney disease which is well-known to cause muscle wasting 
and weight loss. These in turn are likely to hasten mortality. Attempts to control for 
reverse causation in this study included the exclusion of patients who had died within 
two years of BMI determination and those with comorbid conditions as defined by the 
Charlson comorbidity index. Despite these efforts, mortality risk remained high in the 
lowest weight categories. Nonetheless, this approach does not account for comorbidity 
not measured by hospital admission and depends on the reliability of the hospital 
admissions dataset (SMR01). In a recent quality assurance assessment conducted by the 
Information Services Division (ISD) it was reported that the accuracy rate of recordings 
was typically around 80% (Information Services Division, 2012). However, a number of 
issues with this dataset have been identified including its inability to register more than 
six comorbid conditions and the coding of signs and symptoms of conditions even if 
there is no diagnosis. Nonetheless, the binary coding of the Charlson comorbidity index 
should reduce the impact of failure to record all comorbid conditions. Furthermore, a 
systematic review of studies investigating the association between all-cause mortality and 
BMI also noted that exclusions based on the presence of comorbid conditions and 
deaths within 2 years of follow-up rarely have an effect on estimates (Flegal et al., 2013). 
 STRENGTHS & LIMITATIONS 9.3.2
There were a number of strengths to this work. Firstly, this is a population level dataset 
and therefore the sample was diverse and large enough with a sufficient number of 
events for detailed sub-group analyses. This feature also ensured the risk of selection 
biases were minimised. Additionally, SCI-DC is linked to numerous other clinical 
databases which were able to provide detailed information on some aspects of 
comorbidity status. This information in combination with relatively long term follow-up 
allowed for a reduction in the potential impact of pre-existing diseases. Death data were 
retrieved by register linkage with death registrations which are considerably more 




In addition, these analyses were adjusted for by deprivation status, the SIMD. This is an 
area-based measure of deprivation whose data-zones have an average population of less 
than 800 people. These data-zones should be relatively homogenous.  
Along with those already discussed, the study had other potential limitations which may 
have obscured the true relationship between BMI and all-cause mortality.  Firstly, this 
study was not able to adjust for a number of potentially important confounders such as 
ethnicity, alcohol intake, physical activity, diet, fat distribution and prescription data.  
Ethnicity is very poorly recorded in the SCI-DC database and was not included in the 
analyses. Typically, Asian patients develop DM at lower BMIs than European 
populations, possibly through the high prevalence of the MONW phenotype in these 
populations (Florez & Castillo-Florez, 2012). Failure to stratify by ethnicity may 
therefore have influenced our studies findings. Nonetheless, according to the Scottish 
Diabetes Survey 2013, less than 4% of patients with type 2 DM in Scotland are from 
ethnic minority groups (Scottish Diabetes Survey Monitoring Group, 2013). The effect 
of ethnicity on estimates is therefore likely to be negligible.   
Using all-cause mortality as the outcome of interest may have masked different patterns 
for different causes of death. By investigating cause-specific mortality it may have been 
possible to identify which specific causes of death were driving this obesity paradox. For 
example, the Prospective Studies Collaboration observed a U-shaped relationship 
between BMI and all-cause mortality in a general population, but different patterns of 
mortality by BMI were observed when cause-specific mortality was investigated 
(Prospective Studies Collaboration, 2009). Unsurprisingly, the excess mortality observed 
in the higher BMI categories was primarily driven by vascular deaths, particularly caused 
by ischaemic heart disease. In contrast, lung and aerodigestive cancer deaths and 
respiratory deaths exhibited strong inverse associations with BMI. Though it remains 
uncertain if these patterns would be observed in a DM population it is likely that the 
obesity paradox may be driven by certain diseases only.   
The definition of BMI at diagnosis may also have led to incorrect estimates. 
Measurements taken within 10 months prior to or 2 months after diagnosis may not 
have truly reflected BMI at diagnosis. For example, body weight is influenced by 




this small time-period following diagnosis were deemed likely to be small. There is a 
small amount of evidence to suggest patient BMI typically changes in the year prior to 
diagnosis. Looker et al. (2001) observed that mean BMI rose between 0.43 and 
0.71kg/m² in a population of Pima Indians in central Arizona though this was in a 
relatively small population (n=816) which was likely to differ considerably from the 
Scottish population. Vistisen et al. (2014) found that during 18 years of follow-up, 
patient BMIs typically increased steadily before decreasing a year prior to diagnosis. In 
contrast, De Fine Olivarius et al. (2008) observed an average weight loss of 2.3kg/m² in 
the year preceding diagnosis amongst patients enrolled in the Diabetes Care in General 
Practice study based in Denmark. In the same population, Drivsholm et al. (2005) 
reported that 61% of patients experienced unintentional weight loss in the three months 
preceding diagnosis with DM. Hyperglycaemia prior to the diagnosis of diabetes can 
result in weight loss so BMI at diagnosis of DM may not reflect pre-morbid BMI and 
duration of undiagnosed diabetes and severity of hyperglycaemia may confound the 
association between BMI and mortality. The majority of “BMI at diagnosis” 
measurements used in CCA analyses were recorded a short time after diagnosis (median 
time from diagnosis = 0 days (IQR: -11, 21 days). The definition of BMI at diagnosis 
was chosen on the basis of limiting the amount of incomplete data since missing data 
methods have been shown to produce progressively more biased results as the 
proportion of missing data increases (Graham, 2009). The short time between recording 
and diagnosis may also have limited the potential biases associated with using date of 
diagnosis rather than date of BMI determination as the starting point for follow-up. 
Furthermore, the stability of patient measurements during this time-frame was observed 
and deemed reasonable. In addition, estimates obtained using closest BMI values to 
replace unobserved measurements resulted in similar estimates to those obtained using 
CCA and multiple imputation. Using wider time-intervals therefore may offer a more 
straightforward approach to handling unobserved data.  
A further limitation of the work was grouping together of patients with a BMI below 
25kg/m². This limitation is discussed at length in section 6.4.3. Briefly, this 
categorisation strategy may have obscured the dose-response relationship between BMI 
and all-cause mortality since this group also included underweight patients. However, 




a BMI below 20kg/m². Future work using this dynamic routinely collected data source 
will have larger numbers to explore this dose-response relationship in greater detail.  
 IMPLICATIONS & FUTURE RESEARCH  9.3.3
Weight loss in people with DM is thought to be desirable since it is assumed that weight 
reductions improve morbidity and mortality. Findings from this study suggest that for 
patients with a BMI above 35kg/m², weight loss should be encouraged. Nonetheless, 
current research on the effect of weight loss interventions on health outcomes amongst 
patients with type 2 DM have reported mixed findings (Williamson et al., 2000; Gregg et 
al., 2004; Bodegard et al., 2013; Wing et al., 2013). Further work is required to clarify the 
impact of weight changes following diagnosis with DM on patient health outcomes. A 
randomised controlled trial of weight loss interventions such as bariatric surgery or 
intensive weight management treatments is likely to be the most effective but costliest 
means of identifying the impact of weight changes following diagnosis with type 2 DM. 
As a cheaper alternative, an observational study using the SCI-DC dataset may be useful 
in assessing the association between BMI trajectories following diagnosis and mortality. 
To achieve this, methods used by Vistisen et al (2014) in the Whitehall II study could be 
applied. SCI-DCs data linkage with prescribing records will also allow adjustment for 
pharmacotherapies, an important confounder in this relationship.   
Conversely, results presented here and in several other studies indicate that normal 
weight status at diagnosis with DM may be an important marker for raised mortality 
risk. In contrast, overweight and obese appear to have a protective effect on all-cause 
mortality. Further work is required to assess potential reasons for this obesity paradox 
and whether changes need to be made to current treatment plans for patients diagnosed 
at lower BMIs. More specifically, observing rates of type 2 DM complications by BMI at 
diagnosis may help in interpreting this relationship. If patients with lower BMIs at 
diagnosis develop complications earlier, this may be indicative of a more aggressive 
disease phenotype or a diagnosis at a later stage of the disease. Alternatively a measure 
of disease severity at diagnosis using baseline biochemical measures such as glycated 
haemoglobin could be a useful tool in explaining the paradox. If the paradox is a 
consequence of a later disease diagnosis adjustment for baseline disease severity in 




lower BMIs. This measure of disease severity could subsequently be used to identify 
patients who would benefit from more aggressive DM treatment earlier.  
Where no differences in disease severity by BMI at diagnosis are observed, alternative 
explanations for the obesity paradox should be investigated. For example, the 
observational study assessing the impact of BMI trajectories would also be able to 
identify whether the obesity paradox is a consequence of the cross-sectional study 
design.  
 SUMMARY 9.3.4
In summary, investigations of the association between BMI at diagnosis of type 2 DM 
and all-cause mortality in patients revealed a U-shaped relationship that remained even 
after exclusion deaths in the first two years, smokers and patients with comorbid 
conditions. Previous studies investigating this association have applied used a varied of 
approaches to handle missing data, such as CCA which may have been unsuitable and 
likely to introduce bias. Given the presence of an obesity paradox, it seemed bizarre that 
earlier studies have not explored the possibility that this paradox may have arisen due to 
inappropriate methods for handling unobserved data. This is the only study 
investigating this relationship in patients with DM where the robustness of estimates to 
different methods for handling missing data has been explored. In these analyses, the 
missing data method utilised did not have a large impact on the overall conclusions 
indicating other explanations for the paradox.  
Further work is required to identify whether patients with different baseline BMI would 
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A5.  APPENDICES FOR CHAPTER 5 
 
Table A. 5.1. Survival status by missingness. Strat ified by sex. 
 Male Female 
 Complete BMI Missing BMI Complete BMI Missing BMI 
Crude HR (95% 
CI) 
1 0.91 (0.89, 0.93) 1 0.98 (0.94, 1.02) 
Age adjusted HR 
(95% CI) 
1 0.99 (0.97, 1.01) 1 1.01 (0.99, 1.02) 
     
Deaths 12,349 31,615 10,034 30,974 
Person-years 390,655 861,100 325,950 758,310 
Crude mortality, 
deaths per 1,000 
person-years 
31.6 36.7 30.7 40.8 
Age-standardised 
mortality, per 1,000 
person years (95% 
CI 
24.8                   
(24.3, 25.3) 
36.1                  
(35.7, 36.5) 
20.2                        
(19.8, 20.7) 





A6. APPENDICES FOR CHAPTER 6 
Table A.6.1 Estimates of relative hazard of all-cau se mortality and age-standardised 
mortality by categories of BMI using CCA for males  
MALES BMI category (kg/m²) 
< 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  




adjusted HR (95% 
CI)a 
1.53              
(1.39, 1.70) 
1.00 
0.99              
(0.90, 1.08) 
1.02      
(0.90, 1.16) 
1.40              
(1.17, 1.67) 
Standard Error 
0.0791  0.0445 0.0675 0.1260 
      
No. deaths 558 1,166 768 292 143 
Person years 16,156 56,659 51,316 23,473 11,782 
Crude mortality 
rate 
34.5 20.6 16.0 12.4 12.1 
Age-standardised 
mortality rate 
21.5         
(19.2, 23.9) 
12.9             
(12.0, 13.8) 
12.5             
(11.5, 13.6) 
12.9             
(10.9, 14.8) 
14.7                 
(11.7, 17.7) 
 
Table A. 6.2 Estimates of relative hazard of all-ca use mortality and age-standardised 
mortality by categories of BMI using CCA for female s 
FEMALES BMI category (kg/m²) 
< 25 25 to < 30 
(REF) 
30 to < 35 35 to < 40 ≥ 40  
N 2,701 (11.41) 6,291 (26.58) 6,711 (28.36) 4,330 (18.30) 3,634 (15.35) 
      
Multivariable 
adjusted HR (95% 
CI)a 
1.48          
(1.33, 1.66) 
1.00 




1.35              
(1.16, 1.57) 
Standard Error 0.0838  0.0547 0.0716 0.1057 
      
No. deaths 543 752 610 318 232 
Person years 15,061 35,853 38,155 24,451 20,679 
Crude mortality 
rate 
36.1 21.0 16.0 13.0 11.2 
Age-standardised 
mortality rate 
16.3               
(13.2, 19.40 
9.6                 
(8.7, 10.4) 
10.1                
(9.0, 11.1) 
10.8                
(9.3, 12.3) 









Table A. 6.3. Baseline characteristics of patients included in population mean 
imputation by BMI category (n=66,372) 
a Measurement recorded closest to date of diagnosis 
 
 
 BMI category, kg/m² 
<25 25 to < 
30 
30 to < 
35 
35 to < 
40 
≥ 40 Total 


























% Male 52.22 61.38 56.23 49.08 37.18  54.59 
% Alive 80.49 88.22 88.12 92.80 93.45 97.62 























23.03 21.83 22.82 26.07 29.99 23.64 
2 21.77 22.27 22.37 23.99 24.32 22.67 
3 19.07 19.93 21.40 21.24 20.31 20.73 
4 18.29 18.56 18.98 16.21 15.23 18.13 
5 (Least 
deprived) 
17.85 17.41 14.43 12.49 10.15 14.83 
Median Charlson 
Comorbidity Score (IQR) 
1 (1,2) 1 (1,2) 1 (1,2) 1  (1,2) 1 (1,2) 1 (1,2) 
% Never smoker 40.60 40.32 42.07 43.30 47.68 42.16 














Mean Diastolic BP, mmHg 
(SD) a 
77 (10.69) 79 (10.49) 81 (10.83) 83 (10.90) 84 (10.80) 81   
(10.91) 
Mean glycated 












Mean serum creatinine, 






































2.54 (2.64)  
Mean HDL-cholesterol, 
















Table A. 6.4 Estimates of relative hazard of all-ca use mortality and age-standardised 
mortality by categories of BMI using MICE (includin g Nelson Aaelen estimate of 
cumulative hazard rather than follow-up time) 
 BMI category (kg/m²) 
 < 25 25 to < 30  30 to < 35 35 to < 40 ≥ 40  









in N from CCA 
(%)a 
1,528 (11.04) 4,140 (30.43) 4,229 (31.02) 2,354 (16.36) 1,527 (11.14) 
      
Multivariable 
adjusted HRbc 
1.40           
(1.30, 1.50) 
1.00 
0.98          
(0.90, 1.06) 
0.99            
(0.91, 1.08) 
1.21              
(1.08, 1.34) 
Standard Error 0.049  0.039 0.046 0.07 
      
No. deaths 1,452 2,749 2,013 857 510 
Person years 39,708 116,678 116,984 61,423 40,854 
Crude mortality 
rate d 
36.6 23.6 17.2 14.0 12.5 
Age-standardised 
mortality rate c d 
19.5               
(17.7, 20.9) 
13.2             
(12.5, 13.9) 
12.2               
(11.1, 13.3) 
12.2        
(11.2, 13.2) 
14.2            
(12.6, 15.9) 
a Percentage of missing data, b Adjusted for age, sex and smoking status, deprivation status and Charlson comorbidity 
index c with 95% CI, d deaths per 1,000 person-years. CCA: CCA  
 
Table A. 6.5. Estimates of relative hazard of all-c ause mortality by categories of BMI 
(including BMI as a continuous variable) 
BMI category (kg/m²) Multivariable adjusted HR 
(95% Confidence intervals) 
Standard Error 
 
< 25 1.23 (1.04, 1.46) 0.104 
25 to < 30 1.00  
30 to < 35 1.07 (0.82, 1.12) 0.074 
35 to < 40 1.07 (0.89, 1.30) 0.105 





Figure A6.1. Relationship between BMI and all-cause  mortality using CCA following 
re-categorisation of BMI at diagnosis variable. Est imates adjusted for age, sex and 
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A7.  APPENDICES FOR CHAPTER 7 
Table A. 7.1 Characteristics of patients with unobs erved BMI at diagnosis by number of BMI measurement s per person  
 Number of BMI measurements*   
0 1 2 3-10 >10 TOTAL 
N (%) 1,395 (10.13) 1,301 (9.44) 1,711 (12.42) 8,568 (62.20) 800 (5.81) 13,775 
(100.00) 
Mean age at diagnosis, yrs (SD) 64.31 (14.14) 61.93 (14.10) 61.83 (13.83) 61.87 (12.68) 59.84 (11.83) 62.00 (13.10) 
% Male 51.83 54.57 53.59 53.14 48.75 52.94 
% Alive  80.86 83.55 84.34 85.27 88.75 84.75 
Median no. of years follow-up 
(IQR) 
4.61                 
(4.05, 5.37) 
4.88              
(4.16, 6.08) 








% With additional comorbidities 37.20 34.59 32.96 33.44 34.50 33.93 
% Never smoker 47.31 45.89 47.81 44.00 43.50 44.96 
Mean BMI (Median of within-
patient recordings), kg/m2 (SD) 
- 31.04 (6.50) 31.02 (6.49) 31.26 (6.29) 33.43 (7.47) 31.34 (6.45) 
Mean Systolic BP, mmHg (SD)  a 140 (20.32) 139 (19.00) 139 (19.21) 140 (19.39) 141 (20.58) 140 (19.50) 
Mean Diastolic BP, mmHg (SD)  a 80 (11.52) 80 (11.10) 80 (10.86) 81 (10.91) 81 (11.44) 81 (11.01) 
Mean HbA1c, % (SD)  a 8.07 (2.13) 7.95 (2.08) 7.84 (2.01) 7.84 (1.99) 8.05 (2.02) 7.89 (2.02) 
Mean serum creatinine, umol/L 
(SD)  a 
89.59 (24.48) 89.74 (33.42) 88.80 (25.17) 91.40 (28.50) 92.03 (28.74) 90.78 (28.74) 
Mean Total cholesterol, mmol/L 
(SD)  a 
5.10 (1.29) 5.07 (1.31) 5.11 (1.31) 5.18 (1.31) 5.25 (1.30) 5.16 (1.31) 





 Number of BMI measurements*   
(IQR)  a (1.37, 1.80) (1.49, 3.00) (1.41, 2.92) (1.42, 2.90) (1.44, 2.90) (1.40, 2.90) 
Mean HDL-cholesterol, mmol/L 
(SD) a 
1.23 (0.37) 1.22 (0.40) 1.25 (0.39) 1.27 (0.42) 1.26 (0.46) 1.26 (0.41) 
* Grouping was changed, owing to only 39 patients having more than 20 measurements 










Figure A.7.1 Box and whiskers plots of number of me asurements by a. Deprivation status (1=most deprive d) and year of diagnosis for 





Table A.7.2 Agreement between categories of closest  BMI measurements before 
diagnosis and BMI at diagnosis 
 BMI at date of diagnosis (kg/m²) Diagonal 
Total (% of 

















































725       
(1.88) 





Total (% of 
38,820) 
 12           
(0.03) 
27       
(0.07) 







Table A.7.3 Agreement between categories of closest  BMI measurements after 
diagnosis and BMI at diagnosis 
 BMI at date of diagnosis, kg/m² (column percentage) Diagonal 
Total (% of 


















< 25 4,163 
(83.14) 
1,426  (9.83) 46         
(0.32) 
11         
(0.15) 











63           
(0.83) 
11               
(0.21) 




36         
(0.72) 




53         
(1.03) 




12           
(0.24) 
35          
(0.24) 




911           
(17.62) 
162          
(0.35) 
≥ 40 11 (0.22) 10             
(0.07) 
35          
(0.24) 







Total (% of 
52,591) 
 11         
(0.02) 
22            
(0.05) 
106             
(0.22) 












Table A.7.4. Estimates of relative hazard of all-ca use mortality and age-standardised 
mortality by categories of BMI using multiple imput ation (+ before and after 
measurements). 
 BMI category (kg/m²) 
 < 25 25 to < 30 
(REF) 











Increase in N 









1,423   
(10.49) 




1.40               
(1.31, 1.51) 
1.00 
      0.98 
(0.91, 1.05) 
1.00         
(0.91, 1.09) 
1.20              
(1.08, 1.33) 
Standard Error 0.052  0.034 0.044 0.064 
      
No. deaths 1,419 2,587 1,997 825 487 
Person years 38,875 114,398 115,070 59,885 40,809 
Crude mortality 
rate d 
36.5 22.6 17.4 13.8 11.9 
Age-standardised 
mortality ratec d 
19.3          
(17.7, 20.9) 
12.7            
(12.1, 13.4)  
12.3           
(11.6, 12.9) 
12.2             
(11.2, 13.2)   
13.7             
(12.0, 15.3)  
a Percentage of missing data, b Adjusted for age, sex and smoking status, deprivation status and Charlson comorbidity 
index c with 95% CI, d deaths per 1,000 person-years. CCA: Complete case analysis  
Table A.7.5. Extent of incompleteness in BMI at dif ferent timepoints relative to 
diagnosis timeframe 
Variable Observed (% of 64,971) Unobserved (% of 64,971) 
BMI t-2 19,457 (29.95) 45,514 (70.05) 
BMI t-1 14,966 (23.03) 50,005 (76.97) 
BMI t (at diagnosis) 52,591 (80.94) 12,380 (19.05) 
BMI t+1 53,107 (81.74) 11,864 (18.26) 
BMI t+2 40,028 (61.61) 24,943 (38.39) 
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OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
% Age at 
diagnosis, years  
< 50 69.23 30.77 
1                       
(Ref) 














OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
50 – 59 71.36 28.64 
0.90                 
(0.86, 0.95) 
1.02                      
(0.94, 1.10) 
60 – 69 73.02 26.98 
0.84             
(0.80, 0.88) 
0.97                    
(0.90, 1.05) 
70 – 79 71.76 28.24 
0.92                
(0.87, 0.96) 
0.99               
(0.91, 1.08) 
≥80 62.33 37.67 
1.58              
(1.48, 1.68) 
1.45               
(1.31, 1.61) 
% Sex 
Female 67.46 32.54 
1                           
(Ref) 
1                         
(Ref) 
Male 69.50 30.50 
0.90                    
(0.88, 0.93) 
0.89            
(0.84, 0.93) 
% Vital status 
Alive 71.35 28.65 
1                             
(Ref) 
1                         
(Ref) 
Deceased 51.02 48.98 
2.26              
(2.18, 2.35) 
1.25                          
(1.13, 1.39) 
% SIMD 1 (Most 
deprived) 
70.49 29.51 
0.95                
(0.91, 1.00) 
0.99                
(0.91, 1.07) 
2 69.63 30.37 
1.01                   
(0.96, 1.06) 
1.06                
(0.98, 1.15) 
3 68.15 31.85 
1.07               
(1.02, 1.13) 
1.08                
(1.00, 1.17) 
4 66.61 33.39 
1.15                 
(1.10, 1.22) 





1                 
(Ref) 
1                         
(Ref) 
% Year of 
diagnosis 
2004 67.05 32.96 
1                         
(Ref) 
1                   
(Ref) 
2005 71.56 28.44 
0.81                    
(0.78, 0.85) 
0.87               
(0.81, 0.94) 
2006 73.31 26.69 
0.74               
(0.71, 0.78) 
0.71               
(0.65, 0.77) 
2007 72.42 27.58 
0.77                     
(0.74, 0.81) 
0.79               
(0.71, 0.87) 
2008 69.58 30.42 
0.88              
(0.83, 0.95) 
0.86                  
(0.75, 0.98) 
Median Follow-up time, years 
(IQR) 
5.67          
(4.63, 6.79) 
5.71               
(4.52, 6.95) 
0.95           (0.94, 
0.96) 









1                         
(Ref) 
1                         
(Ref) 
>  1 
Additional 
63.25 36.75 
1.48               
(1.43, 1.53) 














OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
% Smoking 
status 
Current 84.96 15.04 
1.06                
(1.00, 1.13) 
1.00              
(0.95, 1.05) 
Former 86.89 13.11 
0.91              
(0.86, 0.96) 
0.93                    
(0.88, 0.99) 
Never 85.72 14.28 
1                         
(Ref) 
1                         
(Ref) 
Mean SBP, mmHg (SD) a 
139          
(18.59) 
140            
(19.32) 
1.001               
(1.000, 1,002) 
- 
Mean DBP, mmHg (SD) a 
81            
(10.87) 
80.67 (11.02) 
0.998               
(0.996, 0.999) 
- 
Mean HbA1c, % (SD) a 8.04 (2.12) 7.92 (2.04) 
0.97                
(0.96, 0.98) 
- 
Mean serum creatinine, umol/L 
(SD) a 
90.28 (25.87) 90.81 (28.01) 
1.005               
(1.002, 1.007) 
- 
Mean total cholesterol, mmol/L 
(SD) a 
5.18 (1.29) 5.16 (1.30) 
0.98              
(0.97, 1.00) 
1.02               
(1.00, 1.04) 
Median triglycerides, mmol/L 
(SD) a 
2.01           
(1.42, 2.90) 
2.00         
(1.40, 2.90) 
0.99             
(0.98, 1.00) 
- 
Mean HDL-cholesterol, mmol/L 
(SD) a 
1.24 (0.39) 1.25 (0.41) 
1.09                   
(1.04, 1.14) 
- 
Health Board Area 
Ayrshire & Arran 65.64 34.36 
1.27                 
(1.19, 1.34) 
1.28                  
(1.17, 1.40) 
Borders 71.39 28.61 
0.98             
(0.88, 1.09) 
1.07                      
(0.91, 1.26) 
Dumfries & Galloway 69.88 30.12 
1.06               
(0.97, 1.17) 
1.18              
(1.03, 1.36) 
Fife 70.20 29.80 
1.05            
(0.98, 1.12) 
1.14              
(1.03, 1.26) 
Forth Valley 71.76 28.24 
0.95                    
(0.89, 1.03) 
1.16              
(1.04, 1.29) 
Grampian 66.54 33.46 
1.21                     
(1.15, 1.28) 
0.85               
(0.77, 0.94) 
Greater Glasgow 70.92 29.08 
1                         
(Ref) 
1                         
(Ref) 
Highlands 55.66 44.34 
1.95               
(1.82, 2.08) 
1.14             
(1.01, 1.29) 
Lanarkshire 70.93 29.07 
1.00                           
(0.95, 1.06) 
1.03                    
(0.95, 1.12) 
Lothian 66.70 33.30 
1.22                    
(1.15, 1.28) 














OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Orkney 49.68 50.32 
2.56               
(2.06,  3.19) 
1.15               
(0.76, 1.74) 
Shetland 60.64 39.36 
1.63                
(1.29, 2.06) 
1.29              
(0.88, 1.88) 
Tayside 71.89 28.11 
0.96               
(0.90, 1.02) 
0.93                 
(0.84, 1.03) 
Western Isles 68.18 31.82 
1.21             
(0.97, 1.51) 
0.76             
(0.51, 1.15) 
a Recorded closest to date of diagnosis 
Table A. 8.2: Biochemical predictors at date of dia gnosis (defined as a measurement 
recorded 10 months prior to or 2 months after diagn osis) of missingness in variables 










OR (95% CI) 
Multivariate 
model* 
OR (95% CI) 
Mean Systolic BP, mmHg (SD) a 
(n=62,674) 
140 (18.56) 141 (19.02) 
1.002                     
(1.002, 1.004) 
1.003                
(1.002, 1.004) 
Mean Diastolic BP, mmHg (SD) a  
(n=62,676) 
81 (10.86) 81 (10.90) 
1.000                
(0.998, 1.002) 
1.006                  
(1.004, 1.007) 
Mean Glycated haemoglobin, % 
(SD) a     (n=52,510) 
8.23 (2.21) 8.34 (2.23) 
1.02                   
(1.01, 1.03) 
1.03                
(1.02, 1.04) 
Mean serum creatinine, umol/L 
(SD) a (n=59,258) 
90.46 (25.98) 91.70 (27.44) 
1.002                  
(1.001, 1.003) 
1.001                
(1.000, 1.002) 
Mean total cholesterol, mmol/L 
(SD) a (n=61,761) 
5.19 (1.30) 5.26 (1.32) 
1.03                    
(1.02, 1.05) 
1.01               
(1.00, 1.072 
Median triglycerides, mmol/L 
(IQR) a (n=17,994) 
2.11           
(1.50, 3.02) 
2.05           
(1.47, 2.92) 
1.00                      
(0.98, 1.01) 
1.01              
(0.99, 1.01) 
Mean HDL cholesterol, mmol/L 
(SD) a (n=41,622) 
1.24 (0.38) 1.24 (0.40) 
1.07                        
(1.01, 1.14) 
1.03             
(0.97, 1.10) 
* Adjusted for Age, sex, vital status, deprivation status and charlson comorbidity index 
 
 
Table A.8.3: Survival status by presence of missing  data in any variable to be included 
in final analysis model I. 
 Complete case Missing data 
Crude HR (95% CI) 1 1.34 (1.28, 1.40) 
Age and sex adjusted HR (95% CI)  1 1.27 (1.22, 1.33) 




Deaths 5,484 2,682* 
Person-years 300,593 104,370 
Crude mortality, deaths per 1,000 
person-years 
18.2 25.7 
Age-standardised mortality, per 
1,000 person years (95% CI)  
12.6 (12.2, 13.0) 16.1 (15.4, 16.7) 
* 2,485 patients could not be included in absolute mortality calculations due to incomplete age/date of 
diagnosis data. Amongst these patients there were 2,116 deaths. The total person-years for these patients 



























OR (95% CI) 
Multivariate 
model 














OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years % 
< 50 36.22 63.78 
1                 
(Ref) 
1                         
(Ref) 
50 – 59 38.45 61.55 
0.91               
(0.87, 0.95) 
0.94              
(0.89, 1.00) 
60 – 69 39.00 61.00 
0.89                
(0.85, 0.93) 
0.91               
(0.86, 0.97) 
70 – 79 37.24 62.76 
0.96             
(0.91, 1.01) 
0.95           (0.89, 
1.01) 
≥80 32.21 67.79 
1.20                
(1.12, 1.28) 
1.03             
(0.94, 1.13) 
Sex, % Female 32.52 64.48 1 (Ref) 1 (Ref) 
Male 36.90 63.10 
1.06           (1.03, 
1.09) 
1.04            
(1.01, 1.08) 
Vital status, % Alive 38.00 62.00 1 (Ref) 1 (Ref) 
Deceased 25.38 74.62 
1.80                 
(1.72, 1.89) 
1.46             
(1.33, 1.61) 
SIMD, % 1 (Most 
deprived) 
36.83 63.17 
1.09            
(1.04, 1.14) 
1.10            
(1.03, 1.17) 
2 36.91 63.09 
1.08            
(1.03, 1.14) 
1.14              
(1.07, 1.21) 
3 35.31 64.69 
1.16             
(1.10, 1.22) 
1.14                     
(1.07, 1.21) 
4 35.09 64.91 
1.17                           
(1.11, 1.24) 





1                 
(Ref) 




2004 30.05 69.95 
1                         
(Ref) 
1                         
(Ref) 
2005 38.15 61.85 
0.70              
(0.67, 0.73) 
0.75                 
(0.71, 0.80) 
2006 40.62 59.38 
0.63                 
(0.50, 0.66) 
0.71                    
(0.65, 0.77) 
2007 40.89 59.11 
0.62               
(0.59, 0.65) 
0.67                 
(0.60, 0.75) 
2008 41.25 58.75 
0.61                     
(0.57, 0.65) 
0.42                   
(0.36, 0.49) 
Median Follow-up time, years 
(IQR) 
5.56          
(4.57, 6.64) 
5.76                
(4.61, 6.95) 
1.09                  
(1.07, 1.10) 








71.27 28.73 1 (Ref) 1 (Ref) 
>  1 
Additional 
63.25 36.75 
1.23             
(1.19, 1.27) 















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Smoking status, 
%a 
Current 84.96 15.04 
1.00                  
(0.96, 1.04) 
0.99               
(0.94, 1.04) 
Former 86.89 13.11 
0.94                 
(0.91, 0.98) 
0.96                
(0.92, 1.00) 
Never 85.72 14.28 1 (Ref) 1 (Ref) 
Mean BMI, kg/m² (SD) 32.03 (6.40) 32.07 (6.55) 
1.001                 
(0.998, 1.004) 
- 
Mean Systolic BP, mmHg (SD) a 140 (18.61) 139 (18.92) 
0.999                
(0.997, 1.000) 
- 
Mean Diastolic BP, mmHg (SD) a 80 (10.86) 81 (10.94) 
0.999            
(0.997, 1.000) 
- 
Mean Glycated haemoglobin, % 
(SD) a 
8.20 (2.18) 7.88 (2.04) 
0.93              
(0.92, 0.94) 
0.92                     
(0.91, 0.93) 
Mean serum creatinine, umol/L 
(SD) a 
90.12 (23.89) 90.62 (27.98) 
1.000             
(1.001, 0.999) 
- 
Mean total cholesterol, mmol/L 
(SD) a 
5.18 (1.30) 5.16 (1.29) 
0.99               
(0.98, 1.00) 
- 
Median triglycerides, mmol/L 
(IQR) a 
2.03            
(1.45, 2.95) 
2.00                 
(1.40, 2.90) 
0.99                     
(0.98, 1.00) 
- 
Mean HDL cholesterol, mmol/L 
(SD) a 
1.24 (0.39) 1.25 (0.41) 
1.08               
(1.04, 1.12) 
1.04                
(0.99, 1.09) 
Health Board Area 
Ayrshire & Arran 45.98 54.02 
0.55                 
(0.52, 0.59) 
0.68                     
(0.63, 0.74) 
Borders 10.66 89.34 
3.94                
(3.34, 4.66) 
3.08                     
(2.54, 3.73) 
Dumfries & Galloway 29.62 70.38 
1.12                
(1.01, 1.23) 
1.63                  
(1.45, 1.83) 
Fife 34.50 65.50 
0.89             
(0.84, 0.95) 
1.45             
(1.34, 1.58) 
Forth Valley 23.55 76.45 
1.53                  
(1.41, 1.65) 
1.69                   
(1.52, 1.87) 
Grampian 38.30 61.70 
0.76                
(0.72, 0.80) 
1.12                 
(1.05, 1.20) 
Greater Glasgow 32.01 67.99 1 (Ref) 1 (Ref) 
Highlands 30.63 69.37 
1.07                
(0.99, 1.15) 
1.06                
(0.96, 1.18) 
Lanarkshire 46.38 53.62 
0.54                
(0.52, 0.57) 
0.73                 
(0.68, 0.79) 
Lothian 33.01 66.99 
0.96                  
(0.91, 1.01) 















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Orkney 25.80 74.20 
1.35               
(1.05, 1.75) 
0.92                  
(0.65, 1.30) 
Shetland 35.46 64.54 
0.86                 
(0.67, 1.10) 
0.94               
(0.70, 1.26) 
Tayside 48.94 51.06 
0.49                 
(0.46, 0.52) 
0.77               
(0.70, 0.83) 
Western Isles 37.27 62.73 
0.79              
(0.63, 0.99) 
1.08                  
(0.82, 1.41) 
a Recorded closest to date of diagnosis 
Table A.8.5: Biochemical predictors at date of diag nosis of missingness in variables 











OR (95% CI) 
Multivariate 
model* 
OR (95% CI) 
Mean Systolic BP, mmHg (SD) 
a(n=62,674) 
140 (18.58) 141 (19.02) 
1.002                     
(1.002, 1.004) 
1.000                
(0.999, 1.001) 
Mean Diastolic BP, mmHg (SD) a  
(n=62,676) 
81 (10.84) 81 (10.88) 
0.999               
(0.998, 1.001) 
1.002                  
(1.000, 1.003) 
Mean Glycated haemoglobin, % 
(SD) a (n=49,992) 
8.20 (2.18) 8.32 (2.24) 
1.02                   
(1.01, 1.03) 
1.02                
(1.01, 1.03) 
Mean serum creatinine, umol/L 
(SD) a (n=56,254) 
90.28 (24.68) 91.09 (27.59) 
1.001                 
(1.000, 1.002) 
1.001                
(1.000, 1.002) 
Mean total cholesterol, mmol/L 
(SD) a (n=58,829) 
5.19 (1.30) 5.23 (1.30) 
1.02                    
(1.01, 1.04) 
1.04               
(1.02, 1.05) 
Median triglycerides, mmol/L 
(IQR) a (n=17,153) 
2.10            
(1.50, 3.01) 
2.10            
(1.48, 3.00) 
1.01                      
(1.00, 1.02) 
1.01              
(1.00, 1.02) 
Mean HDL cholesterol, mmol/L 
(SD) a (n=39,785) 
1.24 (0.39) 1.24 (0.38) 
1.04                        
(0.98, 1.09) 
1.00            
(0.95, 1.06) 





Table A.8.6: Survival status by presence of missing  data in any variable to be included 
in final analysis model. 




Crude HR (95% CI) 1 1.21 (1.16, 1.27) 
Age and sex adjusted HR (95% CI)  1 1.17 (1.12, 1.23) 
   
Deaths 2,700 5,466 
Person-years 154,589 250,373 
Crude mortality, deaths per 1,000 
person-years 
17.5 21.8 
Age-standardised mortality, per 
1,000 person years (95% CI)  
12.0 (11.5, 12.5) 14.6 (14.2, 15.0) 
* 2,485 patients could not be included in absolute mortality calculations due to incomplete age/date of 
diagnosis data. Amongst these patients there were 2,116 deaths. The total person-years for these patients 




























OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years, % 
< 50 75.63 24.37 
1                    
(Ref) 
1                    
(Ref) 
50 – 59 76.67 23.33 
0.94                 
(0.90, 1.00) 
1.02                     
(0.94, 1.10) 
60 – 69 78.02 21.98 
0.87                 
(0.83, 0.92) 
0.97               
(0.90, 1.04) 
70 – 79 77.26 22.74 
0.91              
(0.86, 0.97) 
1.01                        
(0.93, 1.09) 
≥80 67.22 32.78 
1.51              
(1.41, 1.63) 
1.42                 
(1.28, 1.58) 
Sex, % 
Female 72.93 27.07 
1                 
(Ref) 
1                   
(Ref) 
Male 74.61 25.39 
0.92                          
(0.89, 0.95) 
0.89               
(0.84, 0.93) 
Vital status, % 
Alive 76.83 23.17 
1                      
(Ref) 
1                     
(Ref) 
Deceased 55.10 44.90 
2.70                    
(2.59, 2.82) 
1.31                   
(1.17, 1.47) 
SIMD, % 1 (Most 
deprived) 
74.72 25.28 
1.03                    
(0.97, 1.09) 
0.99                  
(0.91, 1.07) 
2 74.08 25.92 
1.07                 
(1.01, 1.13) 
1.03              
(0.94, 1.11) 
3 73.40 26.60 1.10 (1.04, 1.17) 
1.07                
(0.98, 1.16) 
4 71.98 28.02 
1.19                     
(1.12, 1.26) 





1                   
(Ref) 




2004 72.78 27.22 
1                        
(Ref) 
 1                       
(Ref) 
2005 77.21 22.79 
0.79                      
(0.75, 0.83) 
0.86                
(0.80, 0.93) 
2006 78.61 21.39 
0.73                   
(0.69, 0.76) 
0.73                
(0.66, 0.81) 
2007 77.42 22.58 
0.78                   
(0.74, 0.82) 
0.83              
(0.73, 0.94) 
2008 74.79 25.21 
0.90                    
(0.84, 0.97) 
0.98                   
(0.82, 1.16) 
Median Follow-up time, years 
(IQR) 
5.68               
(4.63, 6.80) 
5.68            
(4.49, 6.98) 
1.00                        
(0.99, 1.01) 




None 76.87 23.13 
1                     
(Ref) 














OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
CCI) % 
One or more 67.93 32.07 
1.57                       
(1.52, 1.62) 




Current 85.61 14.39 
1.05                   
(1.00, 1.13) 
1.08               
(1.01, 1.15) 
Former 87.38 12.62 
0.91                   
(0.86, 0.96) 
0.91                     
(0.86, 0.97) 
Never 86.32 13.68 
1                  
(Ref) 
1 (Ref) 
Mean BMI, kg/m² (SD) b 32.03 (6.48) 31.37 (6.67)   
Mean Systolic BP, mmHg (SD) a 140 (15.54) 141 (19.24) 
1.004               
(1.003, 1.005) 
- 
Mean Diastolic BP, mmHg (SD) a 81 (10.87) 81 (10.86) 
1.000                   
(0.998, 1.002) 
- 
Mean Glycated haemoglobin, % 
(SD) a 
8.24 (2.21) 8.34 (2.23) 
1.02               
(1.01, 1.03) 
1.00              
(0.99, 1.01) 
Mean serum creatinine, umol/L 
(SD) a 




Mean total cholesterol, mmol/L 
(SD) a 
5.20 (1.30) 5.27 (1.32) 
1.04                  
(1.02, 1.06) 
1.001                
(1.000, 1.003) 
Median triglycerides, mmol/L 
(IQR) a 
2.01             
(1.42, 2.91) 
2.00                 
(1.38, 2.88) 
1.00                
(0.99, 1.02) 
- 
Mean HDL cholesterol, mmol/L 
(SD) a 
1.24 (0.39) 1.25 (0.39) 
1.09                   
(1.02, 1.17) 
1.02                 
(1.00, 1.04) 
Health Board Area 
Ayrshire & Arran 70.99 29.01 




Borders 75.89 24.11 
1.00                  
(0.88, 1.13) 
1.03                      
(0.87, 0.97) 
Dumfries & Galloway 75.33 24.67 
1.03                  
(0.93, 1.14) 
1.20                  
(1.04, 1.38) 
Fife 73.70 26.30 
1.12                      
(1.04, 1.20) 
1.11                 
(1.01, 1.23) 
Forth Valley 75.02 24.98 
1.04                    
(0.96, 1.13) 
1.14               
(1.02, 1.27) 
Grampian 73.99 26.01 
1.10             
(1.04, 1.17) 
0.85                  
(0.77, 0.94) 
Greater Glasgow 75.81 24.19 1 (Ref) 1 (Ref) 
Highlands 66.02 33.98 
1.61                 
(1.50, 1.74) 
1.16            
(1.02, 1.27) 
Lanarkshire 73.71 26.29 
1.12                 
(1.05, 1.18) 














OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Lothian 73.46 26.54 
1.13                      
(1.07, 1.20) 
1.15                 
(1.06, 1.25) 
Orkney 63.06 36.94 
1.84                      
(1.46, 2.31) 
1.20                
(0.80, 1.80) 
Shetland 73.40 26.60 
1.14                  
(0.87, 1.48) 
1.17                 
(0.79, 1.73) 
Tayside 75.74 24.26 
1.00                       
(0.94, 1.08) 
0.90               
(0.81, 1.00) 
Western Isles 74.24 25.76 
1.09             
(0.85, 1.39) 
0.72                              
(0.47, 1.10) 
a Recorded at date of diagnosis 
b Closest measurement recorded outside date of diagnosis time-frame 
  
Table A. 8.8: Survival status by presence of missin g data in BMI at diagnosis variable 
 Complete smoking status Missing smoking status 
Crude HR (95% CI) 1 1.44 (1.37, 1.51) 
Age and sex adjusted HR (95% CI)  1 1.37 (1.31, 1.44) 
   
Deaths 5,645 2,521 
Person-years 309,172 95,792 
Crude mortality, deaths per 1,000 
person-years 
18.3 26.3 
Age-standardised mortality, per 
1,000 person years (95% CI)  
12.5 (12.2, 12.9) 16.9 (16.1, 17.6) 
* 2,485 patients could not be included in absolute mortality calculations due to incomplete age/date of 
diagnosis data. Amongst these patients there were 2,116 deaths. The total person-years for these patients 

























OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years, % 
< 50 90.09 9.91 1 (Ref) 1 (Ref) 
50 – 59 91.28 8.72 
0.85                     
(0.72, 0.81) 
0.82                 
(0.77, 0.87) 
60 – 69 91.37 8.63 
0.77              
(0.72, 0.81) 
0.70               
(0.66, 0.74) 
70 – 79 91.85 8.15 
0.81                     
(0.76, 0.85) 
0.70                   
(0.66, 0.75) 
≥80 89.71 10.29 
1.26                   
(1.17, 1.35) 
0.98                
(0.90, 1.07) 
Sex, % 
Female 88.56 11.44 1 (Ref) 1 (Ref) 
Male 88.09 11.91 
0.95                   
(0.91, 0.98) 
0.97                  
(0.93, 1.01) 
Vital status, % 
Alive 90.83 9.17 1 (Ref) 1 (Ref) 
Deceased 72.39 27.61 
2.24                
(2.16, 2.37) 






0.92                  
(0.87, 0.98) 
0.90                   
(0.84, 0.96) 
2 88.61 11.39 
0.95           (0.90, 
1.01) 
0.92                 
(0.86, 0.98) 
3 88.27 11.73 
1.04                 
(0.98, 1.11) 
0.98               
(0.91, 1.05) 
4 86.95 13.05 
1.15             
(1.08, 1.22) 




89.59 10.41 1 (Ref) 1 (Ref) 
Year of 
diagnosis, % 
2004 90.33 9.67 1 (Ref) 1 (Ref) 
2005 92.16 7.84 
0.77                   
(0.74, 0.82) 
0.75                     
(0.71, 0.80) 
2006 92.06 7.94 
0.75                   
(0.72, 0.80) 
0.67              
(0.64, 0.71) 
2007 90.94 9.06 
0.71                
(0.68, 0.75) 
0.61                 
(0.58, 0.65) 
2008 87.43 12.57 
0.77                 
(0.71, 0.84) 
0.55               
(0.50, 0.61) 
Median Follow-up time, years 
(IQR) 
5.68              
(4.61, 6.83) 
5.58             
(4.41, 6.92) 
1.00 (0.99. 1.01) 






















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
(derived from 
CCI) % 
>  1 
Additional 
82.94 17.06 
1.51                
(1.45, 1.56) 
1.12                   
(1.06, 1.17) 
Mean BMI, kg/m² (SD)b 31.89 (6.49) 
32.27 (6.99) 
*n = 3,798 
1.01               
(1.00, 1.02) 
- 
Mean SBP, mmHg (SD) a 139 (18.79) 139 (19.42) 
0.999                
(0.998, 1.000) 
- 
Mean DBP, mmHg (SD) a 80 (10.94) 80 (11.24) 
0.999                   
(0.997, 1.000) 
- 
Mean HbA1c, % (SD) a 8.03 (2.12) 7.88 (2.03) 
0.965                
(0.956, 0.975) 
0.97               
(0.96, 0.98) 
Mean serum creatinine, umol/L 
(SD) a 
90.91 (27.21) 92.09 (30.53) 
1.001                
(1.000, 1.002) 
- 
Mean total cholesterol, mmol/L 
(SD) a 
5.16 (1.30) 5.11 (1.30) 0.97 (0.96, 0.99) 
0.97              
(0.96, 0.99) 
Median triglycerides, mmol/L 
(IQR) a 
2.00             
(1.41, 2.90) 
2.05              
(1.40, 3.03) 
1.00 (0.99, 1.01) - 
Mean HDL cholesterol, mmol/L 
(SD) a 
1.24 (0.40) 1.25 (0.41) 
1.06                  
(1.00, 1.12) 
- 
Health Board Area 
Ayrshire & Arran 85.67 14.33 
1.23             
(1.15, 1.31) 
1.09              
(1.00, 1.18) 
Borders 91.39 8.61 
0.88             
(0.77, 1.01) 
0.88           (0.75, 
1.04) 
Dumfries & Galloway 92.80 7.20 
0.94                   
(0.84, 1.05) 
1.17               
(1.03, 1.33) 
Fife 90.93 9.07 
0.99                  
(0..91, 1.07) 
1.06            
(0.96, 1.16) 
Forth Valley 92.01 7.99 
0.81               
(0.74, 0.89) 
0.80                      
(0.72, 0.89) 
Grampian 85.92 14.08 
1.44                
(1.35, 1.53) 
1.58               
(1.46, 1.70) 
Greater Glasgow 90.48 9.52 1 (Ref) 1.00 (Ref) 
Highlands 78.35 21.65 
2.32               
(2.16, 2.50) 
2.63                  
(2.41. 2.87) 
Lanarkshire 88.14 11.86 
1.00               
(0.94, 1.07) 
0.93              
(0.86, 1.00) 
Lothian 87.09 12.91 
1.21                   
(1.14, 1.29) 
1.35           (1.26, 
1.45) 
Orkney 73.25 26.75 
3.15                
(2.53, 3.93) 

















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Shetland 82.62 17.38 
1.84                
(1.43, 2.37) 
2.20                 
(1.68, 2.89) 
Tayside 90.31 9.69 
0.98                  
(0.91, 1.06) 
1.21            
(1.11, 1.32) 
Western Isles 88.18 11.82 
1.34              
(1.04, 1.72) 
1.44               
(1.07, 1.93) 




Table A.8.10: Survival status by presence of missin g data in smoking status at 
diagnosis variable 
 Complete smoking status Missing smoking status 
Crude HR (95% CI) 1 1.25 (1.20, 1.30) 
Age and sex adjusted HR (95% CI) 1 1.22 (1.16, 1.27) 
   
Deaths 7,335 831 
Person-years 369,282 35,681 
Crude mortality, deaths per 1,000 
person-years 
23.3 23.3 
Age-standardised mortality, per 
1,000 person years (95% CI) 

























OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years, % 
< 50 83.24 16.76 1 (Ref) 1 (Ref) 
50 – 59 87.25 12.75 
0.73               
(0.68, 0.77) 
0.70             
(0.62, 0.79) 
60 – 69 89.14 10.86 
0.60                 
(0.57, 0.64) 
0.61            
(0.54, 0.68) 
70 – 79 90.11 9.89 
0.55            
(0.51, 0.58) 
0.55              
(0.48, 0.63) 
≥80 87.11 12.19 
0.69              
(0.63, 0.76) 
0.51           
(0.41, 0.63) 
Sex, % 
Female 84.92 15.08 1 (Ref) 1 (Ref) 
Male 84.82 15.18 
1.01              
(0.97, 1.05) 
0.95                 
(0.87, 1.04) 
Vital status, % 
Alive 87.42 12.58 1 (Ref) 1 (Ref) 
Deceased 68.76 31.24 
3.16               
(3.01, 3.31) 






1.20             
(1.12, 1.29) 
1.17              
(1.00, 1.36) 
2 84.95 15.05 
1.16               
(1.08, 1.24) 
1.11           
(0.96, 1.30) 
3 84.74 15.26 
1.17           
(1.09, 1.26) 
1.21            
(1.04, 1.42) 
4 84.29 15.71 
1.22                  
(1.13, 1.31) 




86.71 13.29 1 (Ref) 1 (Ref) 
Year of 
diagnosis, % 
2004 85.90 14.20 1 (Ref) 1 (Ref) 
2005 89.41 10.59 
0.72                 
(0.67, 0.76) 
0.68              
(0.59, 0.79) 
2006 88.73 11.27 
0.77               
(0.72, 0.82) 
0.81             
(0.67, 0.97) 
2007 87.85 12.15 
0.84             
(0.78, 0.89) 
1.19              
(0.93, 1.52) 
2008 84.70 15.30 
1.09               
(1.00, 1.19) 
1.34           
(0.98, 1.84) 
Median Follow-up time, years 
(IQR) 
5.68            
(4.61, 6.81) 
5.64            
(4.47, 7.00) 
1.01               
(0.99, 1.02) 








87.29 12.71 1 (Ref) 1 (Ref) 
>  1 
Additional 
80.10 19.90 
1.71            
(1.64, 1.78) 















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Smoking status, 
% 
Current 94.97 5.03 
1.27             
(1.15, 1.41) 
1.20                
(1.07, 1.33) 
Former 96.33 3.67 
0.92             
(0.83, 1.01) 
1.00            
(0.90, 1.11) 
Never 96.01 3.99 1 (Ref) 1 (Ref) 
Mean BMI, kg/m² (SD) a 
32.04           
(6.45) 
32.34          
(7.40) 
1.01              
(0.99, 1.02) 
- 
Mean Systolic BP , mmHg (SD)b 137 (17.85) 136 (19.46) 
1.004        
(1.003, 1.005) 
 
Mean Diastolic BP, mmHg (SD) a 81 (10.90) 80 (11.02) 
0.994                  
(0.992,  0.997) 
- 
Mean glycated haemoglobin, % 
(SD) a 
8.02 (2.11) 7.94 (2.06) 
0.98                 
(0.97, 0.99) 
- 
Mean serum creatinine, umol/L 
(SD) a 
90.68 (26.47) 88.21 (26.38) 
0.995              
(0.994, 0.996) 
- 
Mean total cholesterol, mmol/L 
(SD) a 
5.18 (1.29) 5.12 (1.30) 
0.97              
(0.95, 0.99) 
1.02          (0.99, 
1.06) 
Median triglycerides, mmol/L 
(IQR) a 
2.00             
(1.41, 2.90) 
2.01              
(1.36, 2.95) 
1.00               
(0.99, 1.02) 
- 
Mean HDL cholesterol, mmol/L 
(SD) a 
1.24 (0.40) 1.24 (0.38) 
0.98               
(0.92, 1.05) 
- 
Health Board Area 
Ayrshire & Arran 81.58 18.42 
1.44            
(1.33, 1.55) 
1.78            
(1.53, 1.06) 
Borders 86.62 13.38 
0.98                 
(0.84, 1.15) 
0.96         (0.69, 
1.35) 
Dumfries & Galloway 87.16 12.84 
0.94                 
(0.82, 1.07) 
1.38           
(1.08, 1.77) 
Fife 84.89 15.11 
1.13          
(1.04, 1.24) 
1.16               
(0.97, 1.40) 
Forth Valley 84.17 15.83 
1.20 (1.09, 
1.32) 
1.83           
(1.54, 2.18) 
Grampian 87.49 12.51 
0.91               
(0.84, 0.99) 
0.79             
(0.65, 0.95) 
Greater Glasgow 86.41 13.59 1 (Ref) 1 (Ref) 
Highlands 81.19 18.81 
1.47             
(1.35, 1.61) 
1.39               
(1.13, 1.72) 
Lanarkshire 82.74 17.26 
1.33          
(1.24, 1.42) 
1.23          (1.06, 
1.43) 
Lothian 84.70 15.30 
1.15             
(1.07, 1.23) 















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Orkney 75.48 24.52 
2.07            
(1.59, 2.68) 
1.31              
(0.64, 2.70) 
Shetland 85.46 14.54 
1.08                       
(0.77, 1.51) 
3.18               
(1.95, 5.19) 
Tayside 86.10 13.90 
1.03           
(0.94, 1.12) 
0.88 (0.72, 1.08) 
Western Isles 81.82 18.18 
1.41             
(1.06, 1.88) 
1.34               
(0.70, 2.55) 
a Recorded at date of diagnosis 
b Closest measurement recorded outside date of diagnosis time-frame 
 
Table A.8.12: Survival status by presence of missin g data in systolic blood pressure 
at diagnosis variable 
 Complete systolic blood 
pressure 
Missing systolic blood pressure 
Crude HR (95% CI) 1 1.13 (1.06, 1.20) 
Age and sex adjusted HR (95% CI)  1 1.29 (1.22, 1.38) 
   
Deaths 7,034 1,643 
Person-years 350,954 48,567 
Crude mortality, deaths per 1,000 
person-years 
20.0 23.0 
Age-standardised mortality, per 
1,000 person years (95% CI)  


























OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years, % 
< 50 70.65 29.35 1 (Ref) 1 (Ref) 
50 – 59 70.32 29.68 
1.02               
(0.97, 1.07) 
1.07                    
(1.00, 1.15) 
60 – 69 70.64 29.36 
1.00              
(0.95, 1.05) 
1.11            
(1.03, 1.19) 
70 – 79 69.80 30.20 
1.04              
(0.99, 1.10) 
1.18                  
(1.10, 1.27) 
≥80 65.07 34.93 
1.29             
(1.21, 1.38) 
1.31              
(1.18, 1.45) 
Sex, % 
Female 67.41 32.59 1 (Ref) 1 (Ref) 
Male 67.94 32.06 
0.98               
(0.95, 1.01) 
1.00                    
(0.95, 1.04) 
Vital status, % 
Alive 70.03 29.97 1 (Ref) 1 (Ref) 
Deceased 52.98 47.02 
2.07            
(1.99, 2.16) 






0.96              
(0.91, 1.01) 
1.01               
(0.94, 1.09) 
2 68.57 31.43 
0.98 (0.93, 
1.03) 
1.00               
(0.93, 1.08) 
3 66.64 33.36 
1.07               
(1.01, 1.13) 
1.05                
(0.97, 1.13) 
4 65.96 34.04 
1.10                 
(1.04, 1.16) 




68.11 31.89 1 (Ref) 1 (Ref) 
Year of 
diagnosis, % 
2004 65.44 34.56 1 (Ref) 1 (Ref) 
2005 70.57 29.43 
0.79               
(0.75, 0.83) 
0.89             
(0.83, 0.96) 
2006 71.84 28.16 
0.74                 
(0.71, 0.78) 
0.94             
(0.85, 1.03) 
2007 82.11 27.89 
0.73           
(0.70, 0.77) 
0.97               
(0.86, 1.10) 
2008 71.37 28.63 
0.76                 
(0.71, 0.82) 
0.94 (0.80,1.12) 
Median Follow-up time, years 
(IQR) 
5.64                              
(4.59, 6.75) 
5.79                  
(4.61, 7.00) 
1.06              
(1.05, 1.07) 






















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
(derived from 
CCI) % 
>  1 
Additional 
62.68 37.32 
1.41               
(1.36, 1.45) 




Current 76.44 23.56 
1.01            
(0.96, 1.05) 
1.04          (0.98, 
1.10) 
Former 75.68 24.32 
1.05                
(1.00, 1.10) 
1.03               
(0.98, 1.09) 
Smoker 76.54 23.46 1 (Ref) 1 (Ref) 
Mean BMI, kg/m² (SD) 32.00 (6.47) 32.22 (6.49) 
1.005               
(1.002, 1.008) 
- 
Mean SBP, mmHg (SD) a 139 (18.66) 140 (19.13) 
1.002             
(1.001, 1.003) 
- 
Mean DBP, mmHg (SD) a 81 (10.85) 81 (11.06) 
1.001             
(0.999, 1.002) 
- 
Mean HbA1c, % (SD) b 7.35 (1.53) 7.33 (1.59) 
0.99              
(0.98, 1.00) 
 
Mean serum creatinine, umol/L 
(SD) a 
90.01 (25.80) 91.49 (28.08) 
1.002               
(1.001, 1.003) 
- 
Mean total cholesterol, mmol/L 
(SD) a 
5.19 (1.30) 5.12 (1.28) 
0.96              
(0.95, 0.97) 
0.98            
(0.96, 1.00) 
Median triglycerides, mmol/L 
(IQR) a 
2.10             
(1.50, 3.02) 
2.09            
(1.48, 2.97) 
0.99                
(0.98, 1.00) 
- 
Mean HDL cholesterol, mmol/L 
(SD) a 
1.24 (0.40) 1.25 (0.40) 
1.05                 
(1.00, 1.10) 
1.04            
(0.98, 1.09) 
Health Board Area 
Ayrshire & Arran 71.08 28.92 
0.97              
(0.91, 1.04) 
0.78               
(0.71, 0.85) 
Borders 52.32 47.68 
2.18              
(1.96, 2.43) 
3.48              
(2.94, 4.10) 
Dumfries & Galloway 65.43 34.57 
1.26           
(1.15, 1.39) 
1.43               
(1.26, 1.62) 
Fife 56.39 43.61 
1.85           
(1.74, 1.97) 
2.18            
(2.01, 2.37) 
Forth Valley 64.93 35.07 
1.29           
(1.20, 1.39) 
1.48                     
(1.33, 1.64) 
Grampian 60.13 39.87 
1.59            
(1.50, 1.68) 
1.90                
(1.76, 2.05) 
Greater Glasgow 70.53 29.47 1 (Ref) 1 (Ref) 
Highlands 66.27 33.73 
1.22           
(1.13, 1.31) 
1.07             
(0.96, 1.20) 
Lanarkshire 70.96 29.04 
0.98               
(0.93, 1.04) 

















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Lothian 71.98 28.02 
0.93            
(0.88, 0.98) 
0.84              
(0.77, 0.92) 
Orkney 61.78 38.22 
1.48             
(1.18, 1.86) 
1.20              
(0.81, 1.77) 
Shetland 75.18 24.82 
0.79              
(0.60, 1.04) 
0.93             
(0.65, 1.33) 
Tayside 70.47 29.53 
1.00               
(0.94, 1.07) 
1.18             
(1.08, 1.28) 
Western Isles 67.88 32.12 
1.13               
(0.90, 1.43) 
0.99              
(0.72, 1.36) 
a Recorded at date of diagnosis 
b Closest measurement recorded outside date of diagnosis time-frame 
 
Table A. 8.14: Survival status by presence of missi ng data in glycated haemoglobin at 
diagnosis variable 
 Complete glycated 
haemoglobin 
Missing glycated haemoglobin 
Crude HR (95% CI) 1 1.13 (1.08, 1.18) 
Age and sex adjusted HR (95% CI)  1 1.09 (1.04, 1.14) 
   
Deaths 5,426 2,727 
Person-years 278,144 121,379 
Crude mortality, deaths per 1,000 
person-years 
19.5 22.5 
Age-standardised mortality, per 
1,000 person years (95% CI)  

























OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years, % 
< 50 77.51 22.49 1 (Ref) 1 (Ref) 
50 – 59 82.13 17.87 
0.75            
(0.71, 0.79) 
0.70           
(0.64, 0.76) 
60 – 69 84.63 15.37 
0.63             
(0.59, 0.66) 
0.57           
(0.52, 0.63) 
70 – 79 84.87 15.13 
0.61           
(0.58, 0.65) 
0.54               
(0.49, 0.60) 
≥80 78.57 21.43 
0.94            
(0.87, 1.02) 
0.73         (0.63, 
0.84) 
Sex, % 
Female 78.69 21.31 1 (Ref) 1 (Ref) 
Male 80.47 19.53 
0.90            
(0.86, 0.93) 
0.86               
(0.81, 0.92) 
Vital status, % 
Alive 82.43 17.57 1 (Ref) 1 (Ref) 
Deceased 62.23 37.77 
2.85               
(2.72, 2.98) 






1.11              
(1.04, 1.17) 
1.10              
(0.99, 1.23) 
2 79.94 20.06 
1.06              
(1.00, 1.13) 
1.01               
(0.91, 1.13) 
3 79.83 20.17 
1.07             
(1.00, 1.13) 
0.97             
(0.87, 1.08) 
4 79.04 20.96 
1.12               
(1.05, 1.19) 




80.84 19.16 1 (Ref) 1 (Ref) 
Year of 
diagnosis, % 
2004 75.93 24.07 1 (Ref) 1 (Ref) 
2005 83.18 16.82 
0.64                
(0.60, 0.67) 
0.69             
(0.63, 0.76) 
2006 84.98 15.02 
0.56                
(0.53, 0.59) 
0.63            
(0.55, 0.720 
2007 85.69 14.31 
0.53              
(0.50, 0.56) 
0.58                
(0.49, 0.70) 
2008 83.15 16.85 
0.64                 
(0.59, 0.70) 
0.32              
(0.14, 0.42) 
Median Follow-up time, years 
(IQR) 
5.64             
(4.59, 6.75) 
5.93            
(4.65, 7.15) 
1.12            
(1.10, 1.13) 






















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
(derived from 
CCI) % 
>  1 
Additional 
75.35 24.65 
1.48            
(1.42, 1.53) 




Current 88.48 11.52 
1.04                 
(0.97, 1.11) 
1.03            
(0.95, 1.12) 
Former 90.55 9.45 
0.83             
(0.78, 0.89) 
0.92             
(0.86, 0.99) 
Smoker 88.87 11.13 1 (Ref) 1 (Ref) 
Mean BMI, kg/m² (SD) 32.05 (6.42) 32.07 (7.02) 
1.000                  
(0.996, 1.004) 
- 
Mean SBP, mmHg (SD) a 140 (18.66) 139 (19.51) 
0.998                  
(0.997, 0.999) 
- 
Mean DBP, mmHg (SD) a 80.75 (10.89) 80.66 (11.05) 
0.999           
(0.997, 1.001 
- 
Mean HbA1c, % (SD) a 8.05 (2.12) 7.77 (1.98) 
0.93               
(0.92, 0.94) 
0.95                 
(0.94, 0.97) 
Mean serum creatinine, umol/L 
(SD) a 
90.53 (25.62) 89.88 (30.70) 
0.999              
(0.998, 1.000) 
- 
Mean Total cholesterol, mmol/L 
(SD) b 
4.69 (1.13) 5.03 (1.25) 
1.27             
(1.25, 1.29) 
 
Median triglycerides, mmol/L 
(IQR) a 
2.10               
(1.50, 3.00) 
2.60               
(1.60, 3.98) 
0.99               
(0.98, 1.00) 
- 
Mean HDL cholesterol, mmol/L 
(SD) a 
1.24 (0.40) 1.26 (0.42) 
1.12               
(1.06, 1.18) 
1.12             
(1.04, 1.21) 
Health Board Area 
Ayrshire & Arran 81.07 18.93 
0.98                  
(0.92, 1.06) 
0.83               
(0.73, 0.95) 
Borders 78.87 21.13 
1.13               
(0.99, 1.28) 
1.41            
(1.06, 1.89) 
Dumfries & Galloway 78.86 21.14 
1.13           
(1.01, 1.26) 
1.75             
(1.47, 2.09) 
Fife 76.79 23.21 
1.27           
(1.18, 1.37) 
1.76           
(1.56, 1.99) 
Forth Valley 81.67 18.33 
0.95          
(0.87, 1.03) 
1.10           
(0.93, 1.30) 
Grampian 78.52 21.48 
1.15           
(1.08, 1.23) 
1.74              
(1.55, 1.95) 
Greater Glasgow 80.83 19.17 1 (Ref) 1 (Ref) 
Highlands 74.45 25.55 
1.45            
(1.33, 1.57) 
1.63             
(1.39, 1.90) 
Lanarkshire 79.48 20.52 
1.09            
(1.02, 1.16) 

















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Lothian 78.90 21.10 
1.13              
(1.06, 1.20) 
1.34          (1.19, 
1.50) 
Orkney 70.38 29.62 
1.77               
(1.39, 2.27) 
1.37            
(0.77, 2.46) 
Shetland 85.11 14.89 
0.74 (0.53, 
1.03) 
1.16           
(0.70, 1.93) 
Tayside 82.92 17.08 
0.87           
(0.80, 0.94) 
1.35             
(1.19, 1.52) 
Western Isles 76.06 23.94 
1.33 (1.03, 
1.71) 
1.64                     
(1.08, 2.50) 
a Recorded at date of diagnosis 
b Closest measurement recorded outside date of diagnosis time-frame 
 
Table A. 8.16: Survival status by presence of missi ng data in total cholesterol at 
diagnosis variable 
 Complete total cholesterol Missing total cholesterol 
Crude HR (95% CI) 1 1.22 (1.16, 1.28) 
Age and sex adjusted HR (95% CI)  1 1.30 (1.23, 1.37) 
   
Deaths 6,376 1,777 
Person-years 327,722 71,803 
Crude mortality, deaths per 1,000 
person-years 
19.5 24.7 
Age-standardised mortality, per 
1,000 person years (95% CI)  

























OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Age at diagnosis, 
years, % 
< 50 52.63 47.37 1 (Ref) 1 (Ref) 
50 – 59 56.15 43.85 
0.87             
(0.83, 0.91) 
0.90            
(0.85, 0.95) 
60 – 69 57.26 42.74 
0.83               
(0.79, 0.87) 
0.87               
(0.83, 0.92) 
70 – 79 56.67 43.33 
0.85                 
(0.81, 0.89) 
0.89              
(0.84, 0.94) 
≥80 52.52 47.48 
1.00 (0.94, 
1.07) 
0.92             
(0.84, 1.00) 
Sex, % 
Female 52.90 47.10 1 (Ref) 1 (Ref) 
Male 54.67 45.33 
0.93               
(0.90, 0.96) 
0.96           
(0.92, 0.99) 
Vital status, % 
Alive 56.13 43.87 1 (Ref) 1 (Ref) 
Deceased 39.68 60.32 
1.95            
(1.86, 2.03) 






1.25              
(1.19, 1.32) 
1.22             
(1.14, 1.29) 
2 53.05 46.95 
1.20             
(1.14, 1.26) 
1.27                
(1.20, 1.35) 
3 54.20 45.80 
1.15              
(1.09, 1.20) 
1.19              
(1.12, 1.27) 
4 54.29 45.71 
1.14               
(1.08, 1.20) 




57.54 42.46 1 (Ref) 1 (Ref) 
Year of 
diagnosis, % 
2004 43.16 56.84 1 (Ref) 1 (Ref) 
2005 55.22 44.78 
0.62             
(0.59, 0.64) 
0.68             
(0.64, 0.72) 
2006 60.45 39.55 
0.50                  
(0.48, 0.52) 
0.60            
(0.56, 0.65) 
2007 62.84 37.16 
0.45            
(0.43, 0.47) 
0.58            
(0.52, 0.65) 
2008 64.08 35.92 
0.43                
(0.40, 0.46) 
0.51             
(0.44, 0.49) 
Median Follow-up time, years 
(IQR) 
5.50           
(4.52, 6.60) 
5.93            
(4.72, 7.08) 
1.18             
(1.17, 1.19) 








55.67 44.33 1 (Ref) 1 (Ref) 
>  1 
Additional 
50.5 49.65 
1.24               
(1.20, 1.28) 

















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Smoking status, 
% 
Current 60.01 39.99 
1.00               
(0.96, 1.05) 
0.95             
(0.90, 0.99) 
Former 62.28 37.72 
0.91                 
(0.88, 0.95) 
0.94               
(0.90, 0.98) 
Smoker 60.07 39.93 1 (Ref) 1 (Ref) 
Mean BMI, kg/m² (SD) 32.07 (6.41) 32.01 (6.59) 
0.998              
(0.996, 1.001) 
- 
Mean SBP, mmHg (SD) a 140 (18.64) 139 (19.01) 
0.998            
(0.997, 0.999) 
- 
Mean DBP, mmHg (SD) a 81 (10.89) 81 (10.93) 
0.997         
(0.995, 0.998) 
- 
Mean HbA1c, % (SD) a 8.05 (2.13) 7.95 (2.07) 
0.98             
(0.97, 0.99) 
- 
Mean serum creatinine, umol/L 
(SD) a 
90.68 (24.46) 90.08 (28.96) 
0.999            
(0.998, 1.000) 
- 
Mean total cholesterol, mmol/L 
(SD) a 
5.19 (1.30) 5.14 (1.29) 
0.97             
(0.96, 0.98) 
0.97                  
(0.96, 0.98) 
Median triglycerides, mmol/L 
(IQR) a 
2.10           
(1.50, 3.00) 
2.20            
(1.50, 3.28) 
1.00             
(0.99, 1.01) 
- 
Mean HDL-cholesterol , mmol/L 
(SD) b 
1.25 (0.37) 1.25 (0.42) 
0.99                        
(0.95, 1.03) 
 
Health Board Area 
Ayrshire & Arran 68.32 31.68 
0.39             
(0.37, 0.41) 
0.29                
(0.27, 0.31) 
Borders 21.66 78.34 
3.02                
(2.67, 3.43) 
3.43              
(3.00, 3.93) 
Dumfries & Galloway 44.93 55.07 
1.02              
(0.94, 1.12) 
1.11            
(1.00, 1.23) 
Fife 57.40 42.60 
0.62              
(0.58, 0.66) 
0.56             
(0.52, 0.60) 
Forth Valley 34.95 65.05 
1.56              
(1.45, 1.67) 
1.71               
(1.58, 1.85) 
Grampian 68.12 31.88 
0.39              
(0.37, 0.41) 
0.34             
(0.32, 0.37) 
Greater Glasgow 45.54 54.46 1 (Ref) 1 (Ref) 
Highlands 51.08 48.92 
0.80              
(0.75, 0.86) 
0.69            
(0.63, 0.75) 
Lanarkshire 62.53 37.47 
0.50              
(0.48, 0.53) 
0.38           
(0.36, 0.41) 
Lothian 42.84 57.16 
1.12              
(1.06, 1.17) 

















OR (95% CI) 
Multivariate 
model 
OR (95% CI) 
Orkney 43.34 56.69 
1.09                
(0.87, 1.37) 
0.88             
(0.65, 1.19) 
Shetland 62.77 37.23 
0.50           
(0.39, 0.63) 
0.48             
(0.36, 0.65) 
Tayside 72.31 27.69 
0.32            
(0.30, 0.34) 
0.26           
(0.24, 0.28) 
Western Isles 56.67 43.33 
0.64                   
(0.51, 0.80) 
0.53                 
(0.41, 0.70) 
a Recorded at date of diagnosis 
b Closest measurement recorded outside date of diagnosis time-frame 
 
Table A. 8.18: Survival status by presence of missi ng data in HDL-cholesterol at 
diagnosis variable 
 Complete HDL-cholesterol Missing HDL-cholesterol 
Crude HR (95% CI) 1 1.15 (1.10, 1.20) 
Age and sex adjusted HR (95% CI)  1 1.17 (1.12, 1.22) 
   
Deaths 4,062 4,091 
Person-years 217,604 181,920 
Crude mortality, deaths per 1,000 
person-years 
18.7 22.5 
Age-standardised mortality, per 
1,000 person years (95% CI)  













Table A.8.19: Distribution of smoking status by imp uted dataset number (only first 20 
of 60 are presented. 
Imputation 
Number 
Current Smokers Ex-Smokers Never Smokers 
1 16,721(22.63) 25,245 (34.17) 31,924 (43.20) 
2 16,682 (22.58) 25,324 (34.27) 31,884 (43.15) 
3 16,724 (22.63) 25,250 (34.17) 31,916 (43.19) 
4 16,719 (22.63) 25,349 (34.31) 31,822 (43.07) 
5 16,721 (22.63) 25,280 (34.21) 31,889 (43.16) 
6 16,684 (22.58) 25,277 (34.21) 31,929 (43.21) 
7 16,692 (22.59) 25,317 (34.26) 31,881 (43.15) 
8 16,690 (22.59) 25,236 (34.15) 31,964 (43.26) 
9 16,763 (22.69) 25,211 (34.12) 31,916 (43.19) 
10 16,619(22.49) 25,367 (34.33) 31,904 (43.18) 
11 16,709 (22.61) 25,301 (34.24) 31,880 (43.15) 
12 16,779 (22.71) 25,207 (34.11) 31,904 (43.18) 
13 16,773 (22.70) 25,245 (34.17) 31,872 (43.13) 
14 16,723 (22.63) 25,267 (34.19) 31,900 (43.17) 
15 16,720 (22.63) 25,325 (34.27) 31,845 (43.10) 
16 16,632 (22.51) 25,314 (34.26) 31,944 (43.23) 
17 16,648 (22.53) 25,297 (34.24) 31,945 (43.23) 
18 16,651 (22.53) 25,249 (34.17) 31,990 (43.29) 
19 16,738 (22.65) 25,182 (34.08) 31,970 (43.27) 
20 16,718 (22.63) 25,257(34.18) 31,915 (43.19) 
 
 
